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ABSTRACT
Atherosclerosis is a chronic inflammatory disease leading to plaque buildup in the major 
arteries. The plaques consist of cholesterol, calcium, inflammatory cells, extracellular matrix 
and fibrous material. Under inflammatory conditions IFN-• stimulation of human monocytes 
and macrophages generates reduced pteridine, 7,8-dihydroneopterin (78NP) which has been 
shown to be an effective cytoprotective agent to some cell types against oxidative damage by 
reactive oxygen species (ROS). 7,8-dihydroneopterin is oxidized to fluorescent neopterin in 
the presence of hypochlorite (HOCl). Although a considerable amount of work has been 
published on the composition of neopterin in atherosclerotic plaques, very little is known 
about the variation of 78NP and other oxidative biomarkers across the length of the carotid 
and femoral and their contribution to plaque progression, which was researched in this work. 
Atherosclerotic plaques excised from patients with carotid and femoral plaques were sliced
into 3-5 mm sections, and each section was analyzed for concentrations of neopterin, 7,8-
dihydroneopterin, •-tocopherol, TBARS, DOPA, cholesterol, dityrosine, protein carbonyls •-
aminoadipic semialdehyde (AAS) and •-glutamic semialdehyde (GGS), free and esterified 7-
ketocholesterol (7-KC). Cultured live plaque as a source of 7,8-dihydroneopterin and 
neopterin was also investigated in this study. 
It was shown that carotid plaques significantly vary from femoral plaques, in the levels and 
range of most oxidative biomarkers. Carotid plaques showed a high variation in the biomarker 
concentrations between plaques but also between sections of an individual plaque. Femoral 
plaques on the other hand showed lower amounts of biomarkers with very little variation in
biomarker concentrations. High variation with pterin concentrations and other biomarkers 
suggests dynamic and active changes in inflammation within the plaque. Collectively, it was 
observed that every plaque was unique with respect to its composition and correlations 
between the biomarkers. 
Though shown to be a well-known antioxidant and a radical scavenger, there is no published 
literature on 7,8-dihydroneopterin’s mode of entry into and out of the cell. To understand how 
it enters the cells could explain the difference in its protective ability of different cell types 
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against oxidative stress-mediated cell death. Knowledge of transport of 7,8-dihydroneopterin 
will provide insights about its protection of monocyte/macrophage cell death which could 
potentially reduce atherosclerotic plaque growth and progression. As 7,8-dihydroneopterin is 
produced from guanosine, a nucleoside that is transported using specialized nucleoside 
transporters (equilibrative nucleoside transporters (ENT's) and concentrative nucleoside 
transporters (CNT's), their role was examined and characterized for 7,8-dihydroneopterin 
transport.  
It was found that 7,8-dihydroneopterin and neopterin are transported via nucleoside 
transporters in U937 cells, THP-1 cells and human monocytes. ENT 2 was the major 
transporter in U937 cells while ENT 1 transported bulk of 7,8-dihydroneopterin in THP-1 
cells. Both ENT's and CNT's are involved in 7,8-dihydroneopterin uptake in human 
monocytes. In all the cell lines tested, 7,8-dihydroneopterin protection against AAPH 
mediated oxidative cell death was inhibited by nucleoside transport inhibitors, suggesting that 
nucleoside transporters are indispensible for 7,8-dihydroneopterin mediated intracellular 
protection against oxidative stress. 
Accurate measurement of neopterin, as a biomarker of inflammation in plaques and cells is 
critical aspect to assess disease progression. The current C18 HPLC method used in our 
laboratory for neopterin measurement lacks sensitivity due to interference of acetonitrile 
(ACN) over time. Acidic tri-iodide conversion of 7,8-dihydroneopterin to neopterin was also 
variable at times giving inconsistent measurement of neopterin so the manganese oxide 
(MnO2) method was looked at as an alternative. Electrochemical detector (ECD) was another 
option studied as it did not require any precolumn oxidation of 7,8-dihydroneopterin to 
neopterin.  
A new method using strong cation exchange (SCX) column was developed for a precise, 
sensitive neopterin assay which got rid of the ACN interference completely. The MnO2
method of 7,8-dihydroneopterin oxidation did not work with biological samples such as serum 
or plaque homogenates. Electrochemical detection was also found to be very unreliable and 
inconsistent.
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1. INTRODUCTION
1.1 Overview
The pterins 7,8-dihydroneopterin and its oxidized form neopterin, are released by human 
macrophages when activated by •-interferon (IFN-•). Plasma and urinary neopterin has been 
used for a number of years as a clinical marker of a range of disease pathologies including 
cardiovascular disease. Research conducted in this laboratory over the last 15 years has shown 
7,8-dihydroneopterin is a potent antioxidant and cytoprotective against oxidative stress. 
Atherosclerotic plaques taken from the artery wall during surgery have been found to contain 
high levels of 7,8-dihydroneopterin. The working hypothesis that has been developed is that 
macrophages on activation generate 7,8-dihydroneopterin as an antioxidant agent to protect 
themselves from the high levels of oxidants found within sites of inflammation. The research 
described in this thesis characterizes levels and location of 7,8-dihydroneopterin and neopterin 
in excised atherosclerotic plaques and compares its levels to other markers of oxidative stress. 
Previous research in this laboratory had suggested that the cytoprotective effect of 7,8-
dihydroneopterin in plaques macrophages is dependent on the uptake of 7,8-dihydroneopterin 
into the cells but surprisingly little is known on the mechanism of pterin enter into the cells. 
The role of ENT and CNT transports is examined in human monocytes and monocyte-like 
cells lines to characterize the mechanism of 7,8-dihydroneopterin uptake by cells. Both aspects 
of this research required a more robust 7,8-dihydroneopterin/neopterin assay method than
what had been previously used in the laboratory so a new HPLC based method was developed.
1.2 Cardiovascular disease and its types 
Cardiovascular disease (CVD) is any disease that affects the cardiovascular system and/or its 
vasculature itself. Although causes of cardiovascular disease are diverse, collectively they 
claim around 18 million lives around the globe every year. Cardiovascular disease accounted 
for about 40% of all deaths in New Zealand in 2004, though a large percentage of these are 
elderly (Heart Foundation report 2004).  The most prevalent type of CVD is an obstructive
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disease caused by the formation of ‘plaques’ within the artery wall, which blocks the 
downstream blood flow to the organs or tissues. Sudden blockage of coronary arteries 
supplying the heart results in ‘myocardial infarction’ or ‘heart attack’, where the affected heart 
muscle dies. Occlusion of cerebral arteries results in infarction or death of the brain tissue 
causing strokes. Weakening of the arterial wall due to plaque formation in the brain can lead 
to its rupture leading to hemorrhagic stroke. When this disease affects peripheral arteries 
blocking the blood flow to limbs it is known as peripheral artery disease, which is a common 
complication in diabetes. The general narrowing of arteries also increases blood pressure and 
increases the strain on heart which could further cause a range of cardiovascular pathologies. 
1.2.1 Atherosclerosis
Atherosclerosis is the major cause of cardiovascular disease. Atherosclerosis is made up of 
two words, ‘athero’, which means soft, gruelly substance and ‘sclerosis’, which literally means 
hardening. Felix Marchand introduced the term ‘Atherosclerosis’ in 1904 and also suggested 
that atherosclerosis was responsible for almost all obstructive processes in the arteries. In 
1908, A.I Ignatowski described the relationship between cholesterol-rich food and 
experimental atherosclerosis. In 1910, Adolf Windaus showed that atheromatous lesions 
contained 6 times more free cholesterol and 20 times more esterified cholesterol than the 
normal arterial wall. Soon after Nikolai N. Anichkow, along with his student S. Chalatow, in 
1913 showed that cholesterol alone caused atheromatous changes in the arterial wall. This 
discovery opened a new era in the study of atherosclerosis. 
Atherosclerosis is hardening of the arterial wall of large arteries due to accumulation and death 
of lipid filled macrophages, T-cells , cholesterol, calcium and connective tissue forming what 
is known as ‘plaques’. It is this plaque, which advances to occlude the arterial lumen, 
restricting the normal blood flow. As the plaque grows it becomes more and more unstable 
and prone to rupture. When the plaque ruptures, it spills its thrombogenic contents into the 
blood, forming a ‘thrombus’ or a ‘clot’, eventually leading to its clinical manifestation in the 
form of a stroke or a myocardial infarction (heart attack). Ischemic heart disease and stroke are 
the two most common causes of death worldwide. It is now widely accepted as a chronic 
inflammatory disease resulting due to a complex, multi-factorial pathophysiology (Gieseg et 
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al., 2008a, Libby, 2002, Stadler et al., 2004). Some of the earliest signs of its occurrence like 
‘fatty streaks’ have been found in adolescents (McGill Jr et al., 2000). It appears to develop 
over time, which might span decades, the clinical effect usually observed during the latter part 
of their life. Although it has been accepted widely that chronic inflammation plays a major 
role in its progression, the actual mechanism of plaque initiation, formation and development 
are poorly understood. 
1.2.2 Risk factors of atherosclerosis
A number of risk factors have been associated with atherosclerosis ranging from age, gender, 
ethnicity, genetics, along with hypertension, hyperlipidemia, dyslipidemia, obesity, smoking, 
lack of exercise, hypercholesterolemia, diabetes, high-fat diet, hyperhomocysteinemia and 
some kinds of infection (Falk, 2006; Scott, 2004; Wu & Wu, 2006; Libby et al., 2002; Wilson 
et al., 1999). In many cases, it has been seen that atherosclerotic risk is associated with high 
plasma concentrations of triglycerides and low-density lipoprotein (LDL) cholesterol (so 
called ‘bad cholesterol’) and decreased concentrations of high-density lipoprotein (HDL) 
cholesterol (‘good cholesterol’). High-fat diets, sedentary lifestyles, genetic predispositions 
and gender may also contribute to dysregulate the lipoprotein levels and predispose an 
individual to cardiovascular risk (Scott, 2004)
Imbalance in the normal lipid profile due to improper utilization of lipoprotein cholesterol 
may lead to oxidative stress, leading to formation of ‘modified’ or ‘oxidized’ LDL (oxLDL).  
OxLDL has been shown to activate T-cells, cause IFN-• production (Geng et al., 1995) and 
also has been shown to be toxic to macrophages leading to their death. OxLDL can induce 
endothelial dysfunction, monocyte recruitment, foam-cell formation, lead to the production of 
reactive oxygen species (ROS) in macrophages, all of which corroborate its involvement in 
atherosclerosis. 
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1.2.3 Pathogenesis of atherosclerosis
Atherosclerosis is a disease of large and medium-sized arteries. Arteries are blood vessels that 
carry blood from the heart to different organs. A normal, healthy artery is made up of three 
distinct layers:
1) Tunica Intima- a monolayer of flattened endothelial cells and their basement membrane 
which lines the lumen of blood vessels
2) Tunica media- concentric layers of vascular smooth muscle cells, elastin fibers and 
extracellular matrix that set and control the vascular tone and
3) Tunica adventitia or externa- surrounding layer of connective tissue like collagen 
containing micro-vessels (vasa vasorum) that nourish the media (figure 1.1). 
A number of theories have been proposed to explain the initiation and progression of 
atherosclerotic lesion. 
Figure 1.1 Structure of a normal large artery (Lusis, 2000). A large artery consists of three
morphologically distinct layers. The intima, the innermost layer, is bounded by a monolayer of 
endothelial cells on the luminal side and a sheet of elastic fibers, the internal elastic lamina, on 
the peripheral side. The normal intima is a very thin region (size exaggerated in this figure) 
and consists of extracellular connective tissue matrix, primarily proteoglycans and collagen. 
The media, the middle layer, consists of SMCs. The adventitia, the outer layer, consists of 
connective tissues with interspersed fibroblasts and SMCs.
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1.2.4 The Response to injury hypothesis
It was put forward by Russell Ross, John Glomset and Laurence Harker in 1977. It postulated 
that the atherosclerotic lesions arise from some form of ‘injury’ to arterial endothelium 
resulting in its alteration or desquamation. This results in enhanced endothelial permeability 
and LDL deposition in the subendothelial space, followed by leukocyte adhesion and 
transmigration, foam cell formation, smooth muscle migration and proliferation, platelet 
aggregation with new connective tissue formation and fibrous cap formation at the injury site
(Stocker and Keaney, 2004) (figure 1.2).
Figure 1.2 Schematic of the Ross/Glomset response-to-injury hypothesis (Stocker and 
Keaney, 2004). In this hypothesis atherosclerosis begins with endothelial injury or 
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dysfunction (A)  characterized by enhanced endothelial permeability and low-density 
lipoprotein (LDL) deposition in the subendothelial space. This is followed by leukocyte 
adhesion and transmigration across the endothelium. In intermediate stages (B), 
atherosclerosis is characterized by foam cell formation and an inflammatory response 
including T-cell activation, the adherence and aggregation of platelets, and further entry of 
leukocytes into the arterial wall along with migration of smooth muscle cells into the intima. 
Finally, advancedatherosclerosis (C) is characterized by continued macrophage accumulation,
fibrous cap formation, and necrosis in the core of the lesion.
As per this theory, three events are principal in lesion formation in atherosclerosis:
a) Endothelial injury or dysfunction
b) Deposition of intra- and extracellular lipid 
c) Formation of large amounts of connective tissue matrix (collagen, elastic fiber 
proteins, proteoglycans) 
Which results in formation of a lipid filled core and cellular debris forming more advanced 
lesions.
1.2.5 The Response to retention hypothesis 
According to this hypothesis, lipoprotein retention is the inciting event for atherosclerosis. It is 
postulated that around 85% of subendothelial lipoprotein delivery is the result of passive 
transcytosis between endothelial cells and this process is restricted to particles <70nm in 
diameter. The retention of LDL by the extracellular matrix appears to be mediated by specific 
residues (3359-3369) of apo B-100, the major protein molecule associated with LDL. 
Mutation in these residues protects experimental animals from development of atherosclerosis.  
Lipoprotein lipase mediated adherence leads to formation of aggregated LDL that is avidly 
taken up by macrophages, and can aid in foam cell formation (Stocker and Keaney, 2004)
(figure 1.3).
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Figure 1.3 Response to retention hypothesis of atherosclerosis (Stocker and Keaney, 
2004). Initial stages of lipoprotein entry into the arterial wall (1-2), retention (3) and 
lipoprotein efflux from the arterial wall (4) into the blood stream. Accumulation of LDL (5) is 
thought to further trigger different stages of the proinflammatory cascade (6-13).
1.2.6 The Oxidation hypothesis
This postulates that the low-density lipoprotein must be oxidatively modified in order to 
trigger the pathological events of atherosclerosis. Research has shown that individuals with 
elevated LDL, either due to lifestyle or genetic predisposition are at an increased risk for 
myocardial infarction (Stocker and Keaney, 2004). Since cholesterol-filled macrophages are a 
hallmark of early atherosclerotic lesions, early experiments aimed to mimic the formation of  
lipid-laden foam cells, which are macrophages filled with lipid globules making them ‘foam’ 
like in appearance, hence the name. This hypothesis is supported by the fact that macrophages
incubated with high concentrations of LDL, failed to accumulate cholesterol in unregulated 
manner, in spite of LDL being the major cholesterol carrier in blood while acetylated LDL is 
rapidly taken up (Stocker and Keaney, 2004) (figure 1.4). 
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Figure 1.4 Oxidation hypothesis of atherosclerosis (Stocker and Keaney, 2004). LDL 
becomes entrapped in the subendothelial space where it is subject to oxidative modification by 
resident vascular cells such as smooth muscle cells, endothelial cells, and macrophages. 
Oxidized LDL stimulates monocyte chemotaxis (A), prevents monocyte egress (B), and 
supports foam cell formation (C). Once formed, oxidized LDL also results in endothelial 
dysfunction and injury (D), and foam cells become necrotic due to the accumulation of 
oxidized LDL (E).
Although the aforementioned hypotheses differ, the events of atherosclerosis across the 
hypothesis have a common theme such that each one includes LDL as the central element and 
inflammation as the major player and modulator.
1.3 Initiation of plaque formation and progression into advanced plaque
Formation of an atherosclerotic plaque over a period of time is shown in figure 1.5.  Although 
the initiating event of atherosclerosis is debated, it is generally accepted that endothelial 
damage, LDL oxidation and inflammation are the main components of atherosclerotic plaque 
formation. It is possible that the complex lesion formation is a combination of all the above 
mentioned hypotheses. It has been noted that atherosclerotic plaques form within the intima of 
these large ‘susceptible arteries’. In these arteries, atherosclerotic plaques are usually found at 
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specific sites in the vasculature (for e.g. branch points and bifurcations, or curvatures) which 
suggest that the blood flow dynamics may play a critical role in their initiation. These areas 
are subjected to non-laminar (turbulent) blood flow which results in a reduced shear stress. 
Laminar endothelial shear stress is an important stimulus for the well-being of endothelium 
and low shear stress has been shown to promote local lipid accumulation, oxidative stress and 
inflammation (Chatzizisis et al., 2007). Due to these blood flow dynamics, endothelial cells 
become dysfunctional with increased permeability to LDL and expression of cell adhesion 
molecules on its surface. 
Entry and trapping of LDL particles in the sub-endothelial space marks an early event in 
plaque formation (Lusis, 2000). LDL which is transported across the endothelial cells in to the 
vascular sub-endothelium by the ‘caveolae’, is retained in the sub-endothelial space by its 
charged interaction with matrix proteoglycans (Skalen et al., 2002). This trapped LDL is 
possibly modified by reactive oxygen species, leading to the formation of oxidized or 
modified LDL (oxLDL). OxLDL has been shown to affect growth factor and cytokine 
production in a range of cell types (Chisolm and Chai, 2000). 
An alternative theory suggests an injury to the endothelium as a primary event. Monocyte 
migration in the subendothelial space follows (Jang et al. 1993; Halliwell and Gutteridge, 
1999). Entry of lipoproteins following the injury and its subsequent oxidation is a secondary 
event. This LDL entry and subsequent oxidation induces the upregulation of vascular cell 
adhesion molecules (VCAM-1) and intracellular adhesion molecules (ICAM-1) on the surface 
of endothelial cells. These molecules are not expressed on healthy endothelial cells and is 
induced by modified LDL particle mediated by NF-•B mediated increase in pro-inflammatory 
cytokines and inflammatory response (Hansson and Libby, 2006, Libby et al., 2002). 
Monocytes and lymphocytes attach to these molecules and migrate into the intimal space.
LDL enters the intima of the blood vessel, followed by its modification. Oxidation of LDL 
also involves modification of apolipoprotein B-100 which makes it susceptible to macrophage 
uptake (Stocker and Keaney, 2004). This modified LDL initiates migration of monocytes into 
the intimal space followed by their differentiation to macrophages that take up oxLDL in a 
rapid and unregulated manner through the scavenger receptors A (SR-A) and cluster of 
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differentiation 36 (CD36) giving them a “foamy” appearance. They are referred to as “foam 
cells” and are the characteristic feature of the earliest manifestation of atherosclerotic plaque, a 
“fatty streak”. Since oxLDL is toxic to cells, it causes oxidative stress to cells, ultimately 
leading to their death via necrosis and release of intracellular contents. Over time the dead 
cells accumulate in the region, which becomes lipid rich referred to as “necrotic core” of the 
plaque. 
Figure 1.5 Formation of an early atherosclerotic plaque over time (Libby, 2002). 
Endothelial dysfunction followed by LDL entry into the arterial intima and 
modification/oxidation leads to inflammatory response characterized by T-cells and 
macrophage entry into the intima. Unregulated uptake of modified LDL causes increased 
oxidative stress in macrophages leading to their death and spilling of the lipid contents
forming the lipid rich ‘necrotic core’ of atherosclerotic plaques. 
This monocyte migration into the intimal space is guided by the chemoattractant gradient of 
MCP-1, a monocyte chemoattractant protein, plays an important biochemical role in chronic 
progression of atherosclerotic plaque (Libby, 2003). Monocytes differentiate into 
macrophages under the influence of macrophage colony-stimulating factor (M-CSF). 
Although mechanisms of LDL oxidation are poorly understood, it is acknowledged that 
macrophage mediated ROS production also could modify and oxidize the LDL and potentiate 
atherosclerosis (Falk, 2006, Libby, 2003, Madamanchi et al., 2005). 
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Continued migration of monocytes and lymphocytes throughout the atherogenic process, 
along with increased LDL entry and oxidation further amplifies the inflammatory response. 
Over time this inflammation becomes chronic adding up to the necrotic core of the plaque.  
The lesion progression is marked by the proliferation of vascular smooth muscle cells, the 
development of an acellular lipid pool covered by a fibrous cap and mineral deposition. 
Proliferation and migration of smooth muscle cells in to the intimal lesion is initiated by 
continual cytokine release by foam cells, macrophages and T-cells along with growth factor 
release by activated platelets. Monocytes continue to be recruited at the lesion site, where 
continual formation of “foam cells” and their death releases the lipid content. This 
accumulation of the lipid content over time forms an acellular lipid core. 
Mineral deposition in plaques is another important feature that has been associated with 
advanced lesions. It is a complex, regulated process of bio-mineralization that resembles 
osteogenesis involving osteoclast- like cells and proteins controlling bone mineralization 
(Abedin et al., 2004). Two major types of calcification have been characterized viz. 
calcification of the tunica media layer, sometimes referred to as Mönckeberg’s sclerosis and 
calcification within the subdomains of atherosclerotic plaque within the intima of arteries 
(Doherty et al., 2004). Calcification has been positively correlated with atherosclerotic plaque 
burden and increased risk of myocardial infarction in coronary arteries (Speer and Giachelli, 
2004). 
1.4 Classification of atherosclerotic plaques
Atherosclerotic plaque progression has been characterized into six major types based on the 
histological morphology and increasing complexity of the lesions. The very early stage of 
lesion formation which is designated as type I, through to the advanced clinically complicated 
lesions type VI (figure 1.6). 
Type I lesions are identified by the adaptive intimal thickening of the arterial wall and very 
early lipid deposits at the lesion prone histological sites. The lipids are contained in the 
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macrophages in small isolated groups forming the first foam cells. These initial lesions are 
often found in children and most of them are invisible to the naked eye (Stary et al., 1994). 
Type II lesions are seen as yellow colored streaks on the intimal surface at the lesion sites of 
the artery which may not be always clearly visible. The majority of lipids in this type of 
lesions are still contained within the macrophages, but some muscle cells might have a few 
lipid droplets in them. Type II lesions can be further classified into type IIa, referred to as 
‘advanced lesion-prone’ and type IIb, referred to as ‘advanced lesion-resistant’ (Stary et al., 
1994). Type IIa are found in locations with mechanical forces such as low shear stress, often at 
the branching points and major curvatures of big arteries, while type IIb lesions either do not 
progress, progress slowly or progress only in individuals with extremely high plasma 
cholesterol levels (Stary et al., 1994). 
Type III lesion or intermediate lesions show the early signs of formation of the necrotic lipid 
core. This is the stage at which the macrophage foam cells begin to undergo necrosis and the 
lipids contained within them is released forming small extracellular pools of lipid within the 
confined intimal space. 
In type IV lesions or atheroma’s, the extracellular lipids form a dense core in a well-defined 
region of the intima. At this stage, some smooth muscle cells might also show signs of 
calcification and there is minimal narrowing of the arterial lumen (Stary et al., 1995, Stocker 
and Keaney, 2004).
Type V lesions, also referred to as fibro-atheroma’s, are typified by formation of thick, fibrous 
connective tissue layers between the lipid core and the endothelial cells, which is referred to as 
a ‘fibrous cap’ (Stary et al., 1995, Stocker and Keaney, 2004). At this stage if the lesion grows 
further, there are two possibilities or outcomes; the plaque could undergo extensive 
constrictive remodeling further narrowing the arterial lumen or it could progress via expansive 
remodeling increasing the diameter of the artery, with a relatively little effect on the lumen 
and the blood flow. Expansive remodeling often makes the plaque unstable as the larger 
luminal circumference enhances the stress on the fibrous cap, making the fibrous cap more 
prone to rupture (Falk, 2006, Libby et al., 2002). 
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Type VI lesions are complicated lesions which are characterized by disruptions to the lesion 
surface due to formation of the thrombus, hemorrhage or hematoma all of which can make a 
plaque more prone to rupture (Stary et al., 1995, Stocker and Keaney, 2004). 
Figure 1.6 Varying stages of atherosclerotic plaque morphology with complexity (Stary
et al., 1994). The progression of atherosclerosis is depicted from the earliest stages (top left) to 
the most advanced (bottom right) culminating in plaque rupture and associated thrombosis.
Fibrous cap plays a very important role in delineating and encasing the lipid core, and 
providing stability to the plaque. It also serves as a barrier to the pro-coagulant material in the 
plaque from the blood flow (Libby, 2003). Figure 1.7 is a typical example showing different 
regions in the atherosclerotic plaque. As the lipid core increases in size and volume and 
macrophage infiltration increases, the fibrous cap becomes thin, especially at the edges or the 
so called ‘shoulder’ regions. Macrophages express matrix metalloproteinases (MMP’s) which 
are proteases degrading extracellular matrix, that cause the breakdown of the fibrous cap. Thin 
fibrous cap, with increasing lipid core make the plaque more susceptible to rupture, resulting 
in pro-coagulant material in the plaque to form a ‘thrombus’ or a clot. This thrombus 
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formation and resultant blockage of the blood flow is the major cause of most of the clinical 
events associated with atherosclerosis (Stary et al., 1995). 
Figure 1.7 A light micrograph showing different regions of a fibroatheromatous plaque 
in the coronary artery. Different areas of the remodeled atherosclerotic plaque- Healed 
fissure (F), Fibrous cap (FC), Myeloproliferative tissue (MP), Calcified areas (C), Adventitia 
(A) and Elastic Lamina (*) (Stocker and Keaney, 2004). 
1.5 Oxidative stress in atherosclerosis
Reactive oxygen species (ROS) are oxygen containing, chemically reactive, oxidant molecules 
formed due to normal oxygen metabolism in cells. Examples include superoxide (O2•¯), 
hydrogen peroxide (H2O2), hypochlorite (HOCl) and hydroxyl radicals (OH•). There are 
number of physiological sources of ROS, mainly the NADPH oxidase (NOX), lipoxygenases 
(LOX), superoxide dismutase (SOD), xanthine oxidase, mitochondria, uncoupled NOS 
myeloperoxidase and also the transition metal ions (Madamanchi et al., 2005). There is 
growing evidence that indicates the involvement of acute and chronic overproduction of 
reactive oxygen species (ROS) under pathophysiological conditions of cardiovascular disease 
and its development. This results in the imbalance between oxidants and antioxidant in favor 
of the oxidants potentially leading to oxidative stress and damage (Stocker and Keaney, 2004).  
This oxidative damage to the cell components leads to a disturbance in the normal cellular and 
molecular function of the cells and is considered to be a major factor in the initiation and 
progression of atherosclerosis (Libby, 2002).  Elevated levels of oxidized proteins, lipids and 
sterols have been detected in all the different stages of atherosclerotic plaques suggesting that 
the oxidative events are a continual process within the plaques (Upston et al., 2002). The 
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oxidative damage of LDL is considered to be a crucial process. Some ROS are also mediators 
of a variety of signaling pathways underlying vascular inflammation in atherogenesis from the 
initiation of fatty streak development through to lesion progression and ultimately plaque 
rupture (Madamanchi et al., 2005). Interplay between reactive nitrogen species or RNS and 
ROS has also been observed, and so the term ‘nitrosative stress’ has been coined to underscore 
its importance. (Stocker and Keaney, 2004, Libby, 2002). 
1.6 Free radicals 
A free radical is defined as any species that contains one or more unpaired electron capable of 
independent existence. ROS on the other hand are highly reactive ions, free radicals or non-
radical oxidants containing oxygen molecules. In biological systems, a range of radicals are 
generated continuously as byproducts of cellular metabolism. Their reactivity depends on their 
nature as well as the molecule(s) they encounter. Free radicals may either react with another 
free radical, or add a non-radical molecule or extract a hydrogen atom from a C-H, O-H or a 
S-H bond of non-radical molecules forming a non-radical, non-reactive product (Stocker and 
Keaney, 2004). Molecules potentially affected include low molecular weight compounds like 
antioxidants, coenzymes, lipids, proteins, nucleic acids and sugars. In such cases, a new 
radical is formed that can set up a chain reaction. A typical example of this kind of chain 
reaction is lipid peroxidation (reactions 1, 2 and 3). 
LH + ·OH         L· + H2O    (1)
L· + O2  LOO·   (2)
LOO· + LH           L· + LOOH (3)
A radical might also be an oxidizing agent accepting a single electron from a non-radical or a 
reducing agent, donating a single electron to a non-radical. The most significant free radicals 
in aerobic cells involve molecular oxygen and its radical derivatives forming reactive oxygen 
species or ROS. Superoxide for example is formed by univalent reduction of oxygen and can 
be dismutated enzymatically to H2O2 via the action of SOD (Madamanchi et al., 2005).   This 
H2O2 formed can then react with the reduced transition metals via the Fenton chemistry to 
produce highly reactive hydroxyl radicals. 
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2O2• + 2H+  H2O2 + O2 (4)
H2O2 + Fe+2/Cu+2  Fe+3/Cu+3 + OH¯ + OH• (5)
Table 1.1 Examples of free radicals in biological systems (Stocker and Keaney, 2004)
Name Formula Comments
Carbon-centered radical
-C
These radicals with the unpaired electron 
residing on carbon, usually react rapidly with 
O2 to make peroxyl radicals
Superoxide anion and 
hydroxyl radical 
O2-, HO2- The “primary” oxygen-centered radicals in its 
anionic and protonated form
Peroxyl and alkoxyl radical RO2-, RO- Oxygen-centered radicals that can be formed 
from reaction of carbon-centered radicals with 
O2 (RO2-), or from the breakdown of organic 
peroxides, such as LOOH (RO2-, RO-)
Hydroxyl radical -OH• Highly reactive, oxygen-centered radical that 
reacts with all biomolecules
Nitric oxide (nitrogen 
monoxide) and nitrogen 
dioxide
NO, NO2 Nitric oxide is formed from L-arginine, and 
nitrogen dioxide from reaction of –NO with O2
Thiyl and perthiyl radical RS-, RSS- A group of radicals with the unpaired electrons 
residing on sulfur
Transition-metal ions Fe, Cu, 
etc.
Ability to change oxidation numbers by one, 
allowing them to accept/donate single electrons; 
they can be catalysts of free radical reactions.
Advanced atherosclerotic plaques contain considerable amount of catalytic iron and copper 
which could facilitate these reactions (Smith et al., 1992, Stadler et al., 2004). Reduced iron 
can catalyze the lipid peroxidation directly via Fenton-type reactions further contributing to 
the atherosclerotic environment (Gieseg and Esterbauer, 1994). A few examples of free 
radicals are listed in table 1.1.
As with radicals, the reactivity of different non-radical species also differs. Hydrogen peroxide 
is generally a weak oxidant, although it can directly oxidize thiol (-SH) groups at the active 
site of the enzymes like GAPDH. It can also react with some heme proteins forming iron or 
ferryl plus amino acid radicals propagating radical reactions. The most important oxidative 
damage due to H2O2 is its ‘decomposition’ due to metal catalysed ·OH radical formation 
(Stocker and Keaney, 2004). Peroxynitrite (ONOO¯ ) is also a relatively weak oxidant at 
alkaline pH, but its protonated form ONOOH, peroxynitrous acid is highly reactive, more than 
the hypochlorite/hypochlorous acid ( ¯OCl/HOCl).
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As the pKa value of ONOOH is ~7.5, in biological systems formation of ONOO¯ likely results 
in strong oxidizing environment. Non-radical oxidants like ONOOH and HOCl preferentially 
react with proteins than lipids. Cysteine and methionine are the preferred target molecules, 
followed by tyrosine, tryptophan and phenylalanine residues. Lysine residues could also be a 
target due to their abundance, and may account for majority of the ONOOH or HOCl reactions 
with proteins. This preference for proteins as the targets differentiates non-radical from radical 
oxidants as the latter commonly initiate lipid peroxidation (see reaction 1,2 and 3) (Stocker 
and Keaney, 2004). Thiol oxidation by HOCl gives rise to complex array of products, 
including disulfides (RSSR), sufenic (RSOH), sulfinic (RSO2H) and sulfonic acids (RSO3H) 
as well as intra- and intermolecular sulfenamides (RSN-), sulfinamides [RS(O)N-], and 
sulfonamides [RS(O2)N-]. The local environment governs which amino acids in the protein 
will react with which non-radical oxidant (Stocker and Keaney, 2004).  
A small amount of ROS are produced as a part of cells’ signaling pathways and defense 
mechanisms that do not normally result in biological damage. Overproduction of ROS might 
be potentially deleterious damaging biomolecules like lipids, proteins and nucleic acids can 
lead to cell death and tissue injury. ROS mediated damaged biomolecules can be used as 
‘biomarkers’ of oxidative damage. These biomarkers could be formed due to the direct 
interaction of ROS or due to the reaction of the secondary reaction products of ROS with the 
biological molecules. Cells are equipped with a range of antioxidant systems to scavenge and 
eliminate the harmful ROS to prevent cellular damage. Measure of antioxidants also is a good 
indicator of the cells redox status, as theoretically, the level of antioxidants will go down as 
the oxidant stress increases. In addition to free radicals, there are several non-radical oxidants 
which play an important role in oxidative modifications in the atherosclerotic 
microenvironment (Table 1.2).
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1.7 Biomarkers
Biomarkers have been used as the measure of normal biological processes, indicators of 
oxidative stress, pathogenic processes or pharmacological responses to therapeutics that could 
be objectively measured. Information regarding the localization of oxidative stress has been 
obtained from the analysis of discrete biomarkers isolated from tissues/organelles/body fluids 
(Griffiths et al., 2002). Biomarkers have been used to monitor the extent of disease in a variety 
of pathological conditions and could be lipid oxidation products, protein oxidation products or 
oxidation products of nucleic acids.
Ideally a biomarker will accumulate to detectable concentrations, and correlate to disease
severity. Biomarkers not only relate directly to functional changes and ultimately disease, but 
also are useful to analyze the  nature of oxidative damage, antioxidant loss due to their specific 
oxidative pathways of formation (Dalle-Donne et al., 2006). This makes quantification of 
biomarker levels as an excellent measure of the amount of oxidative stress in a cell or in 
atherosclerotic plaque samples. 
Proportion of a specific biomarker in relation to the levels of other markers could provide a 
better idea of the oxidative processes involved in a specific region of the plaque, which would 
give better insights of the development and progression of atherosclerotic plaques. 
Understanding the oxidative processes involved in the initiation, formation and progression of 
plaque ultimately resulting in clinical outcomes could help in developing strategies to control 
or treat this disease. 
A number of studies have identified oxidatively damaged products of lipid oxidation, protein 
oxidation, transition metal-oxidized, cell-mediated and enzymatically oxidized molecules in 
plaques (figure 1.8), which can contribute to the cytotoxicity to immune cells entering the 
plaque milieu. Immune cells like macrophages also contribute to the oxidative stress by 
production of various oxidative species. 
Chapter 1
19
Table 1.2 Some non-radical oxidants in oxidative stress (Stocker and Keaney, 2004)
Name Formula Comments
Hydrogen peroxide H2O2 A diffusible oxidant that is only a weak 
oxidizing agent and is generally poorly 
reactive. It may participate in cellular 
signaling and, in the presence of available 
transition metals, can give rise to OH•
Hypochlorite, 
hypochlorous acid
-OCl, HOCL Weak acid (pKa~7.5) but strong oxidant. 
Reacts with Fe-S clusters, metal ions held in 
proteins by thiolate ligands, heme, and amino 
acid residues (methionine, cysteine) of 
proteins, and GSH. Can give rise to 
secondary, reactive species including 
chloramines and amino acid-derived 
aldehydes. 
Ozone O3 Strong oxidant that attacks protein and lipids 
including cholesterol. Singlet oxygen may be 
formed as a by-product. 
Singlet oxygen 1•gO2 Reacts with other molecules chemically or 
by transfer of its excitation energy. Reaction 
with carbon-carbon double bonds is best 
known. The relevance 1•gO2 in the 
vasculature is unknown. 
Oxoperoxonitrate (1–) or 
peroxynitrite, 
peroxynitrous acid
ONOO–, 
ONOOH
Can be formed via reaction of O2–• with 
NO that gives to nitrating, nitrosating and 
oxidizing species 
Alkylperoxynitrites, 
dinitrogen trioxide, nitryl 
chloride, and nitronium 
(nitryl) ion 
ROONO, N2O3, 
NO2Cl, and 
NO2+
Additional reactive nitrogen species. N2O3 is 
a major nitrosating species. 
Nitrosothiols RSNO Formed via reactions of RS• with •NO, or 
thiols with higher oxides of nitrogen. 
Nitrosothiols are weak oxidants. 
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Figure 1.8 Overview of free radicals, oxidants and oxidative damage identified within 
atherosclerotic plaques. It is within the intima, that LDL gets oxidized through cell-mediated 
or metal catalysed oxidation. OxLDL contains protein hydroperoxides (PrOOH) and lipid 
hydroperoxides (LOOH). LOOH can breakdown forming oxysterols and reactive aldehydes. 
The peroxyl radicals (LOO•) and aldehydes can further mediate protein carbonyl (Pr carbonyl) 
formation and PrOOH. PrOOH themselves can be mediators of oxidative damage including 
protein carbonyl formation. Macrophage released superoxide (O2•-) can mediate hydrogen 
peroxide H2O2 formation as well as reduce iron and copper maintaining the pool of redox 
active ions. Electrons from the plasma membrane electron transport system (TPMET) within 
macrophages can also maintain this pool. MPO converts H2O2 to HOCl, which along with 
•OH radicals can induce PrOOH and LOOH formation, exacerbating the oxidative damage on 
the oxLDL molecule. Tyrosine residues are prone to DOPA and dityrosine formation due to 
oxidative modification. (Gieseg et al., 2008b)
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1.7.1 Biomarkers of Lipid oxidation
When the double bond in polyunsaturated fatty acid (PUFA) is attacked by free radicals, lipids 
get oxidized. This lipid oxidation is initiated by the removal of a hydrogen atom from the 
PUFA (LH) by a free radical (R•) generating a fatty acid radical (L•) (reaction 6). Various 
mechanisms can initiate this fatty acid oxidation, like singlet oxygen mediated or metal 
catalysed oxidation. This leads to the formation of a fatty acid radical which in turn can react 
rapidly with oxygen to form a fatty acid peroxyl radical (reaction 7). This free radical chain 
reaction propagates by abstracting a hydrogen atom from adjacent fatty acid, further damaging 
lipids (reaction 8). This self-propagating oxidation chain reaction can lead to lipid 
hydroperoxide formation. This chain reaction can end if one radical reacts with another 
forming, what is called a non-radical product or when it reacts with a chain breaking 
antioxidant, which would accept the unpaired electron with itself getting oxidized. Lipid 
hydroperoxides can also breakdown to produce further radicals and range of other compounds 
including aldehydes, that can diffuse from the original site spreading the damage (reaction 10) 
(Cheeseman and Slatter, 1993). 
LH + R•  L• + RH  (6)
L• + O2  LOO •  (7)
LOO • + L’H          LOOH + L’ •  (8)
LOO • + LOO •  NR  (9)
LOOH             LO•, LOO•, aldehydes (10)
Lipid oxidation occurs in three distinct steps; a lag phase, with little or no oxidation where the 
initiating or propagating radicals are tackled by antioxidants, a propogation phase of 
increasing lipid oxidation and a final phase of decreased lipid oxidation where more products 
are degraded than formed (Esterbauer et al., 1992). The presence of lipid oxidation products 
has been reported in all the different stages of atherosclerotic plaque development and the 
source of most of the oxidized lipids is believed to be LDL and its oxidized products (Jache•
et al., 2003, Suarna et al., 1995). TBARS and oxysterols are the most commonly studied lipid 
oxidation biomarkers.  
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1.7.1.1 TBARS or Thiobarbituric acid reactive substances
MDA is a physiologic ketoaldehyde produced by peroxidative decomposition of unsaturated 
lipids as a byproduct of arachidonate oxidation and prostaglandin synthesis. The excess MDA 
produced as a result of tissue injury can combine with free amino groups of proteins producing 
MDA-modified protein adducts, lysine residues being their major targets. Proteins modified 
by MDA may potentially have altered biological properties and could be immunogenic. LDL 
reacted with MDA is rapidly taken up by macrophages. High titers of MDA and TBARS has 
been associated with increased burden and progression of atherosclerosis and myocardial 
infarction (Dalle-Donne et al., 2006). MDA-LDL along with oxLDL mediates various pro-
inflammatory and pro-atherogenic processes leading to foam-cell formation. Adducts of apo-
B100 lysine residues with MDA have been characterized in human atherosclerotic lesions 
(Dalle-Donne et al., 2006).
1.7.1.2 Oxysterols
7-Ketocholesterol (7-KC) is the second most abundant form of oxysterol found in 
atherosclerotic plaques after enzymatically formed 27-hydroxycholesterol. Approximately 
90% of the 7-KC is found in the form of its esters (Lyons and Brown, 1999). Oxysterols, 7-KC 
in particular is the major oxidation product of cholesterol found in human atherosclerotic 
lesions and so is a good marker of lipid oxidation as its increased concentration has been well 
established in pathological processes  (Fu et al., 1998, Lyons and Brown, 1999). Around 50% 
of cholesterol is converted to oxysterols during LDL oxidation. 7-KC is formed by a direct 
radical attack on cholesterol by ROS at C-7 position (figure 1.9) (Lyons and Brown, 1999). 
In normal cells the esterification of excess cholesterol is mediated by acyl-CoA cholesterol 
acyl transferase (ACAT). Esterification is the normal cellular process to maintain normal 
membrane structure by limiting the excess amount of free cholesterol in the cell membranes. 
The bulk of the 7-KC in the atherosclerotic lesions has been known to be produced non-
enzymatically in vivo, but the dietary contributions or enzymatically generated 7-KC cannot 
be excluded as 7-KC is also a major oxysterol found in cholesterol rich processed foodstuffs 
(Lyons and Brown, 1999). Its atherogenic potential stems from its capacity to inhibit reverse 
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Figure 1.9 Major free radical oxidation products of cholesterol are 7-
hydroperoxycholesterols. These molecules are labile and rapidly get converted to 7-
hydroxycholesterols and 7-ketocholesterol (Lyons and Brown, 1999).
sterol transport, an important process by which cholesterol is returned to the liver for 
catabolism and excretion (Lyons and Brown, 1999). It is hypothesized to that 7-KC may be 
formed on plasma membrane via free radical attack on cholesterol in the membrane or enter 
the cell membrane from the intracellular pool. Membrane model system studies with 7-KC 
have a membrane-condensing effect similar to cholesterol, which results in decreased glucose 
permeability and affects Na+/K+ ATPase activity along with Ca+2/ Mg+2 ATPase activity. It 
also inhibits nitric oxide (NO) formation at high concentrations and is known to decrease the 
endothelial monolayer barrier function (Lyons and Brown, 1999).   
7-KC has been shown to have potent cytotoxic effects on cell viability when given directly to 
cultures of monocytes, macrophages, endothelial cells and smooth muscle cells through 
disruption of lipid raft (Berthier et al., 2004). 7-KC at higher concentrations also inhibits NO 
release in endothelial cells (Lyons and Brown, 1999). All the above mentioned effects of 7-KC 
make it a key player in development and progression of atherosclerosis. 
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1.7.2 Protein oxidation
There is a large body of evidence implicating the oxidative modification of proteins in a 
number of human diseases like Alzheimer’s, diabetes, atherosclerosis and also aging 
(Akagawa et al., 2006, Fu et al., 1998, Stadtman, 2001). Products of oxidized protein 
production is complex and depends on the rate of formation of various forms of ROS, the 
levels of antioxidant defense against the ROS mediated damage and the sensitivity of proteins 
to the oxidative attack (Stadtman, 2001). The damage caused to proteins by ROS range from 
protein carbonyls, protein hydroperoxides, 3,4-dihydroxyphenylalanine (DOPA) and 
dityrosine (Davies et al., 1999, Dean et al., 1997, Gieseg et al., 1993). Many of these protein 
oxidation biomarkers have been previously reported in atherosclerotic plaques (Davies et al., 
1999).
The accumulation of oxidized protein reflects a balance between pro-oxidant, antioxidant and 
proteolytic activities (figure 1.10) (Stadtman, 2001). Most of the oxidatively modified proteins 
are not repaired and have to be removed by proteolytic degradation, while a decrease in 
proteolytic activity can lead to an increased accumulation of oxidized proteins (Stadtman and 
Levine, 2000). Environmental and dietary conditions along with any of the other pro-oxidant 
systems as illustrated in figure 1.10 can mediate protein oxidation and damage. However, 
under normal conditions metal-catalysed oxidation seems to be the major source of protein 
damage (Stadtman and Levine, 2000). 
The oxidation of aromatic side chains on tyrosine can form DOPA and dityrosine (Gieseg et 
al., 1993), oxidation of lysine, arginine and proline can lead to protein carbonyl formation. 
Since protein carbonyls can be induced by a number of free radicals and primary radical 
inducing the formation of protein carbonyl within a biological system cannot be identified, it 
is used as a general marker of protein oxidation (Dalle-Donne et al., 2003a). The fact that not 
all the amino acids in proteins are susceptible to oxidation by metal-catalysed oxidation, but 
phenylalanine, tryptophan and tyrosine are preferred targets for •-radiolysis mediated radicals, 
is noteworthy (Giulivi et al., 2003).
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Figure 1.10 Factors affecting ROS and the level of oxidatively modified proteins. 
Accumulation of oxidized protein reflects balance between pro-oxidant, antioxidant and 
proteolytic activities. (MSR, methionine sulfoxide reductase; Gpx, glutathione peroxidase; 
CAT, catalase; RSHPx, thiol-specific peroxidase (peroxiredoxins); NOS, nitric oxide synthase; 
SOD, superoxide dismutase; GST, glutathione transferase (Stadtman, 2001). 
1.7.2.1 Protein-bound DOPA 
Exposure of proteins to oxidative attack generates both oxidative and reductive species that 
are long-lived. Protein-bound DOPA (PB-DOPA) is the major reducing species formed when 
hydroxyl radicals formed by metal catalysed Fenton-systems, gamma radiation and UV light 
reacts with protein tyrosyl residues or to a limited extent when proteins are oxidized by HOCl 
(Sutherland et al., 2003, Rodgers and Dean, 2000, Gieseg et al., 1993). Free amino acid 
DOPA is a normal metabolite in certain neural tissues in man, and is a therapeutic agent for 
Parkinsonism. In mammalian cells, protein bound DOPA (PB-DOPA) could be formed by 
both controlled enzymatic pathway as well as by uncontrolled radical reactions (Rodgers and 
Dean, 2000, Gieseg et al., 1993) (figure 1.11). 
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Figure 1.11 Possible pathways of PB-DOPA formation and removal in mammalian 
tissues. PB-DOPA can be formed from tyrosine residues on proteins by enzymatic 
(tyrosinase) or non-enzymatic (radical) mechanisms. PB-DOPA can be further oxidized to 
dopaquinone. DOPA containing proteins can be directly degraded by proteinases or may first 
form Michael adducts with free amino acids such as cysteine. Free DOPA and cysteinyl 
DOPA then can be excreted which have been found in mammalian urine. Another possibility 
for free DOPA is incorporation into proteins by protein synthesis. 
The reducing activity of PB-DOPA has the capacity to inflict secondary damage on other 
important biomolecules by forming ROS via redox cycling. This secondary damage might be 
mediated via replenishment of transition metals or from catechol-quinone-catechol redox 
cycles in presence of cellular components like ascorbate or cysteine, amplifying the radical 
damaging events. It has been hypothesized that DOPA is one of the sources of oxidative stress 
driving the progression of plaque development (Rodgers and Dean, 2000).
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Figure 1.12 Possible reaction mechanisms of PB-DOPA (Rodgers and Dean, 2000). PB-
DOPA can be oxidized further to dopaquinone donating two electrons to transition metal ions 
such as iron or copper present in chelates or metalloproteins. Auto-oxidation of these 
transition metal ions can generate ROS which can then transfer the oxidative damage to other 
biomolecules. The proposed scheme of PB-dopaquinone resulting in ring closure and release 
of four electrons has been described by Gieseg (Gieseg et al., 1993).
Tissue levels of PB-DOPA are elevated in a number of age-related ailments such as 
atherosclerosis and cataract formation (Rodgers and Dean, 2000). PB-DOPA is of particular 
interest amongst other protein oxidation products due to its potential to initiate further 
oxidative reactions via binding and reducing transition metal ions such as iron or copper, 
which can further mediate redox processes and amplify the damage. Possible reaction schemes 
of PB-DOPA are shown in figure 1.12.
1.7.2.2 Dityrosine
Dityrosine is a very important and stable marker of protein oxidation which has been 
identified within atherosclerotic plaques (Fu et al., 1998). Its concentration depends on the 
radical flux determined by the degree of oxidative stress and radical formation rate (Davies et 
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al., 1999). Tyrosine residues, apart from forming DOPA, could also form tyrosyl radicals, that 
can interact with each other to form dityrosine (Stadtman, 2001) (figure 1.13). It has been 
shown that the myeloperoxidase (MPO) enzyme produced by macrophages along with H2O2
react with proteins to yield tyrosyl radical that react to form a stable dityrosine product
(Heinecke et al., 1993). In support of this mechanism of dityrosine formation, Heinecke et al., 
(1993) treated neutrophils and macrophages with heme inhibitors that knocked out the MPO 
resulting in the inhibition of dityrosine formation. It is also found in several proteins as a 
product of UV radiation, •-irradiation, aging, exposure to oxygen free radicals, nitrogen 
dioxide, peroxynitrite and lipid hydroperoxide. It is a particularly important biomarker for 
protein oxidation products as it is also believed to be the endogenous marker for selective 
degradation of oxidatively modified proteins (Giulivi and Davies, 1994). 
Figure 1.13 Mechanism of dityrosine formation (Giulivi et al., 2003).
Dityrosine was shown to be 100-fold higher in LDL isolated from atherosclerotic plaques than 
in normal arterial tissue and was also reported to be elevated during systemic bacterial 
infections (Giulivi et al., 2003). Dityrosine is also important within hypoxic tissues such as 
atherosclerotic plaques as under these conditions, hydroxyl radicals (produced by radiolysis) 
were shown to produce extensive dityrosine formation (Giulivi et al., 2003).
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1.7.3 Protein carbonyls
Protein carbonyls have been shown to increase in a variety of diseases and pathologies and 
have been found in atherosclerotic plaques. Lysine, arginine, proline and threonine protein 
residues are particularly sensitive to oxidation by transition metals, which in each case leads to 
the formation of carbonyl derivatives (Stadtman, 2001). Carbonyls may also be formed in 
proteins due to reaction with aldehydes (HNE, acrolein or MDA) produced during lipid 
peroxidation. Oxidative cleavage of proteins by either •-amidation pathway or by oxidation of 
glutamyl side chain (reducing sugar) also leads to formation of carbonyl groups on proteins 
(Berlett and Stadtman, 1997, Dalle-Donne et al., 2003b). 
Protein carbonyls are relatively stable and unreactive which makes them the most commonly 
used biomarker of protein oxidation (Dalle-Donne et al., 2003b). It has also been observed 
that protein carbonyls accumulate on tissue proteins during aging, and carbonyl content 
increases dramatically after the sixth decade of life, where on an average one out of three 
protein molecules carries a modification (Akagawa et al., 2006). •-aminoadipic semialdehyde 
(AAS) and •-glutamic semialdehyde (GGS) represent major oxidized amino acid residues 
formed in oxidized proteins by metal-catalysed oxidation systems (Akagawa et al., 2006). An 
HPLC method for detection of AAS and GGS has  been developed by Akagawa et al.,  and 
since their generation has been shown in vivo, AAS & GGS measurement could provide vital 
information about the oxidative stress on various diseases (Akagawa et al., 2006) (figure 
1.14). 
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Figure 1.14 Reaction scheme for the formation of AAS and GGS and their detection 
after derivatisation by reductive amination with aminobenzoic acid (ABA) and sodium 
cyanoborohydride (NaBH3CN) (Akagawa et al., 2006).
1.8 Antioxidants in oxidative stress
Since oxidative stress is caused by an imbalance between oxidants and antioxidants it is 
important to assess the antioxidant defense mechanisms in biological systems. Antioxidant 
systems help to combat and reduce oxidative stress and therefore could play a pivotal role in 
the pathophysiology of atherosclerosis and various diseases, Antioxidants are capable of 
neutralizing or converting free radicals or ROS into less reactive state and protecting from 
oxidative damage when present in much smaller quantities than the substance that it protects 
(Stocker and Keaney, 2004). In terms of atherosclerosis, the antioxidant systems could be 
intracellular or extracellular. The antioxidant defense systems can be enzymatic, metal 
sequestering, or non-proteinaceous water-soluble or lipid soluble. For example enzymes like 
SOD removes superoxide, catalase and glutathione decompose H2O2, metal binding protein 
like ferritin bind iron, and •-tocopherol and ascorbic acid scavenge free radicals (Stocker and 
Keaney, 2004). 
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There are a number of antioxidant systems present in the biological systems to circumvent the 
oxidative damage and promote the normal well-being and function of a cell. They include 
catalase, superoxide dismutase (SOD’s), glutathione, thioredoxins peroxiredoxins, ascorbic 
acid, •-tocopherol, ubiquinol-10, ascorbic acid and uric acid etc. Although a number of those 
antioxidants like •-tocopherol, ubiquinol-10, ascorbic acid, uric acid, glutathione peroxidase 
and SOD’s have been found in atherosclerotic plaques, it has been seen that oxidative damage 
is still significant. Another important antioxidant that belongs to the pterin family of 
compounds is produced by macrophages during inflammation and found in atherosclerotic 
plaques is 7,8-dihydroneopterin (Gieseg et al., 2009). 
1.8.1 •-Tocopherol and Ascorbic acid
•-Tocopherol (Vitamin E) is the major antioxidant present in LDL that protects from oxidation 
and has been found in significant amount in atherosclerotic plaques (Suarna et al., 1995). Both 
•-tocopherol and ascorbic acid have been used in a number of studies to limit the oxidative 
damage and therefore lower the risk of certain diseases in humans. •-Tocopherol, an active 
form of vitamin E, is a major lipid soluble antioxidant along with ubiquinols in lipoproteins 
and cells that help in preventing the oxidative stress mediated damage (Stocker and Keaney, 
2004, Suarna et al., 1995). Being lipid-soluble, •-tocopherol is localized to membranes where 
it protects both membrane lipids and membrane bound proteins from oxidative stress. In 
lipoproteins, it is the major antioxidant that protects the LDL particles from lipid peroxidation 
by directly scavenging free radicals or rapidly reacting with lipid peroxyl radical (LOO•)
forming a less reactive •-Tocopherol radical (•-toc•) (Stocker and Keaney, 2004).
•-TocH + LOO•  •-Toc• + LOOH (11)
•-Toc• + LOO•  LOOH + non radical product (12)
•-Toc• + LH  •-TocH + L• (13)
•-Toc• + R•  Non radical product (14)
•-TocH as well as •-Toc• are able to scavenge radical, therefore every molecule of •-TocH 
has the capacity to terminate two radicals (reactions 11, 12, 13 and 14) (Stocker and Keaney, 
2004). •-Toc• produced by initial radical scavenging can be reduced by ascorbate to 
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regenerate •-TocH. Several other reducing agents like ubiquinols, bilirubin, epinephrine also 
can reduce •-Toc• to •-TocH (Stocker and Keaney, 2004). 
Ascorbic acid is a water-soluble antioxidant (Halliwell and Gutteridge, 1999). Like •-TocH, it 
also can act both as antioxidant and a pro-oxidant in biological systems. It is also important for 
its ability to rescue •-Toc• and oxidized glutathione to •-TocH and reduced glutathione. 
Ascorbic acid also strongly attenuates, but does not completely protect LDL and plasma 
proteins from HOCl oxidation (Stocker and Keaney, 2004). Ascorbate supplementation is also 
capable of restoring defective endothelium-dependent vasodilation and improves hypertension 
in patients. Ascorbate is also the first line of defense against oxidative damage in human 
plasma (Stocker and Keaney, 2004). There have been studies suggesting that ascorbic acid 
protects against the loss of •-tocopherol in plasma of smokers hinting that both ascorbate and 
•-tocopherol could work better in combination (Buettner, 2006). 
Apart from its antioxidant effects, •-tocopherol has been shown experimentally to be a pro-
oxidant, by reducing the transition metals including copper and iron that can contribute to the 
pool of redox active metals in the system (Stocker and Keaney, 2004). 
1.8.2 Neopterin and 7,8-dihydroneopterin 
IFN-• stimulation of macrophages during inflammation causes the production of 7,8-
dihydroneopterin via upregulation of GTP cyclohydrolase 1 (GTPCH 1) (figure 1.15). GTPCH 
1 is the rate-limiting enzyme in the formation of tetrahydrobiopterin (BH4), an important co-
factor for nitric oxide (NO) synthesis that is vital for endothelial well-being and normal 
endothelial function. 7,8-dihydroneopterin tri-phosphate is formed as an intermediate in BH4 
synthesis which is further acted upon by the enzyme 6-pyruvoyltetrahydropterin and 
sepiapterin reductase to form BH4. However in macrophages, the levels of the enzyme 6-
pyruvoyltetrahydropterin synthase are very low so the 7,8-dihydroneopterin tri-phosphate 
produced is cleaved to 7,8-dihydroneopterin by the action of intracellular phosphatases. This 
7,8-dihydroneopterin is then secreted out of the macrophages into the intracellular spaces and 
plasma (Gieseg et al., 2008b, Schoedon et al., 1987). 7,8-dihydroneopterin can be then 
oxidized to neopterin in presence of HOCl (Widner et al., 2000). HOCl is  one of the major 
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ROS produced  in the body from H2O2 and Cl- ions by the action of heme-containing enzyme 
myeloperoxidase (reaction 15) (Widner et al., 2000).
H2O2 + Cl- + H+  HOCl + H2O (15)
Myeloperoxidase is the only human enzyme known to generate HOCl, and so chlorinated 
molecules are considered to be specific markers of myeloperoxidase catalysed oxidation 
(Widner et al., 2000, Stocker and Keaney, 2004). Both myeloperoxidase and 7,8-
dihydroneopterin have been detected in atherosclerotic lesions suggesting that 7,8-
dihydroneopterin could be oxidized to neopterin within the plaques.
Figure 1.15 Production of 7,8-dihydroneopterin and neopterin (Gieseg et al., 2008a). IFN-
• stimulation of macrophages results in intracellular conversion of GTP to 7,8-
dihydroneopterin via the enzyme GTPCH 1, that is further oxidized to highly fluorescent  
neopterin by HOCl or to 7,8-dihydroxanthopterin by peroxyl or hydroxyl radicals. 
Neopterin which is relatively stable and highly fluorescent, may be a specific product of 
myeloperoxidase mediated HOCl production as well as a good marker of inflammation and 
immune cell activation (Gieseg et al., 2008a, Widner et al., 2000). Due to its high 
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fluorescence neopterin is easily detected by HPLC in urine and plasma samples (Widner et al., 
2000, Flavall et al., 2008). Neopterin levels have been found to be elevated in a number of 
pathological conditions such as infections, septicemia, diabetes, cancer, HIV, arthritis, 
multiple sclerosis and atherosclerosis (Gieseg et al., 2008b, Hoffmann et al., 2003) and its 
levels correlate to the severity of the inflammation and disease (Hoffmann et al., 2003). 
7,8-dihydroneopterin has been reported to have antioxidant as well as pro-oxidant properties. 
It has been demonstrated to be a potent scavenger of superoxide, peroxyl and nitrogen 
centered radicals (Baird et al., 2005, Gieseg and Cato, 2003, Oettl et al., 2004, Weiss et al., 
1993). At micromolar concentrations 7,8-dihydroneopterin has been found to be a strong 
inhibitor of protein and lipid hydroperoxide formation on LDL (Firth et al., 2008). It was also 
found to inhibit oxLDL induced cell death in U937 cells, THP-1 cells and human 
macrophages (Baird et al., 2005, Gieseg and Cato, 2003). 7,8-dihydroneopterin has been 
shown to protect both U937 cells and THP-1 cells from AAPH-derived peroxyl radicals and 
subsequent cell death (Baird et al., 2005). 7,8-dihydroneopterin also protects U937 cells from 
the Fe+2 and HOCl oxidation (Gieseg et al., 2001) as well as protein hydroperoxide formation 
and peroxyl mediated thiol loss (Duggan et al., 2001). Higher concentrations of 7,8-
dihydroneopterin is also known to act as a pro-oxidant and induce apoptosis in several cell-
lines due to increased oxidative stress (Baier-Bitterlich et al., 1995, Enzinger et al., 2002, 
Wirleitner et al., 2003). 7,8-dihydroneopterin also enhances H2O2 activity at slightly alkaline 
pH (Weiss et al., 1993). Thus the properties of 7,8-dihydroneopterin depends on the 
concentration and the chemical environment and oxidants it can react with. Normal plasma 
levels of neopterin as previously studied in our laboratory were recorded about 20 nM while 
total pterin which is neopterin and 7,8-dihydroneopterin combined was about 30 nM (Flavall
et al., 2008).
Neopterin also has been reported to possess pro-oxidant properties as it enhances the cytotoxic 
effect of oxidants produced during inflammation, but only at very high micromolar 
concentrations (Hoffmann et al., 1998, Hoffmann et al., 2003). Neopterin in presence of H2O2
or chloramines enhanced the killing effect of H2O2 with E.coli but 7,8-dihydroneopterin 
displayed an opposite effect on the same through scavenging of radicals. This effect on H2O2
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mediated oxidation also suggests that the balance of neopterin and 7,8-dihydroneopterin could 
play an important role in protection or enhanced oxidative stress (Weiss et al., 1993). 
On similar lines it has also been proposed by Gieseg et al (Gieseg et al., 2008b) that the 
pro/oxidative effect and its balance due to neopterin and 7,8-dihydroneopterin in the 
microenvironment of atherosclerotic plaque depends on the relative concentrations of these 
compounds. In the early stages 7,8-dihydroneopterin would slowdown or inhibit oxLDL 
formation and during chronic inflammation, increased neopterin would shift the balance to a 
pro-oxidative state. So it has been suggested that modulation of this 7,8-
dihydroneopterin/neopterin synthesis and balance could protect monocytes/macrophages 
against oxidative stress in plaque and influence the plaque progression (Gieseg et al., 2008b, 
Gieseg et al., 2009).
1.9 HPLC detection of neopterin and 7,8-dihydroneopterin 
The quantification of neopterin and 7,8-dihydroneopterin in plasma, urine and other body 
fluids is a rapid, inexpensive and sensitive diagnostic tool of vital clinical importance that is 
frequently used to assess the immune activation status of an individual, to monitor organ 
transplant rejection, for follow-up control of chronic infections, as a prognostic measure in 
cancers and HIV (Werner et al., 1987a, Kramer et al., 1989, Fuchs et al., 1989) . The original 
HPLC method for neopterin and 7,8-dihydroneopterin was described by Fukushima and Nixon 
(Fukushima and Nixon, 1980). Using a reverse phase C18 column and a mobile phase of water 
and methanol neopterin is detected by its native fluorescence but as 7,8-dihydroneopterin is 
only weakly fluorescent, its detection by HPLC requires it to be oxidized to neopterin. 
Fukushima and Nixon’s method employed acidic and basic iodine oxidation to oxidize the 
dihydro/tetrahydro and dihydro- forms of neopterin/pterins respectively. 
A number of non-chromatographic methods have been developed for neopterin detection 
using ELISA, radioimmunoassay (RIA) (Bührer-Sekula et al., 2000, Werner et al., 1987a). 
ELISA is a preferred technique, due to its higher sensitivity, strong specificity and relatively 
easier handling and processing compared to RIA method. HPLC is the most widely used 
technique for neopterin detection and quantification. Although the initial purchase cost of 
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HPLC is relatively higher as compared to ELISA equipment, the cost of consumables per 
sample is relatively inexpensive making it a method of choice in most of the research 
laboratories around the world. 
Most of the HPLC methods described in the literature for neopterin use a slightly modified 
reverse-phase C-18 method adapted from Fukushima and Nixon, using phosphate buffers 
between pH 6 to 7 instead of water, with very little change in the sample preparation for 
analysis of reduced forms of pterins. Fuchs et al., (Fuchs et al., 1989) used C18 column with  
potassium phosphate buffer at pH 6.4, De Castro et al., (De Castro et al., 2004) used 150 mM 
sodium phosphate pH 4, Svoboda et al., (Svoboda et al., 2008) employed 10 mM phosphate 
buffer pH 6.7 with 5% methanol while Krcmova et al., (Krcmova et al., 2011) and Carru et 
al., (Carru et al., 2004) used 15mM phosphate buffer (KH2PO4 + KHPO4 3H2O) pH 4.5 and 
water/ACN (99:1) respectively as mobile phases for separation of neopterin in serum and 
urine samples. All the methods in the literature used the fluorescent nature of neopterin for its 
detection and quantification after C18 separation. Electrochemical detection for analysis of 
reduced pterins has also been tested by different laboratories in the past (Niederwieser et al., 
1984c, Blau, 1988, Lunte and Kissinger, 1986, Hyland, 1985). This utilizes the 
electrochemically active nature of reduced pterins to transfer electrons to an electrode to 
oxidize them completely enabling their detection by natural fluorescence. 
Sample preparation, another important aspect of HPLC method development, has also been 
researched in depth for neopterin detection in different body fluids. For urinary neopterin most 
methods do not use precolumn sample preparation, but neopterin determination in 
plasma/serum/cerebrospinal fluids by HPLC is more difficult due to the presence of large 
amounts of proteins and lower neopterin concentrations. The original method by Fukushima 
and Nixon used solid phase extraction, but it has become technically demanding and time 
consuming with poor recovery of neopterin. More common methods such as acid precipitation 
of proteins prior to HPLC analysis have now been employed to deproteinize the plasma and 
tissue samples (Zeitler and Andondonskaja-Renz, 1986). But it was found that the acidic 
conditions used for protein precipitation oxidized 7,8-dihydroneopterin to neopterin with 
varying yields (Werner et al., 1987b, Flavall et al., 2008) due to which ethanol (Krcmova et 
al., 2011) and acetonitrile (Flavall et al., 2008) have been used as protein precipitating agents. 
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As 7,8-dihydroneopterin and neopterin analysis formed a significant part of this thesis 
research, the development of a more robust pterin analysis method was a key goal of this 
research. The development of a new method is described in detail in chapter 3 of this thesis. 
1.10 Role of Nucleoside transporters in Inflammation and Oxidative stress
7,8-dihydroneopterin is produced in response to inflammatory stimulus involving IFN-• using 
guanosine tri-phosphate (GTP) by the enzyme GTP cyclohydrolase 1 (GTPCH 1). Guanosine 
and other nucleosides, being hydrophilic cannot diffuse directly through the plasma membrane 
and require special ‘nucleoside transporters’ that mediate their transport in and out of the cells. 
Nucleosides are building blocks of DNA and RNA and are also the sources of energy driving 
the biochemical reactions of the cells. Although many cells possess the enzymes for the de 
novo synthesis of nucleosides, most of the cells also utilize a ‘salvage’ pathway (described 
later) that recovers and recycles nucleotides and nucleosides formed via the degradation of 
DNA and RNA. Nucleoside transporters are important as they could transport nucleosides 
from the surroundings into the cells to be used as raw materials via the salvage pathway. The 
salvage pathways are particularly important for cells that do not express the enzymes required 
for the conversion of the purines and pyrimidine bases to nucleosides and nucleotides e.g.
monocytes and macrophages, erythrocytes, bone marrow cells and some cells in the brain 
(Baldwin et al., 2004). Natural nucleosides and nucleobases can have a huge impact on the 
cell’s in vivo activity, kinetics and disposition, which under oxidative stress and inflammatory 
conditions could affect 7,8-dihydroneopterin production as well as its transport in and out of 
cells.
IFN-• stimulation in endothelial cells, leads to the formation of tetrahydrobiopterin (BH4) 
using GTP, an important co-factor for nitric oxide (NO) synthesis by endothelia nitric oxide 
synthase (eNOS) essential for normal endothelial functioning. BH4 can also be produced from 
its intermediate sepiapterin (SP) using the enzyme sepiapterin reductase to form BH2 which is 
converted to BH4 using an enzyme dihydrofolate reductase (DHFR). This route of BH4
retrieval from SP or BH2 is termed as “salvage pathway”, as opposed to the de novo BH4 
synthesis pathway from GTP to produce NO using the intermediates in case the de novo
pathway is impaired by oxidative stress or GTPCH 1 deficiency.  Loss of biological NO 
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activity is the hallmark of endothelial dysfunction in vascular disease (Douglas and Channon, 
Fuster and Sanz, 2007) that could then favor LDL internalization into the intima initiating 
cascade of atherosclerotic events like LDL oxidation, adhesion molecule expression followed 
by inflammation. Lack of the BH4 co-factor is also responsible for hyperphenylalaninemia and 
neurotransmitter (dopamine, epinephrine, norepinephrine and serotonin) deficiency where BH4
supplementation has been used successfully in treatment of these diseases. Thus nucleoside 
transporter mediated transport of pterins like BH4, BH2 and its intermediates is crucial during 
the salvage pathway in restoring the well-being of endothelial cells. Similarly, sepiapterin, 
member of the pterin family which is the precursor of BH4 synthesis has also been shown to 
be transported via nucleoside transporter (Ohashi et al., 2011b).
7,8-dihydroneopterin is also an intermediate in this process of BH4 synthesis. 
Monocytes/macrophages lack the activity of the final two enzymes required for conversion of 
7,8-dihydroneopterin to BH4. So they accumulate 7,8-dihydroneopterin on IFN-• stimulation 
which is oxidized to neopterin. 7,8-dihydroneopterin has been shown to be a potent radical 
scavenger and antioxidant protecting U937 cells from AAPH and oxLDL induced oxidative 
stress and cell death as well as LDL oxidation in vitro (Gieseg et al., 1995, Gieseg et al., 2001, 
Gieseg et al., 2002). Although 7,8-dihydroneopterin inhibited cell-mediated LDL oxidation, it 
did not show any protection against oxLDL and oxidative stress in THP-1 cells (Baird et al., 
2005, Gieseg and Cato, 2003). This difference between U937 cells and THP-1 cells was 
thought to be due to the inability of 7,8-dihydroneopterin to get into the cells based on the 
observation that preincubation of cells with 7,8-dihydroneopterin was essential for its 
production. Research on quantification of oxidative biomarkers in atherosclerotic plaques 
where neopterin and 7,8-dihydroneopterin were also measured showed that lower neopterin 
was associated with higher oxidative biomarkers (Baird, 2003, Genet, 2010). This led to a 
hypothesis that 7,8-dihydroneopterin could be produced to protect macrophages from 
oxidative stress during inflammation and the relative concentration of 7,8-dihydroneopterin 
and neopterin were important determinants of plaque development in vivo (Gieseg et al., 
2008b, Gieseg et al., 2009).  
In some of the plaque sections, in spite of 7,8-dihydroneopterin concentrations being in the 
micromolar range, the oxidative biomarker levels were very high (Flavall, 2008). This meant 
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that 7,8-dihydroneopterin formed and released in the atherosclerotic plaque could not protect 
the monocyte/macrophage which succumbed to intracellular oxidative stress. This is similar to 
the situation in THP-1 cells where 7,8-dihydroneopterin was unable to protect in spite of being 
present in sufficient amounts in the surroundings. Inability of 7,8-dihydroneopterin to enter the 
cells could be a possible reason for this. Understanding the routes of 7,8-dihydroneopterin 
entry into the cells would elucidate the difference in protection provided by 7,8-
dihydroneopterin. Understanding if impairment of  transporters during oxidative stress 
underlies the inability of 7,8-dihydroneopterin to protect, could help us to device strategies to
modulate transporters thereby enabling protection of monocyte/macrophages from oxidative 
stress by 7,8-dihydroneopterin and possibly aid in reversing plaque progression. 
1.10.1 Nucleoside transporters are affected during oxidative stress
Role of nucleoside transporters and 7,8-dihydroneopterin in atherosclerosis cannot be fully 
understood unless we understand the role of oxidative stress in modulating them. 
Inflammation is the body’s protective response to harmful agents, irritants or damaged tissue, 
to initiate a healing process, which is generally mediated by monocytes, macrophages, T-cells 
and other immune cells of the body. Hallmarks of inflammation are activation of immune 
cells, production of pro-inflammatory cytokines and reactive oxygen intermediates (ROI’s)
that sometimes add up to the oxidative load. Thus understanding oxidative stress and how it 
modulates nucleoside transporters becomes important. Although the impact of oxidative stress 
on nucleoside transporters is not extensively studied in humans, their role in adenosine 
mediated rescue of oxidative stress has been studied in a number of animal models. For 
example, the adenosine based rescue of ischemic heart and brain injury, and its protective 
effect in seizures and inflammation have been widely studied (Noji et al., 2004). Adenosine 
has been reported to protect against excessive cellular damage and organ dysfunction in a few 
studies by acting as an anti-inflammatory agent. Protection of retinal microglial cells due to 
inhibition of adenosine uptake by adenosine receptor (A2A) activation by cannabidiol is 
equilibrative nucleoside transporter (ENT) mediated (Liou et al., 2008). However, in case of 
lung endothelial cells, sustained adenosine exposure has been described to cause endothelial 
barrier dysfunction oxidative stress via nucleoside transporter mediated signaling and 
activation of p38, MAPK and RhoA (Lu et al., 2012). 
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There are other evidences that implicate oxidative stress in controlling nucleoside transporters. 
Studies performed with rat astrocytes, where the cells were exposed to oxidative stress in the 
form of peroxynitrite, resulted in a reduced adenosine uptake via ENT proteins (Tanaka et al., 
2011) (figure 1.16). This reduced uptake was attributed to increased Km (Michaelis constant), 
as the expression levels and the maximum rate of the uptake remained unaltered. 
Figure 1.16 Peroxynitrite effect on ENT mediated adenosine transport (Tanaka et al., 
2011).
The importance of nucleoside transporters in cardio protection was also demonstrated by Rose 
et al., (Rose et al., 2010) after ischemia and reperfusion in mouse hearts that lacked ENT 1. 
ENT 1 null mice, showed significantly higher cardio protection than their normal counterparts 
after ischemia and reperfusion. This reiterates the purinergic cardio protection in the 
cardiovascular system involving adenosine and the role of inhibition of adenosine in 
protecting from reperfusion injury. Since ENT 1 is expressed predominantly in heart tissue 
(Marvi et al., 2010) in spite of the observed differences in the nucleoside transporter 
expression profiles, ENT 1 might play a role in oxidative stress mediated damage. 
The effect of both exogenous and intracellular ROS on nucleoside transporters was tested in 
bovine heart micro vascular endothelial cells (BHMEC) by Barankiewicz and colleagues 
(Barankiewicz et al., 1994). They exposed BHMEC’s to H2O2 or HOCl, to find a 
concentration dependent decrease in ENT mediated adenosine transport. When BHMEC were 
exposed to intracellular ROS generating compound menadione, that generates large amounts 
of intracellular superoxide, H2O2 and hydroxyl radicals , at different concentrations for 30 
minutes a strong dose-dependent inhibition of adenosine transport was observed 
(Barankiewicz et al., 1994). This effect was partially reversed by adding scavenger of ROS 
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such as dimethylthiourea (DMTU) and SOD to cells. Thus oxidative stress could alter the 
functioning of nucleoside transporters affecting the influx and efflux of important cellular 
biomolecules needed for homeostasis of cells. So if 7,8-dihydroneopterin is transported via 
these specialized transporters, the transporter dysfunction could result in reduced/impaired 
7,8-dihydroneopterin transport into the cells and reduced protection. This could possibly 
provide an explanation to the situation where higher 7,8-dihydroneopterin concentrations were 
found in plaques, but the oxidative biomarkers were also present in large amounts. 
Nucleoside transporters as possible candidates for 7,8-dihydroneopterin transport was based 
on the observation of Sawabe et al., (Sawabe et al., 2005) who showed that the transport of the 
pterin sepiapterin (SP), across the plasma membrane was equilibrative and bidirectional. Later 
transport of dihydrobiopterin (BH2) and tetrahydrobiopterin (BH4) was also demonstrated via 
these transporters, albeit less efficient than SP (Sawabe et al., 2008, Ohashi et al., 2011b). It 
was also shown that BH4, BH2 and SP supplementation, and their transport via nucleoside 
transporters restores eNOS function in cells protecting them from the oxidative stress 
(Sugiyama et al., 2009).
1.11 Types of Nucleoside transporters
With studies on mammalian cells, two types of nucleoside transport systems have been 
identified: equilibrative, bi-directional, facilitators or transporters and the concentrative, 
inwardly directed, Na+-ion coupled transporters. ENT’s are further classified into equilibrative 
sensitive (es) and equilibrative insensitive (ei), while concentrative nucleoside transporter 
(CNT’s) are classified into CNT 1, CNT 2 and CNT 3 based on their transport substrates. 
Some groups have also reported the presence of CNT 4 and CNT 5 in cells (Pastor-Anglada et 
al., 2008, Flanagan and MecklingGill, 1997, Buolamwini, 1997) . These two structurally 
different proteins belong to two unrelated gene families: the concentrative nucleoside 
transporter family (SLC 28) and equilibrative nucleoside transporter family (SLC 29). 
(Baldwin et al., 2004, Young et al., 2008, Jache• et al., 2003, Hyde et al., 2001, Griffith and 
Jarvis, 1996, Kong et al., 2004). ENT's  are present in most, if not all cell types while the 
CNT’s are found in specialized cells like intestinal and renal epithelia where they function in 
Chapter 1
42
tandem with ENT’s in absorption, distribution and elimination of nucleosides and nucleoside 
analogue drugs (Kong et al., 2004). 
1.11.1 Equilibrative nucleoside transporter (ENT) Family
Historically, the facilitate-diffusion systems of transporters or ENT’s were further classified 
into es and ei systems based on their sensitivity to inhibition by nitrobenzylmercaptopurine 
ribonucleoside (NBMPR) or nitrobenzylthioinosine (NBTI). Equilibrative sensitive (es) 
transporters are highly sensitive and inhibited by low nanomolar (>10 nM) concentrations of 
NBMPR whereas the Equilibrative insensitive (ei) transporters are comparatively resistant to 
NBMPR inhibition, requiring micromolar concentrations (>10µM)(Young et al., 2013). These 
proteins belong to the SLC29 gene family, which consists of 4 transporter genes SLC29A1, 
A2, A3 and A4 that express the equilibrative family of transporters. SLC29A1 encodes the 
ENT 1 protein, SLC29A2 encodes the proteins for ENT 2, SLC29A3 encodes ENT 3 protein 
and SLC29A4 encodes protein for ENT 4. Of the 4 ENT’s, ENT 1 and ENT 2 are the best 
characterized members. ENT 3 likely corresponds to the low affinity transport system for
nucleosides in lysosomes. The cation-dependence and low pH activation of ENT 3 and ENT 4
have not been fully understood yet (Baldwin et al., 2004, Young et al., 2008, Young et al., 
2013, Molina-Arcas et al., 2009). 
Human ENT 1 and ENT 2 are present in most cell types and tissues and are known to transport
a broad range of purine and pyrimidine residues (Baldwin et al., 2004, Young et al., 2008, 
Young et al., 2013). ENT 2 and, ENT 1 to a lesser extent, additionally are able to transport 
nucleobases. ENT 3 also is widely distributed and has broad substrate selectivity, but 
functions predominantly intracellular organelles like lysosomes and mitochondria. ENT 4 has 
been found to transport adenosine and monoamines in the brain and heart. All four members 
of the ENT family are able to transport adenosine, but they differ in their permeant 
selectivity’s and abilities to transport other nucleosides and nucleobases. 
Table 1.3 lists the major types of ENT found in humans and more detailed information about 
the chromosomal location of the different genes that encode the different ENT transport 
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proteins, their type of transport, tissue distribution and single nucleotide polymorphisms or 
splice variants with altered ENT function. 
1.11.2 Concentrative nucleoside transporter family or SLC28
Based on their substrate selectivity and inhibitor sensitivity, 5 types of Na+-ion coupled, Na+-
dependent nucleoside transporters have been reported in mammalian tissues. Four of these 
transporters are insensitive to NBMPR inhibition, which are designated as N1 or cif
(concentrative inhibitor insensitive, accepting formycin B as substrate, but not thymidine), N2 
or cit (concentrative inhibitor-insensitive, accepting thymidine as substrate but not formycin 
B), N3 or cib (concentrative inhibitor-insensitive, with broad substrate specificity) and N4 
(like N2 but also accepts guanosine as a substrate) and the fifth one, N5 or cs (concentrative 
inhibitor-sensitive) owing to its sensitivity to NBMPR (Buolamwini, 1997, Young et al., 2013, 
Pastor-Anglada et al., 2005, Pastor-Anglada et al., 2008).
Table 1.3 Equilibrative nucleoside transporter family SLC29. (Young et al., 2013)
Human 
gene name 
and locus
Protein name 
and UniProt 
accession
Transport 
type/cation 
coupling 
stoichiometry
Predominant tissue 
and subcellular 
distributions
SNPs and splice 
variants with 
altered function
SLC29A1 
6p21.1
ENT1 Q99808 Facilitated diffusion Widely expressed, 
primarily in the plasma 
membrane but also in 
nuclear and 
mitochondrial 
membranes
Exon 4 splice 
variant forming N-
terminally 
truncated, inactive 
protein (HNP36). 
Exon 9 splice 
variant forming C-
terminally truncated 
inactive protein 
(ENT2A). M116R, 
G427S, G437R and 
T449R, & various 
frameshift mutations 
abolish or reduce 
transport activity, or 
cause mistrafficking 
or protein
instability, variously 
associated with H, 
FHC & PHID 
syndromes & Rosai-
Dorfman disease. 
SLC29A2 
11q13
ENT2 Q14542 Facilitated diffusion Particularly abundant 
in skeletal muscle but 
widely expressed, 
primarily plasma 
membrane-located but 
has also been detected 
in nuclear membranes.
SLC29A3 
10q22.1
ENT3 
Q98BZD2
Unclear, possibly 
proton-linked
Widely expressed 
intracellular (late 
endosomal/lysosomal 
and mitochondrial 
membranes)
SLC29A4 
7p22.1
ENT4 (alias 
PMAT) 
Q7RTT9
Unclear, possibly 
proton-linked
Heart, brain, and 
skeletal muscle. 
Primarily plasma 
membrane-located 
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N1 and N2 systems are mainly purine- and pyrimidine-selective respectively, but N1 also 
accepts uridine and N2 also transports adenosine. The N3 system is broadly selective in its 
substrate, transporting both purine and pyrimidine nucleosides. The N4 system transports both 
purine and pyrimidine nucleosides with high specificity towards guanosine and N5 system 
transports guanosine. Details of concentrated nucleoside transporters are mentioned in table 
1.4. 
Table 1.4 Concentrative nucleoside transporter family SLC28. (Young et al., 2013)
Human gene 
name and 
locus
Protein name 
and Uniprot 
accession
Transport 
type/cation coupling 
stoichiometry
Predominant 
tissue and 
subcellular 
distribution
SNPs and 
splice variants 
with altered 
function
SLC28A1 
15q25.3
CNT 1 
O00337
Concentrative 1:1 
sodium:nucleoside
Kidney, liver, 
small intestine. 
Primarily 
plasma 
membrane-
located
S546P, V1891 
and 1153del
SLC28A2 
15q15
CNT2 (alias 
SPNT) 
O43868
Concentrative 1:1 
sodium:nucleoside
Heart, skeletal 
muscle, liver, 
kidney, 
intestine, 
pancreas, 
placenta &
brain. Primarily 
located in 
plasma 
membrane
F355S, E385K
SLC28A3 
9q22.2
CNT3 
Q9HAS3
Concentrative 2:1 
sodium:nucleoside 1:1 
proton:nucleoside 
probably 1:1:1 
sodium:proton:
nucleoside
Abundantly 
expressed in 
mammary 
gland, pancreas, 
bone marrow, 
trachea &
intestine. 
Primarily in 
plasma 
membrane, but 
intracellular in 
some cell types 
& splice 
variants. 
Splice variant 
CNT3ins lacks 
the N-terminal 
69 residues and 
is retained in 
the 
endoplasmic 
reticulum (but 
is still 
functional) 
Chapter 1
45
Unlike ENT's which mediate facilitated diffusion and sodium-independent flow of 
nucleosides, the CNT's mediate a unidirectional flow of nucleosides in an active, energy 
dependent process coupled to the transmembrane sodium gradient. CNT's 1(N2), 2 (N1) and 3 
(N3) have been studied in greater detail than CNT 4 and 5. Na+-ion dependent transporters 
tend to be expressed in more specialized tissues and cells such as intestines, kidney brush-
border cells, choroid plexus macrophages, splenocytes, liver and cultured cell lines (Young et 
al., 2013, Pastor-Anglada et al., 2005, Pastor-Anglada et al., 2008, Kong et al., 2004).
1.11.3 Other transporters involved in nucleoside and nucleoside analog transport
As discussed previously, the intracellular concentration and effects of physiologically 
important nucleosides and nucleobases along with their analogs depends on the efflux 
pathways as much as they do on the uptake. 
Figure 1.17 Major transporters involved in the influx and efflux of therapeutic antiviral 
nucleoside derived drugs. A model of an ideal, polarized epithelial cell showing apical and 
basolateral membrane domains. Transporters implicated in the uptake and efflux of nucleoside 
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analog-based antiviral drugs located at the corresponding poles of the membrane. Those 
known to be basolateral are shown in the basal membrane for simplicity. MRP8 for which 
there is no information on its location is shown on the lateral side. This is just a representation 
of an idealized cell type and does not imply that any cell will co-express all the transporters 
shown. (Pastor-Anglada et al., 2005)
Apart from the equilibrative and concentrative nucleoside transporters, there are other 
transporter types which are known to transport nucleosides and nucleoside analogs, in and out 
of the cells (figure 1.17). Pastor-Anglada and colleagues have reviewed 14 different transport 
proteins belonging to 6 gene families that are involved in uptake and efflux processes of 14 
representative anti-viral drugs (Pastor-Anglada et al., 2005). 
It was hypothesized in the beginning that transporters belonging to the same gene family are 
responsible for the uptake of structurally related compounds which was found to be valid at 
least for the uptake processes but not for the export pumps such as multidrug resistance 
proteins (MRP’s). But it has been seen often that structurally related compounds can be 
substrates of completely unrelated carrier proteins (figure 1.18). 
Figure 1.18 Structure of 14 representative nucleoside-derived antiviral drugs and their 
corresponding transporter proteins (Pastor-Anglada et al., 2005). 
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This also implies how modified natural substrates for pharmacological purposes are 
recognized by a varied spectrum of transporter proteins. One can see the plethora of 
transporters and the varied structures and substrate that they transport (figures 1.18 and 1.19). 
A)
B)
Figure 1.19 Chemical structures of representative nucleoside transport inhibitors (A) 
and therapeutic nucleoside analogues (B) (Young et al., 2013).  
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Apart from ENT's and CNT’s, other transporters that are involved are organic anion 
transporter (OAT) proteins (OAT 1-5), organic cation transporter (OCT) proteins, peptide 
transporters (PEPT’s) and efflux proteins of ABC transporter proteins, the MRP’s (Pastor-
Anglada et al., 2005). 
OAT’s and OCT’s belong to SLC22 family. OAT’s transfer several nucleoside analogs like 
AZT, ddI, ddC, ACV and GCV (figure 1.17). OAT’s also mediate the transport of cyclic 
nucleotides, prostaglandins, uric acid, antibiotics and NSAID’s. OCT’s mediate transport of 
organic cations, non-charged compounds and some anions in a facilitative manner. ACV and 
GCV are also transported by OCT 1. Tissue distribution of OAT’s and OCT’s seems to be 
restricted to a few cell types and their regulatory and functional properties are yet to be 
comprehensively studied (Pastor-Anglada et al., 2005). PEPT’s (PEPT 1 and 2), belong to the 
proton oligopeptide co-transporter family SLC15. As the name implies, PEPT’s are primarily 
transporters of peptide molecules, but are also known to transport a wide range of molecules 
like •-lactam antibiotics and nucleoside derivatives (Pastor-Anglada et al., 2005). 
Of all the transporters mentioned above, MRP’s are of particular interest due to their efflux 
capacity. MRP’s are members of the expanding ATP-binding cassette protein family, a 
complex transporter protein family with a vast tissue expression, wide structural variation and 
substrate selectivity. MRP’s transport the monophosphorylated derivatives of nucleoside-
derived analogs, nucleosides and nucleobases, but not the nucleoside analogs or nucleoside 
and nucleobases themselves. They function mainly as efflux pumps. They are widely 
distributed in the tissues like epithelia, endothelia, smooth muscles and immune system cells. 
They have been reported to be overexpressed in a lot of tumors (Pastor-Anglada et al., 2005).   
Also another putative Na+-dependent nucleoside transporter (SNST) 1 was cloned which is 
similar to Na+-dependent glucose transporter PEPT’s (PEPT 1 and 2), belong to a family 
different from ENT's or CNT's, that is able to transport a broad range of substrates, albeit with 
very low activity (Kong et al., 2004). The wide range of substrate binding and transport by 
nucleoside transporters can also be seen in the variety of different structures of nucleoside 
transport inhibitors and the therapeutic nucleoside analogues (figure 1.18).
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1.12 Regulation of nucleoside transporters
Since nucleosides and nucleobases play an important role in the physiology of the cell, and 
nucleoside transporters play a critical role in maintaining their intra- as well as extracellular 
concentrations, it becomes imperative to understand their regulatory mechanisms to 
understand their effects on cellular metabolism in relation to 7,8-dihydroneopterin and 
oxidative stress. 7,8-dihydroneopterin which is derived from guanosine plays an important 
role as a radical scavenger in protection of monocytes/macrophages in atherosclerosis. Factors 
regulating nucleoside transporters could in turn control the entry of 7,8-dihydroneopterin into 
the cells, and its ability to protect the cells from oxidative stress. Also since nucleoside 
transporters display a vast heterogeneity in their substrate specificity, inhibitor sensitivity, 
tissue and cellular distribution, varying affinity of interaction with nucleoside substrate, it is
important to understand the factors that regulate these important transport proteins and 7,8-
dihydroneopterin. This will in turn enable more precise drug targets in a wide range of 
therapeutic applications, improving its efficacy. 
Earlier very little was known about the regulation or modification of nucleoside transport apart 
from the changes in the transport activity due to cellular differentiation. However, over the 
past few years increasing evidence suggests that the transport protein expression and activity, 
both can be regulated by a variety of factors including hormones, cytokines, intracellular 
signaling, nucleotides, growth stimulation/progression through the cell cycle (Young et al., 
2013, Griffith and Jarvis, 1996). There have been conflicting reports in some of these cases 
too. For example, protein kinase C (PKC) activation in chromaffin cells was reported to 
decrease adenosine transport by reduction in the transporter number in the plasma membrane, 
whereas acute stimulation of HeLa and MCF-7 cells resulted in an increase in nucleoside 
uptake. In other cell types such as bovine adrenal endothelial cells, activation via PKC or 
protein kinase A (PKA) did not impact adenosine transport (Kong et al., 2004). This suggests 
that the nucleoside transport and transporter protein regulation is dependent on the cell type, 
and might involve multiple mechanisms. 
Given how important the nucleoside drugs are in the treatment of various cancers, where the 
transformation is often characterized by increased nutrient consumption, much of investigation 
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has been carried out to analyze transformation-dependent changes in nucleoside uptake. 
Studies on macrophages have shown that transport activity changes during the cell cycle along 
with the type of transporter expressed. In quiescent S1 macrophages, the majority of the 
nucleoside transport is via the equilibrative insensitive (ei) transport system, but when CSF-1 
is added to the cells, nucleoside activity increases 3-fold mediated by the equilibrative 
sensitive (es) transporter (Griffith and Jarvis, 1996). Cytokine stimulation with GM-CSF over 
72 hours to patients with acute myeloid leukemia progressively increased the es transporter 
expression. An increase in es and CNT transporter expression and transport has also been 
demonstrated in a variety of hematopoietic cells and in liver respectively. hENT 1 content of 
human cancer cells, in culture appears to be co-ordinated with the cell-cycle, levels of 
transporter approximately doubling between the G1 and G2-M phases (Baldwin et al., 2004, 
Young et al., 2008). In general, es transport increase has been associated with proliferation 
while increase in CNT 1 and CNT 2 have been found to be increased following cell activation 
(Pastor-Anglada et al., 2005). Valdes et al., (Valdes et al., 2002) also reported a cell-cycle 
dependent increase in CNT 1 expression in hepatocytes. 
Cellular differentiation has been another major modulator of nucleoside transporters and their 
resultant transport activity. In human promyelomonocytic cell line HL-60, nucleoside 
transport via hCNT 3 increased with the concomitant decrease in hENT 1 and hENT 2 
transport activity, during differentiation (Ritzel et al., 2001). Similar results were obtained 
when HL-60 were differentiated into monocytes using PMA (Kong et al., 2004) or 
differentiated into granulocytes by DMSO (Lee et al., 1994).  In sheep reticulocytes maturing 
into erythrocytes, the high es transport activity in the reticulocytes was lost (Griffith and 
Jarvis, 1996). In murine bone marrow macrophages however, M-CSF stimulation upregulated 
ENT 1 transporters at mRNA and protein levels, and there was no change in ENT 2, CNT 1 
and CNT 2 transporters. Increase in ei transporter expression and function was noticed in 
human neuroblastoma cell line LA-N-2 during cellular differentiation. Differential regulation 
of nucleoside transporters has also been reported at the various developmental stages of the 
cell type (Guzman-Gutierrez et al., 2010). This is of direct relevance in 7,8-dihydroneopterin 
production where inflammatory stimulus like IFN-• differentiate the monocytes to 
macrophages in the plaque milieu, resulting in increased 7,8-dihydroneopterin production and 
subsequent inflammation. 
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Various cytokines, hormones and other stimuli also modify transporter activity in a cell-type 
dependent manner. As described above, M-CSF, DMSO and PMA can bring about changes in 
the nucleoside transporter levels in different cell types. IFN-•  is also known to regulate the 
nucleoside transport systems in wild type bone marrow macrophages (Soler et al., 2003). IFN-
• was shown to downregulate ENT 1 transport activity blocking their proliferation and 
upregulate CNT 1 and 2 transport activity (Soler et al., 2003). CNT 1 seems to be a target for a 
variety of multifunctional cytokines implicated in hepatocyte priming and activation. PKC and 
PKA activation, directly or via membrane receptors has been shown to inhibit adenosine 
transport via ENT 1 transporter in cultured chromaffin cells. Insulin and hyperglycemia also 
seem to affect the nucleoside transport expression and function, in a cell-specific manner 
(Sakowicz et al., 2004). Stress activated C-Jun K pathway negatively regulates ENT 1 in 
mouse leukemic cell line (Young et al., 2013). IFN-• that activates macrophages and blocks 
their proliferation down-regulates ENT 1 and upregulates CNT 1 and CNT 2 expression. Thus 
various stimuli in macrophages that selective regulate the nucleoside transporters are critical 
for macrophage proliferation and activation. A distinct pH dependent activation for hENT 3 
and hENT 4 also has been reported, that suggests that the culture conditions and/or pH might 
also alter the nucleoside transporter expression and function in these cells. This is again 
relevant to atherosclerotic plaques as the pH varies across the plaque (Naghavi et al., 2002). 
Slight changes in pH could also protect macrophages from oxLDL induced apoptosis (Gerry 
and Leake, 2008).
A direct regulatory role for the cellular nucleotides (eg. ATP) has also been reported in 
controlling the es transporter activity in chromaffin cells (Kong et al., 2004). This has also 
been shown with experiments using inhibitors of nucleotide synthesis, suggesting that cellular 
deoxynucleotide levels regulate nucleoside transporter synthesis or cell surface expression in 
some way, that is not known yet (Young et al., 2008). CNT 1 expression has been documented 
to be highly dependent on intracellular nucleotide metabolism status by Valdes et al (Valdes et 
al., 2002). Oxidative stress could potentially inhibit cellular nucleotide synthesis affecting 
GTP mediated 7,8-dihydroneopterin production. Reduced GTP production like ATP can affect 
nucleoside transporter expression or activity. Infection can also play a vital role in nucleoside 
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transporter expression. It one of the studies with HIV-1 infected and non-infected individuals, 
it was found that hCNT 1, 2 and 3 were expressed differently (Koczor et al., 2012).
Taken together, oxidative stress and inflammation could regulate the nucleoside transporter 
expression/function potentially influencing 7,8-dihydroneopterin concentration/function in 
atherosclerosis. Alternatively, nucleoside transporter expression and activity might influence 
oxidative stress and inflammation in 7,8-dihydroneopterin mediated monocyte/macrophage 
protection in progression of atherosclerosis. 
1.11 Objectives of this study
Precise 7,8-dihydroneopterin and neopterin measurement on HPLC was of utmost importance 
for studies involving oxidative stress and cellular protection provided by 7,8-dihydroneopterin. 
Previous studies done in our laboratory with plaques using C18 assay method was not robust 
enough for the type of analysis and required continuous adjustments in the method to achieve 
the results. To get around the inconsistencies in neopterin and 7,8-dihydroneopterin detection 
and quantification, modifications to the HPLC method were required.  Strong cation exchange 
(SCX) column using the cation-exchange principle instead of the reverse-phase as in C-18 
columns was tested as an alternative method. As an alternative method to acidic tri-iodide 
conversion of 7,8-dihydroneopterin to neopterin, manganese oxide oxidation was investigated. 
ECD as an option to convert 7,8-dihydroneopterin to neopterin has also been examined in 
chapter 3. 
One of the objectives of this study described in chapter 4 was to quantify the oxidative 
biomarker and antioxidant content across the length of the carotid and femoral atherosclerotic 
plaques to examine the inter-relationships and compare the oxidative stress and 7,8-
dihydroneopterin between carotid and femoral plaques. Many studies have examined the 
concentration of various biomarkers within atherosclerotic plaques, but none have investigated 
their localization and variation across the length of the plaque or with respect to each other. 
Our laboratory is the first to quantify the amount of neopterin and 7,8-dihydroneopterin in 
carotid and femoral plaques. Already 25 plaques have been analyzed in our laboratory but due 
to the complexity and advanced disease states accompanied by a small sample size it has been 
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challenging to obtain significant trends and correlations between plaques. In this study 10 
additional plaques have been analyzed to better understand any possible correlations between 
biomarkers and in between carotid and femoral plaques. Also induction of 7,8-
dihydroneopterin production in freshly excised plaques on IFN-• stimulation will be 
investigated for the first time,  to establish plaques as the source of neopterin. Also plasma 
from atherosclerotic patients was compared with healthy subjects for neopterin and 7,8-
dihydroneopterin. 
Study described in chapter 5 was aimed at elucidating the role of nucleoside transporters in the 
transport and protection of 7,8-dihydroneopterin against the oxidative stress in U937 cells, 
THP-1 cells and human monocytes using specific nucleoside transport inhibitors. Although it 
has been shown that 7,8-dihydroneopterin protects U937 cells and macrophages, how it gets 
into the cells was still unknown. Differences in the 7,8-dihydroneopterin protection against the 
oxidative stress mediated cell death in U937 cells and THP-1 cells led us to a possibility that 
differential uptake could be an important determinant in 7,8-dihydroneopterin mediated 
protection. As a few of the other members of the pterin family have been shown to be 
transported via nucleoside transporters and 7,8-dihydroneopterin was derived from a 
nucleoside, we hypothesized that nucleoside transporters could be a plausible route of 7,8-
dihydroneopterin entry into the cells. 
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2. MATERIALS AND METHODS
2.1 Materials 
2.1.1 Chemicals 
All solutions were prepared in de-ionised and ultrafiltrated water from a NANO-pure ultra-
filtration system supplied by Barnstead/Thermolyne, IA, USA or Milli-Q®, Millipore, MA,
USA. All reagents used are of analytical grade or better, unless otherwise stated. 
Acetic acid (glacial)    JT Baker, Mallinckrodt Baker Inc. 
Acetone Merck 
Acetonitrile JT Baker, Mallinckrodt Baker  
Inc. BDH Chemicals Ltd 
Argon gas BOC gasses, N.Z. 
4-Aminobenzoic acid (ABA) Sigma Chemical Co. 
Ammonium phosphate dibasic minimum 98% Sigma Chemical Co. 
Ammonium ferrous sulphate Hopkins and Williams Ltd 
2,2-azobis (2-aminopropane) dihydrochloride (AAPH) Arcos, N.J., U.S.A. 
Bicinchoninic acid (BCA) protein Pierce, U.S.A.
determination kit 
Bovine serum albumin (BSA) Sigma Chemical Co. 
Bromophenol blue 
Butylated hydroxytoulene (BHT) Sigma Chemical Co. 
Cholesterol reagent Roche Diagnostics, USA 
Diethyl ether Merck 
Diethylenetriaminepentaacetic acid (DTPA) Sigma Chemical Co. 
7,8-Dihydroneopterin (7,8-NP) Schircks Laboratory 
2,4-Dinitrophenylhydrazine (DNPH) Aldrich 
Dipyridamole Sigma Chemical Ltd. 
Ethanol Scharlau Chemie S.A. 
BDH Chemical Ltd 
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Ethyl acetate BDH Chemical Ltd  
Ethylenediaminetetraacetic acid (EDTA) BDH Chemical Ltd 
Guanidine hydrochloride Sigma Chemical Co. 
Glycerol Sigma Chemical Co. 
n-Hexane Unichrom, ARS 
Hydrochloric acid Merck 
Indomethacin Sigma Chemical Co. 
Iodine BDH Chemicals Ltd 
L-3,4-Dihydroxyphenylalanine Sigma Chemical Co. 
L-Ascorbic acid Sigma Chemical Co. 
BDH Chemicals Ltd 
Mercaptoacetic acid Sigma Chemical Ltd 
2-Mercaptoethanol Sigma Chemical Co. 
Methanol Scharlau Chemie S.A. 
Merck 
2-(N-Morpholino)ethanesulfonic acid Sigma Chemical Co. 
Neopterin Schircks Laboratory 
Nitrogen gas Boc Gasses, N.Z. 
Nitrogen liquid Cryogenics, Department of 
Chemistry, 
University of Canterbury 
NBMPR Sigma Chemical Co. 
Orthophosphoric acid (85%) BDH Chemicals Ltd 
Phenol Sigma Chemical Co. 
Potassium Hydroxide Merck 
Potassium Iodide Merck 
2-Propanol (Isopropanol) Merck 
Sigma Marker Wide Range Sigma Chemical Co. 
Sodium acetate Merck 
Sodium chloride Merck 
Sodium carbonate BDH Chemicals Ltd.
Sodium cyanoborohydride Fluka 
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Sodium dihydrogen phosphate monohydrate Scharlau Chemie S.A. 
Sodium dodecyl sulphate Sigma Chemical Co. 
Sodium Hydroxide Merck
1,1,3,3-Tetramethoxypropane Sigma Chemical Co. 
2-Thiobarbituric acid, minimum 98% Sigma Chemical Co. 
•-Tocopherol Sigma Chemical Co. 
Trichloricacetic acid Merck 
Trifluroacetic acid anahydrous Sigma Chemical Co. 
2.1.2 HPLC system
The high performance liquid chromatography or HPLC is an analytical process which utilizes 
the differences in the partitioning behavior between a flowing mobile phase and a stationary 
phase to separate, identify and quantify components of a sample mixture.  The samples 
collected were subjected to HPLC analysis using two separate systems from Shimadzu ™ 
Corporation, Japan. 
Shimadzu SCL 10A (system 1) is equipped with the controller SCL-10A VP, a solvent 
delivery module LC-10AD, a fluorescence detector RF-10AXL (xenon lamp), UV-Vis 
detector SPD-10A (deuterium lamp), autosampler SIL-10A with a column oven CTO-10A and 
DGU-14A on-line degasser.
Shimadzu CBM 20A (system 2) is equipped with a central bus module CBM-20A,  a solvent 
delivery module LC-20AD, a fluorescence detector RF-10AXL (xenon lamp), UV-Vis 
detector (deuterium lamp) detector SPD-M20A, autosampler SIL-20ACHT with a column 
oven CTO-20A and a degasser DG-20 As. 
Each treatment was performed and analyzed in triplicate unless mentioned otherwise. Peak 
areas were determined using LC solutions™ software. 
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2.1.3 Solutions and buffers 
2.1.3.1 HPLC mobile phases
HPLC mobile phase buffers were prepared in fresh nanopure water (Milli Q™, Millipore) and 
filtered through a 0.45 •m filter.  All mobile phases were degassed by sonication for 5-10 
minutes before running through the HPLC. 
A) 7,8-dihydroneopterin and neopterin analysis solutions and buffers
For 7,8-dihydroneopterin and neopterin analysis on a C18 reverse phase column 
(Phenomenex™ ODS, 250 mm × 4.6 mm ID, 5 µm) column, a solvent mixture of 20 mM 
ammonium phosphate pH 6 buffer with 5% (v/v) Methanol was used as a mobile phase. To 
prepare this, ammonium phosphate was dissolved in 900 mL nanopure water and pH was 
adjusted to 6 using concentrated phosphoric acid. Final volume was made up to 950 mL and 
50 mL HPLC grade methanol was added to it. The buffer was degassed by sonication before 
use. For SCX column, a solvent mixture of 20 mM ammonium phosphate pH 3 with 50% or 
10% acetonitrile (ACN) was used as a mobile phase. It was prepared by dissolving 2.64 g 
ammonium phosphate in 900 mL nanopure water and adjusting the pH to 3 using concentrated 
phosphoric acid.  Volume was made up to 1 liter using nanopure water. Buffer was sonicated 
before use. Required concentration to achieve the gradient of acetonitrile (HPLC grade 100%)
was mixed online. Acidic tri-iodide solution for 7,8-dihydroneopterin conversion to neopterin 
was prepared by dissolving 2.7 g solid iodine and 5.4 g potassium iodide in 35 mL of 
nanopure water in measuring cylinder. To this mixture, 4.37 mL of concentrated HCl (12.08 
M) was added in the fume cupboard. Iodine in the mixture was completely dissolved, using 
magnetic stirrer and final volume was made up to 50 mL. Ascorbic acid (0.6 M) was prepared 
by dissolving 1.057 g L-ascorbic acid in 10 mL of nanopure water in Falcon tube. As the 
solution cannot be kept for more than a day, a fresh solution was prepared each time. A 
standard neopterin stock solution was prepared in 20 mM ammonium phosphate pH 6, 
sonicated for 2 minutes and stored at -20ºC in 1 mL aliquots. When required an aliquot was 
thawed and diluted to 50 nM with the mobile phase buffer based on the assay employed.
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B) BCA Protein Assay working solution. 
Reagent A- Sodium carbonate/bicarbonate buffer, bicinchoninic acid, sodium tartarate in 0.1 
M NaOH. 
Reagent B - 4% Copper sulphate. 5 H2O 
Working reagent- The working reagent for the protein assay was prepared by mixing 50 parts 
of Reagent A with 1 part Reagent B.
C) TBARS assay solutions
A solution of 150 mM phosphoric acid was prepared by adding 1 mL of 85% orthophosphoric 
acid (14.7 M) to 99 mL of nanopure water. For butylated hydroxy toluene (BHT) in methanol 
(20 mg/mL), 200 mg of BHT was dissolved in 10 mL methanol (store at 4°C). To prepare a 
100 mg/mL solution of EDTA, required amount of EDTA was dissolved in nanopure water 
and the pH was adjusted to 7.4 with 10 M NaOH and stored at 4°C. Thiobarbituric acid 
solution (42 mM) for this assay was freshly made each time by dissolving 301 mg of 2-
thiobarbituric acid in 40 mL (approximately) nanopure water by stirring on a hot plate at 50-
55°C. Solution was allowed to cool and then diluted to 50 mL using nanopure water. For 
33.33 mM sodium dihydrogen phosphate monohydrate buffer, 4.14 g (MW 137.99) sodium
dihydrogen phosphate monohydrate was dissolved in 550 mL nanopure water and pH was 
adjusted to 6.8 using 10 M NaOH. Final volume was made up to 600 mL. The solution was 
filtered through 0.45 µM filter. The buffer was degassed by sonication before use. Sodium 
dihydrogen phosphate monohydrate buffer (55%) was mixed with 45% (v/v) methanol online 
using the HPLC pumps. 
D) DOPA and dityrosine analysis solutions
A solution of 0.1% trifluoroacetic acid (anhydride) pH 2.5 was prepared by adding 1 mL of 
TFA to 800 mL nanopure water. The pH was adjusted to 2.5 using 10 M NaOH and the 
volume was made up to 1 liter. This solution was then filtered through 0.45 µM filter and 
degassed by sonication before use. Mobile phase used for this assay was 99% line A (0.1% 
TFA) and 1% line B (100% acetonitrile). A solution of 6 M HCl with 1% phenol was prepared 
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by adding 200 mg of phenol to the mixture of 10 mL of nanopure water and 10 mL
concentrated HCl (12.08 M). 
E) Protein carbonyls (AAS and GGS) assay solutions
Sodium acetate (50 mM) solution, pH 5.4 was prepared by adding 4.10 g sodium acetate to 
900 mL nanopure water; pH was adjusted to 5.4 using 10% acetic acid. Final volume was 
made up to 1 liter and was filtered through 0.45 µm filter. The mobile phase was degassed by 
sonication before used. For 0.25 M MES buffer pH 6 with/without 0.5% SDS, 2.44 g MES 
was added to 50 mL of nanopure water. The pH was adjusted to 6 using 10 M NaOH. This 
solution was split into 2 aliquots of 25 mL each. SDS (0.15 g) was added to one of the bottles. 
To prepare amino benzoic acid (50 mM) in 0.25 M MES buffer pH 6, 41 mg ABA was added 
to 6 mL of MES Buffer (without SDS). Sodium cyanoborohydride (100 mM) in 0.25 M MES 
buffer pH 6 was prepared by adding 19 mg NaCNBH3 to 3 mL of MES buffer (without SDS). 
A solution of 6 M HCl was prepared by adding 49.7 mL of concentrated HCl (12.08 M or 37% 
fuming) to 50.3 mL of nanopure water. Trichloroacetic acid solutions, 50% and 10% (w/v) 
were prepared by adding 50 g and 10 g of trichloroacetic acid to 100 mL in nanopure water 
respectively. 
F) •-tocopherol and 7-ketocholesterol analysis solutions
Potassium hydroxide in methanol solution, 20% (w/v) was prepared by dissolving 20 g KOH 
in 100 mL of methanol using magnetic stirrer. Acetic acid solution, 20% (v/v) was prepared in 
nanopure water. 
2.1.3.2 Cell Culture Media and solutions
All solutions used in Cell culture were autoclaved or filter sterilized using a 0.22 µm filter 
before use, in class II (refer section 2.2.8) cabinet under sterile conditions. 
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A) RPMI 1640
RPMI 1640 was prepared fresh from the powder obtained from Life Technologies™, (CA, 
USA) following manufacturer’s instructions. Sodium bicarbonate was added and pH was 
adjusted to 7.4 using concentrated. HCl (12.08M). Media was filtered using a 0.22 µm
Millex®-GP50 Filter Unit (Molsheim, SA) and peristaltic pump (CP 600, Life technologies; 
New York, USA).  The solution was stored at 4ºC until used. 
For cell culture work, a 500 mL bottle of RPMI 1640 with phenol red and glutamine was 
supplemented with 5% fetal calf serum. Penicillin (100 U/mL) and streptomycin (100 µg/mL), 
were added under sterile conditions. Media which was stored at 4°C was warmed to 37°C in a 
water bath before use.
B) Phosphate buffered saline (PBS) 
Phosphate buffered saline with a final concentration of 150 mM sodium chloride and 10 mM 
sodium dihydrogen orthophosphate pH 7.4 was prepared in nanopure water and washed with 
Chelex 100 resin overnight to remove traces of transition metals prior to use. Chelex resin was 
removed by filtration through 0.45 µm filter. For sterile use, PBS was autoclaved and stored at 
room temperature. PBS was warmed in 37°C water bath before use. 
C) Propidium Iodide (PI) buffer solution 
A stock solution of 1 mg/mL propidium iodide (Sigma Chemical Co.) dye was prepared in 
nanopure water and kept wrapped in foil at 4°C. Working solution of 2 µg/mL was prepared in 
fresh PBS before use. 
D) Interferon Gamma (IFN-•) Solution
Interferon gamma (Roche diagnostics, Manheim, Germany) was diluted in PBS with 2.5% 
sucrose (sterile-filtered), as per manufacturer’s instructions, but without HSA to give a 
solution of 10,000 units (U)/mL. This stock solution was aliquoted into 500 µl aliquots and 
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stored at -20ºC until used. A new vial was used after one vial was thawed 2 times as IFN- • 
activity was lost after 2 freeze-thaw cycles.
E) Nucleoside transport inhibitor solutions
All the nucleoside transport inhibitors (from Sigma-Aldrich, St Louis, MO, USA) stock 
solutions were prepared in DMSO and stored in small brown vials (as light-sensitive) at -20ºC.  
Dilutions as required were also performed using DMSO and 5 µl of the solution was used to 
give a final concentration as required per mL of the medium. 
F) MTT assay solution
MTT stock solutions were prepared by dissolving 5 mg/mL of MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) in phenol red free RPMI 1640. Since MTT is light 
sensitive, it was stored in dark (wrapped in aluminium foil) at -20ºC after filter sterilization 
through 0.22 µm MS® PES syringe filter. 
Sodium dodecyl sulphate (SDS) solution (10% w/v) was prepared by dissolving 10 g of SDS 
in 100 mL of 0.01M HCl. This solution was stored at room temperature, warmed at 37ºC using 
water bath before use. 
2.2 Methods 
2.2.1 Plaque Homogenization 
Carotid and femoral atherosclerotic plaques were surgically removed from consented patients 
in their advanced stages of the disease undergoing carotid or femoral endarterectomy
respectively at the Christchurch Hospital; the plaques were transported to the free radical 
biochemistry laboratory on ice. All the plaques were snap-frozen in liquid nitrogen before 
storing at -80ºC. For analysis, the plaques were sectioned into 3-5 mm segments along their 
longitudinal axis beginning from the proximal broad end to the distal narrow end in the
direction of the blood flow while still frozen. In plaques with bifurcation, numbering of the 
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sections began at the basal end, opposite to the bifurcation. In plaques without any bifurcation, 
numbering began from a broader proximal end to thinner distal end. 
In case of carotid plaques which usually tend to be bifurcated, the dissection was done starting 
at the base of the ‘Y’, to the bifurcated ends. Sections were named serially from the base to the 
larger bifurcation followed by smaller bifurcation, wherever possible. During homogenization, 
the plaques were qualitatively assessed on their general morphology, overall composition 
including the degree of calcification, presence of ‘gruel’, which is the large areas of lipid core, 
and presence of clot.
Each plaque and its sections were photographed before homogenizing to a fine powder in
liquid nitrogen. Each powdered section was weighed before homogenizing. Next, 3.5 mL of 
water along with 35 •L of 100 mg/mL EDTA (as chelating agent) and 35 •L of 20 mg/mL
BHT in methanol (as an antioxidant) were added and vortexed thoroughly. Total final volume 
of the homogenate in the Falcon tube for each section was noted using the graduated markings 
of the Falcon tube. This homogenate was then used for analysis of various oxidative 
biomarkers by fluorometric or UV detection using the HPLC.
2.2.2 Cholesterol Determination 
Cholesterol content of the homogenate was measured using a spectrophotometric assay first 
developed by Roeschlau et al., (Roeschlau et al., 1974) and Allain et al., (Allain et al., 1974). 
It is based on a series of reactions involving the enzymes cholesterol esterase, cholesterol 
oxidase and peroxidase ultimately resulting in the development of a red dye.  First, cholesterol 
esters are cleaved by the action of cholesterol esterase to yield free cholesterol and fatty acids. 
Cholesterol oxidase then catalyzes the oxidation of cholesterol to cholest-4-en-3-one and 
hydrogen peroxide. The hydrogen peroxide thus formed is used to oxidize an indicator in the 
presence of peroxidase (POD). In this test, hydrogen peroxide oxidizes 4-aminoantipyrine and 
phenol to a quinoneimine dye in presence of peroxidase (POD). The color intensity of the dye 
formed is directly proportional to the cholesterol concentration in the sample which is 
determined by measuring the absorbance at 500 nm. To 10 •L of plaque homogenate, 1 mL of 
cholesterol reagent (CHOL™, Roche Diagnostics, Auckland, New Zealand) was added and 
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incubated in the dark for 10 minutes at room temperature. The absorbance was read at 500 nm 
against a cholesterol reagent as a blank. 
2.2.3 Protein determination 
Protein content in the homogenate/cell lysates were measured using the Pierce BCA Protein 
determination kit (Pierce, Illinois, USA). This is a detergent-compatible formulation based on 
bicinchoninic acid for colorimetric detection and quantification of total protein. This method 
combines the property of proteins to reduce Cu+2 to Cu+1 in an alkaline medium (biuret 
reaction) with highly sensitive and selective detection of Cu+1 using BCA, which can be 
detected colorimetrically. Two molecules of BCA chelate one Cu+1 ion, to form a purple dye. 
This water soluble complex exhibits a strong absorption at 562 nm, and the intensity of the 
purple dye formed is linearly proportional with the increase in protein concentration. 
Optimally, the protein concentration within the sample is required to be between 25 and 250 
•g/mL therefore plaque homogenate was diluted with nanopure water by a factor of 20. 
Working reagent was prepared fresh from two reagents in the kit, Reagent A (containing
sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1 M 
sodium hydroxide) and Reagent B (containing 4% hydrated copper sulphate) by mixing them 
together in a 50:1 ratio.  Freshly prepared working reagent (1 mL) was added to 50 •L of 
diluted sample and placed on a heated block at 60ºC with gentle shaking for 30 minutes. The 
reaction was stopped by transferring the samples on ice immediately before reading the
absorbance at 562 nm against water as a blank. Concentrations were determined from a bovine 
serum albumin standard curve analyzed by Prism (version 4.0; GraphPad Software, USA). 
2.2.4 Lactic Acid determination
Lactic acid content in plaque culture was determined using the lactate assay kit from Roche 
Diagnostics (Indianapolis, Indiana, USA). The kit employs an enzyme lactate oxidase which 
converts lactic acid to pyruvate and hydrogen peroxide. Hydrogen peroxide thus produced 
reacts with a hydrogen-donor (H-donor), a reaction catalysed by peroxidase, which in presence 
of 4-aminoantipyrine produces a purple colored chromogen. The intensity of the color formed 
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is directly proportional to the concentration of lactic acid present in the sample. Live cells in 
culture utilize glucose in the culture media to produce lactic acid. Thus, measure of lactic acid 
gives an indication of active metabolism by cells. This kit method can detect lactate in the 
range of 0.22 mM to 15.5 mM. The kit consists of 2 reagents: Reagent 1 (R1 containing 
hydrogen donor, ascorbate oxidase, buffers and preservatives) and Reagent 2 (R2, contains 4-
aminoantipyrine, lactate oxidase, horse peroxidase, buffers and preservatives). To 20 µL of the 
sample in a cuvette 840 µL of R1 was added followed by 168 µL of R2, mixed thoroughly and 
incubated at room temperature for 30 minutes. The absorbance was read at 660 nM using 20 
µL water reacted with R1 and R2 as a blank. 
2.2.5 Antioxidant detection 
2.2.5.1 Pterin Assay 
The pterin assay utilizes neopterin’s natural fluorescence allowing the detection and 
determination of neopterin and 7,8-dihydroneopterin. As 7,8-dihydroneopterin has little or no
natural fluorescence, but its oxidized form, neopterin is highly fluorescent. To determine the 
7,8-dihydroneopterin concentration, it is oxidized to neopterin using acidic tri-iodide, and 
neopterin content is subtracted from the total pterin content (neopterin plus 7,8-
dihydroneopterin) value to give the final 7,8-dihydroneopterin concentration. 
Two HPLC techniques were used for the measurement of neopterin and 7,8-dihydroneopterin 
in the course of this research. First, a reverse phase HPLC technique used was adapted from 
(Flavall et al., 2008) which employed trichloroacetic acid for removal of proteins from the 
sample. As it was observed that trichloroacetic acid used to precipitate proteins, oxidizes 7,8-
dihydroneopterin leading to its underestimation of its concentration (Flavall et al., 2008), an 
alternative method, using acetonitrile to precipitate the proteins from the sample was 
developed replacing trichloroacetic acid which prevented the loss of 7,8-dihydroneopterin. 
Second technique employed a cation exchange chromatography using a strong cation 
exchange column. This utilizes the principle of cation exchange, where the stationary phase is 
made up of negatively charged sulphonyl groups, which interact with the positively charged 
analyte of interest at low pH. Low pH keeps the analyte protonated increasing its retention 
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time onto the column. Neopterin was detected at an excitation wavelength of 353nm and 
emission wavelength of 438 nm using a fluorescence detector. As 7,8-dihydroneopterin is 
labile, the pterin assay was performed on the same day as the plaque was homogenized. 
2.2.5.1.1 Neopterin/Dihydroneopterin quantification in Plaque homogenate/ plasma
For neopterin quantification, the protein was precipitated by adding 100 •L of acetonitrile to
100 •L of plaque homogenate/plasma followed by vortexing and centrifugation at 20,500 g for 
10 minutes at 4ºC. For the total pterin samples, 100 •L of acetonitrile was added to 100 •L 
plaque homogenate/plasma/cell supernatants, vortexed and centrifuged as described above for 
5 minutes. Oxidation of 7,8-dihydroneopterin to neopterin was performed by adding 40 •L of 
acidic tri-iodide (5.4% I
2
/10.8% KI in 1 M HCl) followed by brief vortex. The sample was 
then incubated in the dark for 15 minutes. This was followed by addition of 20 •L of 0.6 M 
ascorbic acid to neutralize excess acidic tri-iodide in the sample. Sample was centrifuged as 
mentioned before for 5 minutes. 
From the 100 µl of the neopterin and total pterin supernatants aliquoted into the inserts 10 •L 
was injected onto either
1) A reverse phase Synergi 4 micron Hydro-RP™ (C18), (250 mm x 4.6 mm ID, 5 •m 
column, Phenomenex, New Zealand) maintained at 35ºC. 20 mM ammonium 
phosphate pH 6 with 5% (v/v) methanol was used as a mobile phase, pumped at a flow 
rate of 1 mL/minute.
2) A cation-exchange LUNA™ SCX (250 mm × 4.6 mm ID, 5µm column, Phenomenex)
maintained at 35ºC. 20 mM ammonium phosphate pH 3 with 50% acetonitrile was 
used as a mobile phase, pumped at a flow rate of 1 mL/minute.
Neopterin was detected at an excitation wavelength of 353 nm and emission 
wavelength of 438 nm. 
The 7,8-dihydroneopterin standard was prepared fresh in mobile phase and kept on ice and in 
the dark to minimize any loss. Where spiking of 7,8-dihydroneopterin was required a known 
concentration was added to samples and allowed to equilibrate on ice for 5 minutes before 
beginning sample preparation. Neopterin peaks from the acidic tri-iodide treated samples were 
retained slightly longer onto the column as compared to standard neopterin, the reason for this 
is still not completely understood. 
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2.2.5.1.2 Preparation of cell culture samples for pterin assay
After the cell culture experiments were performed, the media was collected in an Eppendorf
tube and centrifuged at 500 g for 5 minutes at 4°C to separate the cells. For extracellular pterin 
production in cell culture experiments, supernatant was collected in another Eppendorf tube 
and 100 µl of the supernatant was used to measure each, neopterin and 7,8-dihydroneopterin. 
For intracellular neopterin and 7,8-dihydroneopterin, cell pellet was washed twice in ice-cold 
PBS,  resuspended in 300 µl of  50% acetonitrile/H2O and sonicated on ice to lyse the cells. 
Acetonitrile aids in precipitation of proteins without any loss of 7,8-dihydroneopterin. The 
tubes were vortexed briefly and 10 µl of this was used for BCA protein assay if required. The 
tubes were centrifuged at 20,200 g for 10 minutes at 4°C to remove the proteins. 50 µl of the 
this supernatant was directly used for neopterin analysis while a 100 µl aliquot of it was used 
for measurement of 7,8-dihydroneopterin by acidic tri-iodide oxidation as mentioned above in 
section 2.2.5.1 pterin Assay (20 µL of acidic tri-iodide reagent and 10 µL ascorbate was used 
for intracellular pterin analysis instead of 40 µl acidic tri-iodide and 20 µl ascorbate). 
2.2.5.2 •-Tocopherol assay 
•-Tocopherol is a lipid soluble antioxidant due to its long hydrocarbon chain. It has a cyclic 
structure which is not only important for its antioxidant activity but also allows its detection at 
292 nm by fluorescence. Within a 10 mL glass tube with screw top, 100 •L of plaque 
homogenate was diluted with 400 •L of water. To prevent oxidation, 10 •L of 100 mg/mL
EDTA and 25 •L of 20 mg/mL BHT (in methanol) was added. Protein was precipitated with 
500 •L of ice cold ethanol and vortexed for 10 seconds. The •-tocopherol was extracted by 
adding 5 mL of ice cold hexane and further vortexing for 30 seconds. At this point the samples 
were sometimes stored at -80ºC if required. If frozen, samples were thawed before vortexing
for 60 seconds and centrifuging at 1,600 g for 5 minutes at 4ºC to maximize phase separation. 
Into glass tapered 10 mL centrifuge tubes, 4 mL of the hexane layer was transferred. Hexane 
layer was dried down in a hot water bath under nitrogen gas. The remaining residue was 
dissolved in 100 •L ice cold methanol and transferred into the HPLC vial for analysis. 
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The mobile phase used for this assay was 100% methanol. A 20 •L aliquot of the sample was 
injected onto a reverse phase Phenosphere-NEXT™ C18, (150 mm x 4.6 mm ID, 5 •m 
column, Phenomenex). The column oven was maintained at 35ºC, and •-tocopherol was 
detected at an extinction and emission of 292 and 353 nm respectively. The •-tocopherol 
standard was prepared by diluting approximately 1 mg/mL •-tocopherol in methanol and the
concentration determined spectrophotometrically using an extinction coefficient of 3086 cm
-
1
M
-1 
at a wavelength of 292 nm. •-tocopherol standard stock solution was stored at -20ºC 
under argon gas and when required was diluted to 3 •M concentration with 100% methanol. 
2.2.6 Lipid oxidation detection 
2.2.6.1 TBARS assay 
The TBARS assay provides a general measure of fatty acid oxidation occurring within 
biological systems. One of the breakdown products of lipid oxidation is malondialdehyde 
(MDA). The well-established 2-thiobarbitutic reaction with MDA yields a pink colored 
complex that is detectable at an emission wavelength of 550 nm (Draper et al., 1993). To 
prevent any further oxidation 10 •L of 20 mg/mL was added to 100 •L of plaque homogenate 
into an Eppendorf tube. 50 •L of 150 mM of phosphoric acid was added to the mixture to 
increase the acidity and precipitate the protein. At this point the samples were sometimes 
stored at -80ºC. If frozen the samples were thawed and 50 •L of freshly prepared 42 mM TBA 
was added and the samples were placed on a heated block at 95ºC with gentle shaking for 30 
minutes. This allows the formation of the TBA-MDA adduct which is detected using a 
fluorescence detector on the HPLC. The samples were immediately cooled on ice and 800 µl 
of ice-cold methanol was added. The samples were left on ice for 5 minutes. The samples were 
then centrifuged at 20,000 g at 4ºC for 10 minutes. 100 µl of the 50 mM NaH
2
PO
4 
pH 6.8
buffer was added to 100 µl of the supernatant of the sample to equilibrate the sample to the 
mobile phase pH. 100 µl of this solution was loaded into the HPLC vials and 20 µl was 
injected onto the column. The HPLC pumps were set up to pump 55% of 50 mM NaH
2
PO
4 
pH 
6.8 and 45% (v/v) methanol at a flow rate of 1 mL/minutes through a reverse phase 
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Phenosphere™ C-18, (150 mm x 4.6 mm ID, 5 •m column, Phenomenex) with the column 
oven set at 30ºC. The TBA-MDA adduct was detected at an excitation of 525 nm and emission 
of 550 nm. Both blank and 1 •M TBA-MDA standards were used to determine the 
concentration of TBARS within the samples. A solution of 1,1,3,3-tetramethoxypropane was 
prepared in of ethanol:water (2:3), and further dilutions to  0.5 µM and 1 µM were made using
nanopure water. Since MDA is very labile, the standards were prepared fresh on the day of 
analysis. To prepare MDA standards, a known concentration of the MDA precursor 1,1,3,3-
tetramethoxypropane was made to react with TBA on the heating block at 95ºC. 1,1,3,3-
tetramethoxypropane hydrolyses to MDA during the heated incubation step forming a known 
concentration of TBA-MDA adduct. A set of standards (0 µM and 1 uM MDA) were 
incubated along with the samples to confirm the working of the assay.
2.2.6.2 Combined 7-ketocholesterol and •-tocopherol assay 
7-ketocholesterol is one of the major oxidation products of cholesterol, which has also been 
found in atherosclerotic lesions. It is due to its reported cytotoxicity to a range of vascular 
cells that makes it an important biomarker for oxidative stress. The current method used in our 
laboratory was adapted from Kritharides et al., (Kritharides et al., 1993) and Brown et al.,
(Brown et al., 1997).
To 100 •L of the plaque homogenate in a black top glass tube, 400 µl of water was added. To 
prevent any oxidation, 10 •L of 20 mg/mL BHT (in methanol) and 20 •L of 100 mg/mL
EDTA were added. Protein precipitation was induced by adding 1 mL of ice-cold methanol 
and samples were vortexed briefly. 7-ketocholesterol and •-tocopherol were extracted by the 
addition of 5 mL of hexane to the samples and then vortexing for 60 seconds. Samples were 
then stored at -80ºC until analyzed. On the day of the analysis, the samples were thawed and 
vortexed briefly before centrifuging them at 200 g for 5 minutes at 4ºC, to ensure phase 
separation. Of the top hexane layer, 4 mL was transferred into a glass tapered 10 mL 
centrifuge tube and dried under oxygen free nitrogen gas, before re-solubilizing the residue in 
100 •L of acetonitrile:isopropanol (4:5) and injecting on to the HPLC column. For total 7-
ketocholesterol analysis, the residue obtained after drying down of hexane under nitrogen gas 
was dissolved in 20% KOH (in methanol) and 2.5 mL of diethyl ether was added to it before 
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flushing the tubes with argon gas to remove all the air. Samples were vortexed thoroughly 
before incubating on ice for 3 hours. The samples were briefly vortexed every 30 minutes. The 
reaction was stopped by adding 2 mL of 20% acetic acid and 2.5 mL of hexane was added. 
The samples were vortexed for 60 seconds and 4 mL of the upper layer was transferred into a 
glass tapered centrifuge tube. This solution was dried down under nitrogen gas, before 
resolubilizing the residue in 100 µl of mobile phase and placing into a glass autosampler vial.  
20 •L of this sample was injected onto a Phenosphere-NEXT™ C18, (250 mm x 4.6 mm, 5•m 
,Phenomenex) maintained at 35ºC, pumping a mobile phase of 54 isopropanol:44 
acetonitrile:2 water at 1 mL/minute,. The eluent first runs through the UV-Vis detector set at a 
wavelength of 234 nm for the detection of 7-ketocholesterol, and continues through to the 
fluorescence detector set at an excitation of 292 nm and emission of 335 nm for the detection 
of •-tocopherol. The 7-ketocholesterol standard was freshly prepared in and diluted to 5µM 
using acetonitrile:isopropanol (4:5) , and the •-tocopherol standard of 3 µM was prepared by 
diluting the stock solution (which was stored in the -20ºC,under argon gas)  using 100% 
methanol. 
2.2.7 Protein oxidation detection 
2.2.7.1 DOPA and dityrosine assay 
DOPA and dityrosine are oxidative products derived from the tyrosine residue and thus are a 
measure of protein oxidation. Protein bound DOPA and dityrosine are measured through a 
reverse phase gradient HPLC method, following the acid hydrolysis of proteins into free 
amino acids (Gieseg et al., 1993) Hydrolysis enables separation of the oxidation products the 
products after its release from the protein, allowing simultaneous detection of both protein 
oxidation products in one assay. 
To 100 •L of plaque homogenate in a 7.5 mm glass durham tube 10 •L of 100 mg/mL EDTA 
plus 10 •L 20 mg/mL BHT was added. To precipitate the proteins, 900 •L of ice-cold acetone 
(stored at -20ºC) was added and incubated on ice for 10 minutes. Samples were centrifuged at 
4000 g at 4ºC for 15 minutes. The supernatant was discarded and the pellet was washed with 
500 •L of diethyl ether and centrifuged as before. This procedure removes all free lipid, salts 
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and carbohydrates, which could otherwise interfere with the analysis. After draining off the 
supernatant, the pellets were dried under vacuum for 1 hour and then placed into Pico-Tag vial 
(Millipore, USA) with 1 mL of 6 M HCl (with 1% (w/v) phenol) and 50 •L mercaptoacetic 
acid. Argon gas was flushed through the Pico-Tag vials for 5 minutes and the argon in the 
vials was evacuated using the vacuum pump on the Speed Vac for 2 seconds (ensuring that the 
vacuum gauge pressure was below 200 milli Torr) creating an anaerobic environment. To 
carry out the acid hydrolysis, the vials were incubated in a 110ºC oven for 24 hours. After 
cooling them down to room temperature, the samples were centrifuged under vacuum (Speed 
Vac ® Plus AR, Savant instruments) for 2 hours before re-solubilizing the pellet with 200 •L 
of 0.1% TFA. To enable the samples to be spun at 21,000 g for 5 minutes at 4ºC, the samples 
were transferred to Eppendorf tubes. After centrifugation, 10µl of the supernatant was injected 
onto a reverse phase Aqua™ C18, (250 mm x 4.6 mm ID, 5 •m column, Phenomenex) with a 
gradient mobile phase pumping at 1 mL/minute. The gradient began at 100% 0.1% TFA pH 
2.5 with 1% acetonitrile where the acetonitrile linearly increased to 5% by the 10
th 
minute, 
10% by the 14
th 
minute and 50% by the 16
th 
minute. This was maintained for 5 minutes to 
clean the column, after which the acetonitrile concentration was returned and maintained at 
1% until the 30
th 
minute. As DOPA elutes first, the fluorescence detector was set initially at an 
excitation of 280 nm and an emission of 320 nm. At the 11
th 
minute the emission was changed 
to 410 nm for the detection of dityrosine. Column temperature was maintained at 35ºC. The 
concentrations and identities of DOPA and dityrosine were confirmed using commercially 
available standards. The DOPA standard was prepared fresh and a dityrosine stock stored at -
20ºC were diluted to 2 •M each with mobile phase. The two standards were mixed in 1:1 ratio 
to give a concentration of 1 µM each for simultaneous detection in the assay. 
2.2.7.2 Protein Carbonyls (AAS and GGS) Assay
Protein carbonyls formed by various oxidative events could be used as a general measure of 
the extent of oxidative injury.  This method detects the two main protein carbonyl products •-
aminoadipic semialdehyde (AAS) and •-glutamic semialdehyde (GGS). AAS is an oxidative 
deamination product of lysine residue, while GGS originates from arginine and proline 
residues. AAS and GGS account for 23% of the total carbonyls within native BSA (Akagawa
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et al., 2006) Protein carbonyls as biomarkers are useful as they are formed relatively early in 
an oxidative event and are more stable once formed. 
The samples were prepared in glass durham tubes with 200 •L of plaque homogenate. For the 
prevention of further oxidation 50 •L of 20 mM DTPA was added followed by protein 
precipitation using 50 •L of 50% TCA. The samples were kept on ice for 10 minutes and then 
centrifuged at 5000 rpm at 4ºC for 10 minutes. The supernatant was removed and using sealed 
pasteur pipettes the protein pellet was re-suspended in 125 •L of MES buffer pH 6 with 0.5% 
SDS. To the mixture 250 •L of 50 mM aminobenzoic acid (in MES buffer pH 6) and 125 •L 
of 100 mM sodium cyanoborohydride (in MES buffer pH 6) was added and the tubes inverted 
before incubating at 37ºC at 80 rpm for 90 minutes, allowing the condensation of ABA to 
AAS and GGS. After the samples were cooled on ice the protein was precipitated with 500 •L 
of acetonitrile and samples were centrifuged at 1,500 g at 4ºC for 15 minutes. To ensure the 
protein was precipitated the protein pellet was washed with 1 mL of 10% of TCA and 
centrifuged as before. Once the supernatant was removed the pellets were re-suspended using 
a sealed pasteur pipette in 500 •L ice cold ethanol and spun as before. For the final time the 
supernatant was removed and residual ethanol was drained off by inverting the tubes for 5 
minutes. The pellets were dried under vacuum for 1 hour before placing them into Pico-Tag 
vials with 1.5 mL 6 M HCl for acid hydrolysis. Air was flushed out using argon gas for 5 
minutes before the argon in the vials was evacuated by using the vacuum line of a solvent 
Speed Vac for 2 seconds (ensuring that the vacuum gauge pressure was below 200 milli Torr). 
Acid hydrolysis began once the vials were placed into the 110ºC oven for 24 hours. After the 
vials had cooled the vacuum was released from the Pico-Tag vials and the durham tubes were 
spun under vacuum for 2 hours in Speed Vac before re-solubilsing in 200 •L of 50 mM 
sodium acetate pH 5.4. For the samples to be centrifuged at a high g force the samples were 
transferred to an Eppendorf tube and centrifuged for 5 minutes at 21,000 g. 
Onto a reverse phase Synergi™ Fusion (250 mm x 4.6 mm ID, 4 •m column Phenomenex) 
with a gradient mobile phase pumping at 1 mL/minute, 20 •L of the sample was injected. The 
mobile phase began at 95% of 50 mM sodium acetate pH 5.4 and 5% (v/v) acetonitrile and 
was maintained until the 20
th 
minute. The acetonitrile concentration linearly increased 
reaching 50% by the 25
th 
minute. This was maintained for 5 minutes to clean the column, after 
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which the acetonitrile concentration returned to 5% and was maintained at 5% until the end of 
the run (40 minutes). The AAS-ABA and GGS-ABA compounds were detected at an 
excitation of 283 nm and an emission of 350 nm. For the standard, ABA was prepared fresh in 
mobile phase, sonicated for 2 minutes and injected at a concentration of 1 •M.
2.2.8 Cell culture 
Class II biological safety cabinet (Clyde-Apex BH200 series) was used under aseptic 
conditions for all cell culture experiments. Sterile plastic ware was supplied by Nunc™, Nalge 
International or Cellstar™ (Greiner Bio-one; North Carolina, USA). All other materials were 
sterilized either by autoclaving or by using a 0.22 •m membrane filter. 
2.2.8.1 Cell lines used in this study
We have employed two monocyte like cell lines U937 cells and THP-1 cells to study the role 
of nucleoside transporters in 7,8-dihydroneopterin uptake and protection of oxidative stress. 
Human monocytes were prepared from the fresh blood taken from hemochromatosis patients 
and used in this study.
2.2.8.2 U937 cells
U937 is a human histiocytic lymphoma cell line obtained from the pleural fluid of a 37 year-
old man with generalized lymphoma It was developed in 1976 by Sundstrom and Nilsson 
(Sundstrom and Nilsson, 1976, Liu and Wu, 1992). ‘U’ represents upsilon. It is a monoblast 
cell in its early stages of monocytic development (Liu and Wu, 1992, Oberg et al., 1993). 
These cells possess all the characteristics of the cells from the monocytoid lineage, such as 
positive staining for napthyl acetate esterases, secretion of lysozyme in the media which is a 
characteristic of monocytes and macrophages. They also possess no acid phosphatase activity 
or peroxidase activity which is in accordance with normal monocytes, confirming its 
histiocytic origin (Sundstrom and Nilsson, 1976, Liu and Wu, 1992). These cells also showed 
antibody dependent cell mediated cytotoxicity on activation by supernatants from human 
mixed cell cultures (Tsuchiya et al., 1980). Phorbol esters for eg. PMA, are known class of 
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signal transduction pathway inducers for a class of enzymes PKC which modulate 
differentiation of myeloid cells. A critical isoform of PKC, necessary for differentiation is 
PKC •. On activation of PKC, PKC-• translocates from cytosol to membrane and promotes 
myeloid cell differentiation. Since U937 cells express low levels of PKC-• (Hass et al., 1993), 
they were found to be resistant to PMA dependent c-myc downregulation during monocytic 
differentiation. Also in U937 cells differentiation by PMA into monocytes/macrophages was 
accompanied by ERK1-ERK 2 activation, which is the mode of differentiation in HL-60 into 
mononuclear and K562 cells into megakaryocytic lineage by this agent. Inhibition of ERK1-
ERK 2 activation, blocked U937 cells differentiation (Okuma et al., 2002).
2.2.8.3 THP-1 cells
THP-1 cells are human monocyte-like cell line established in 1980 (Tsuchiya et al., 1980, 
Schwende et al., 1996). It was derived from the blood of a 1 year-old boy with acute 
monocytic leukemia. This cell line has distinct monocytic markers like •-napthyl butyrate 
esterase activity which could be inhibited by sodium fluoride (NaF), lysozyme production, 
phagocytosis of latex particles and sensitized sheep erythrocytes and their ability to restore T-
cell response to concanavalin A (Con A). This cell line expresses Fc and C3b receptors but no 
surface immunoglobulins (Tsuchiya et al., 1980).  This cell line belongs to the monocytic 
lineage, similar to U937 cells but with a few exceptions. These cells have a different HL-A 
type from U937 cells and did not show antibody dependent cell-mediated cytotoxicity 
(Tsuchiya et al., 1980). THP-1 cells have binding cites for endothelin-1 while U937 cells do 
not THP- 1 cells have around fourfold less expression of scavenger receptor CD36 than U937 
cells, both before and after differentiation (Nguyen-Khoa et al., 1999) Overall, this cell line is 
more differentiated into monocytic lineage than U937 cells and behave more like native 
monocyte derived macrophages as compared to U937 cells (Auwerx, 1991).
Both U937 cells and THP-1 cells lines were grown and maintained as a suspension culture in a 
75cm2 tissue culture flasks. The media used was RPMI 1640 medium with phenol red, 
supplemented with 5% fetal bovine serum, penicillin (100 U/mL) and streptomycin (100 
µg/mL) at 37°C in a humidified atmosphere containing 5% CO2 (Precision Scientific, 
Chicago, Ilinois., USA). The cell media was changed every 3 days. Cell concentrations were 
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maintained between 0.2 and 1 million through passages. Cells were ideally used for about 25-
30 passages or until the suspension cells became adherent. A fresh batch of cells was removed 
from the liquid nitrogen storage every 3-4 months. Cell viability and density was confirmed by 
trypan blue exclusion staining using a haemocytometer. 50 µl sample of cell suspension was 
mixed with 0.4% trypan blue dye and left for 20-30 seconds. 10 µl of the diluted sample was 
placed onto each of the two fields of haemocytometer and cells were counted using the 
following formula:
Cells/mL of medium= No. of cells in 8 squares × dilution factor × 10 (volume 
of the chamber) ×103 per mL)
2.2.8.4 Isolation and culture of Human monocytes
Blood from autologous bags from the NZ blood bank (Riccarton Road, Christchurch) was 
transferred into 50 mL FalconTM tubes and centrifuged at 1000g for 30 minutes with slow 
deceleration. The buffy coat (upto 15 mL per tube) was transferred into fresh 50 mL tubes and 
PBS was added to make up the volume to 35 mL. An aliquot of 15 mL of Lymphoprep, a 
Ficoll-Isopaque density gradient medium (Medica Pacifica, NZ) which causes the aggregation 
and sedimentation of red blood cells, was then underlaid carefully and the tubes were 
centrifuged for another 30 minutes. The white monocyte layer was collected and transferred to 
fresh tubes (about 15 mL per tube) as before. These tubes were topped up with 50 mL PBS 
and centrifuged at 500 g, for 15 minutes with the brake on, to pellet the monocytes. The 
supernatant was discarded. Pellet was re-suspended into fresh 50 mL PBS to wash away the 
excess Lymphoprep. Tubes were then centrifuged as before, at 500 g for 10 minutes with 
brake on. The washing step with PBS was repeated twice more to remove any remaining 
Lymphoprep. Finally, the pellet was suspended in serum-free RPMI 1640 (37ºC) at a 
concentration of 5 million cells/mL. Cells were then transferred to 6 well suspension plates
(Cellstar, Greiner Bio-one; North Carolina, USA) and placed into a humidified 5% CO2 
incubator (Sanyo MCO-5AC; Osaka, Japan) at 37ºC. 
Monocytes isolated from the whole blood of hemochromatosis patients using lymphoprep 
were incubated for 40 hours in 6 well plates to allow death of T-cells and adherence of any
platelets. Monocytes were removed without disturbing any adherent particles. The collected 
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cells were centrifuged at 500 g for 10 minutes. The monocytes were then suspended in fresh 
RPMI 1640 at 5 million cells/mL and 5 mL each of this was pipetted into 6 well suspension 
plates with RPMI 1640 with 1% human serum and stored for use within one week. 
For experiments, the cells from all the wells in a plate were pooled together, counted using 
trypan blue exclusion staining on a haemocytometer, and resuspended in fresh RPMI 1640 
with 10% human serum at a concentration of 2 million cells/mL. A 500 µl aliquot of this 
suspension was used per well to give a final concentration of 1 million cells/mL required for 
the experiments. 
2.2.9 Cell culture experiments
For experiments in RPMI 1640 without 5% FCS or EBSS only, the wells of the suspension 
plates were coated with 5µl of 50 mg/mL BSA. This prevents the cells adhering to plastic in 
the absence of serum. Cells were counted and the numbers of cells required were aliquoted, 
washed twice with PBS and suspended in RPMI 1640, no serum or EBSS only to a 
concentration of 2 million cells/mL. 500 µl of this suspension was used per well to give a final 
concentration of 1 million cells /mL/ well required for the experiments. For experiments in 
RPMI 1640 with 5% FCS, cells were counted and suspended in fresh medium with serum at 2 
million cells/mL, 500 µl of which was used per well to give 1 million cells/mL/well. To 
demonstrate production of 7,8-dihydroneopterin by U937 and THP-1 cells, 10, 20 and 50 µl of 
10,000 U/mL IFN- • was added to cells. For the neopterin/7,8-dihydroneopterin uptake 
experiments, neopterin/7,8-dihydroneopterin was prepared fresh at a concentration of 2 mM in 
the required medium for the experiment. 100 µl of this solution was added to each well, before 
topping it up with the medium to make up 1 mL/well. 
For experiments involving nucleoside transport inhibitors, 5µl of the inhibitors were added 
just before adding 100 µl of 2 mM Neopterin/7,8-dihydroneopterin, and then topped up with 
the medium to make it up to 1 mL in each well. In experiments where protection of 7,8-
dihydroneopterin against AAPH induced cell death was tested, cells were washed twice with 
PBS before resuspending in sterile EBSS and adding to the wells at the concentration of 1 
million cells/ml. Cells were incubated with 200 µM 7,8-dihydroneopterin for 15 minutes prior 
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to adding AAPH (prepared fresh in ice-cold EBSS, and stored on ice). When nucleoside 
transporters were used in these experiments, they were added just before 7,8-dihydroneopterin 
and incubated for 15 minutes as before. The supernatant and/or cell lysate sample were 
prepared and analyzed for neopterin and 7,8-dihydroneopterin uptake as described in 2.2.5.2 
and 2.2.5.1 respectively. 
2.2.9.1 Plaque Culture- Production of 7,8-dihydroneopterin and neopterin 
For quantification of neopterin and 7,8-dihydroneopterin in plaque culture, freshly excised 
plaques collected from the endarterectomy patients at Christchurch Hospital and transported to 
the laboratory on ice within an hour of surgical removal. The plaques were cut into 3-5 mm 
sections, cultured in RPMI 1640 with 10% human serum for 48 hours, replenishing fresh 
medium every 24 hours. The medium from Day 1 and Day 2 were used to measure lactate 
production using Roche Lactate assay kit. On 3rd day and Day 4, the sections were stimulated 
with 500 U/mL of IFN-• in RPMI 1640 + 10% human serum. The medium was collected after 
24 hours and fresh medium (RPMI 1640 + 10% human serum) was added with 500 U/mL
IFN-• and medium was added.  The medium (Day 3 and Day 4) was collected for neopterin 
and 7,8-dihydroneopterin testing by SCX column using fluorescence detection on the HPLC. 
2.2.10 Cell Viability Assays
2.2.10.1 MTT Cell viability assay 
Thee MTT Assay is based on the method described by Mosmann (Mosmann, 1983). The 
tetrazolium salt MTT or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide is 
reduced to a colored formazan end product by metabolically active cells. The absorbance of 
the dissolved formazan is proportional to the number of ‘live’ cells present in culture. The 
experiment was performed in EBSS only using well plates coated with BSA. The cells from 
the experiment were collected in 1.5 mL Eppendorf in the hood and washed twice with 1 mL 
of warm, sterile PBS. The cells were suspended in 500uL of warm sterile EBSS. This 500 µl 
of cells was added to 500 µl of the sterile EBSS added to a sterile plate to give a final volume 
of 1 mL. A 100 µl aliquot of 5 mg/mL MTT reagent was added to each well, and the plates 
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were incubated for 2 hours at 37ºC in humidified atmosphere. The purple crystals thus formed 
were dissolved by adding 1 mL of 10% SDS-HCl and thorough mixing with pipette tip. 1 mL 
of this solution was aliquoted into cuvettes and its absorbance was measured at 570nm, using 
water as blank on a Shimadzu UV-1601PC UV visible spectrophotometer (Kyoto, Japan). The 
percentage of live cells was measured by comparing with the control cell viability for that 
experiment. 
2.2.10.2 Propidium Iodide assay using Flow cytometry
Viability of U937 cells and THP-1 cells before and after various treatments was measured 
using propidium iodide (PI) staining on flow cytometer. Briefly, 100 µl of cell suspension was 
spun at 500 g for 5 minutes, supernatant discarded, resuspended in 100 µl of 2 µg/mL solution 
of PI in PBS. It was briefly vortexed and incubated in dark for 10 minutes. 10000 events or
volume (µl) of cell suspension which gave approximately 10,000 events was assessed for cell 
viability using the fluorescence filter 3 (FL-3a) on a flow cytometer (BD Accuri™ C6 flow 
cytometer, BD Biosciences, California, USA). The cell viability was compared with the 
control cell viability used in the experiment. 
2.2.10.3 Trypan Blue exclusion Assay
This assay for cell viability was adapted from the method of Moldeus et al., (Moldeus et al., 
1978). This assay was used to count the viable cells in a culture flask so as to aliquot required 
amount of cells for an experiment.  For non-adherant cells, the cells from the 50 mL 
suspension flask were gently mixed using a pipette. 1 mL of the media was transferred in an 
Eppendorf.  A 50 µl aliquot was transferred into another Eppendorf tube. To this, 50 µl of 
0.4% trypan blue stain was added and gently mixed with a pipette. Tubes were left for about 2 
minutes to allow the stain to permeate any dead cells. A haemocytometer (Marienfeld, 
Germany) was used to count the number of live (non-stained) cells from a 10 µl aliquot of the 
cells suspension with trypan blue. Proportion of live (non-stained) and dead (stained) cells/mL
of the media were calculated as required for the experiment. Otherwise the required 
concentration of cells was aliquoted from the flask and suspended into fresh media for an 
experiment. 
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2.2.11 Ethics approval for the study
Collection of blood and isolation of human monocytes was approved by Upper South B ethics 
committee (ethics approval number CTY/98/07/069). Biochemical analysis of plaques and 
healthy plasma neopterin analysis was approved by Upper South A ethics committee (ethics 
approval number CTY/01/04/036 and URA/07/16/EXP)
2.2.12 Statistical analysis
Unless otherwise stated, the data shown represent the mean ± standard error of the mean 
(SEM) of triplicates of samples. The SEM is represented on each bar and data point within the 
graphs. Statistical analysis was performed using the Prism (version 5.0 and 6.0, Graphpad 
software, USA). Data on all the biomarkers was statistically analyzed with Graphpad prism 
software, using One-way analysis of variance (ANOVA) and Tukey’s post-test. In the 
biomarker analysis of an individual plaque, an asterisk (*) placed on the top of any bar/point 
to indicates a statistically significant change in the concentration of a section from the 
previous section to designate significant variations between the mean values. Statistics on the 
correlation data was performed using ANOVA on Statistica’s correlation matrices.
For biomarker comparison between carotid and femoral plaques, biomarker concentrations for 
all the sections from the carotid and femoral plaques were taken together and log transformed 
to analyze using one-way ANOVA. Levene’s test for homogeneity of variance was performed 
and corrected by log transforming the raw data.  If the log transformation could not correct for 
the homogeneity of variance a non-parametric Welsh’s correction test was used to analyze 
significance (shown by ‘#’). Data represented as Box and whisker graphs where whiskers 
extend from the minimum to maximum value. Box extends from 25th to 75th percentiles and 
the horizontal line in the middle shows the ‘median’ and ‘+’ sign represents the Mean, on 
which ANOVA was performed. All statistics on the nucleoside transporter data used one-way 
ANOVA followed by Tukey’s test. Statistical significances for the above statistical analyses 
are represented by (P<0.05) *, (P<0.01) **, (P<0.001)***.
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3. HPLC METHOD DEVELOPMENT FOR DETECTION OF NEOPTERIN 
AND 7,8-DIHYDRONEOPTERIN
3.1 Introduction 
3.1.1 Importance of neopterin and 7,8-dihydroneopterin detection and quantification
This thesis focuses on the synthesis and movement of 7,8-dihydroneopterin/neopterin with in 
cells and plaque.  The primary analytical tool was as a result the measurement of 7,8-
dihydroneopterin and neopterin in cells, tissue and media. The methods in use to measure 
these two pterin in the laboratory at the time of starting this research were time consuming and 
required a significant amount of mobile phase alteration to gain reliable results. This chapter 
described the development of our new analytic HPLC based method using ion exchange 
chromatograph to measure these pterins. The majority of published methods have focused on 
the measurement of neopterin due to its native fluorescence making it relatively easy to 
measure by HPLC. This research though focus on 7,8-dihydroneopterin the bioactive 
antioxidant which is oxidized to neopterin. The primary goal of the research described in this 
chapter was to produce a robust reproducible method suitable for use by all post-graduate 
researchers in the laboratory to measure both 7,8-dihydroneopterin and neopterin .
7,8-dihydroneopterin, the reduced form of neopterin (Figure 3.1) has been shown by this and 
other laboratories to be a potent antioxidant, capable of protecting cells from the oxidative 
damage to cellular proteins and lipoproteins in vitro (Gieseg et al., 1995, Baird et al., 2005, 
Firth et al., 2008, Kojima et al., 1993). As neopterin is one of the oxidative products of 7,8-
dihydroneopterin, increase in neopterin has been suggested to be associated with increased 
ROS production and decrease in serum antioxidants. The ratio of 7,8-dihydroneopterin to 
neopterin has the potential to be used as a biomarker of immune system mediated ROS stress 
(Gieseg et al., 2008a)
Chapter 3
80
A) B)
Figure 3.1 Structure of Neopterin and 7,8-dihydroneopterin.
The importance of quantification of 7,8-dihydroneopterin, has been rather unexplored even 
though its significance was first suggested from the study of urine of HIV patients, where it 
correlated inversely with the CD4+ T-cell populations (Fuchs et al., 1989). The studies 
showed 7,8-dihydroneopterin was of similar prognostic and diagnostic value as neopterin in 
the onset of AIDS in HIV positive patients (Fuchs et al., 1989, Kramer et al., 1989). The key 
problem with measuring 7,8-dihydroneopterin is its native fluorescence which is more than a 
100 fold less than neopterin so nM levels in plasma are not directly detectable. The 7,8-
dihydroneopterin therefore must be oxidized to neopterin reproducibly with a high yield. 
General oxidizing agents do not generate neopterin. All current methods use either tri-iodide 
or manganese oxide. HOCl does oxidize 7,8-dihydroneopterin to neopterin but also oxidizes 
the neopterin to pterin so is not suitable. A key problem with 7,8-dihydroneopterin 
measurements is that air oxidation of 7,8-dihydroneopterin yields dihydroxanthopterin and not 
neopterin (Laura Dántola et al., 2008). As a result 7,8-dihydroneopterin can be oxidized or 
destroyed during sample collection and culture periods due to its relative instability (Fuchs et 
al., 1989, Schroecksnadel et al., 2006). Surprisingly, work carried out in this laboratory has 
not observed these instability problems in a reproducible way or to the level describe in these 
publications. As a result all samples prepared are shielded from direct light and stored at -80ºC 
(unpublished observations).
3.1.2 Problems with neopterin/7,8-dihydroneopterin HPLC method 
The original HPLC method described by Fukushima and Nixon (Fukushima and Nixon, 1980)
was developed using a reverse phase C18 column and a mobile phase of water and methanol. 
This method also employed acidic and basic iodine oxidation to oxidize the H2/H4-neopterin 
and BH2 form of pterins respectively. Since then a number of laboratories have described 
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HPLC methods for detection and quantification of neopterin in body fluids (Carru et al., 2004, 
De Castro et al., 2004, Svoboda et al., 2008, Krcmova et al., 2011).
Our laboratory has used reverse phase C18 columns (Phenomenex) developed with isocratic 
gradient of ammonium phosphate buffer at pH 6 for the mobile phase. As with other methods 
neopterin was detected by the native fluorescence (Fuchs et al., 1989, Wachter et al., 1989, 
Kramer et al., 1989, Schroecksnadel et al., 2006). The majority of biological samples studied 
contain considerable amounts of protein which needs to be removed. The original method used 
in the laboratory and others used trichloroacetic acid (TCA) as the protein precipitating agent. 
To oxidize 7,8-dihydroneopterin to the detectable neopterin, the samples were treated with an 
acidic tri-iodide solution with excess of tri-iodide solubilized with ascorbic acid. 
Work in this lab found that the use of trichloroacetic acid (TCA) during protein precipitation 
step caused significant loss of 7,8-dihydroneopterin during the sample preparation (Flavall et 
al., 2008). Acetonitrile (ACN) was therefore introduced in 2008 as the protein precipitant, 
replacing TCA. Acetonitrile was found to reduce the loss of 7,8-dihydroneopterin due protein 
precipitation compared to TCA and did not affect the chromatography with pH changes. 
Changes in the manufacturing processes for acetonitrile caused by the 2009 recession 
introduced a significant fluorescence contaminant which eluted from the C18 column very 
close to the neopterin peak.  With column usage over time and reduction in column resolution 
caused the merging of the ACN contaminant peak with the neopterin. At the same time 
researchers in the lab were also finding variability in the efficiency of the acidic tri-iodide
conversion of 7,8-dihydroneopterin to the neopterin. This placed considerable demands on the 
post-graduate researchers needing to measure 7,8-dihydroneopterin and neopterin in samples. 
3.1.3 Solutions to sample preparation
The sensitivity of the assay was affected by variable oxidation by acidic tri-iodide which is 
why we have looked at alternative sample preparation method like manganese oxide oxidation 
of 7,8-dihydroneopterin to neopterin. An electrochemical detection method where there is no 
need to carry out the oxidation of the sample after protein precipitation was also studied as a 
possible option. Electrochemical detection for analysis of reduced pterins has been tested by 
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different laboratories in the past (Niederwieser et al., 1984c, Blau, 1988, Lunte and Kissinger, 
1986, Hyland, 1985). Since reduced compounds are electrochemically active, their property of 
transferring electrons onto an electrode results in an electrical current. This property of 
reduced pterins could be employed in electrochemical detection.
3.1.4 Strong Cation Exchange Chromatography as an alternative method for Reverse 
Phase Chromatography 
ACN interfering peaks appearing in the neopterin chromatograms affect the sensitivity and 
introduce inconsistency and inaccuracy in the assay as it can easily result into variable over or 
underestimation of neopterin concentration in the samples. Manual integration of the peaks for 
the samples after data analysis is an option to try and reduce the inconsistencies but it is 
tedious and time consuming. In this chapter we have looked at an alternative method using 
strong cation exchange (SCX) column instead of C18 for neopterin analysis keeping ACN as 
the protein precipitation agent. Cation exchange resin binds to positive ions and since at acidic 
pH neopterin (pKa = 1 (strongest basic) and 10 (strongest acidic)) and 7,8-dihydroneopterin
(pKa = 3.7 (strongest basic) and 11 (strongest acidic)) are positively charged they should bind 
better to the SCX resin. This method is used by Shchirks Laboratories (Switzerland) in the 
preparation and quality control of 7,8-dihydroneopterin and neopterin standards they 
commercial supply. Surprisingly no one appears to have examined the use of SCX columns 
for the measurement of pterins in complex biological samples. We choose to examine the use 
of a Phenomenex SCX column for pterin analysis as this brand of column had proven to be
very robust and economic for other chemistries. 
3.1.5 Electrochemical detection of 7,8-dihydroneopterin 
Electrochemistry involves chemical reactions in which electron are directly transferred from 
an electrode to a substance. These systems are often used as detectors where the magnitude of 
the current is proportional to the concentration of the compound being either oxidized or 
reduced in solution.
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There are two types of electrochemical detectors:
· In amperometric detectors, the eluent flows by the electrode surface often glassy 
carbon. In this design, a fraction of electro active species in the element will be 
oxidized or reduced as most of this compound does come in contact and react with the 
surface. The fraction of the electro active compound that reacts is typically in the order 
of 5-15%. 
· Coulometric detectors are the ones where have the eluent flowing through a porous 
graphite electrode, rather than flowing by the electrode. Due to a large surface area, 
almost all (100%) of the electro active species will be oxidized (or reduced). In 
coulometric detectors, about 10-20 times more of the electro active compound gets 
oxidized (or reduced), without corresponding increase in noise providing enhanced 
sensitivity. 
Electrochemical detector used in this study was Coulochem III® (ESA Inc., MA, USA) 
connected to ESA 5011 analytical cell and an ESA 5020 guard cell. An ESA 5011 A high 
sensitivity analytical cell is an enhanced response coulometric electrode coupled with a 
standard coulometric electrode. 
A)
B)
Figure 3.2 Electrochemical cells used with ECD Coulochem III® for 7,8-
dihydroneopterin/neopterin detection. A) ESA 5011 A High Sensitivity Analytical Cell and 
B) ESA 5020 Guard cell
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An ESA guard cell is placed between the pump and the injector in the HPLC. A typical 
functional arrangement of the Coulochem III® in an HPLC system is shown in the figure 
below (figure 3.3). The guard cell is used to oxidize (or reduce) any electroactive 
contaminants from the mobile phase prior to the analytical cell. This reduces the background 
current and baseline noise. 
In this chapter the use of the electrochemical detectors was explored to both detect and 
quantify 7,8-dihydroneopterin and convert 7,8-dihydroneopterin to neopterin for detection. 
Figure 3.3 Typical arrangement of guard cell and analytical cell for HPLC analysis.
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3.2 Results
3.2.1 Current reverse phase C18 method of neopterin and 7,8-dihydroneopterin 
detection on HPLC
Reverse phase C18 method is based on the principle of hydrophobic interaction between the 
analyte of interest and the hydrophobic stationary phase using a polar mobile phase. Stationary 
phase is made up of octadecyl carbon chain (C18) bonded to silica. It is the most popular 
analytical technique as it applies to a wide range of molecules, allows control of the 
chromatographic conditions along with being a robust, stable and efficient technique. 
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Figure 3.4 C18 method- HPLC chromatograms of neopterin and ACN. Mobile phase used 
was 20 mM AmPO4 pH 6 and 5% (v/v) MeOH at the rate of 1 ml/min. 10µL injections of A)
100 nM Neopterin standard; B) 50% ACN in buffer; C) 50 nM Neopterin + ACN standard. 
Using the C18 method, neopterin elution time is ~4 minutes while ACN elutes at ~4.3 
minutes. There is an additional unknown peak at ~3 minutes which seems to be another 
impurity in ACN, which is also seen in the ACN only sample (figure 3.4). 
3.2.2 ACN interference with neopterin
Acetonitrile (50%) used for the precipitation of proteins in our assay, ideally should not 
fluoresce. But there was an interfering fluorescence peak observed in the chromatograms, at 
the wavelengths used for neopterin detection eluting very close to neopterin at ~4.3 minutes 
(as compared to ~4 minutes for neopterin). This peak could be the unknown impurity which 
shows fluorescence that varies with the batch of ACN used. As the column ages, and wears off 
its retention capacity due to the increased number of samples going through it, it was noticed 
that the ACN peak merged with that of the neopterin peak. This decreased resolution of the 
column to base resolve the neopterin and ACN peak is a major issue, as it could lead to a 
substantial over estimation of neopterin in the samples being tested. Also, the process of 
manual integration needed to separate the two peaks due to insufficient resolution introduces 
another factor of human error, which could lead to a potential under or overestimation of 
neopterin. The effect of ACN on neopterin is shown in the figure below (figure 3.5). 
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Figure 3.5 C18 method- HPLC chromatograms of neopterin and ACN. 10 µL of 100 nM 
Neopterin standard with 50% ACN was injected onto a C18 column using 20 mM AmPO4 pH 
6 and 5% (v/v) MeOH mobile phase pumping at the rate of 1 ml/min. 
This ACN interference is also a problem as 7,8-dihydroneopterin elutes at almost the same 
time as ACN on the fluorescence detector (figure 3.6). As 7,8-dihydroneopterin elutes within 
0.1 minutes of each other on C18 column, they cannot be distinguished from each other.
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Figure 3.6 C18 method-7,8-dihydroneopterin elution time using C18 method. 10 µL of 
100 nM 7,8-dihydroneopterin was injected onto a C18 column using 20 mM AmPO4 pH 6 and 
5% (v/v) MeOH mobile phase pumping at the rate of 1 ml/min. 
To confirm and understand if the presence of ACN is the reason that causes the under or 
overestimation of neopterin, we tested the variation in the fluorescence area with increasing 
concentrations of ACN. ACN interference with neopterin peak could cause a variation in the 
apparent concentration of 15-20% (figure 3.7). The ACN interference impact could be 
stronger with lower neopterin concentrations and the columns which had seen more use.
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Figure 3.7 C18 method- Neopterin with increasing concentrations of ACN. 10 µL of 100 
nM Neopterin (final concentration) with varying ACN amounts were injected onto a C18 
column using 20 mM AmPO4 pH 6 and 5% (v/v) MeOH mobile phase pumping at the rate of 
1 ml/min. A) Neopterin only; B) ACN only C) Neopterin + 5% ACN, D) Neopterin + 10% 
ACN, E) Neopterin + 20% ACN, F) Neopterin + 30% ACN, G) Neopterin + 40% ACN, H) 
Neopterin + 50% ACN.
7,8-dihydroneopterin and neopterin binding to C18 column is not particularly strong. The 
addition of ACN as an organic modifier by previous researchers in our laboratory further 
decreased their binding to the column and retention times, further complicating the 
interference problem. So we were forced to look at a principally different chromatographic 
technique like strong cation exchange (SCX) to device a more sensitive and robust method. 
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3.2.3 SCX column using pH 3 buffer as an alternative method for neopterin 
quantification
Due to all of the previously described problems, another method which employs a completely 
different separation chemistry of cation exchange was examined as an alternative to the C18 
method. Strong cation exchange (SCX) column provides better resolution compared to other 
HPLC methods due to its strong binding and specificity. As the SCX column operates on the 
cation exchange, the analyte neopterin has to be protonated having a net positive charge. At 
lower pH neopterin is more positively charged so pH 3 was chosen as a suitable mobile phase 
for neopterin detection. 
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Figure 3.8 SCX method- Chromatograms of standards using pH 3 buffer. Standards were 
injected onto a SCX column using 20 mM AmPO4 pH 3 as the mobile phase pumping at the 
rate of 1 ml/min. 10 µL injections of A) Neopterin standard (100 nM), B) 50% ACN in buffer, 
C) 100nM Neopterin with ACN (1:1)
The neopterin elution time was close to about 4 minutes, while ACN eluted at about ~3.6 
minutes when injected separately. When injected together, the neopterin peak elutes at about 
4.1 minutes while ACN peak remains at about ~3.7 minutes (figure 3.8). There was no peak 
splitting observed under these chromatographic conditions. 
3.2.3.1 SCX column using pH 6 buffer 
A set of standards was tested using SCX column with the same mobile phase, at pH 6 to see if 
we get a better separation between ACN and neopterin, without using any organic modifier. 
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Figure 3.9 SCX method- Chromatograms of standards using pH 6 buffer. 10 µL of 1µM 
Neopterin standards were injected onto SCX column using 20  mM AmPO4 pH 6 as the 
mobile phase pumping at the rate of 1 ml/min. A) Neopterin (1µM) standard, b) 50 % ACN in 
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buffer, c) 50% ACN enhanced scale (b), d) 1µM 7,8-dihydroneopterin standard, e) zoom in of 
(d),  f) 1µM Neopterin + ACN standard (1:1)
It was seen that at pH 6 (figure 3.9), ACN eluted exactly at the same time as neopterin, at ~4 
minutes. 7,8-dihydroneopterin was eluted just after neopterin at ~4.2 minutes. So at pH 6, 
ACN peak was merged completely with neopterin which caused an increase in the peak area 
of neopterin. There were two possible ways to resolve the ACN interference, to try using an 
organic modifier to separate contaminant ACN peak from neopterin or to mask the 
fluorescence of that contaminant. 
3.2.3.1.1 SCX column using pH 6 buffer with 5% ACN mobile phase
To separate the ACN peak from the neopterin peak, we tried using 5% (v/v) ACN as an 
organic modifier in the mobile phase (figure 3.10).
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Figure 3.10 SCX method- Chromatograms of standards using 20 mM AmPO4 pH 6 with 
5% (v/v) ACN mobile phase. A) Neopterin (100 nM) only standard, B) 50 % ACN in buffer, 
C) 100 nM Neopterin + ACN standard (1:1)
Adding ACN failed to mask or separate the contaminant ACN peak as both neopterin and 
ACN peak were eluted around 3.6 minutes (figure 3.10). Also since the SCX chromatography 
depends on the analyte kept protonated, and neopterin is more protonated at more acidic pH, 
pH 6 was found not to be suitable for the selectivity of neopterin. 
3.2.4 SCX column using pH 3 buffer with 50% ACN mobile phase 
Mobile phase of 20 mM AmPO4 pH 3 seemed to give better retention and resolve the ACN 
and neopterin peaks. Ion-exchange chromatography can be modulated by exploiting the buffer 
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conditions. Addition of an organic modifier was thought to be a plausible option to work 
around the ACN interference issue.  To mask the possible interference of ACN, another 
alternative was to use higher amounts of ACN in the mobile phase. We used SCX column 
with a mobile phase of 20 mM AmPO4 with 50% ACN in the mobile phase, to see if the ACN 
peak could be removed or reduced so as to not interfere with neopterin (figure 3.11).  
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Figure 3.11 SCX method- Chromatograms of standards using 20 mM AmPO4 pH 3 
buffer with 50% ACN mobile phase. 10 µL of standards were injected onto SCX column 
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using 20 mM AmPO4 pH 3 with 50% ACN as the mobile phase and neopterin fluorescence 
was measured using a fluorescence detector on the HPLC. A) Neopterin (1µM) only standard, 
B) 50 % ACN in buffer at enhanced scale, C) 1µM Neopterin + ACN standard (1:1) D) 1µM 
7,8-dihydroneopterin standard and E) 1uM 7,8-dihydroneopterin standard at enhanced scale.
Using 50% ACN in the mobile phase masked the ACN fluorescence at the excitation and 
emission wavelengths used for neopterin detection (figure 3.11 B). When ACN was injected 
with buffer, there was no peak observed. The neopterin peak elutes at 4.4 minutes and there 
were no interfering peaks. When neopterin and 7,8-dihydroneopterin were injected together, 
neopterin eluted at its usual 4.4 minutes while 7,8-dihydroneopterin peak eluted at 4.9 
minutes. 
3.2.4.1 SCX column using pH 3 with 50% ACN as mobile phase buffer- Standard curve 
in buffer, plasma and plaque homogenate
The SCX column resolved the neopterin and ACN peaks satisfactorily as there was no 
fluorescence peak of ACN observed when ACN was used as an organic modifier in the mobile 
phase. We checked the linearity of neopterin standards diluted with ACN (1:1) and resolved 
on the SCX column with 20 mM AmPO4 with 50% ACN in the mobile phase (figure 3.12 A).  
The addition of 50% ACN to the mobile phase did not alter the fluorescent area of neopterin 
or interfere with neopterin samples in the buffer nor in the biological samples such as human 
plasma or plaque homogenate in any way. 
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Figure 3.12 SCX method- Standard curves for neopterin in buffer (A), human plasma 
(B) and plaque homogenate (C) using 20 mM AmPO4 pH 3 buffer with 50% ACN. 
Known neopterin concentrations of standards were added to 20 mM AmPO4 pH 3 buffer (A), 
human plasma (B) and plaque homogenate (C) and pre-treated with 1:1 ratio of ACN before 
centrifugation. Supernatants were injected onto SCX column using 20 mM AmPO4 pH 3 
buffer with 50% ACN as the mobile phase to quantify neopterin using the fluorescence 
detector on the HPLC. 
Neopterin standards combined 1:1 with ACN were linear over the concentration range 
examined (figure 3.12). Known standard concentrations were added to human plasma and then 
subjected to sample preparation by protein precipitation using 1:1 ACN followed by 
centrifugation. The supernatant was tested for neopterin (figure 3.12 B). With the spiked 
plasma sample neopterin was recovered completely after ACN precipitation of the protein and 
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the measured neopterin concentration was comparable to the standard concentrations it was 
spiked with. 
After successful testing of neopterin linearity on SCX in human plasma samples, the linearity 
of neopterin was measured in plaque homogenates. Known neopterin concentrations of 
standards were added to plaque homogenate and then the samples were prepared for neopterin 
analysis after protein precipitation with ACN and centrifugation. Supernatants were injected 
on the SCX column (figure 3.12 C). When known neopterin concentrations were added to 
plaque homogenates, ACN protein precipitation recovered the entire neopterin from the 
samples, without affecting its fluorescence or retention times. 
3.2.4.2 SCX column using 10% ACN in the mobile phase
The use of 50% ACN in the mobile made this analysis relatively expensive though it did 
remove the ACN interference.  We examined 10% ACN in mobile phase as a cheaper method 
(figure 3.13). With only 10% ACN in the mobile phase there was a small ACN contaminant 
peak which eluted approximately 0.5 minutes earlier than neopterin. 
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Figure 3.13 Chromatograms of Neopterin with 50% ACN standard using SCX column 
with 20 mM AmPO4 pH 3 with 10% ACN mobile phase. 10 µL of 50 nM Neopterin + ACN 
standard (1:1) standards were injected onto SCX column using 20 mM AmPO4 pH 3 with 10% 
ACN as the mobile phase and neopterin fluorescence was measured using a fluorescence 
detector on the HPLC. 
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Considering the cost involved in using 50% ACN for the amount of samples tested for 
neopterin analysis in the laboratory, this method was considered a good compromise as the 
peak was tiny and well resolved from neopterin. Standard curves for neopterin with 50% ACN 
using 10% ACN in the mobile phase are shown below (figure 3.14). 
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Figure 3.14 SCX method- Neopterin linearity using using 20 mM AmPO4 pH 3 buffer 
with 10% ACN in mobile phase. 10 µL of standards were injected onto SCX column using 
20 mM AmPO4 pH 3 with 10% ACN as the mobile phase and neopterin fluorescence was 
measured using a fluorescence detector using the HPLC. A) Neopterin in buffer, B) Neopterin 
+ ACN (1:1), C) Comparison between (A) and (B). 
3.2.4.3 Coefficient of variation for neopterin using SCX column
The coefficient of variation is a statistical measure of the dispersion of data points in a series 
of data around the mean. It represents the ratio of standard deviation to the mean, represented 
by the formula:
where, CV stands for  Coefficient of variation, 
• is the standard deviation and
µ is the mean of the population
CV is a useful statistical tool to compare the degree of variation between the sample data sets 
even if the means differ drastically. It is usually expressed as a ‘percentage’. 
Once the mobile phase conditions were established for neopterin testing using SCX column 
the intraday and interday coefficients of variation (CV) were calculated. For this a known 
concentration of neopterin was added to a known volume of plasma. Aliquots (100 µL) of this 
were used for neopterin measurements on the SCX column. 
For intraday CV, 100 µL of the plasma aliquot was treated with ACN (1:1) and after 
centrifugation the sample supernatant was injected on to the SCX column. The intraday CV 
was calculated as 2.97% for ten replicates. 
Interday variation between neopterin measurements on SCX column, represented by CV was 
calculated by using 100 µL aliquots of the plasma for neopterin quantification, every day for 
over 5 days. The average CV measured over 5 days was 4.2% which was within the usually 
acceptable range of > 5%. 
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Previously used C18 method’s intraday CV was measured 2.9% and interday CV was 
measured 3.8%, which was comparable to the CV observed with the SCX method. 
3.2.4.4 Comparison of urinary neopterin in healthy controls using SCX and C18 methods
A comparison was further made between C18 and SCX methods for neopterin measurement in 
biological urine samples of healthy individuals. This was performed to compare the variability 
and sample through put between the two methods. The urine samples were collected and 
stored at -80ºC until analysis. On the day of analysis the urine samples were thawed and 
diluted 1:20 before injecting directly on to the C18 and SCX columns for neopterin. For 7,8-
dihydroneopterin analysis as total pterin, 100 µL aliquot of urine was subjected to acidic tri-
iodide oxidation as mentioned in the methods. 
Figure 3.15 Comparison of SCX and C18 columns for neopterin (NP) and total pterin 
quantification in urine of healthy control volunteers. 10 µL of diluted urine (1 in 20) was 
injected directly onto SCX using 20 mM AmPO4 pH 3 with 10% ACN as mobile phase and 
C18 method using 20 mM AmPO4 pH 6 with 5% (v/v) MeOH as mobile phase. Neopterin and 
total pterin in urine of healthy control volunteers measured using fluorescence detection on the 
HPLC. Comparison between SCX and C18 is shown.
Both the methods recover similar amounts of neopterin and total pterin (figure 3.15). But 
when the concentrations obtained by C18 column were compared to the SCX column, C18 
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column recorded about 37-184% more of neopterin whereas approximately about 10-33% less 
total pterin in the same set of urine samples. SCX method was more accurate in measurement 
of neopterin than the C18 method. The decrease and the variation in the total pterin 
measurements in C18 method might have been due to a combination of acidic tri-iodide
variation and manual peak integration due to the ACN interference in the acidic tri-iodide
oxidized samples. 
3.2.5 Alternatives for sample preparation
We examined some alternative sample preparation techniques to increase the sensitivity and 
decrease the variation due to acidic tri-iodide oxidation of 7,8-dihydroneopterin to neopterin. 
Electrochemical detector (ECD) was examined as one of alternative method to convert 7,8-
dihydroneopterin to neopterin without using acidic tri-iodide using both C18 and SCX 
columns. Manganese oxide has been shown to oxidise 7,8-dihydroneopterin to neopterin (Blau
et al., 2003, Blau et al., 1992) . This method was also examined as an alternative to tri-iodide 
oxidation. 
3.2.5.1 Electrochemical conversion of 7,8-dihydroneopterin to neopterin using C18 
method
For successful use of an electrochemical detector in conjunction with HPLC, knowledge of the 
applied potential to effect the desired electrochemical reaction (oxidation or reduction of the 
species of interest (analyte) is required. To achieve this, the oxidative or reductive current of 
the analyte (at a constant concentration) over a range of working potential is measured. A plot 
of current generated vs. applied potential is known as hydrodynamic voltammogram (HDV). 
Based on this curve, maximal oxidative (or reductive) potential can be determined. This 
potential is dependent on large number of factors including the nature of the electrode surface, 
the pH, composition of the mobile phase and the chemical nature of the analyte.
Electrochemical detection was used to check if the conversion of 7,8-dihydroneopterin to 
neopterin was possible, and how much of it was converted to neopterin. To understand the 
optimal potential for the complete conversion of 7,8-dihydroneopterin to neopterin using the 
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already known condition of the C18 method, a hydrodynamic voltammogram (HDV) was 
constructed (figure 3.16). For this a 500 nM standard of 7,8-dihydroneopterin was prepared in 
20 mM AmPO4 pH 6 buffer, the same buffer used as the mobile phase, and its oxidation to 
fluorescent neopterin was measured using fluorescence detector, at increasing electrode 
potential on the detector. Higher nanomolar (nM) concentrations of 7,8-dihydroneopterin were 
used to overcome any possible contaminants or co-eluting compounds. The maximum 
oxidation reached a plateau at 600mV. At this applied positive electrode potential, maximal 
neopterin was detected on the fluorescence detector. For future experiments, +700mV was the 
potential used to account for any changes in the mobile phase. 
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Figure 3.16 C18 method- Hydrodynamic Voltammogram for 500 nM 7,8-
dihydroneopterin at different voltages. Conversion of different concentrations of 7,8-
dihydroneopterin to neopterin using electrochemical detector (ECD) connected post-column,  
on C18 column pumping 20 mM AmPO4 with 5% (v/v) MeOH at 1 ml/minute as the mobile 
phase. Fluorescence and ECD areas of neopterin were measured using fluorescence detector 
and electrochemical detector connected in line (post-column) on the HPLC. 
From HDV, the maximum oxidation potential for 7,8-dihydroneopterin was found to be 
around +700mV, this applied potential was checked for the conversion of a range of 7,8-
dihydroneopterin concentrations, from 1 nM to 1µM. These concentrations were run with and 
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without the ECD electrode potential so as to check the efficiency of 7,8-dihydroneopterin 
conversion to neopterin using ECD (figure 3.17). 
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Figure 3.17 C18 method- 7,8-dihydroneopterin conversion to neopterin using ECD.
Oxidation of a range of 7,8-dihydroneopterin concentrations to neopterin was tested using 
ECD (connected post column) with and without the applied electrode potential (+700mV). 
Corresponding neopterin concentrations were measured using C18 method using 20 mM 
AmPO4 with 5% (v/v) MeOH as the mobile phase at 1 ml/minute. 7,8-dihydroneopterin 
conversion using ECD (A) and (B) shows comparison of 7,8-dihydroneopterin samples with 
their corresponding neopterin standards. 
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The 7,8-dihydroneopterin concentrations after ECD conversion were compared with the 
corresponding neopterin concentrations to measure if the conversion was 100%. The 
maximum conversion of 7,8-dihydroneopterin to neopterin obtained using ECD was ~82%, at 
the highest concentration of 1µM 7,8-dihydroneopterin (figure 3.17). At lower 7,8-
dihydroneopterin concentrations at 10-100 nM, which is  often found in the plasma of patients, 
the conversion was between 32-54%. 
3.2.5.2 Effect of the applied potential on neopterin stability using C18 method
The effect of this applied potential on neopterin stability was also examined by injecting 
known concentrations of neopterin through ECD with and without the applied electrode 
potential (figure 3.18). 
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Figure 3.18 C18 method- Effect of the applied potential (+700mV) on different neopterin 
concentrations flowing through the ECD. 10 µL of different concentrations of neopterin 
standards in buffer were injected onto C18 column with an ECD connected in line (post-
column) using 20 mM AmPO4 with 5% (v/v) MeOH as the mobile phase. Neopterin levels 
were measured on the fluorescence detector placed after the ECD detector. 
The neopterin fluorescence areas were not affected by the applied potential.  This assures that 
the neopterin in the sample would remain unaffected when the potential is applied. This is an 
important aspect of ECD as no neopterin should be lost during the electrochemical conversion 
of 7,8-dihydroneopterin to neopterin. 
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3.2.5.3 ECD conversion of 7,8-dihydroneopterin to neopterin in plaque homogenate using 
C18 method
Finally the C18 method for neopterin and ECD conversion of 7,8-dihydroneopterin was tested 
on an actual biological sample. A plaque homogenate sample was analyzed for neopterin and 
7,8-dihydroneopterin content using ECD to oxidize 7,8-dihydroneopterin to neopterin.  
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Figure 3.19 C18 method- Plaque homogenate analysis for neopterin and 7,8-
dihydroneopterin using ECD. 100 µL Plaque homogenate from plaque 25 was treated 1:1 
ACN to precipitate the protein. 10 µL of the supernatant after centrifugation was injected onto 
C18 column with an ECD connected post column, pumping 20 mM AmPO4 with 5% (v/v) 
MeOH as the mobile phase. A) 100 µL plaque homogenate + 100 µL ACN, ECD off ; B) 
Magnified scale of sample with ECD off (a); C) 100 µL plaque homogenate + 100 µl ACN, 
ECD on +700mV; D) Enhanced scale of (C)
The peak at ~4.2 minutes has increased which probably indicates conversion of 7,8-
dihydroneopterin to neopterin by ECD (figure 3.19). When plaque homogenate samples are 
compared before and after ECD conversion of 7,8-dihydroneopterin, it was interesting to note 
that there was an  increase in the fluorescence area of ACN at ~4.5 minutes from about 27000 
to 72000 units (figure 3.20). The conversion of 7,8-dihydroneopterin to neopterin by 
Neopterin 
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electrochemical oxidation seems to have occurred with the plaque sample. But as previously 
described the ACN contaminant interference on C18 made the analysis unreliable. 
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Figure 3.20 C18 method- Chromatogram comparison of plaque sample for neopterin and 
7,8-dihydroneopterin using ECD. 100 µL of Plaque homogenate was treated with 1:1 ACN 
to precipitate all the proteins and 10 µL of the supernatant was injected after centrifugation 
onto C18 column connected to an ECD. Neopterin was measured with ECD off, while 7,8-
dihydroneopterin was measured by its oxidation to  neopterin ECD turned on at (+700mV) 
using fluorescence detector. 
The ECD conversion of 7,8-dihydroneopterin to neopterin was efficient only at higher 
concentrations (figure 3.17). So ECD was an unsuitable method to use in conjunction with 
C18 separation. 
3.2.5.4 SCX column using pH 3 buffer with 5% (v/v) MeOH as mobile phase
The C18 method was examined by using 5% (v/v) methanol as an organic modifier at pH 6, 
but the mobile phase at pH 3 on the SCX column without the ECD gave good retention of 
neopterin (figure 3.21 A), but as before ACN gave measureable impurities which eluted close 
to elution times of neopterin. Using 5% (v/v) methanol fails to move the ACN impurities 
significantly away from the neopterin peak (figure 3.21 B & C). The presence of 50% ACN in 
the injected sample of neopterin caused the neopterin peaks to split (figure 3.21 E). 7,8-
dihydroneopterin by itself gave a small fluorescent peak at 7.3 minutes and neopterin can be 
seen at 5.3 minutes (figure 3.21 D).
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Figure 3.21 SCX method- Chromatograms of standards using 20 mM AmPO4 with 5% 
(v/v) MeOH mobile phase with only fluorescent detector attached. 10 µL of standards 
were injected onto SCX column using 20 mM AmPO4 with 5% (v/v) MeOH mobile phase and 
neopterin was detected using fluorescence detector. A) Neopterin (1µM) only standard, B) 50 
% ACN in buffer, C) Enhanced scale of 50% ACN in buffer, D) 1µM 7,8-dihydroneopterin 
standard, E) 1µM Neopterin + 50% ACN 
The retention time of neopterin on to the SCX column was ~5.3 minutes (figure 3.20). Elution 
of ACN time was 4 minutes, but there was a small shoulder peak at 4.5 minutes in the ACN in 
buffer sample which could be an impurity. The presence of 50% ACN in the neopterin sample 
had a peak splitting effect on the neopterin peak as two peaks appeared one at 4.7 and the 
other one at 5.3 minutes (figure 3.21). 
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3.2.5.5 SCX column using ECD to oxidize 7,8-dihydroneopterin to neopterin using pH 3 
buffer with 5% (v/v) MeOH as mobile phase
The effectiveness of the 7,8-dihydroneopterin conversion to neopterin by ECD with 50% ACN 
added to the sample (as required for protein precipitation) was examined in the pH 3 using 5% 
(v/v) methanol mobile phase on SCX column. 
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Figure 3.22 SCX method- ECD conversion of 7,8-dihydroneopterin to neopterin with 
post column ECD guard cell using 20 mM AmPO4 with 5% (v/v) MeOH mobile phase. 10 
µL of standards were injected onto SCX column using 20 mM AmPO4 with 5% (v/v) MeOH 
mobile phase and neopterin was detected using fluorescence detector. A) 100 nM Neopterin 
standard (100 nM), B) 50% ACN in buffer, C) Enhanced scale of ACN in buffer sample, D) 
100 nM 7,8-dihydroneopterin standard, E) 100 nM Neopterin + 50% ACN standard, F) 7,8-
dihydroeopterin + 50% ACN standard.
There was a better separation and resolution between neopterin and ACN using the SCX 
column (figure 3.22). Neopterin eluted at ~4.8 minutes while ACN peak appears at ~ 4.3 when 
injected separately. There was a good resolution between neopterin and 7,8-dihydroneopterin 
as 7,8-dihydroneopterin elution time was ~6 minutes. The elution times for neopterin and 7,8-
dihydroneopterin were different with the ECD guard cell switched off. Neopterin eluted at 5.3 
and 7,8-dihydroneopterin eluted at about 7.3 minutes (figure 3.22) which was unusual.
With the guard cell on, the retention time of ACN increased from 4 minutes to 4.3 minutes. 
There were two additional peaks in the ACN in buffer sample, one at 3.1 minutes and another 
smaller peak at 4 minutes, which were absent with the guard column switched off. 
When neopterin is mixed with ACN (1:1) and injected as a standard, it was noticed that there 
were three peaks instead of two as noticed before (figure 3.22 E).  It appeared that neopterin 
peak had been split into two smaller peaks; most of it co-eluting with ACN at ~4.3 minutes 
and a small amount eluting at its usual elution time of ~4.8 minutes. This was seen in the 
fluorescence peak areas of the different peaks. Peak 3.7 seems to be an impurity in ACN. Peak 
observed at 4.3 which was the elution time of ACN, had a peak area of 169375 instead of 
ACN
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about 32835, which was about 5 times more than expected for ACN. Peak at ~4.8 minutes 
where neopterin was expected, should have measured around 110,000 but measure about 
65000 instead. Similar peak splitting was observed when 7,8-dihydroneopterin standard was 
injected with 50% ACN (figure 3.22F). So using of 50% ACN for protein precipitation in the 
samples could have split the neopterin peak. Also presence of another organic modifier in the 
form of MeOH could be resulting into complex ionic interactions between the ACN, stationary 
phase, and the mobile phase along with neopterin.
3.2.5.6 SCX column using pH 3 buffer only with ECD guard cell 
As MeOH and ACN were suspected to play a role in neopterin peak splitting, the SCX column 
was used this time without any organic modifier in the mobile phase and without any ACN in 
the samples. Using the ECD guard cells turned on with an applied potential of +700mV, 
conversion of 7,8-dihydroneopterin to neopterin was again examined. 
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Figure 3.23 SCX method- Chromatograms of standards using 20 mM AmPO4 only as 
mobile phase. 10 µL of standards were injected onto SCX column using 20 mM AmPO4 only 
as mobile phase and neopterin was detected using fluorescence detector. A) Neopterin 
standard (100 nM), B) 100 nM 7,8-dihydroneopterin with the ECD guard cell off and C) 100 
nM 7,8-dihydroneopterin with the ECD guard cell on.
The use of the ECD guard cell did result in a small amount of conversion of 7,8-
dihydroneopterin to neopterin, but it was a tiny percentage of what was expected (figure 3.23). 
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3.2.6 Manganese oxide (MnO2) oxidation- an alternative for acidic tri-iodide treatment
As ECD conversion of 7,8-dihydroneopterin to neopterin was inconsistent and unpredictable 
with C18 and SCX columns, an alternative oxidation method to both ECD and acidic tri-
iodide method was examined. 
Manganese oxide under acidic conditions is widely used as an oxidant in the literature for 
pterin oxidation in urine (Niederwieser et al., 1984b) and in cerebrospinal fluid (Blau et al., 
2003), but has not been reported with serum. To begin with MnO2 oxidation of 7,8-
dihydroneopterin was tested in the mobile phase buffer. In order to understand which reagent 
should be added to the sample first in order to get a 100% conversion of 7,8-dihydroneopterin 
to neopterin and if it makes a difference we tested the following protocols:
1) Protocol 1-100 µL 100 nM 7,8NP standard + 95 µL ACN, centrifuge 20,500g 5 
minutes + 5 µL (1 M HCl) + 10 mg MnO2 15 minutes shaking (ACN before HCl and 
MnO2)
2) Protocol 2-100 µL 100 nM 7,8NP standard + 5 µL HCL+ 10 mg MnO2 15 minutes 
shaking  + 95 µL ACN centrifuge 20,500g 5 minutes (ACN after HCl and MnO2)
3) Protocol 3-100 µL 100 nM 7,8NP standard + 5 µL HCL + 10 mg MnO2 + 95 µL ACN, 
15 minutes shaking, centrifuge 20,500g 5 minutes (ACN together with HCl and MnO2)
The final concentration of 7,8-dihydroneopterin after addition of ACN and HCl was 50 nM. 
So the conversion was compared with 50 nM pure neopterin standard. 
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Figure 3.24 Effect ACN on conversion of 7,8-dihydroneopterin to Neopterin using MnO2
and 1 M HCl using SCX method. 10 µL of samples treated as mentioned below were 
injected onto SCX column using 20 mM AmPO4 with 10% ACN as the mobile phase. 1) 
Protocol 1-100 µL 100 nM 7,8-dihydroneopterin standard + 95 µL ACN, centrifuge 20,500g 5 
minutes + 5 µL (1 M HCl) + 10 mg MnO2 15 minutes shaking (ACN before HCl and MnO2), 
2) Protocol 2-100 µL 100 nM 7,8-dihydroneopterin standard + 5 µL (1 M HCl) + 10 mg MnO2
15 minutes shaking  + 95 µL ACN spin (ACN after HCl and MnO2), 3) Protocol 3-100 µL 100 
nM 7,8-Neopterin standard + 5 µL (1 M HCl) + 10 mg MnO2 + 95 µL ACN 15 minutes 
Shaking, spin inject (ACN together with HCl and MnO2). Neopterin was measured using 
fluorescence detector on the HPLC.  Results are shown as Mean ± SEM for samples in 
duplicates.
The conversion of 7,8-dihydroneopterin to neopterin was 100% following the method 2 
protocol, where HCl was added first followed by MnO2 which converts 7,8-dihydroneopterin 
to neopterin and then ACN was added to replicate the conditions for protein precipitation in 
plasma. With the other 2 protocols, the conversion was approximately 80%. 
It seemed that ACN was interfering with the reaction of MnO2 conversion of 7,8-
dihydroneopterin to neopterin in methods 1 and 3. Another possibility was that the acidic 
buffer used might be affecting the reaction, so the MnO2 oxidation was performed in 
phosphate buffered saline (PBS) to check if acidic conditions were necessary for MnO2 for 
complete conversion (figure 3.25). Similar results were obtained when the MnO2 oxidation 
was carried out in PBS. It was observed that only the addition of 5 µL of HCl and MnO2
before ACN gave complete conversion of 7,8-dihydroneopterinto neopterin and ACN does 
interfere with MnO2 conversion of 7,8-dihydroneopterin to neopterin. It was also seen that 
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addition of HCl itself oxidized about 40% of 7,8-dihydroneopterin to neopterin. When the 
MnO2 was carried out without HCl, the conversion was approximately 25% suggesting that 
MnO2 by itself converts only about 25% of 7,8-dihydroneopterin to neopterin and acidic 
conditions are necessary for complete MnO2 oxidation of 7,8-dihydroneopterin to neopterin 
(figure 3.25). 
Figure 3.25 7,8-dihydroneopterin (prepared in PBS) converted to neopterin using MnO2
and HCl using SCX method. 10 µL of the samples treated as mentioned below were injected 
onto SCX column using 20 mM AmPO4 pH 3 buffer with 10% ACN as mobile phase. 1) 100 
µL standard + 100 µL ACN + 5 µL 1 M HCl, incubate in dark for 15 minutes, 2) 100 µL 
standard + 5 µL 1 M HCl + MnO2, incubate in dark for 15 minutes, then add 100 µL ACN, 3) 
100 µL standard + 5 µL 1M 1 M HCl + 100 µL ACN, NO MnO2, incubate in dark 15 minutes, 
4) 100 µL standard + MnO2 only, incubate in dark 15 minutes + 100 µL ACN, 5) 100 µL 
standard + 100 µL ACN + MnO2, incubate in dark 15 minutes. Neopterin was measured using 
fluorescence method on HPLC. Results are shown as Mean ± SEM for samples in duplicates.
The effect of MnO2 only, HCl by itself and MnO2 with HCl was tested on neopterin to check if 
neopterin was susceptible to oxidation using the conditions used for 7,8-dihydroneopterin 
oxidation to neopterin. MnO2, HCl and MnO2 with HCl did not affect the size and area of 
neopterin peaks and its fluorescence quantification using fluorescence detector (figure 3.26). 
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Figure 3.26 Neopterin (prepared in PBS) treated with MnO2 and HCl and quantified 
using SCX method. 10 µL of the samples treated as mentioned below were injected onto 
SCX column using 20 mM AmPO4 pH 3 buffer with 10% ACN as mobile phase. 1) 100 µL 
standard + 100 µL ACN + 5 µL 1 M HCl + MnO2, incubate in dark for 15 minutes, 2) 100 µl 
standard + MnO2 + 5 µL 1 M HCl, incubate in dark for 20 minutes, then add 100 µL ACN, 3) 
100 µl standard + 5 µl 1M 1 M HCl + 100 µl ACN, NO MnO2, incubate in dark 15 minutes, 4) 
100 µl standard + MnO2 only, incubate in dark 15 minutes + 100 µl ACN, 5) 100 µl standard + 
100 µl ACN + MnO2, incubate in dark 15 minutes
3.2.6.1 Comparison of MnO2 conversion of 7,8-dihydroneopterin to neopterin (linearity) 
in buffer with that in plaque and plasma
The efficiency/linearity of MnO2 conversion was tested in the mobile phase buffer and 
compared with that in the biological samples of plaque and plasma. Plaque or plasma samples 
were spiked with known concentration of 7,8-dihydroneopterin and MnO2 oxidation was 
carried out to oxidize 7,8-dihydroneopterin to neopterin. Since ACN appeared to affect the 
conversion of 7,8-dihydroneopterin to neopterin, 5 µL of 1M HCl and 10 mg of MnO2 were 
added first followed by incubation in dark 15 minutes and then ACN was added to precipitate 
the proteins from the sample. The supernatant, after centrifugation was injected on to the SCX 
column for neopterin quantification (figure 3.27). 
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Figure 3.27 Linearity of MnO2 conversion of 7,8-dihydroneopterin to neopterin in buffer, 
plaque and plasma samples using SCX method. 10 µL supernatants from the 7,8-
dihydroneopterin conversion to neopterin in buffer, plaque homogenate and human plasma 
using MnO2 oxidation using SCX column pumping 20 mM AmPO4 with 10% ACN as mobile 
phase. HCl and MnO2 were added to the samples before ACN. Neopterin was measured using 
fluorescence detector on HPLC. Results are expressed as Mean ± SEM of triplicate of 
samples. 
MnO2 conversion of 7,8-dihydroneopterin to neopterin using MnO2 was linear across the 
concentration range tested (figure 3.27). But in the biological samples like plaque and plasma, 
this conversion is not 100%. In plaque homogenate samples the conversion is only about 63% 
while in plasma it is only about 43%. MnO2 oxidation is not suitable for 7,8-dihydroneopterin 
to neopterin oxidation in protein containing samples.
3.2.7 Alternative methods of protein precipitation 
3.2.7.1 Ultracentrifugation units as an option to ACN for protein removal
As MnO2 conversion was very efficient in the buffer, but addition of ACN (for protein 
removal) was interfering with its oxidation an alternative method of protein removal was 
examined. Ultracentrifugation units (with membrane filters) that filter proteins greater than 
10,000 kDa are often used to remove proteins from the biological samples and have been 
successfully used by laboratories in Austria for neopterin analysis (personal communication). 
Unfortunately the filtration units used by the laboratory are no longer available. So a similar 
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product from Millipore was examined. Two sets of 500 µL of straight serum samples were 
aliquoted into an ultrafiltration tube (Amicon, Millipore™ ),  and centrifuged at 20,000 g for 
about 2 hours as shorter times did not generate enough ultrafiltrate for analysis. The filtrate 
was either injected straight onto the HPLC or treated with either MnO2 or acidic tri-iodide for 
7,8-dihydroneopterin conversion to neopterin. Serum deproteinated with 1:1 ACN was also 
measured for neopterin as a control. 
Figure 3.28 Ultrafiltration unit as an alternative to ACN protein precipitation-Human 
serum ultrafiltrate testing for neopterin and 7,8-dihydroneopterin using acidic tri-iodide 
and MnO2 treatment using SCX method. 10 µL of the samples treated as mentioned below 
were injected onto SCX column using 20 mM AmPO4 pH 3 buffer with 10% ACN as mobile 
phase. 1) Filtrate only, 2) Serum treated with 1:1 ACN, 3) Serum acidic tri-iodide reaction -
100 µL Serum + 100 µL ACN + 40 µL acidic tri-iodide + 20 µL ascorbate, 4) Filtrate acidic 
tri-iodide treatment for 7,8-dihydroneopterin conversion to neopterin- 100 µL Sample + 50 µL 
ACN + 20 µL acidic tri-iodide + 10 µL ascorbate, 5) Filtrate MnO2 treatment for 7,8-
dihydroneopterin oxidation to neopterin - 100 µL Sample + 5 µL 1M HCl + 10 mg MnO2. 
Neopterin was measured using fluorescence detector on the HPLC. Results expressed as Mean 
± SEM of duplicate of samples. 
The ultrafiltrate of human serum contained approximately 7 nM neopterin (figure 3.28 (1)) 
which was approximately what was measured by analysis of ACN treated serum (figure 3.28
(2)). Serum oxidized with acidic tri-iodide showed the expected increase in neopterin as the 
7,8-dihydroneopterin in serum was oxidized to neopterin (figure 3.28 (3)). Ultrafiltrate treated 
with acidic tri-iodide showed no such increase suggesting that 7,8-dihydroneopterin had 
oxidized to a pterin other than neopterin during the ultrafiltration (figure 3.28 (4)). Oddly 
though the MnO2 oxidation did show an increase (figure 3.28 (5)) but not to the amount 
expected as seen in figure 3.27 (3). When the serum sample were spiked with known 7,8-
dihydroneopterin before ultracentrifugation (figure 3.29), filtrate acidic tri-iodide treatment of 
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the filtrate gave a conversion of about 80% whereas MnO2 treated filtrate gave about 103% 
conversion of 7,8-dihydroneopterin. There appears to be considerable inconsistency in this 
method. 
Figure 3.29 Ultracentrifugation unit testing as an alternative to ACN protein 
precipitation-Serum spiked with known 7,8-dihydroneopterin concentration (300 nM) 
and treated using acidic tri-iodide and MnO2 to oxidize 7,8-dihydroneopterin to 
neopterin and neopterin measured using SCX. 10 µL of the samples treated as mentioned 
below were injected onto SCX column using 20 mM AmPO4 pH 3 buffer with 10% ACN as 
mobile phase. 1) Filtrate only, 2) Serum treated with 1:1 ACN, 3) Serum acidic tri-iodide
reaction - 100 µL Serum + 100 µL ACN + 40 µL acidic tri-iodide + 20 µL ascorbate, 4) 
Filtrate acidic tri-iodide treatment for 7,8-dihydroneopterin conversion to neopterin- 100 µL 
Sample + 50 µL ACN + 20 µL acidic tri-iodide + 10 µL ascorbate, 5) Filtrate MnO2 treatment 
for 7,8-dihydroneopterin oxidation to neopterin - 100 µL Sample + 5 µL 1M HCl + 10 mg 
MnO2 . Neopterin was measured using fluorescence detector on the HPLC. Results expressed 
as Mean ± SEM of duplicate of samples. 
3.2.7.2 Alternative precipitating agents
Since ACN interference with the MnO2 was making MnO2 oxidation method not suitable to 
use, and MnO2 oxidation of 7,8-dihydroneopterin to neopterin was only sometimes 100% 
efficient, we tried looking at some alternative protein precipitating agents like ice-cold 
methanol, ethanol, isopropanol and acetone. Concentration used for protein precipitation was 
in the ratio of 1:1 as in case of ACN. When the ability of these protein precipitating agents 
was tested on serum samples, it was found that all the reagents above did not result in 
complete precipitation of the samples protein. The supernatants were cloudy due to proteins 
still present after 10 minutes of centrifugation at 20,500 g at 4ºC. On the contrary ACN 
resulted in clear supernatant at the 1:1 ratio used using the same method.
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3.2.8 Discussion
3.2.8.1 Problems with C18 column 
Neopterin detection and its accurate quantification is an essential tool in monitoring the 
progression of many diseases including atherosclerosis where the 7,8-dihydroneopterin and 
neopterin levels are elevated through macrophage activation. Several methods have been 
reported in the literature for neopterin detection and quantification using HPLC, most of them 
using the reverse-phase technique. Werner et al., (Werner et al., 1987a) used a reverse phase 
C18 method with 15 mM potassium phosphate buffer at pH 6.4 for neopterin measurement in 
urine and a two-step C18 column method using water and 0.1g/L SDS (adjusted to pH 4 using 
TCA) as the mobile phase. Marfella et al., (Marfella et al., 1992) used C18 method for urinary 
neopterin detection using similar conditions as Werner et al., (1987), whereas Rippin (Rippin, 
1992) and Carru et al., (Carru et al., 2004) also utilized reverse phase C18 method for serum 
neopterin quantification using 50 mM potassium phosphate buffer pH 6 with 5% (v/v) MeOH 
and water and ACN (99/1, v/v) respectively for the same. 
Our lab also used a reverse-phase C18 method with 20 mM AmPO4 buffer pH 6 with 5% (v/v) 
MeOH as the mobile phase and TCA as a protein precipitant. TCA caused loss of 7,8-
dihydroneopterin from the samples so ACN was used as a protein precipitant to prevent the 
loss of 7,8-dihydroneopterin. With ACN a contaminant peak which fluoresced at the same 
wavelengths as neopterin was noticed about 5 years ago due to the changes in the 
manufacturing practices of ACN after the financial crisis. This contaminant in the HPLC grade 
ACN used for protein precipitation for biological samples for neopterin and 7,8-
dihydroneopterin detection and quantification eluted very close to neopterin (at about ~4.3 
minutes, compared to neopterin at ~4 minutes) (figure 3.4). This is an acceptable level of 
separation when the C18 column is new but over time the retention times of both neopterin 
and ACN contaminant changes, such that ACN contaminant interferes with neopterin and co-
elutes with neopterin (figure 3.5). Elution time of 7,8-dihydroneopterin was also almost the 
same as ACN and very close to neopterin which could potentially add to the interference 
and/or over/underestimation of neopterin in the biological samples (figure 3.6). ACN 
interference can be clearly seen when increasing concentrations of ACN are mixed with 
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neopterin (figure 3.7). The neopterin peak is altered such that a shoulder peak appears in the 
presence of 20% ACN, and the peak splitting increases as ACN concentration increases to 
50% (figure 3.7). Also addition of ACN to the mobile phase by other researchers previously 
has been found to reduce the retention time of neopterin further complicating the sensitivity of 
the assay (unpublished observations).
When ECD was used in combination with C18 column to oxidize 7,8-dihydroneopterin to 
neopterin, the maximum ECD conversion of 7,8-dihydroneopterin to neopterin was only 82%. 
This conversion was much less (about 30-50%) at the lower concentrations of 7,8-
dihydroneopterin normally found within the plasma of atherosclerotic patients (figure 3.17). 
The C18 column method using ECD conversion of 7,8-dihydroneopterin also posed problems 
when used for neopterin quantification in plaque homogenate where 1:1 ACN was used to 
precipitate the proteins. Although 7,8-dihydroneopterin appeared to be oxidized to neopterin, 
there was an increase in fluorescence of the ACN contaminant peak too. The ACN 
contaminant peak fluorescence increased with ECD oxidation which increased the interference 
with the (figure 3.20). This could amplify the interference of ACN with neopterin affecting its 
detection and quantification at lower neopterin and 7,8-dihydroneopterin concentrations. 
3.2.8.2 SCX method development issues
ECD conversion of 7,8-dihydroneopterin to neopterin using SCX column was inconsistent and 
unpredictable. Although the SCX and ECD method gave a good resolution between neopterin 
and 7,8-dihydroneopterin using 5% (v/v) MeOH, the presence of 50% ACN led to peak 
splitting of neopterin (figure 3.21 and 3.22). This could be due to the complex interactions 
between neopterin, methanol, water and ACN. The possibility of any residual or applied 
charge on the guard cell affecting the behavior of the analyte and the mobile phase 
components could also be a possibility. When the ECD guard cell conversion of 7,8-
dihydroneopterin to neopterin without any organic modifier was only about 30% (figure 3.23). 
It could be due to the fact that the applied potential for 7,8-dihydroneopterin oxidation to 
neopterin at pH 3 is different from that of the applied potential obtained at pH 6. 
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The urinary neopterin and total pterin when measured by both SCX and C18 methods, showed 
that neopterin concentrations could be overestimated by C18 method by up to 40-50%. The 
total pterin values appeared higher with SCX, probably due to better separation and retention 
of neopterin without any interference due to acidic tri-iodide or ascorbate used in 7,8-
dihydroneopterin treatment (figure 3.21). 
When the buffer (pH 3) without any organic modifier was used, the ACN contaminant and 
neopterin were well separated on the SCX (figure 3.8). The same buffer at pH 6 resulted in co-
elution of ACN and neopterin at ~4 minutes, with very little resolution between neopterin and 
7,8-dihydroneopterin which eluted at ~4.2 minutes (figure 3.9). Addition of 5% (v/v) ACN to 
increase the polarity of the mobile phase reduced the retention time of neopterin and the 
contaminant and did not resolve the peaks (figure 3.10). Since SCX chromatography resulted 
in better separation of neopterin and contaminant peak as neopterin is more protonated at pH 
3, these mobile phase conditions were further used to develop the method. Although the 
neopterin and the contaminant peaks were resolved, over time the contaminant could interfere 
with neopterin. So to separate ACN contaminate peak or mask its fluorescence in the 
chromatography, we added 50% ACN as an organic modifier to the mobile phase. The 
fluorescence ACN contamination peak disappeared with 50% ACN in the mobile phase 
(figure 3.11 B-D) while neopterin and 7,8-dihydroneopterin were also better separated by 0.5 
minutes. Using 50% ACN was not cost-effective for the assay considering a large amount of 
samples are analyzed for neopterin and 7,8-dihydroneopterin in our laboratory. So the ACN 
percentage was dropped down to 10% to mask the contaminant peak. 
Using 10% ACN did not mask the contaminant peak completely (figure 3.13) but masked its 
fluorescence to leave a very tiny peak, eluting about 0.5 minutes earlier than neopterin (figure 
3.13). As the peak was very small and well resolved from neopterin, using 10% ACN as the 
mobile phase was finalized. The standard curves for neopterin using 50% ACN and 10% ACN 
in the mobile phase were both very similar (figure 3.12 and 3.14) and did not affect the 
neopterin fluorescence area for a range of neopterin concentrations. This method which 
employed 20mM AmPO4 pH 3 + 10% ACN as the mobile phase was used for neopterin 
analysis throughout this research as it removed ACN interference with neopterin giving 
reproducible, robust and accurate neopterin/7,8-dihydroneopterin measurements. 
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3.2.8.3 MnO2 oxidation as an alternative for acidic tri-iodide oxidation for SCX column
Polar solvents inhibit or have a deactivating effect on the MnO2 oxidation (Organic synthesis 
Smith 1999 edition), which could explain why the MnO2 oxidation was incomplete in the 
presence of ACN (figure 3.24 and 3.25). As a result ACN could not be added to precipitate the 
proteins in the biological samples like plasma/serum or plaque homogenate. Although MnO2
oxidation method has been successfully used previously in oxidation of pterins in urine (Blau
et al., 1992) and in cerebrospinal fluid (Blau et al., 2003), it was not effective when the 
oxidation of 7,8-dihydroneopterin was performed in plasma and in plaque homogenate (figure 
3.27). Oxidation was about 62% in plaque homogenate and 43% in the plasma suggests that 
the large amount of protein interfered with MnO2 oxidation. So this method of oxidation of 
7,8-dihydroneopterin to neopterin could not be used for our HPLC quantification of 7,8-
dihydroneopterin in plaques or plasma/serum. 
3.2.8.4 Protein precipitation alternatives 
Although the ultrafiltration units seem to work well in combination with MnO2 oxidation 
method of 7,8-dihydroneopterin to neopterin, the procedure took 2 hours. There was some 
problems of reproducibility with the long spin times where the 7,8-dihydroneopterin was 
being oxidized to pterins other than neopterin. The volume of filtrate was also low due to the 
serum proteins blinding the filter making it sample volume insufficient for HPLC analysis. 
Protein precipitation studies done by Polson et al., (Polson et al., 2003) shows that ethanol and 
methanol are not as efficient as ACN in precipitating the proteins due to their higher ionization 
effects as compared to ACN. This could explain why addition of other organic solvents such 
as ice-cold ethanol, isopropanol, showed incomplete precipitation of serum. Low efficiency of 
alcohols in protein precipitation has been documented in the literature (Biddlecombe and 
Pleasance, 1999). Although acetone are used routinely in protein precipitation of biological 
samples (eg serum), the volume used is often 2-4 times the sample (Jiang et al., 2004) which is 
again ideal for neopterin and 7,8-dihydroneopterin due to their lower concentrations in serum. 
An additional problem was the ethanol, isopropanol as well as acetone also caused inhibition 
of MnO2 oxidation of 7,8-dihydroneopterin to neopterin. 
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4. QUANTIFICATION AND COMPARISON OF BIOMARKERS IN 
CAROTID AND FEMORAL PLAQUES
4.1 Introduction
4.1.1 Carotid and femoral artery plaques differ in their morphology
In theory the entire coronary and femoral arterial tree is exposed to the atherogenic effect of 
the systemic risk factors. Atherosclerotic lesions are often found at specific arterial regions 
such as branch points and bifurcation of arteries where the blood flow is often disturbed. This 
lesion formation has been attributed to the changes in hemodynamic forces that include flow-
generated shear stress and blood pressure generated tensile stress. Endothelial shear stress 
(ESS) is often found to be low and oscillatory at these sites and has been implicated to play a 
fundamental role in the pathogenesis of atherosclerosis (Chatzizisis et al., 2007).  It was 
previously accepted notion that the arterial system remodels itself to maintain a constant wall 
shear stress throughout.  But studies have shown that the shear rate which is defined as the 
spatial gradient of blood flow velocity which determines the shear stress differs significantly 
between different arterial beds (Stroev et al., 2007, Wu et al., 2004, Chatzizisis et al., 2007). 
ESS is an important determinant of endothelial function where it modulates endothelial gene 
expression via complex mechanotransduction and mechanoreception processes inducing 
atherogenic phenotype (Chatzizisis et al., 2007). 
Moreover the differences in the wall shear rate reflected the difference in propensity of 
atherosclerosis in the different arterial beds. The lowest and most oscillatory wall shear rate 
was seen in superficial femoral artery and the occurrence of atherosclerosis was higher than in 
common carotid or brachial arteries using MRI (Wu et al., 2004). Similar results were 
obtained where the wall shear stress was found to be highest in carotid artery than in brachial 
artery and lowest in femoral artery using specially designed ultrasound system (Reneman and 
Hoeks, 2008). This could potentially explain why the morphology of carotid and femoral 
plaques is significantly different where carotid arteries displayed more lipid and inflammatory 
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content than in femoral plaques, whereas femoral plaques displayed greater calcification than 
carotid and osteoid metaplasia (Herisson et al., 2011). Furthermore, intrinsic differences in the 
arterial wall could also explain why the blood vessels show a disparate behavior to common 
systemic risk factors.  It was shown that aortic homograft which are more prone to 
atherosclerosis transplanted to atherosclerotic-resistant positions like thoracic aorta still 
developed severe atherosclerotic lesions when the adjoining regions of the thoracic aorta 
remained lesion free (Herisson et al., 2011). Studies have also implicated the diversity in the 
origin of vascular cells to play a role in developmental role of atherogenesis. For example, 
smooth muscle cells arise from distinct sources of progenitors, each with its own unique 
lineage and developmental history and so their behavior in atherosclerosis is specific to the 
vascular bed (Herisson et al., 2011). Taking all the above factors one can understand that site 
specific arterial wall structure along with the differential blood flow patterns could have a 
profound impact on the development and progression of plaques and the clinical outcome.
Differences in morphology of carotid and femoral plaques are further emphasized by the 
heterogeneity in the macrophage subtypes and/or numbers and T-cell numbers that inhabit 
these plaques (Shaikh et al., 2012). Carotid plaques have been shown to have a significantly 
increased percentage of macrophage and T-cell infiltrates per unit area as compared to femoral 
plaques consistent with the more inflammatory phenotype (Shaikh et al., 2012). In carotid 
plaques, the proportion of M1 macrophage phenotype that are pro-inflammatory was 
significantly more than M2 phenotype which are anti-inflammatory in carotid plaques, 
whereas femoral plaques displayed a greater proportion of M2 macrophages (Shaikh et al., 
2012). 
4.1.2 Biomarker comparison between carotid and femoral artery plaques
Different vascular beds are subjected to a different degree of shear stress on the walls of the 
arteries, which depend on their location from the heart, blood vessel diameter and the velocity 
of the blood flow. As reported by Stroev et al., (Stroev et al., 2007) shear wall stress is highest 
in carotid artery followed by femoral artery and  lowest in brachial artery. Degree of shear 
stress may play a role in the initiation, formation, progression and rupture of these plaques
(Chatzizisis et al., 2007, Helderman et al., 2007).  The plaques formed under different levels 
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of shear stress potentially represent different oxidative environments influencing its initiation, 
growth and progression. As site specific arterial wall structure could also have a potential 
influence on how a plaque develops due to the marked differences in its blood flow patterns 
and the origin of the vascular cells, we decided to look at the variation in the oxidative 
biomarker patterns in the two most common arteries where an atherosclerotic plaque develops, 
carotid and femoral artery.   
Although many epidemiologic studies have been carried out to link biomarkers of 
cardiovascular risk to the incident and prevalence of atherosclerosis, exact anatomic 
relationships between the biomarkers of carotid and femoral arteries is still unclear. Inherent 
differences in the plaque morphology of carotid and femoral plaques combined with their 
variations in clinical outcome suggest the need to better understand the inflammation, 
oxidative modifications of lipids and proteins associated with the different patterns of 
coronary and femoral plaque formation. Some work has been published with regards to 
assessing the cardiovascular risk of carotid and femoral plaques  using different parameters 
like the intima-media thickness using ultrasound, lipid profile, CRP/immune activation, 
smoking/smokeless tobacco use, morphology, cellular composition, inflammatory mediators 
and the echogenicity (Wallenfeldt et al., 2001, Herisson et al., 2011, Zhou et al., 2010, Craiem
et al., 2009). There has been a study to determine the association of blood biomarkers of 
inflammation and oxidation with varying forms of coronary plaques as quantified coronary CT 
angiography (Bamberg et al., 2012). This study by Bamberg et al., showed that subjects with 
non-calcified plaque had significantly higher levels of high-sensitivity C-reactive protein and 
oxidized LDL (oxLDL) in their blood, when compared with subjects with calcified plaques.  It 
would be ideal to study the blood biomarkers associated with femoral plaques as well and 
compare the variation in the different oxidative biomarkers. But practically it might be 
difficult to find a person with only a coronary plaque or a femoral plaque. Usually the 
occurrence of plaque in one vascular territory means that the individual is likely to be prone to 
development of plaques in other areas (Rothwell et al., 2003). The association of blood 
biomarkers in the study of Bamberg et al., (Bamberg et al., 2012) could be a combination of 
markers released from coronary and femoral plaques. 
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We hypothesized that the biomarkers associated with carotid and femoral plaques will be 
different to each other. Biomarkers have been studied in plaques but none of the studies have 
looked at their variation across the length of the plaque. There have been no studies looking at 
whether oxidative biomarkers differ between carotid and femoral plaques. So we set out to 
understand the distribution of biomarkers in carotid and femoral plaques. This will help us to 
understand how biochemical processes such as oxidative stress and inflammation relate to the 
changes in morphology and cellular compositions of atheromatous plaques. Biomarker 
variances and their correlations could provide us with vital information about the pathogenesis 
of the disease, their role in differential clinical outcomes and potentially tailoring appropriate 
therapy. 
To better understand the oxidative microenvironments within these morphologically and 
physiologically distinct plaques, a range of biomarkers such as inflammatory marker neopterin 
as well as total pterin (neopterin + 7,8-dihydroneopterin), lipid soluble antioxidant •-
tocopherol, the general lipid oxidation marker thiobarbituric acid reactive substances 
(TBARS), oxysterol 7-ketocholesterol, protein oxidation markers DOPA, Dityrosine and 
protein carbonyls (AAS and GGS) along with total protein and cholesterol were measured. 
This could potentially give more detailed information on the kind of oxidative stress and 
degree of inflammation that ensues, directing the course of progression of this cardiovascular 
disease. This will also shed more light on the possible relationships if any between the oxidant 
attacks and the antioxidant defenses that occur in the plaque environment. This study will 
provide insights into the role of 7,8-dihydroneopterin in plaques from different arterial beds. 
4.2 Atherosclerotic plaques as the source of plasma 7,8-dihydroneopterin and neopterin
Since 7,8-dihydroneopterin is produced by macrophages on IFN-• stimulation and then 
secreted outside the cells, its concentration along with neopterin is most likely to be highest at 
the sites of inflammation. Previous studies using neopterin as a biomarker measure the 
amounts of this pterin in the serum/plasma of the patients where the source of the neopterin 
could be from multiple sites of inflammation in the body. Although many studies have showed 
the localization of IFN-• and macrophages in plaques, none of the studies to date have 
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demonstrated that IFN-• stimulation of freshly excised, advanced atherosclerotic plaques can 
produce 7,8-dihydroneopterin in vitro. 
4.3 Plasma neopterin and 7,8-dihydroneopterin concentrations in Healthy volunteers and 
Atherosclerotic patients
Elevated neopterin levels occur in response to a wide range of infections, such as viral 
infection, bone marrow transplants, septicaemia, diabetes, cancers, HIV, arthritis, multiple 
sclerosis and atherosclerosis (Hoffmann et al., 2003). It has been observed that there are high 
correlations between neopterin increase and the severity of the inflammatory infection or 
malignant disease (Hoffmann et al., 2003). Neopterin and 7,8-dihydroneopterin concentrations 
were measured in patient plasma undergoing carotid and femoral endarterectomy taken during 
the therapeutic procedure and compared with that of the healthy volunteers. Their levels were 
also compared between carotid and femoral atherosclerotic patients to understand if there are 
any variations. 
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4.4 Results
Previously in our laboratory, 24 atherosclerotic plaques have been biochemically analyzed 
designated as ‘Laboratory plaques’. In addition to them, 11 more atherosclerotic plaques A-K 
(serially labeled as per their analysis sequence) were analyzed during this study. So plaques A-
K correspond to the ‘Laboratory plaques’ 25 to 35. They have further been grouped together 
as per the origin of the plaque. Results from the 5 carotid plaques (B, C, E, F and I) are 
presented first, followed by the 5 femoral plaques (A, D, G, H and J) and a control iliac artery 
(K). 
A brief summary of the patient information and the plaque information for the 10 
atherosclerotic plaques and the control is listed in table 4.1.1 and 4.1.2. Information about the 
medications that the patients were put on, along with the blood pressure, stenosis, dietary 
supplements, smoking and diabetes was also obtained wherever possible. 
The plaques were excised from the patients within the age range of 62-86 years, out of which 
2 plaques were in the range of 60-70 years, 4 plaques in the range of 71-80 and 4 plaques in 
the range of 81-90. All the 10 plaques analyzed were in the advanced stages of the disease, 
with patients presenting a range of the symptoms including stroke, transient ischemic attack 
(very short lived occlusion of the artery in brain) and amaurosis fugax (temporary loss of 
vision) among others.
Blood pressure, stenosis, smoker and diabetic status information for all the patients could not 
be obtained due to logistical issues (table 4.2). The plaques were analyzed based on the 
information available for all the plaques to avoid any ambiguity in the correlations observed. 
Based on their morphology, plaques were classified as thrombus (thrombus-containing), 
calcified (no thrombus and calcification) or neither.
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Table 4.1 Summary of Patient Information for Plaques A-K.
Plaque LabPlaque
No.
Age Sex(M/F)
Stenosis
(%)
Blood 
Pressure
Smoker
(Y/N)
Diabetic
(Y/N)
Location
Carotid Femoral
A 25 64 F - - Y N Þ
B 26 76 M 96 159/62 N N Þ
C 27 86 M 79 - - - Þ
D 28 81 F 70-90 154/72 N Y Þ
E 29 78 M 60-69 - N N Þ
F 30 63 F 80-95 128/68 Y N Þ
G 31 70 M - 162/81 N Y Þ
H 32 81 F - - - - Þ
I 33 75 F 50-59 220/80 N N Þ
J 34 81 M 70 - Ex - Þ
K 35 62 F - - - - Þ
Table 4.2 Summary of Plaque Information in Plaques A-K.
Plaque PlaqueNo.
Plaque
Database
No.
Total
Mass (mg) Morp. Comp.
Sections
N
Location
Carotid Femoral
A 25 27 0.948 Linear Calcified 6 Þ
B 26 30 1.270 Y Thrombus 7 Þ
C 27 26 0.667 Y Neither 9 Þ
D 28 38 1.071 Linear Calcified 7 Þ
E 29 41 1.376 Y Thrombus 7 Þ
F 30 44 1.507 Y Thrombus 9 Þ
G 31 54 2.616 Linear Calcified 5 Þ
H 32 59 1.435 Linear Calcified 6 Þ
I 33 64 0.852 Y Neither 5 Þ
J 34 66 3.240 Linear Calcified 5 Þ
K 35 52 0.441 Y Neither 3 Þ
Overall morphology (Morp.): Y – Y shaped, Small – small secondary branch and linear; 
Overall composition (Comp.): Thrombus (with a thrombus), calcified or neither; Section (N):  
number of sections each plaque was homogenised into. Location: Arterial location of the 
plaque
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4.4.1 Carotid Plaques
4.4.1.1 Plaque B (Laboratory Plaque no. 26)
Plaque B was excised from left internal carotid artery of a 76 year-old male patient. It was 
characterized by 96% stenosis as measured by ultrasound, and was 30 mm in length with a 
small branch of bifurcation. The patient was a non-smoker and a non-diabetic. There was little 
calcification across the sections, with visible yellowish tinge of soft, lipid-like material across 
all the 7 sections (figure 4.1). 
The protein content in this plaque was in the range of 78-166 mg/g plaque. Highest 
concentration of 166 ± 1 nmole/g plaque was found in the 1st section while the lowest content 
of 79 ± 10 nmole/g plaque was found in section 3 (figure 4.2 A). Apart from a significant drop 
in protein concentration in section 3, there was little variation in the other sections. Cholesterol 
concentration followed a similar trend as protein till the 3rd section, dropping down in the 4th
only to significantly rise across 5th, 6th and 7th section (figure 4.2 B). Neopterin was in the 
range of 3.5-5.5 pmoles/g plaque while total pterin was 38-76 pmoles/g plaque (figure 4.2 C). 
A significant variation in total pterin content was found in sections 2, 4, 5 and 7. •-tocopherol 
also followed cholesterol decreasing continuously till the 3rd section and rising across sections 
4 to 7 (figure 4.2 D). 
TBARS content was lowest in section 3, positively correlating with •-tocopherol and protein
(figure 4.3 A). Highest concentration of lipid oxidation was found in section 7. Protein 
carbonyls- AAS showed positive correlation with the protein content across the 7 sections, 
lowest concentration being found in section 3 (figure 4.3 B). GGS content did not show any 
significant variation across any sections. Although dityrosine did not show any particular trend 
across the sections (figure 4.3 D). DOPA concentrations varied significantly across most of 
the sections (figure 4.3 C). It showed positive correlation with AAS in sections 1 to 4 and with 
protein content for sections 1 to 3. Free and total KC levels did not show any significant 
variations or correlations across all the 7 sections. Highest concentration of total KC was 
found in section 7 and lowest in section 3 (figure 4.3 E). Overall in this plaque, there was a 
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strong positive trend in the concentrations of cholesterol and •-tocopherol as seen before in 
plaque A.
Figure 4.1 Sectioning of Plaque B.Plaque B was excised from the left carotid artery of a 76 
year-old male, cut into 7 sections of about 3-5 mm. 
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Figure 4.2 Plaque B: Protein, Cholesterol, Neopterin and •-Tocopherol content. Protein 
(A) and cholesterol (B) concentrations were determined spectrophotometrically while 
neopterin/Total pterin (C) and •-tocopherol (D) were quantified by SCX and reverse-phase
C18 methods respectively using the HPLC as described in methods. Each bar represents the 
Mean ± SEM of the samples analyzed in triplicates.
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Figure 4.3 Plaque B: Lipid and Protein oxidation markers. TBARS (A), Protein carbonyls 
AAS & GGS (B), DOPA (C), Dityrosine (D) and 7-KC (E) were quantified by reverse-phase
C18 method using HPLC as described in methods. Each bar represents the Mean ± SEM of the 
samples analyzed in triplicates.
Both, cholesterol and •-tocopherol were related to the amount of protein in the proximal 3 
sections, but not in the rest of the 4 sections. There was a large variation across the 7 sections 
tested in this plaque. 
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4.4.1.2 Plaque C (Laboratory Plaque no. 27)
Plaque C with a total mass of about 0.67 grams was removed from the right internal carotid 
artery of an 86 year-old male patient. It showed 79% stenosis. This plaque was cut into 9 
sections.
To make it easier for sectioning this plaque, the sections were cut as shown in the figure 4.4. 
The thinner branch of the two had a small outgrowth, which looked similar to a bifurcation. 
This plaque did not show any signs of calcification throughout its length, nor did it show any 
signs of thrombotic or lipid-like core in its sections. 
Protein content showed a significant increase between section 2 and 3, which remained similar 
until a significant drop between section 6 and 7 (figure 4.5 A). Most of the protein in this 
plaque is concentrated in the thinner branch of the plaque made up by sections 1-5. 
Cholesterol levels across the 9 sections varied significantly across the 9 sections. Section 3 
had highest cholesterol (figure 4.5 B). Interestingly, section 2 which forms the base of section 
3 had approximately 5 times less cholesterol per mg of the tissue, than section 3. This also was 
true for total pterin content, which sharply dropped in section 4, remained steady in sections 5 
and 6, dipping sharply in section 7 (figure 4.5 C). Total pterin concentration was 18.9 nmol/g 
plaque and neopterin concentration was highest at 2.8 nmol/g plaque, found in section 6.  
Section 3 which had the highest concentration of 7,8-dihydroneopterin in the tissue, which 
reached micromolar in its range, the range where 7,8-dihydroneopterin can protect 
macrophages from an oxidative insult (figure 4.5 C). •-Tocopherol content correlated 
negatively with total pterin, cholesterol and protein in section 3 (figure 4.5 D). The 
concentration of •-tocopherol was in the range of 22-133 nmoles/g plaque. Sections 3, 4, 5 
and 6 had lower levels than sections 1 and 2 or sections 7,8 and 9. 
TBARS concentration showed a positive correlation with cholesterol, protein and total pterin, 
but negative correlation with •-tocopherol in section 3 (figure 4.6 A). Apart from section 3 
and 5 which had 49 and 38 nmoles/g plaque respectively, all the other sections had TBARS 
content in the range of 9-21 nmoles/g plaque. AAS content did not vary significantly across 
sections 1-6, but dropped sharply in section 7. The concentration ranges within 29–117 
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nmoles/g plaque for AAS, lowest being in section 7 and highest being in section 5. There were 
no correlations of AAS content with other biomarkers (figure 4.6 B).  
Figure 4.4 Sectioning of Plaque C. Plaque C was ectomised from the right carotid artery of 
an 86 year-old male and cut into 9 sections of about 3-5 mm. 
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Figure 4.5 Plaque C:  Protein, Cholesterol, Neopterin and •-Tocopherol content. Protein 
(A) and cholesterol (B) concentrations were determined spectrophotometrically while 
neopterin/Total pterin (C) and •-tocopherol (D) were quantified by SCX and reverse-phase
C18 methods respectively using the HPLC as described in methods. Each bar represents the 
Mean ± SEM of the samples analyzed in triplicates.
GGS content was similar in the first 7 sections, but significantly rose in section 8 (figure 4.6 
B). The majority of the DOPA in this plaque was present in the first 6 sections, which 
significantly dropped between section 1 and 2, as well as 5 and 6 and rose between section 4 
and 5 (figure 4.6 C). 5th section had highest amount of DOPA which positively correlated with 
AAS in the same section. With regards to dityrosine, highest concentration was found in 
section 1, which dropped significantly in section 2 (figure 4.6 D). It remained consistent 
across all the other sections except a brief but significant rise between section 5 and 6. Most of 
the ketocholesterol was esterified across all the section of plaque C. Free KC levels did not 
vary much except a significant drop between section 3 and 4. The total KC levels were highest 
in section 3 and 4, and lowest in section 2 (figure 4.6 E). 
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Figure 4.6 Plaque C Lipid and Protein oxidation markers. TBARS (A), Protein carbonyls 
AAS & GGS (B), DOPA (C), Dityrosine (D) and 7-KC (E) were quantified by reverse-phase
C18 method using HPLC as described in methods. Each bar represents the Mean ± SEM of the 
samples analyzed in triplicates.
Total KC across sections 2 and 3 had a significant increase while the levels dropped 
significantly between section 4 and 5 (figure 4.6). 
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Notable in this plaque was section 3 which had highest amounts of protein, cholesterol total 
pterin, TBARS and total KC, while lowest amounts of •-tocopherol. This plaque was very 
interesting in the oxidative biomarker concentrations across its sections. Sections 1 and 6, 
although both being a part of the base of the plaque, showed a significant variation in the 
oxidative biomarker concentrations of cholesterol, 7,8-dihydroneopterin, •-tocopherol, 
TBARS and total KC.
A strong positive correlation was found between cholesterol, pterins and TBARS and total 
KC, while a negative relationship was observed between TBARS and dityrosine, •-tocopherol 
and dityrosine as well as 7,8-dihydroneopterin and dityrosine, and 7,8-dihydroneopterin and •-
tocopherol. Section 2 and section 3 were also of interest in their biomarker variations. 
Significant differences were noted within these sections for cholesterol, 7,8-dihydroneopterin 
(as total pterin), •-tocopherol, TBARS and total KC. 7,8-dihydroneopterin, cholesterol 
TBARS and total KC concentrations were significantly higher (P<0.001) in section 3 while •-
tocopherol was significantly lower than section 2. As we analyze the localization of 
biomarkers in section 2 and 4, it becomes clear that although the sections are adjacent to each 
other, they show significant changes in the biomarker concentrations. 7,8-dihydroneopterin 
concentration is significantly higher and so is total KC and protein carbonyl (AAS) content in 
these sections. This plaque is one of the best examples of dynamic and ‘active’ nature of 
constant remodeling of plaque through the process of inflammation and oxidative stress as 
seen by the large variations in the biomarker concentrations. 
. 
4.4.1.3 Plaque E (Laboratory Plaque no. 29)
Plaque E was removed from a right internal carotid artery of a 78 year-old male patient 
without any history of smoking or diabetes. This plaque had 2 branches, a thick, lipid-filled 
(yellowish) main branch, and a thinner branch with a thrombus in it. The second section which 
embodied a thrombus, was also slightly more calcified due to which there was slight 
crumbling of the section. Calcification began in section 2, and seemed to continue throughout 
the rest of the plaque, even across the bifurcation. Sections 4-7 were more lipid-filled and so 
appeared yellowish. 
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This plaque had consistent protein content across 6 of the 7 sections (figure 4.8 A). There was 
a large and significant rise in the 7th section where the protein concentration reaches its highest 
at 142 mg/g plaque. Cholesterol concentration was in the range of 67-117 µmoles/g plaque, 
without any significant rise or fall across the 7 sections (figure 4.8 B). There was, although an 
upward trend as the concentration gradually rose from section 1 to 4. Neopterin in this plaque 
was at its lowest concentration in section 7 and highest in section 3 at 294 pmoles/g plaque. 
Total pterin reached its maximum in section 7 with 2290 pmoles/g plaque (figure 4.8 C). This 
means that majority of 7,8-dihydroneopterin concentration (in the range of 0.7-2.2 µM) within 
these sections was not oxidized. •-Tocopherol content remained in the range of 135-268 
nmoles/g plaque without any significant variations (figure 4.8 D). 
TBARS levels rose from sections 1 to 3, peaking at 8.4 nmoles/g plaque before significantly 
dropping to 3.8 nmoles/g plaque (figure 4.9 A). It then remained similar without any notable 
variations. AAS content was 113 nmoles/g plaque, highest in section 1, and lowest in section 6 
at 46 nmoles/g plaque. AAS remained more or less consistent in sections 1-5 before plunging 
down to its lowest in section 6. GGS varied from 10 to 41 nmoles/g plaque across the 7 
sections. There is a significant rise in section 2 and 4 along with a significant drop in GGS 
concentration in section 6 (figure 4.9 B). DOPA does not vary much across the sections 1-5, 
but it drops significantly in section 6, to remain insignificantly different in section 7 (figure 
4.9 C). Dityrosine content was very low in section 1, but rose significantly in section 2 at its 
highest of 21 nmoles/g plaque (figure 4.9 D). It showed a decreasing, but significant trend 
until the last section where the dityrosine was below the detectable range, if any. This appears 
to follow the trend of neopterin, both of which can be formed by HOCl oxidation. 
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Figure 4.7 Sectioning of Plaque E. Plaque E was from the right internal carotid artery of a 78 
year-old male. It was cut into 7 sections of about 3-5 mm.
Chapter 4
148
A)  B)
C)  D)  
Figure 4.8 Plaque E: Protein, Cholesterol, Neopterin and •-Tocopherol content. Protein 
(A) and cholesterol (B) concentrations were determined spectrophotometrically while 
neopterin/Total pterin (C) and •-tocopherol (D) were quantified by SCX and reverse-phase
C18 methods respectively using the HPLC as described in methods. Each bar represents the 
Mean ± SEM of the samples analyzed in triplicates.
Free KC did not show much change throughout the 7 sections. Total KC showed a rise in 
section 5 and a large drop in section 6. Total KC in section 6 showed positive correlation with 
•-tocopherol in the same section (figure 4.9 E). This plaque showed some correlations across 
the sections for some of the biomarkers tested. Protein concentrations correlated positively 
with 7,8-dihydroneopterin and negatively with neopterin. Overall, cholesterol showed a 
positive relationship with •-tocopherol. For three of the proximal sections, neopterin 
correlated positively and 7,8-dihydroneopterin correlated negatively with TBARS levels. Also 
protein and TBARS for sections 1, 2 and 3 showed negative correlation. GGS protein 
carbonyls showed a positive correlation with free KC levels in sections 5 and 6 (figure 4.9). 
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Figure 4.9 Plaque E: Lipid and Protein oxidation markers. TBARS (A), Protein carbonyls 
AAS & GGS (B), DOPA (C), Dityrosine (D) and 7-KC (E) were quantified by reverse-phase
C18 method using HPLC as described in methods. Each bar represents the Mean ± SEM of the 
samples analyzed in triplicates.
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4.4.1.4 Plaque F (Laboratory Plaque no. 30)
Plaque F was removed from the internal carotid artery of a 63 year-old female patient. The 
plaque shape was beautifully preserved with a small bifurcation. It was excised from a 
severely stenosed artery with 80-95% stenosis. There was little calcification that could be seen 
as white regions in the pictures below. Some calcified areas were also seen in section 2, 3, 6, 7 
and 9.  Also this plaque had lipid-core like region visible from section 1-6. Sections 7-9 did 
not have any lipid and section 6 had a thrombus which also extended into section 7, which is 
on the far-side of the picture seen below. The thrombus appeared old, hardened and much 
deeper in the plaque body, further away from the lumen. 
Protein content in section 4 stood out being highest than any other sections in this plaque. 
Protein concentration was 205 mg/g plaque in section 4 and was lowest in section 8 with 7 
mg/g plaque (figure 4.11 A). The rise in section 4 was significantly higher than section 3, 
which plummeted down significantly to 80 mg/g plaque in section 5. Cholesterol followed 
almost an identical trend, peaking in section 4 at a concentration of 306 µmoles/g plaque, with 
lowest amount found in section 8, which was 67 µmoles/g plaque (figure 4.11 B). Total pterin 
followed an exact pattern as the protein with regards to its levels across the 9 sections. Highest 
concentration of total pterin was 2079 pmoles/g plaque. 7,8-dihydroneopterin was not found or 
was below detection limit in section 8. Another peculiar feature to note in this plaque was 
complete absence of neopterin across all the sections (figure 4.11 C). The bulk of •-tocopherol 
in this plaque was found in the first 4 sections, highest concentration was in section 4. From 
section 5 through till 8, there was a general but significant decreasing trend, lowest in section 
8, rising very slightly in section 9 (figure 4.11 D). 
Section 4 stands out again with respect to lipid oxidation, TBARS content (figure 4.12 A). It 
was recorded the highest in this section at 27 nmoles/g plaque, 7 nmoles/g plaque  being the 
lowest in section 3. There were significant rise and fall in TBARS levels from section 3 to 4 
and from 4 to 5 respectively. AAS protein carbonyl content varied highly significantly across 
the sections 3 to 7. GGS concentrations also followed AAS content closely across these 
sections (figure 4.12 B). Highest protein carbonyls (both AAS and GGS) were found in 
section 3.
Chapter 4
151
Figure 4.10 Sectioning of Plaque F. Plaque F was excised from the left internal carotid artery 
of a 63 year-old female and cut into 9 sections of about 3-5 mm. 
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Figure 4.11 Plaque F: Protein, Cholesterol, Neopterin and •-Tocopherol content. Protein 
(A) and cholesterol (B) concentrations were determined spectrophotometrically while 
neopterin/Total pterin (C) and •-tocopherol (D) were quantified by SCX and reverse-phase
C18 methods respectively using the HPLC as described in methods. Each bar represents the 
Mean ± SEM of the samples analyzed in triplicates.
DOPA concentrations were generally lower in sections with high protein carbonyls content, 
which is why sections 3 and 6 had the lowest amount of it (figure 4.12 C). Section 9 had 
highest DOPA at 25 nmoles/g plaque. Dityrosine was virtually absent in sections 1 and 4, but 
was highest in section 6 (figure 4.12 D). There was no particular pattern of distribution that 
DOPA and dityrosine followed. Total KC followed cholesterol trend for its distribution, 
reaching its peak in section 4. Concentration in section 4 for total KC was 731 nmoles/g 
plaque, lowest amount found in section 8 was 157 nmoles/g plaque.  Free KC also 
significantly varied across the 9 sections, being highest in 2nd section with 108 nmoles/g 
plaque (figure 4.12 E). Section 4, the small bifurcation, stands out in comparison with other 
sections with all the biomarker levels. It recorded highest amounts of 7,8-dihydroneopterin, 
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protein, cholesterol, •-tocopherol, TBARS and total KC, while lowest concentrations of  AAS 
and GGS (carbonyls) and dityrosine (figure 4.12).
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Figure 4.12 Plaque F: Lipid and Protein oxidation markers. TBARS (A), Protein 
carbonyls AAS & GGS (B), DOPA (C), Dityrosine (D) and 7-KC (E) were quantified by 
reverse-phase C18 method using HPLC as described in methods. Each bar represents the 
Mean ± SEM of the samples analyzed in triplicates.
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There were positive correlations found between protein, cholesterol, TBARS and pterin levels 
across the plaque. A strong positive relationship was observed between 7,8-dihydroneopterin 
and total KC contents. It was interesting to note that although section 4 had highest amount of 
protein, it had lowest concentrations of dityrosine and protein carbonyls. Lipid oxidation 
profile showed strong positive correlation in section 4. 
4.4.1.5 Plaque I (Laboratory Plaque no. 33)
Plaque I was collected from a carotid endarterectomy of a 75 year-old female patient. It was 
with a small bifurcation branch. It was not calcified at all, with lipid core-like region 
throughout its main branch. The smaller branch was characterized by the presence of slight 
thrombosis. It was sectioned into 5 sections. 
The protein content in this plaque was in the range of 39-54 mg/g plaque, lowest in section 2
(figure 4.14 A). Highest concentration of 54 ± 1 nmoles/g plaque was found in the 1st section 
while the lowest content of 39 ± 1 nmoles/g plaque was found in section 2. Section 2 protein 
content was significantly lower than section 1. Section 3, 4 and 5 had comparable levels of 
protein, without much variation. Cholesterol concentration followed a decreasing trend till the 
4th section, dropping down in stepwise from in 2nd, 3rd and 4th section, all of which were 
significant, only to significantly rise 5th section (figure 4.14 B). Neopterin was in the range of 
111-208 pmoles/g plaque while total pterin was 478-699 pmoles/g plaque (figure 4.14 C). 
Significant variations in total pterin content were found in sections 3 and 5, whereas for 
neopterin there was a significant rise in section 3. In rest of the sections the neopterin 
concentrations were similar. •-tocopherol also followed a decreasing pattern continuously till 
the 4th section and rising across sections 5. Only the drop from section 1 to section 2 was 
statistically significant (figure 4.14 D).  
TBARS content was lowest in section 5 and highest in section 3, positively correlating with 
total pterin and neopterin (figure 4.15 A). TBARS varied significantly across the sections 2 
and section 5. Protein carbonyls- AAS content across the 5 sections was steady in the range of 
16-21 nmoles/g plaque, lowest concentration being found in section 1. GGS content was 
higher than AAS across all the 5 sections of this plaque, but there was no significant change in 
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its concentration (figure 4.15 B). Although dityrosine did not show any particular trend across 
the sections, it was highest in section 1, with a steep drop in section 2 (figure 4.15 D).
Figure 4.13 Sectioning of Plaque I. Plaque I was excised from a 75 year-old female patient 
and cut into 5 sections of about 3-5 mm.
The dityrosine concentrations rose a bit in section3 and then did not change much. DOPA 
concentrations varied significantly across sections 2 and 3 (figure 4.15 C). There was a 
significant decrease from section 1 to section 2 and section 3 showed a significant rise in 
DOPA concentration. It showed positive correlation with dityrosine. Free and total KC levels 
did show significant variations across all the last 3 sections. Highest concentration of total KC 
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was found in section 3 and lowest in section 2. Free KC showed an increasing trend till section 
3 and then decreased significantly in sections 4 and 5 (figure 4.15 E).
A)  B)
 C)  D)  
Figure 4.14 Plaque I: Protein, Cholesterol, Neopterin and •-Tocopherol content. Protein 
(A) and cholesterol (B) concentrations were determined spectrophotometrically while 
neopterin/Total pterin (C) and •-tocopherol (D) were quantified by SCX and reverse-phase
C18 methods respectively using the HPLC as described in methods. Each bar represents the 
Mean ± SEM of the samples analyzed in triplicates.
7,8-Dihydroneopterin in this plaque correlated positively with AAS protein carbonyls, while 
protein showed strong correlation with DOPA and dityrosine. Cholesterol was in agreement 
with •-tocopherol’s trend across the 5 sections, while TBARS showed strong correlation with 
free and total KC. DOPA and dityrosine also showed a strong correlative relationship. AAS 
and GGS concentrations followed the same trend throughout the sections, while a similar 
behavior was noted for free and total KC across the 5 sections of this plaque. 
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Figure 4.15 Plaque I: Lipid and Protein oxidation markers. TBARS (A), Protein carbonyls 
AAS & GGS (B), DOPA (C), Dityrosine (D) and 7-KC (E) were quantified by reverse-phase
C18 method using HPLC as described in methods. Each bar represents the Mean ± SEM of the 
samples analyzed in triplicates.
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4.4.2 Femoral Plaques
4.4.2.1 Plaque A (Laboratory Plaque no. 25)
Plaque A was removed from an iliac artery of a 64 year-old female non-diabetic, smoker 
patient. It was approximately 36 mm in length with no bifurcation. This plaque had slight 
calcification across its length except for in the 3rd section. It was cut into 6 sections. Sections 5 
and 6 had slightly higher calcification than the preceding sections. It did not have any 
branches or bifurcations and was a straight, cylindrical plaque. Yellowish regions are most 
probably lipids visible throughout the 6 sections, albeit with varied distribution. 
The protein content in plaque A was similar throughout the sections with highest protein in 
section 3 (108 ± 6 mg/g plaque) (figure 4.17 A). There was no significant variation along the 
sections. Cholesterol concentration gradually but significantly increased from section 1 to 4, 4 
having highest level of it (22 ± 3 µmoles/g plaque), and then dropped down in sections 5 and 
6. Section 1 had the lowest amount of cholesterol (6.2 ± 0.7 µmoles/g plaque) (figure 4.17 B). 
Neopterin and Total pterin concentrations were highest in the 1st section where it reached 588 
± 43 pmoles/g plaque for neopterin and 896 ± 183 pmoles/g plaque for total pterin (figure 4.17 
C). Their levels significantly dropped in the 2nd section as they were measured 66 ± 4 and 216 
± 20 pmoles/g plaque for neopterin and total pterin respectively. Both neopterin and total 
pterin decreased gradually till section 5, rising slightly in the 6th section. The lowest 
concentration of neopterin and total pterin was found in section 5 (8.3 ± 0.6 and 76 ± 11 
pmoles/g plaque respectively). The •-tocopherol concentration followed a similar trend as 
cholesterol with highest level found in section 4 of 162 ± 14 nmoles/g of plaque (figure 4.17 
D). 
TBARS content in plaque A showed a significant drop from section 1 (4.90 ± 0.07 nmoles/g 
plaque) to 2 (2.0 ± 0.2 nmoles/g plaque) (figure 4.18 A). Its concentration gradually increased 
from section 2 to 4, but dropped in section 5 only to marginally increase in the last section. 
Section 5 had the lowest amount of TBARS (1.28 ± 0.05 nmoles/g plaque) (figure 4.35). 
Protein carbonyls too showed a significant drop in section 2. AAS was high (49 ± 7 nmoles/g 
plaque) in 1st as well as 4th section (50 ± 3 nmoles/g plaque).
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Figure 4.16 Sectioning of Plaque A. Plaque A was removed from an iliac artery of a 64 year-
old female and cut into 6 sections. 
GGS content was highest in 1st section (14 ± 3 nmoles/g plaque). Lowest concentration of 
AAS was found in section 2 (19 ± 3 nmoles/g plaque) while that of GGS was found in section 
3 (5.30 ± 0.04 nmoles/g plaque) (figure 4.18 B). 
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Figure 4.17 Plaque A: Protein, Cholesterol, Neopterin and •-Tocopherol content in 
Plaque A. Protein (A) and cholesterol (B) concentrations were determined 
spectrophotometrically while neopterin/Total pterin (C) and •-tocopherol (D) were quantified 
by SCX and reverse-phase C18 methods respectively using the HPLC as described in 
methods. Each bar represents the Mean ± SEM of the samples analyzed in triplicates.
DOPA levels did not vary significantly across the length of the plaque (figure 4.18 C), highest 
concentration found in the last section, while dityrosine was consistent throughout the plaque
(figure 4.18 D). Similar levels of free KC were seen in sections 1 and 2, dropping significantly 
in the 3rd section and 5th section. Free KC concentrations remained low throughout the sections 
3-6 (figure 4.35). Highest concentration of total KC was found in the 2nd section (figure 4.18 
E). Neopterin, TBARS, AAS and Total KC biomarkers were significantly higher in the 1st
section. Overall, there was a positive correlation between •-tocopherol and cholesterol levels 
across the plaque, which has been observed in most of the previous plaques analyzed in our 
laboratory. There was also a positive correlation between pterin concentrations (both neopterin 
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Figure 4.18 Plaque A Lipid and Protein oxidation markers. TBARS (A), Protein carbonyls 
AAS & GGS (B), DOPA (C), Dityrosine (D) and 7-KC (E) were quantified by reverse-phase
C18 method using HPLC as described in methods. Each bar represents the Mean ± SEM of the 
samples analyzed in triplicates.
and 7,8-dihydroneopterin) and lipid oxidation (TBARS) across the first 2 sections. A 
correlation was also found with the pterin concentrations and protein carbonyl (AAS and 
GGS) concentrations across the first 2 sections. 
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4.4.2.2 Plaque D (Laboratory Plaque no. 28)
Figure 4.19 Sectioning of Plaque D. Plaque D was removed from the left external iliac artery 
of an 81 year-old female and cut into 7 sections of about 3-5 mm each. 
 
Plaque D was excised from an iliac artery of an 81 year-old female, who was also a diabetic. 
Stenosis in the artery affected by atherosclerosis was 70-90%. It showed calcification across 
all the 7 sections that it was cut into.  This plaque was cylindrical in shape without any 
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bifurcation. It was solid hard and crunchy during its sectioning and homogenization. No 
thrombus was found in any of its sections
A)  B)
C)  D)  
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Figure 4.20 Plaque D: Protein, Cholesterol, Neopterin and •-Tocopherol content. Protein 
(A) and cholesterol (B) concentrations were determined spectrophotometrically while 
neopterin/Total pterin (C) and •-tocopherol (D) were quantified by SCX and reverse-phase
C18 methods respectively using the HPLC as described in methods. Each bar represents the 
Mean ± SEM of the samples analyzed in triplicates.
Highest concentration of protein was found in section 3, which had 83 ± 3 mg/g plaque tissue
(figure 4.20 A). The lowest protein concentration was 38 ± 2 mg/g plaque in section 2. 
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Figure 4.21 Plaque D: Lipid and Protein oxidation markers. TBARS (A), Protein 
carbonyls AAS & GGS (B), DOPA (C), Dityrosine (D) and 7-KC (E) were quantified by 
reverse-phase C18 method using HPLC as described in methods. Each bar represents the 
Mean ± SEM of the samples analyzed in triplicates.
Significant variations were found between sections 2-5, with a large rise in section 3 and 
gradual but significant drop in sections 4 and 5 before a small but significant rise in section 7. 
Cholesterol concentration also showed a significant rise not only between section 2 and 3, but 
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also between section 4 and 5 as it dropped steadily until the last section (figure 4.20 B). There 
was little variation between the lowest and highest cholesterol concentrations.
Although neopterin values were in a very narrow range of 58-73 pmoles/g plaque, there was a 
significant drop between section 1 and 2, and a significant rise between section 6 and 7. Total 
pterin values were in the range of 179-305 pmoles/g plaque (figure 4.20 C). The ratio of 
neopterin to 7,8-dihydroneopterin in most sections was between 1:2 in most of the section 
with an exception of section 3 where it was about 1:4. Highest concentration of 7,8-
dihydroneopterin was found in section 3. •-Tocopherol content rose gradually till section 4 
before it followed a decreasing trend until section 6 (figure 4.20 D). There was a large rise in 
•-tocopherol in section 7, where the concentration reached 187 nmoles/g plaque. There was no 
correlation between •-tocopherol with any of the biomarkers except a negative correlation 
with protein carbonyls in section 7 (figure 4.20). 
TBARS concentrations showed an upward trend between sections 1 to 5 before dropping 
slightly but significantly in section 6 (figure 4.21 A). Lowest lipid oxidation was found in 
section 1 (1.85 ± 0.06 nmoles/g plaque), while highest in section 5 (3.75 ± 0.06 nmoles/g 
plaque). On an average, the TBARS concentrations were higher in the central sections than the 
first 2 and the last 2 sections (figure 4.38). Both AAS and GGS showed a decreasing trend 
from sections 1-7 except for a very small rise in section 5 (figure 4.21 B). Both AAS and GGS 
were measured highest in section 1 (183 ± 3 and 31.4 ± 0.2 nmoles/g plaque respectively). 
Lowest protein carbonyls concentration was found in section 7 (27.6 ± 0.7 for AAS and 14.93 
± 0.03 nmoles/g plaque for GGS). Both showed a significant drop between section 1 and 2, 
more dramatic for AAS than for GGS. Most of the carbonyls were found in the proximal 
sections of this plaque. DOPA was more localized in the proximal 4 sections, with a large rise 
from 20 ± 3nmoles/g plaque to 28 ± 3 nmoles/g plaque between section 1 and 2 respectively
(figure 4.21 C). Its concentration also fell more dramatically in section 3 as it continuously 
dropped till section 6, rising slightly in section 7. Section 6 recorded the lowest DOPA 
concentration of 6.5 ± 0.9 nmoles/g plaque (figure 4.38). Dityrosine concentrations were more 
or less consistent throughout the plaque with lowest concentration being 1.11 ± 0.04 nmoles/g 
plaque in section 1 and highest being 1.8 ± 0.3 nmoles/g plaque in section 2 (figure 4.21 D). 
No significant variations were found with the free and total KC contents, except for a 
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significant rise for free KC in section 7, which also had highest total KC content (figure 4.21
E). 
Throughout the length of this plaque, there were no significant correlations between the 
biomarker levels, except where 7,8-dihydroneopterin showed a positive relationship with 
protein and AAS protein carbonyls showed a strong positive correlation with DOPA.  
4.4.2.3 Plaque G (Laboratory Plaque no. 31)
Approximately 30 mm of plaque material was excised from this 70 year-old male patient’s 
femoral artery who showed a very high blood pressure and also had diabetes. Although not 
completely intact, the arterial lumen shape was well preserved in this plaque. It showed 
calcification throughout the 5 sections, with heavier calcification in the first 3 sections. 
Sections 2 and 3 showed little signs of thrombus formation. It was difficult to cut into sections 
due to its heavy calcification. 
Protein concentrations across the 5 sections of this plaque showed a continuously decreasing 
trend (figure 4.23 A). Section 1 had the highest protein content while 5th section showed 
lowest content of protein. Concentration ranged between 28 and 15 mg/g plaque, with 
significant variations across sections 2 and 4 as compared to section 1 and 3. Cholesterol also 
followed a similar pattern. Its concentration dropped significantly from 9 µmoles/g plaque in 
the 1st section to 4 µmoles/g plaque in the 2nd section (figure 4.23 B). Lowest concentration 
was found in section 5 with 3 µmoles/g plaque. Although neopterin concentrations ranged 
between 23 pmoles/g plaque and 62 pmoles/g plaque and the 7,8-dihydroneopterin 
concentrations were in the range of 234 pmoles/g plaque and 381 pmoles/g plaque across the 5 
sections, there were no significant variations found for both the biomarkers (figure 4.23 C). •-
Tocopherol content was highest in section 2 (32 ± 11 nmoles/g plaque) and lowest in section 4 
(11.7 ± 0.5 nmoles/g plaque), but its concentrations did not vary significantly across any of the 
sections (figure 4.23 D). 
The TBARS content of this plaque remained constant throughout the first 4 sections before 
decreasing significantly in the last section to 1 nmoles/g plaque (figure 4.24 A). Protein 
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carbonyls were more or less consistent throughout the plaque apart from section 1, where both 
AAS and GGS were highest in concentration at 10 and 4 nmoles/g plaque respectively (figure 
4.24 B). From sections 2 to 5 concentrations of both the protein carbonyls remained constant. 
There was a noticeable and highly significant drop in 2nd section as seen from the graph. 
DOPA concentration was highest in section 1 and showed a significantly decreasing trend, 
from section 2 till section 4, before significantly rising in section 5. Lowest DOPA content 
was seen in section 4, which was 3 nmoles/g plaque, while the highest concentration in this 
plaque was 10 nmoles/g plaque (figure 4.24 C).
Figure 4.22 Sectioning of Plaque G. Plaque G was removed from the femoral artery of a 70 
year-old male. It was sectioned into 5 sections of about 3-5 mm.
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Dityrosine showed an opposite trend across the 5 sections, with a gradual increase till section 
3, peaking in section 3, then after a significant drop in section 4, and again a significant rise in 
section 5 (figure 4.24 D). Free and Total KC both were highest in section 3 with values of 43 
and 338 nmoles/g plaque for free and total KC (figure 4.24 E).
In spite of high degree of variance in the biomarker concentrations, there were a few strong 
inter-relationships between them. Protein content correlated positively with cholesterol, 
DOPA and protein carbonyls (AAS).
A)  B)
 C)  D)  
Figure 4.23 Plaque G: Protein, Cholesterol, Neopterin and •-Tocopherol content. Protein 
(A) and cholesterol (B) concentrations were determined spectrophotometrically while 
neopterin/Total pterin (C) and •-tocopherol (D) were quantified by SCX and reverse-phase
C18 methods respectively using the HPLC as described in methods. Each bar represents the 
Mean ± SEM of the samples analyzed in triplicates.
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Figure 4.24 Plaque G: Lipid and Protein oxidation markers. TBARS (A), Protein 
carbonyls AAS & GGS (B), DOPA (C), Dityrosine (D) and 7-KC (E) were quantified by 
reverse-phase C18 method using HPLC as described in methods. Each bar represents the 
Mean ± SEM of the samples analyzed in triplicates.
TBARS showed an inverse relationship with cholesterol and protein, positively correlated with 
free and total KC across the plaque. Neopterin and 7,8-dihydroneopterin levels did not bear 
any significance with any of the other biomarkers tested in this plaque (figure 4.24). 
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4.4.2.4 Plaque H (Laboratory Plaque no. 32)
This plaque was removed from the femoral artery of 81year-old female patient. This was a 
calcified plaque, which is consistent with the other femoral plaques analyzed so far. It was 
very crunchy in texture and difficult to section due to its heavy calcification. Section 2 showed 
some fatty accumulation, which increased gradually in sections 3, 4, 5 and 6. No sign of 
thrombosis was found in any of the sections of the plaque.
The protein content across the 6 sections of plaque H showed little variation except a large 
decrease in section 2, a small but significant decrease across section 4 and an increase in 
section 5 (figure 4.26 A). Highest concentration was found in section 1 with 37 mg/g plaque. 
Cholesterol was also at its highest concentration in section 1 which had 21 µmoles/g plaque. 
Across sections 2 and 3, there was a rise from 11 to 15 µmoles/g plaque, which was 
statistically significant (figure 4.26 B). Also there was a drop in cholesterol content in section 
4. Sections 3, 4 and 5 had very similar amounts of cholesterol with very little variation across 
them. Neopterin values were at its highest in section 1, with 109 pmoles/g plaque and kept on 
decreasing till the last section, with a concentration of 42 pmoles/g plaque in the 6th section. 
Total pterin concentration was at its highest of 324 pmoles/g plaque in section 2, which was 
significantly higher than section 1 (figure 4.26 C). Then the total pterin values gradually 
decreased till section 6, which had 154 pmoles/g plaque, the lowest amongst the 6 sections. 
Sections 3, 4 and 5 together accounted for the bulk of •-tocopherol found in this plaque (figure 
4.26 D).  With 29 nmoles/g plaque, section 3 was the highest amongst the 6 sections. Lowest 
concentration for •-tocopherol was found in section 6 with just 2 nmoles/g plaque. For 
TBARS, section 1 comprised of 2 nmoles/g plaque, after which there was a highly significant 
rise to 4 nmoles/g plaque in section 2 (figure 4.27 A). The TBARS concentration showed a 
decreasing trend from section 3 to section 6, dropping significantly in section 4 and section 6. 
AAS protein carbonyl concentration in section 1 was 26 nmoles/g plaque, which was the 
highest (figure 4.27 B).
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Figure 4.25 Sectioning of Plaque H. Plaque H was cut into 6 sections of about 3-5 mm after 
its removal from the femoral artery of an 81 year-old female.
This correlated positively with protein and cholesterol and negatively with TBARS. It dropped 
significantly in section 2 and was steady throughout the rest of the sections. GGS carbonyls 
showed little variation across the 6 sections of this plaque. Lowest protein bound DOPA was 
found in section 4, which was a significant drop from section 3 (figure 4.27 C). Apart from 
this, the DOPA values across all the other sections were in the range of 2.2-2.8 nmoles/g 
plaque. Dityrosine was not detected across any of the sections (figure 4.27 D). Free KC was 
highest in section 1 which fell highly significantly in section 2 and remained steady 
throughout the rest of the sections (figure 4.27 E). 
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Figure 4.26 Plaque H: Protein, Cholesterol, Neopterin and •-Tocopherol content. Protein 
(A) and cholesterol (B) concentrations were determined spectrophotometrically while 
neopterin/Total pterin (C) and •-tocopherol (D) were quantified by SCX and reverse-phase
C18 methods respectively using the HPLC as described in methods. Each bar represents the 
Mean ± SEM of the samples analyzed in triplicates.
Total KC was in section 1 was 255 nmoles/g plaque which rose highly significantly to 451 
nmoles/g plaque, and then dropped steeply to 230 nmoles/g plaque in section 3. Section 4, 5 
and 6 showed a gradual decrease in the total KC content, which was not significant (figure 
4.27 E). There were very little, if any, correlations across the biomarkers throughout the 
sections of this femoral plaque. Absence of dityrosine in all the sections was a notable feature 
of this plaque. There was positive correlation between 7,8-dihydroneopterin, TBARS and total 
KC contents as well as between cholesterol, free KC and AAS protein carbonyls across the 
sections. Neopterin also seemed to positively correlate with GGS protein carbonyls throughout 
the plaque. 
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Figure 4.27 Plaque H: Lipid and Protein oxidation markers. TBARS (A), Protein 
carbonyls AAS & GGS (B), DOPA (C), Dityrosine (D) and 7-KC (E) were quantified by 
reverse-phase C18 method using HPLC as described in methods. Each bar represents the 
Mean ± SEM of the samples analyzed in triplicates.
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4.4.2.5 Plaque J (Laboratory Plaque no. 34)
Plaque J was excised from the femoral artery of an 81year-old ex-smoker male patient. It was 
cut into 5 sections and was very calcified throughout its length. It was extremely crunchy in its 
texture, difficult to section and homogenise due to heavy calcification. Also the sections were 
heavy due to the same reason. There was no thrombus in any of the sections. 
Figure 4.28 Sectioning of Plaque J. Plaque J was removed from an 81 year-old male patient 
cut into 5 sections of about 3-5 mm.
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Figure 4.29 Plaque J: Protein, Cholesterol, Neopterin and •-Tocopherol content. Protein 
(A) and cholesterol (B) concentrations were determined spectrophotometrically while 
neopterin/Total pterin (C) and •-tocopherol (D) were quantified by SCX and reverse-phase
C18 methods respectively using the HPLC as described in methods. Each bar represents the 
Mean ± SEM of the samples analyzed in triplicates.
Protein in plaque J showed a general trend upward till section 3 and then displayed a 
downward trend in sections 4 and 5  (figure 4.29 A). Highest concentration of protein was 
found in section 3 (43.0 ± 0.4). It was preceded by a significant low concentration in section 2 
and followed by a highly significant drop in section 4. Lowest protein content was found in 
section 1 (24.5 ± 0.6 mg/g plaque). Cholesterol started at its highest concentration of 10 µg/g 
plaque following a downward trend till section 3 and then an upward slope tills section 5
(figure 4.29 B). Lowest cholesterol content found in section 3 was 5 mg/g plaque. Neopterin 
and total pterin both showed an antagonistic trend to cholesterol content, rising from section 1 
to section 3 and then falling down in concentration in sections 4 and 5.  Lowest neopterin 
concentration was found in section 1 (78 ± 4 pmoles/g plaque) while highest total pterin 
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concentration was measured in section 3 (310 ± 21 pmoles/g plaque). There were no 
significant changes between the sections for both neopterin and total pterin (figure 4.29 C). 
A)   B)
C)   D)  
 E)
Figure 4.30 Plaque J: Lipid and Protein oxidation markers. TBARS (A), Protein carbonyls 
AAS & GGS (B), DOPA (C), Dityrosine (D) and 7-KC (E) were quantified by reverse-phase
C18 method using HPLC as described in methods. Each bar represents the Mean ± SEM of the 
samples analyzed in triplicates.
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•-Tocopherol followed the cholesterol trend till section 3, but then dropped again in section 4 
to its lowest concentration of 7 nmoles/g plaque (figure 4.29 D). The highest content of •-
tocopherol was found in section 1 (19 ± 6 nmoles/g plaque). This correlates negatively with 
neopterin and total pterin along with protein content. 
TBARS content increased stepwise from section 1 to 2, before dropping significantly in 
section 3 (figure 4.30 A). From section 3 through to section 5, TBARS showed an upward 
trend, without significance. Lowest TBARS concentration was in section 3 (0.14 nmoles/g 
plaque). Protein carbonyls AAS showed a statistically significant drop in section 2 rising 
gradually till section 4 and then dropping slightly in sections 5 and 6. GGS also shows a 
similar trend, following AAS (figure 4.30 B). The range of AAS was 19-51 nmoles/g plaque 
while for GGS it ranges between 5-14 nmoles/g plaque. DOPA concentration across the 5 
sections of plaque did not vary much (figure 4.30 C). There was no significant change from 
section 1 to section 5, although there was a general increasing trend. Highest DOPA content 
was found in section 5 (1.8 ± 0.1 nmoles/g plaque), while lowest concentration was found in 
section 1 (1.1 ± 0.1 nmoles/g plaque). Dityrosine content was constant in the first 3 sections, 
which dropped significantly to its lowest in section 4 (0.13 ± 0.01 nmoles/g plaque) (figure 
4.30 D). It’s level rose in Section 5, but the rise was not significant. Highest concentration was 
0.32 ± 0.06 nmoles/g plaque in section 2. Free KC was at its highest (39 ± 4 nmoles/g plaque) 
in section 3 which fell significantly in section 4 to its lowest concentration (27 ± 2 nmoles/g 
plaque) in section 4. Total KC was highest in section 1 (72 ± 12 nmoles/g plaque), and lowest 
in section 4 (32 ± 3 nmoles/g plaque). It dropped and rose significantly in sections 2 and 3 
respectively before dropping to its lowest in section 4 (figure 4.30 E). 
Protein content showed positive correlation with neopterin, dityrosine. Cholesterol showed 
strong correlations with •-tocopherol, AAS and GGS protein carbonyls, which was also true 
for •-tocopherol and AAS and GGS carbonyls. Cholesterol exhibited negative correlation with 
TBARS, DOPA and dityrosine, whereas protein levels showed inverse relationship with 
DOPA. Free and total KC went hand in hand with their concentrations across the 5 sections, 
but did not show any kind of correlation with the other biomarkers. 
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4.4.2.6 Plaque K (Laboratory Plaque no. 35) Kidney Artery Control
Plaque K was an iliac artery sample without any plaque formation in it, which was used as a 
control artery to measure the level of oxidative biomarkers. It was a branched section of the 
artery which was collected from a 62 year-old female kidney transplant patient and cut into 3 
small sections. There were no signs of calcification or thrombosis inside any of these sections. 
Figure 4.31 Sectioning of Plaque K. Plaque K was from a 62 year-old female patient, cut 
into 5 sections of about 3-5 mm.
This was a thin walled, muscular section with no abnormal characteristics. It was smooth and 
easy to cut into sections, with intact lumen (figure 4.31). 
The protein content in the control artery from the kidney of this individual varied between 177 
- 103 mg/g plaque (figure 4.32 A). Although we expected a constant protein level throughout 
the 3 sections of this control artery, there was a significant drop in the protein content in 
section 2. Cholesterol was slightly lower in the 1st section (15 ± 2 µmoles/g plaque), which 
rose to its highest in section 2 (22 ± 1 µmoles/g plaque) (figure 4.32 B). Cholesterol changed 
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little in the 3rd section (20.0 ± 0.4 nmoles/g plaque). Contrary to expectations, neopterin was 
higher in the sections, highest in section 2 (191 ± 4 pmoles/g plaque). 7,8-dihydroneopterin 
was highest in section 2 as well (446 ± 6 pmoles/g plaque). Lowest amount of neopterin was 
137 ± 8 pmoles/g plaque in section 1, while for 7,8-dihydroneopterin it was 391 ± 4 pmoles/g 
plaque in section 3 (figure 4.32 C). 
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Figure 4.32 Plaque K: Protein, Cholesterol, Neopterin and •-Tocopherol content. Protein 
(A) and cholesterol (B) concentrations were determined spectrophotometrically while 
neopterin/Total pterin (C) and •-tocopherol (D) were quantified by SCX and reverse-phase
C18 methods respectively using the HPLC as described in methods. Each bar represents the 
Mean  ±  SEM of the samples analyzed in triplicates.
•-Tocopherol levels in this control plaque were in the range of 3.8-4.7 nmoles/g plaque, 
without any significant variations across the 3 sections (figure 4.32 A). TBARS content was 
lowest in section 1 (0.81 ± 0.03 nmoles/g plaque) which rose highly significantly higher to 
1.56 ± 0.06 nmoles/g plaque in section 2 (figure 4.33 A). There was a significant drop in 
section 3, where the TBARS concentration was 1.33 ± 0.03 nmoles/g plaque. 
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Figure 4.33 Plaque K: Lipid and Protein oxidation markers. TBARS (A), Protein 
carbonyls AAS & GGS (B), DOPA (C), Dityrosine (D) and 7-KC (E) were quantified by 
reverse-phase C18 method using HPLC as described in methods. Each bar represents the 
Mean ± SEM of the samples analyzed in triplicates.
TBARS positively correlated with cholesterol content and negatively with the protein content. 
Protein carbonyls showed a positive correlation with the TBARS content across the 3 sections 
of plaque I. Highest concentrations of both AAS and GGS carbonyls were found in section 2 
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although there were no significant changes in AAS contents, there was a significant rise in 
section 2 in GGS concentration (figure 4.33 B). DOPA showed an upward trend from section 
1 through to section 3 (figure 4.33 C). Lowest concentration found in section 1 (2.5 ± 0.2 
nmoles/g plaque) and highest in section 3 (5.2 ± 0.7 nmoles/g plaque). There was no 
correlation between DOPA and other biomarkers tested.
Dityrosine showed a trend similar to protein carbonyls, being lowest in section 1 and highest 
in section 2, falling a little in section 3 (figure 4.33 D). Lowest concentration was 0.75 ± 0.05 
nmoles/g plaque and highest concentration was 0.89 ± 0.05 nmoles/g plaque. Free KC 
concentration was highest in section 1 (125 ± 3 nmoles/g plaque) which fell significantly in 
section 2 before reaching its lowest level in section 3 (88 ± 3 nmoles/g plaque). It showed a 
downward trend from section 1 to section 3. Total KC, however, showed a trend that 
positively correlated with TBARS and cholesterol, where section 2 had highest concentration 
(115 ± 13 nmoles/g plaque). Total KC in section 3 were below detection limits or absent
(figure 4.33 E). 
This was the most interesting artery of all, considering the level of oxidative biomarkers 
across its sections and its origin. In spite of absence of plaque characteristics or any visible 
features of a plaque, this artery control showed presence of all the protein and lipid oxidation 
biomarkers along with neopterin and 7,8-dihydroneopterin,and •-tocopherol. Protein showed 
positive correlation with •-tocopherol.  Positive correlations were found between cholesterol, 
neopterin, 7,8-dihydroneopterin, TBARS, AAS and GGS protein carbonyls as well as 
dityrosine. DOPA and free KC concentrations showed a negative correlation. Although 
thought to be a control, presence of all these oxidative biomarkers in the similar range as that 
of the atherosclerotic plaques disqualifies it as a control. 
4.4.3 Correlation between biomarkers of individual plaque 
Correlation statistics were applied to all the possible biomarkers within each plaque in order to 
establish any significant correlations (positive or negative) as displayed in the table 4.3. 
Although there was a huge range of variation seen in the biomarker correlation between the 
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plaques, there appeared to be a few correlations that occurred more than once among the 
plaques analyzed.
No correlation between the biomarkers was found in all the ten plaques. Correlation between 
cholesterol and •-tocopherol was significant in five of the ten plaques analyzed was significant 
on all occasions (table 4.3). On four of the five occasions the correlation observed was 
positive. This positive correlation between cholesterol and •-tocopherol was also observed in 
nine of the plaques previously analyzed. A significant positive correlation between AAS and 
GGS and free and total KC was observed in four of the ten plaques. Cholesterol and AAS 
protein carbonyls along with total pterin and TBARS were other significant correlations 
observed in four of the ten plaques analyzed in this study. Significant correlations were also 
observed in three of the ten plaques for AAS protein carbonyl and free KC, and TBARS and 
total KC. Positively significant correlations were also found between DOPA and AAS protein 
carbonyls, and protein and AAS protein carbonyls, and protein and DOPA in three of the ten 
plaque analyzed during this study.  A few negative correlations were also found between the 
biomarkers in these plaques. Most frequent was the negative correlation between neopterin 
and •-tocopherol, which was found in three plaques out of ten. No other negative correlations 
were found more than once in these plaques. The number of times cholesterol appeared in the 
significant correlations was the most followed by protein, neopterin and total pterins. 
To examine which correlations occurred in carotids and femoral plaques, the plaques in table 
4.3 were labelled as CA for carotid and FE for femorals (table 4.4). Cholesterol and •-
tocopherol correlation was found in three carotid and two femoral plaques. Positive correlation 
was observed in two carotid plaques and two femoral plaques whereas negative correlation 
was found in one carotid plaque. Significant positive correlation observed between AAS and 
GGS protein carbonyls was exclusive to femoral plaques. Cholesterol content correlated 
positively in three femoral plaques as compared to only one carotid plaque. Free and total KC 
correlation was observed equally in carotid and femoral plaques (two each). Two of the three 
plaques which showed negative correlation between neopterin and •-tocopherol were carotid 
plaques. 
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Table 4.3 Correlation of Inflammatory and Oxidative Markers within Plaques A-K
Significant correlations were determined based on the average of each section (n=3) within 
plaques A-K using Statistica's correlation matrices. (+) Indicates a positive correlation, (-) 
indicates a negative correlation. Letter abbreviations in table correspond to the letters assigned 
to the plaques. Extended table for the correlations in the appendix. Statistical significance 
represented by P<0.05 * P<0.01 ** P<0.001 ***
Pro Chol NP TP •-toc TBA DOPA DT AAS GGS Free 7-KC
Chol
+F***
+G*
+H*
NP
+G* +G**
-I*
+K*
TP +C**+F**
+C*
+F***
+A***
-E**
•-toc
-C** +A**
+B**
-C*
+I**
+J*
-B*
-I*
-J**
-C*
TBA
+C*
+F**
+C**
+D*
+F***
+K*
+A* +A*
+C*
+F*
+H*
DOPA
+C*
+G*
+I*
-J* -B* +B*
+E*
-D*
DT +E** -E*
AAS
+C*
+F**
+H*
+F*
+G**
+H*
+J*
+K*
+G*
+J*
+F* +J*
+C**
+F* +C**
+D*
+E*
GGS
-K** +G*
+J*
+G* +I**
-J**
-D* +D**
+G**
+H**
+J*
Free 
7-KC
+F*
+H*
+C*
+H*
-B*
+D*
+I* +D**
+E*
-K*
+F* +E** +E*
+F*
+H**
+I*
Total 
7-KC
+F** +F** +F**
*
+H*
+A*
+B**
+F*
+F* +E** +D*
+E*
+G*
+I*
AAS – AAS protein carbonyl, Chol – Cholesterol, DT –Dityrosine, GGS – GGS protein 
carbonyl, NP – Neopterin, Pro – Protein, TP– Total pterin, TBA–TBARS, •-toc - •-
tocopherol, 7-KC – 7-ketocholesterol
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Table 4.4 Correlation of Inflammatory and Oxidative Markers within Carotid and 
Femoral Plaques. Letter abbreviations from the table 4.6 were replaced with the location the 
plaque was excised from in the table 4.3 above. Control artery (K) has been excluded. CA-
carotid and FE- femoral. CA- Correlations found only in carotid plaques and FE-Correlations 
found only in femoral plaques. 
Pro Chol NP TP •-toc TBA DOPA DT AAS GGS Free 7-KC
Chol
+CA**
*
+FE*
+FE*
NP
+FE* +FE**
-CA*
TP
+CA**
+CA**
+CA*
+CA**
*
+FE**
*
-CA**
•-toc
-CA** +FE**
+CA**
-CA*
+CA**
+FE*
-CA*
-CA*
-FE**
-CA*
TBA
+CA*
+CA**
+CA**
+FE*
+CA**
*
+FE* +FE*
+CA*
+CA*
+FE*
DOPA
+CA*
+FE*
+CA*
-FE* -CA* +CA*
+CA*
-FE*
DT +CA** -CA*
AAS
+CA*
+CA**
+FE*
+CA*
+FE**
+FE*
+FE*
+FE*
+FE*
+CA* +FE*
+CA*
*
+CA* +CA**
+FE*
+CA*
GGS
+FE*
+FE*
+FE* +CA*
*
-
FE**
-FE* +FE**
+FE**
+FE**
+FE*
Free 
7-KC
+CA*
+FE*
+CA*
+FE*
-CA*
+FE*
+CA* +FE*
*
+CA*
+CA* +CA** +CA*
+CA*
+FE**
+CA*
Total 
7-KC
+CA** +CA** +CA*
**
+FE*
+FE*
+CA**
+CA*
+CA* +CA*
*
+FE*
+CA*
+FE*
+CA*
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4.4.4 Comparison of biomarkers in carotid and femoral plaques
Variation in the biomarker concentrations between carotid and femoral plaques was compared 
between 5 carotid and 5 femoral plaques analyzed during this study. All the femoral plaques 
were calcified and 2 of 5 carotid plaques were classified as neither while 3 of them were 
thrombus containing. 
Significant correlation was observed between protein, and cholesterol (P<0.001) 
concentrations between carotid and femoral plaques. There was a large variation observed in 
neopterin and 7,8-dihydroneopterin concentrations in carotid plaques, but very little in femoral 
plaques. Total pterin was found significant but since the homogeneity of variance could not be 
corrected even after log transformation, the results for it should be treated with caution. 
Welsh’s correction test, a non-parametric test was performed, as the homogeneity of variance 
was violated, but the variation was still found to be significant (figure 4.34 C and D).
Femoral plaques were significantly lower in the •-tocopherol (P<0.001), TBARS (P<0.001),
DOPA (P<0.001) and dityrosine (P<0.05) content (figure 4.35). The variation in the 
concentration of •-tocopherol and the protein oxidation marker dityrosine was higher in 
carotid plaques than in femoral plaques. The distribution and range of TBARS however in 
femoral plaques is a lot less as compared to what is found in carotid plaques. For TBARS, the 
results although showed significant difference, should be treated with caution as the 
homogeneity of variance could not be corrected after log transformation. Significant variations 
were observed even after a non-parametric Welsh’s correction test was performed due to 
violation of the homogeneity of variance. DOPA concentrations showed a higher variation in 
femoral plaques (figure 4.35).
Femoral plaques had a significantly lower amounts of AAS, GGS protein carbonyls (P<0.001) 
as well as free KC (P<0.001) and total KC (P<0.001) (figure 4.36). For GGS, the results 
showed significant difference but should be treated with caution as the homogeneity of 
variance could not be corrected after log transformation. Welsh’s correction test, a non-
parametric test was performed, as the homogeneity of variance was violated, but the variation 
was still significant. The overall content, however, was lower for all the biomarkers in femoral 
plaques as compared to carotid plaques. 
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Figure 4.34 Comparison of protein, cholesterol, neopterin and total pterin content in 
carotid and femoral plaques. Protein (A) and cholesterol (B) were measured using 
spectroscopic based assays while neopterin (C) and total pterin (D) were analyzed using SCX 
column using fluorescence detection on HPLC as described in the methods Biomarker 
concentrations for all the sections from the carotid and femoral plaques were taken together 
and log transformed to analyze using one-way ANOVA. Levene’s test for homogeneity of 
variance was performed and corrected by log transforming the raw data.  If the log 
transformation could not correct for the homogeneity of variance a non-parametric Welsh’s 
correction test was used to analyze significance (shown by ‘#’). Statistical significances are 
represented by (P<0.05) *, (P<0.01) **, (P<0.001)***. Data represented as Box and whisker 
graphs where whiskers extend from the minimum to maximum value. Box extends from 25th
to 75th percentiles and the horizontal line in the middle shows the ‘median’ and ‘+’ sign 
represents the Mean, on which ANOVA was performed. 
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Figure 4.35 Comparison of •-tocopherol, TBARS, DOPA and dityrosine content in 
carotid and femoral plaques. •-Tocopherol (A), TBARS (B), DOPA (C) and dityrosine (D) 
were measured using reverse phase HPLC methods using fluorescence detection as described 
in the methods. Biomarker concentrations for all the sections from the carotid and femoral 
plaques were taken together and log transformed to analyze using one-way ANOVA. Levene’s 
test for homogeneity of variance was performed and corrected by log transforming the raw 
data.  If the log transformation could not correct for the homogeneity of variance a non-
parametric Welsh’s correction test was used to analyze significance (shown by ‘#’). Statistical 
significances are represented by (P<0.05) *, (P<0.01) **, (P<0.001)***. Data represented as 
Box and whisker graphs where whiskers extend from the minimum to maximum value. Box 
extends from 25th to 75th percentiles and the horizontal line in the middle shows the ‘median’ 
and ‘+’ sign represents the Mean, on which ANOVA was performed.
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Figure 4.36 Comparison of protein carbonyls (AAS and GGS), free KC and total KC 
content in carotid and femoral plaques. AAS (A), GGS (B), Free (C) and total KC (D) were 
measured using reverse phase HPLC methods using fluorescence detection as described in the 
methods. Biomarker concentrations for all the sections from the carotid and femoral plaques 
were taken together and log transformed to analyze using one-way ANOVA. Levene’s test for 
homogeneity of variance was performed and corrected by log transforming the raw data.  If 
the log transformation could not correct for the homogeneity of variance a non-parametric 
Welsh’s correction test was used to analyze significance (shown by ‘#’). Statistical 
significances are represented by (P<0.05) *, (P<0.01) **, (P<0.001)***. Data represented as 
Box and whisker graphs where whiskers extend from the minimum to maximum value. Box 
extends from 25th to 75th percentiles and the horizontal line in the middle shows the ‘median’ 
and ‘+’ sign represents the Mean, on which ANOVA was performed.
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4.4.5 Comparison of biomarkers in control artery with carotid and femoral plaques
Biomarker concentrations in carotid and femoral plaques were also compared with a control 
artery section of iliac artery excised from a kidney transplant patient with no sign of plaque 
development or thrombus. 
A significantly low (P<0.001) amount of protein was found in femoral plaques as compared to 
the control artery (figure 4.37 A). Control artery had the highest amount of protein, while 
carotid plaques had slightly lower protein content than control artery, which was not 
significant. Cholesterol content was significantly higher (P<0.001) in carotid plaques, 
although it showed a very high range (figure 4.37 B). Femoral plaque cholesterol 
concentrations were very similar to the control artery.  There was a large amount of variation 
observed in neopterin and 7,8-dihydroneopterin concentrations in carotid plaques, which may 
have masked any significant variations found between them (figure 4.37 C and D). Although 
unexpected, the neopterin and 7,8-dihydroneopterin content in the control artery was very high 
(169 ± 6 pmoles and 425 ± 6 pmoles respectively).
Carotid plaques were significantly different from the control artery in the •-tocopherol 
(P<0.001), TBARS (P<0.001) and DOPA (P<0.01) content (figure 4.38 A). Significantly high 
•-tocopherol was found in femoral plaques as compared to the control artery (P<0.05). The 
variation in the concentrations of TBARS, •-tocopherol and the protein oxidation markers 
DOPA and dityrosine was again higher in carotid plaques than in femoral plaques. The 
distribution and range of these biomarkers in femoral plaques was a lot less as compared to 
what is found in carotid plaques. DOPA, dityrosine and TBARS content was similar in control 
and femoral artery plaques (figure 4.38).
No significant differences were observed between the control artery and the carotid/femoral 
plaques with respect to AAS and GGS protein carbonyls (figure 4.39 A and B). Average of 
both protein carbonyls was however lower than the control artery in femoral plaques and 
higher in carotid plaques. Both free and esterified KC were found to be significantly higher in 
carotid plaques (P<0.01) in comparison to control artery (figure 4.39 C and D). The presence 
of these biomarkers in the control artery was interesting. 
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Figure 4.37 Comparison of protein, cholesterol, neopterin and total pterin content in 
control, carotid and femoral plaques. Protein (A) and cholesterol (B) were measured using 
spectroscopic based assays while neopterin (C) and total pterin (D) were analyzed using SCX 
column using fluorescence detection on HPLC as described in the methods Biomarker 
concentrations for carotid and femoral plaques were compared with the control artery using 
one-way ANOVA. Levene’s test for homogeneity of variance was performed and corrected by 
log transforming the raw data.  Dunnett’s test was performed on the log transformed data 
where both carotid and femoral plaques were compared with control artery for the biomarker 
concentrations. Statistical significances are represented by (P<0.05) *, (P<0.01) **, 
(P<0.001)***. Data represented as Box and whisker graphs where whiskers extend from the 
minimum to maximum value. Box extends from 25th to 75th percentiles and the horizontal line 
in the middle shows the ‘median’ and ‘+’ sign represents the Mean, on which ANOVA was 
performed.
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Figure 4.38 Comparison of •-tocopherol, TBARS, DOPA and dityrosine content in 
control, carotid and femoral plaques. •-Tocopherol (A), TBARS (B), DOPA (C) and 
dityrosine (D) were measured using reverse phase HPLC methods using fluorescence 
detection as described in the methods. Biomarker concentrations for carotid and femoral 
plaques were compared with the control artery using one-way ANOVA. Levene’s test for 
homogeneity of variance was performed and corrected by log transforming the raw data.  
Dunnett’s test was performed on the log transformed data where both carotid and femoral 
plaques were compared with control artery for the biomarker concentrations. Statistical 
significances are represented by (P<0.05) *, (P<0.01) **, (P<0.001)***. Data represented as 
Box and whisker graphs where whiskers extend from the minimum to maximum value. Box 
extends from 25th to 75th percentiles and the horizontal line in the middle shows the ‘median’ 
and ‘+’ sign represents the Mean, on which ANOVA was performed.
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Figure 4.39 Comparison of protein carbonyls (AAS and GGS), free KC and total KC 
content in control, carotid and femoral plaques. AAS (A), GGS (B), Free (C) and total KC 
(D) were measured using reverse phase HPLC methods using fluorescence detection as 
described in the methods. Biomarker concentrations for carotid and femoral plaques were 
compared with the control artery using one-way ANOVA. Levene’s test for homogeneity of 
variance was performed and corrected by log transforming the raw data.  Dunnett’s test was 
performed on the log transformed data where both carotid and femoral plaques were compared 
with control artery for the biomarker concentrations. Statistical significances are represented 
by (P<0.05) *, (P<0.01) **, (P<0.001)***. Data represented as Box and whisker graphs where 
whiskers extend from the minimum to maximum value. Box extends from 25th to 75th
percentiles and the horizontal line in the middle shows the ‘median’ and ‘+’ sign represents 
the Mean, on which ANOVA was performed.
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4.4.6 Plaque culture and 7,8-dihydroneopterin generation
Atherosclerotic plaques obtained by endarterectomy were transported to the laboratory at 
University of Canterbury on ice within an hour of surgical removal. The plaques were cut into 
3-5 mm sections, each section placed in a separate well in a 12-well cell culture plate with 
RPMI 1640 with 10% human serum. The media was replaced every 24 hours. The medium 
from Day 1 and Day 2 were used to measure lactate production using a Roche Lactate assay 
kit. 
On 3rd day and Day 4, the sections were stimulated with 500 U/ml of IFN-• in RPMI 1640 + 
10% human serum. The medium was collected after 24 hours and fresh medium (RPMI 1640 
+ 10% human serum) was added with 500 U/ml IFN-• and medium was added.  The medium 
(Day 3 and Day 4) was collected and neopterin and 7,8-dihydroneopterin levels were 
measured on the HPLC as described in the methods. 
The media was tested for lactic acid generation as a marker of cells being active. Lactate was 
chosen as it is easy to measure, readily diffuses out of the tissue where it is produced and is 
representative of the active cell metabolism. Immune cells including macrophages, T cells and 
mast cells are found in the plaque, and are frequently in an activated state with high 
metabolism. 
Although neopterin has been found in plaques and it has been shown that it is a direct product 
of IFN-• stimulation of macrophages in vitro, there is no published literature demonstrating 
that this process occurs in atherosclerotic plaques. A high amount of neopterin and 7,8-
dihydroneopterin in plasma in patients with cardiovascular disease also suggests that these 
pterins are easily diffusible from their production sites. This study of plaque culture was aimed 
at establishing atherosclerotic plaques as a definitive site for neopterin and 7,8-
dihydroneopterin production and the ability of them to allow the diffusion of pterins in to the 
surrounding media. 
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Figure 4.40 Schematic for culture of plaque for analysis of 7,8-dihydroneopterin and 
neopterin production in vitro. Freshly excised plaques were sectioned into 3-5 mm sections 
and cultured using RPMI 1640 supplemented with 10% human serum into 12-well plates, with 
one section in every well. Each section was stimulated using IFN-• on day 3 and 4 of culture. 
The culture medium was collected every 24 hours and analyzed for neopterin and 7,8-
dihydroneopterin. 
Section the Plaque in to 3-5 mm sections, 
record the weight of each section 
(aseptically) and culture in RPMI 1640  
supplemented with  10%  human serum in 
culture plates
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4.4.6.1 Plaque culture 1
This plaque was a thin-walled elongated plaque, with a slight bifurcation collected from a 63 
year-old female patient (Plaque database no. 68). This plaque was cut into 6 sections, where 
the bifurcation region was in section 2. Section 4,5 and 6 all had calcification in them, but 
section 5 was the most calcified one, but section 2 was the heaviest. Sections 5 and 6 had 
haemolysed blood clot within them. Section 2 was the bulkiest of them all, due the small part 
of the bifurcation in the section. Section 3 which was the leftover of the small bifurcation was 
the least heavy of the 6 sections. Although sections 4, 5 and 6 were of similar dimensions, 
section 5 weighed more than sections 4 and 6, most possibly due to the heavy calcification in 
this section. 
Table 4.5 Plaque weight (in mg) of the 6 sections of plaque 1. 
Plaque section Weight (mg)
1 148.0
2 235.2
3 88.6
4 122.9
5 202.9
6 135.8
The cells in the plaque appear to be utilizing glucose in the culture media to produce lactic 
acid. The range of lactic acid produced was between 11.0 ± 0.4 µmoles/ml/24 hours to 16 ± 1 
µmoles/ml/24 hours on day 1, and 9.0 ± 0.7 µmoles/ml/24 hours to 15 ± 1 µmoles/ml/24 hours
on day 2 across the 5 sections of this plaque (figure 4.41). This shows that cells are 
continuously making lactate and the lactate measured in the media is not just leaching out of 
the tissue.  The lactate production is consistent across the first 2 days in culture in each 
section. On an average, the first 3 sections had higher rate of lactate production as compared to 
the last 3 sections. Differences in lactate production might indicate variation in the 
macrophage and T-cell numbers across the different sections of the plaque.
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Figure 4.41 Plaque 1: Lactate production in Live Plaque sections cultured without IFN-•.
Lactate was measured using Roche Lactate assay kit using UV spectrophotometer.  
On day 2, where there was no IFN-• added, there was neopterin detected but no 7,8-
dihydroneopterin in any of the sections (figure 4.42 (A)). Section 1 stands out as the neopterin 
in it is approximately 4 times higher than the other sections. This neopterin detected could be 
already produced already in the plaque which is leached out into the culture media or also 
produced by the monocytes/macrophages inside the plaque tissue.  This section forms the base 
of the bifurcation where the normal blood flow is split into two branches of the carotid artery. 
Change in the blood flow dynamics could affect this difference in oxidative stress and thus 
neopterin production. 
On stimulation with 250 U/ml of IFN-• on day 3, there is high increase in production of 7,8-
dihydroneopterin in all the 6 sections of plaque 1 (figure 4.42 B). Neopterin formation was 
lowered in most sections along with a sustained increase in 7,8-dihydroneopterin. Sections 4, 5 
and 6 did not show any neopterin on day 3. Highest production of 7,8-dihydroneopterin was 
195 ± 1 pmoles/g plaque in section 5.  
On day 4, with replenished media and fresh IFN-• added to the culture, the highest 
concentration of total pterin was 284.47 ± 0.03 pmoles/g plaque, out of which most of it was 
neopterin (172 ± 3 pmoles/g plaque). Similar was the case with the other sections where most 
of the total pterin (from approximately 50-70%) was in the form of neopterin. This suggests 
that by day 4 significant oxidative events occur oxidizing most of the 7,8-dihydroneopterin to 
neopterin. 
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Of the total pterin produced over the 2 days of stimulation with IFN-•, approximately 1/3rd
was neopterin and 2/3rd was 7,8-dihydroneopterin, which is similar ratio found in plasma for 
neopterin/7,8-dihydroneopterin (figure 4.42). As 7,8-dihydroneopterin is only produced by 
monocytes/macrophages on IFN-• stimulation, it can be safely concluded that 7,8-
dihydroneopterin measured in plaques does indeed involve localized production inside the 
inflammatory atherosclerotic plaque. 
A)
B)
Figure 4.42 Plaque 1: Comparison of neopterin and total pterin produced by plaques 
over 4 days in culture. Freshly excised plaque sections were cultured in RPMI + 10% human 
serum for 4 days. Day 2 was without IFN-• stimulation. Sections were stimulated by 500 U/ml 
of IFN-• on day 3 and 4.  Neopterin (A) and Total Pterin (B) were measured in the supernatant 
for each day using SCX column method on HPLC. Results are expressed as Mean ± SEM of 
duplicate of samples. 
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This has been shown here for the first time, that direct IFN-• stimulation of atherosclerotic 
plaque results in neopterin/7,8-dihydroneopterin production. As we compare the neopterin and 
total pterin over the 3 days in culture (figure 4.42 B), shows that there is increased production 
of neopterin and 7,8-dihydroneopterin with the addition of fresh IFN-• and fresh medium on 
day 3 and day 4 of the culture suggesting increased oxidative stress induced by IFN-• and the 
in vitro culture environment. 
We increased the cytokine dosage to 500 U/ml of IFN-• to see the production of 7,8-
dihydroneopterin in the sections. 
4.4.6.2 Plaque culture 2
Plaque 2 was a thin walled plaque with a bifurcation collected from a 68 year-old male patient 
(plaque database no. 76). For culture, it was cut into 5 sections and cultured in RPMI 1640 
supplemented with 10% human serum. The weight (mg) of each of the section was as follows. 
Section 2 was the bifurcation region which was thicker than the rest of the sections.  Although 
section 2 had a slight bifurcation in it, section 4 weighed the most, as it was heavily calcified. 
Section 3, which the smaller bifurcation branch weighed the least amongst the 5 sections. 
Section 5 was comparatively thin walled, without any calcification.
Table 4.6 Plaque weight (in mg) of the 5 sections of plaque 2 
Plaque section Weight (mg)
1 57.9
2 257.5
3 39.3
4 341.1
5 148.3
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Figure 4.43 Plaque 2: Lactate production in Live Plaque sections cultured without IFN-•. 
Lactate was measured using Roche Lactate assay kit using UV spectrophotometer.
Lactate produced in plaque 2 is in the similar range as observed for plaque 1 (figure 4.43). 
Across the 5 sections of plaque 2, the lactate content was in the range of 6.7 ± 0.3 and 17.0 ± 
0.1 µmoles/ml/24 hours on day 1 while it ranged between 4.0 ± 0.5 and 15 ± 1 µmoles/ml/24 
hours for day 2. Section 2 was the bifurcation region, while section 3 was the smallest of the 5 
sections as it was the leftover of the smaller branch of bifurcation. Although, section 2 was the 
bifurcation region, it was section 5 which produced most lactate on day 1 and day 2. 
Control neopterin and 7,8-dihydroneopterin in the media only, used for plaque culture (RPMI 
1640 + 10% human serum) was also quantified. Neopterin concentration measured was 8.7 ± 
0.4 pmoles/g plaque and 7,8-dihydroneopterin was 20.5 ± 0.4 pmoles/g plaque.
IFN-• stimulation in vitro of these sections resulted in increase in neopterin and total pterin 
content of all the sections (figure 4.44 A and B). In section 2 the total pterin concentration shot 
up to (124 ± 2 pmoles/g plaque), approximately 3 times. There was a proportional increase in 
neopterin too, which increased to 50 ± 2 pmoles/g plaque from 19.4 ± 0.7 pmoles/g plaque. In 
section 4, neopterin levels on day 3 were 73.8 ± 0.7 pmoles/g plaque, which was 
approximately 3.6 times higher than on day 2 (20.5 ± 0.4 pmoles/g plaque). 
On Day 2, highest level of neopterin and 7,8-dihydroneopterin (measured as total pterin) 
production before interferon stimulation was 20.5 ± 0.4 pmoles/g plaque and  49.3 ± 0.8 
pmoles/g plaque in section 4, the section just after the bifurcation. Least amount of neopterin 
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was found in section 3 (10.0 ± 0.9 pmoles/g plaque) while the lowest basal levels of total 
pterin was found in section 1 (27.0 ± 0.2 pmoles/g plaque) closely followed by section 3. 
A)
B)
Figure 4.44 Plaque 2: Comparison of neopterin and total pterin produced by plaques 
over 4 days in culture. Freshly excised plaque sections were cultured in RPMI + 10% human 
serum for 4 days. Day 2 was without IFN-• stimulation. Sections were stimulated by 500 U/ml 
of IFN-• on day 3 and 4.  Neopterin (A) and Total Pterin (B) were measured in the supernatant 
for each day using SCX column method on HPLC. Results are expressed as Mean ± SEM of 
duplicate of samples. 
On IFN-• (500 U/ml) stimulation of the cultured sections on day 3, the total pterin production 
went up from 49.3 ± 0.8 pmoles/g plaque to 166 ± 1 pmoles/g plaque in section 4, recording 
the highest rise in total pterin. Neopterin levels also increased about 3 fold in this section 
indicating the high presence of monocytes/macrophages in this region. Incidentally this 
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section was also the most calcified of them all. Although section 5 showed high rate of lactate 
production similar to section 4 and section 2, 7,8-dihydroneopterin production was not as 
dramatic as the other sections. This hints towards lower concentration of macrophages in the 
region with possible infiltrations of other cell types. 
On day 4 of the culture with a second stimulus of IFN-•, the total pterin content in the sections 
was about 0.5 to 2 fold higher than that on day 3. Highest concentration was detected in 
supernatants of section 4 which recorded (345 ± 1 pmoles/g plaque). The ratio of neopterin to 
7,8-dihydroneopterin which was 1:3 on day 3 of the culture after the first IFN-• stimulus, 
decreased to 1:2 on day 4 of the culture after the second dose of IFN-•. This affirms the 
oxidative stress mediated conversion of 7,8-dihydroneopterin to neopterin. 
By comparing the amount of neopterin and 7,8-dihydroneopterin produced from day 2 through 
to day 4, it could be seen how the stimulus driven inflammatory status of the plaque sections 
could differ tremendously across the length of the plaque. 
4.4.6.3 Plaque culture 3
Plaque 3, a carotid plaque collected from a 82 year-old female patient (plaque database no. 85) 
presented with a stroke. It was thin walled and heavily calcified in section 2. Section 2 also 
had a visible clot in the region, which was the heaviest among the 5 sections. Section 3 was 
the small bifurcation from the main longitudinal stem of the plaque. Section 5 was the thinnest 
section of them all, weighing the least. 
Table 4.7 Plaque weight (in mg) of the 5 sections of plaque 3 
Plaque section Weight (mg)
1 255.2
2  529.5
3 104.3
4 240.2
5 98.7
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Figure 4.45 Plaque 3: Lactate production in Live Plaque sections cultured without IFN-•. 
Lactate was measured using Roche Lactate assay kit using UV spectrophotometer.
Plaque 3 lactate production was high across the 5 sections (figure 4.45). On day 1, section 3 
which produced the least amount of lactate had 7.9 ± 0.3 µmoles/ml/24 hours and section 1 
produced the highest, 15.16 µmoles/ml/24 hours. On day 2, the plaque sections of this plaque 
produced more lactate than day 1, the range being 14 ± 0.4 to 17 ± 0.4 µmoles/ml/24 hours. 
Section 3 showed the highest increase in lactate production, suggesting active and rapid 
metabolism through utilization of glucose in the culture medium. 
On day 2, without IFN-• stimulation, section 1 showed the highest amount of total pterin 
followed by section 5 (figure 4.46 B). Highest concentration of total pterin without any 
stimulus was 66.2 ± 0.3 pmoles/g plaque and lowest being 30 ± 3 pmoles/g plaque in section 
3. Neopterin concentration was highest at 48.8 ± 0.4 pmoles/g plaque, found in section 5. In 
this plaque about 75% of the pterin was neopterin and the rest was in the form of 7,8-
dihydroneopterin suggesting high oxidative stress. On day 3, which is the first day of IFN-• 
stimulation, 7,8-dihydroneopterin produced went up about 4 times in section 2 and about 2-3 
fold in all the other sections. Section 2 had the highest amount of total pterin (208.6 ± 0.2 
pmoles/g plaque) where the ratio of neopterin to 7,8-dihydroneopterin  was 1: 9. Even though 
section 3 measured the lowest on day 3 with 89.2 ± 0.5 pmoles/g plaque, it still showed a 3-
fold increase over day 2 with the neopterin to 7,8-dihydroneopterin ratio increasing from 
approximately 1:1 to 1:4. Day 4 saw the total pterin concentration in section 2 rose from 208.6 
± 0.2 pmoles/g plaque to 342 ± 1 pmoles/g plaque. However there was little increase in 
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neopterin content due to which the ratio of neopterin to 7,8-dihydroneopterin went up to 1:13 
in this section (figure 4.46 A and B). 
A)
B)
Figure 4.46 Plaque 3: Comparison of neopterin and total pterin produced by plaques 
over 4 days in culture. Freshly excised plaque sections were cultured in RPMI + 10% human 
serum for 4 days. Day 2 was without IFN-• stimulation. Sections were stimulated by 500 U/ml 
of IFN-• on day 3 and 4.  Neopterin (A) and Total Pterin (B) were measured in the supernatant 
for each day using SCX column method on HPLC. Results are expressed as Mean ± SEM of 
duplicate of samples.
The lowest concentration of total pterin on day 4 was found in section 3 (159 ± 7 pmoles/g 
plaque). Section 2, which was also the thickest section weighing the most, showed the highest 
increase in total pterin from day 2 (no stimulation) through to day 3 and 4. Section 5 which 
weighed the least, showed an increase of about 4 times from day 2 to day 4. 
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4.4.6.4 Plaque culture 4
Plaque 4 collected from an 81 year-old male patient (plaque database no. 86) was cut into 4 
sections. This was a thin-walled, carotid plaque without any bifurcation. Sections 1 and 2 were 
both heavily calcified, with section 1 weighing the most of the 4 sections. Sections 3 and 4 
were very thin-walled and lacked any calcification or any clots. Sections 1 and 2 showed slight 
clotting along with the calcification. 
Table 4.8 Plaque weight (in mg) of the 4 sections of plaque 4 
Plaque section Weight (mg)
1 366.7
2 285.4
3 96.7
4 96.4
Plaque 4 was cut into 4 sections with section 1 weighing the highest at 366.7 mg and section 4 
was the least in weight with just 96.4 mg. Lactate production in the sections did not change 
much over the first 2 days in culture as seen below in the graph. On day 1, section 2 had the 
most lactate produced, while section 4 had the least. The range was 5.1 ± 0.4 to 14 ± 1 mM on 
day 1, and 6.1 ± 0.3 to 11.06 ± 0.05 mM on day 2, but on day 2 section 1 produced marginally 
more lactate than section 2. 
Lactate production across the 4 sections did not show any trends (figure 4.47). Section 3 
lactate concentrations decreased slightly (from 6.2 ± 0.2 pmoles/ml/24 hours to 6 ± 1 
pmoles/ml/24 hours), while in section 4, lactate production increased from 5.1 ± 0.4 
pmoles/ml/24 hours to 6.1 ± 0.3 pmoles/ml/24 hours. So there could be a range of different 
cellular activities and interactions going on across different sections of this plaque including
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Figure 4.47 Plaque 4: Lactate production in Live Plaque sections cultured without IFN-•. 
Lactate was measured using Roche Lactate assay kit using UV spectrophotometer.
monocytes differentiating into macrophages or cellular cytokines stimulation or ‘activation’ of 
cells that would boost the cellular machinery into producing more proteins and 
macromolecules that cater to its functions. 
Before IFN-• (500 U/ml) stimulation, on day 2 of culture, section 1 had the highest amount of 
neopterin (29.4 ± 0.3 pmoles/g plaque) as well as total pterin (55.9 ± 0.3 pmoles/g plaque) 
(figure 4.48 A). Section 4 had the lowest amount of total pterin (34 ± 1 pmoles/g plaque). The 
highest concentration of both the pterins point at the advanced state of immune activation of 
the cells in this section. On day 3, when the sections were stimulated with IFN-•, the total 
pterin concentrations in all the sections showed a major increase. Section 2, which previously 
showed 39.03 ± 0.02 pmoles/g plaque of total pterin, recorded 173.7 ± 0.6 pmoles/g plaque, 
highest amongst all the sections for day 3. There was, however an increase in neopterin where 
it went up from 24.6 ± 0.1 pmoles/g plaque to 62 ± 2 pmoles/g plaque, approximately about 
2.5 times (figure 4.48 B). 
On day 4 of the culture and day 2 of IFN-• stimulation after replenishing the culture medium, 
the production of neopterin and total pterin showed an increase of about 3 times. Neopterin 
concentration in section 2 was 151 ± 4 pmoles/g plaque whereas the total pterin concentration 
was 443 ± 3 pmoles/g plaque. This proportional increase in neopterin and total pterin did not 
change the ratio of neopterin and 7,8-dihydroneopterin. With IFN-• stimulation on day 3 and 
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day 4, as seen in the graphs above, section 2 shows highest production of 7,8-dihydroneopterin 
and neopterin followed by section 1.  
A)
B)
Figure 4.48 Plaque 4: Comparison of neopterin and total pterin produced by plaques 
over 4 days in culture. Freshly excised plaque sections were cultured in RPMI + 10% human 
serum for 4 days. Day 2 was without IFN-• stimulation. Sections were stimulated by 500 U/ml 
of IFN-• on day 3 and 4.  Neopterin (A) and Total Pterin (B) were measured in the supernatant 
for each day using SCX column method on HPLC. Results are expressed as Mean ± SEM of 
duplicate of samples.
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4.4.7 Plasma Neopterin and 7,8-dihydroneopterin concentrations in 
atheroma patients undergoing endarterectomy
Plasma concentrations of neopterin and 7,8-dihydroneopterin was tested in 45 patients 
undergoing carotid or femoral endarterectomy to see if the levels measured were abnormally 
higher than that of the normal levels found in the healthy individuals. The data is presented in 
two separate graphs for convenience. 
The levels of neopterin and 7,8-dihydroneopterin showed high variation within all the patient 
groups. Most of the pterins in patients’ plasma was in the form of 7,8-dihydroneopterin (figure 
4.49). When the neopterin is represented along with 7,8-dihydroneopterin concentrations (total 
pterin-neopterin), we can see the amount of oxidative stress and the antioxidant status of the 
patient simultaneously. This is because increase in neopterin depicts increased oxidative 
stress, and neopterin by itself is known to enhance the cytotoxicity of the reactive oxygen 
intermediates. The ratio of 7,8-dihydroneopterin to neopterin was in the range of 0.4 to 3.7 
with the exception of patient 8.  For e.g. patient 6 had a higher ratio of 7,8-dihydroneopterin to 
neopterin while patient 8 plasma neopterin or 7,8-dihydroneopterin were below the detectable 
limits, if any (figure 4.49). In some patients neopterin levels were a lot higher than 7,8-
dihydroneopterin suggesting that most of the 7,8-dihydroneopterin produced was converted to 
neopterin during the oxidative stress. For example, in patient 28, the neopterin levels are 
approximately 7.5 times higher than 7,8-dihydroneopterin and in patient 21, ratio of neopterin 
to 7,8-dihydroneopterin is about 5. In other patients, for example, 24 and 25, almost all the 
pterin present is in the form of neopterin. Patient 43 had most of the pterin (almost 98%) as 
neopterin (figure 4.50 B). Overall, the plasma neopterin concentration was in the range of 0–
58 nM whereas 7,8-dihydroneopterin concentration in plasma ranged between 0-74 nM. 
The plasma levels for neopterin as measured by Genet (2010), for the healthy volunteers was 
in the range 1.24 ± 0.04 nM and 16.1 ± 0.2 nM. For 7,8-dihydroneopterin the normal 
concentrations measured were in the range of 5.8 ± 0.2 nM to 40.7 ± 0.6 nM. The overall 
average concentration of neopterin and 7,8-dihydroneopterin for normal individuals was 
measured as 5.1 ± 0.3 nM and 17.6 ± 0.8 nM (figure 4.51). 
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A)
B)
Figure 4.49 Atheroma Patient Plasma Neopterin and Total Pterin levels (1-20). Plasma 
samples collected from patients undergoing endarterectomy were analyzed for neopterin and 
total pterin (A) by fluorescence detection on HPLC using SCX column. Figure (B) represents 
neopterin and 7,8-dihydroneopterin (78NP) (total pterin- neopterin). Results are expressed as 
Mean ± SEM for duplicate of samples
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A)
B)
Figure 4.50 Atheroma Patient Plasma Neopterin and Total Pterin levels (21-45). Plasma 
samples collected from patients undergoing endarterectomy were analyzed for neopterin and 
total pterin (A) by fluorescence detection on HPLC using SCX column. Figure (B) represents 
neopterin and 7,8-dihydroneopterin (78NP) (total pterin- neopterin). Results are expressed as 
Mean ± SEM for duplicate of samples
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A)
B)
Figure 4.51 Healthy Controls Neopterin and Total Pterin testing. Plasma samples 
collected from Healthy control individuals from (Genet, 2010) were analyzed for neopterin 
and total pterin (A) by fluorescence detection on HPLC using SCX column. Figure (B)
represents 7,8-dihydroneopterin (78NP) (total pterin- neopterin). Results are expressed as 
Mean ± SEM for duplicate of samples.
Since control plasma samples were unavailable due to lack of volunteers and time, we have 
used the control neopterin and 7,8-dihydroneopterin values from the work of (Genet, 2010). 
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Although these were measured by the reverse phase C18 method of neopterin and 7,8-
dihydroneopterin detection, it has been proven that the measurements were very similar using 
the SCX method. 
To examine the variation of 7,8-dihydroneopterin/neopterin in the healthy controls and 
atherosclerotic patients, the levels of neopterin and 7,8-dihydroneopterin from 21 healthy 
volunteers measured earlier in our laboratory (Genet, 2010) were compared with the 
atherosclerotic patient plasma samples. The average neopterin concentration in healthy 
controls was 6.8 nM, whereas in the atherosclerotic patients it was more than 4 times elevated 
measuring 27 nM (figure 4.52). 
Figure 4.52 Comparison of neopterin and 7,8-dihydroneopterin levels in atherosclerotic 
patients and healthy volunteers. Plasma from healthy volunteers (N=21), and atheroma 
patients (N=45) was analyzed for neopterin (A), 7,8-dihydroneopterin (B) and total pterin (C). 
Statistical significances analyzed by unpaired t-test are represented by (P<0.05) *, (P<0.01) 
**, (P<0.001)***.
Total pterin measured an average of 25 nM in healthy controls while in patients it was 
elevated significantly to 61 nM (P<0.001). Same was the case with 7,8-dihydroneopterin 
concentrations, where the average concentration was measure about 18 nM in healthy controls, 
it measured 34 nM in plasma of atherosclerosis patients. 7,8-Dihydroneopterin concentrations 
was about 2 fold higher in the patients (P<0.001). 
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4.5 Discussion
4.5.1 Biomarkers in plaques
Biochemical analysis of 10 advanced atherosclerotic plaques along with an artery control was 
performed, to quantify the oxidative biomarkers, as a part of this study. In all, a total of 35 
plaques have been analyzed in our laboratory. It has become apparent through the analysis of 
all these plaques, that each plaque is unique in its biochemical composition. This is an 
indication that atherosclerotic plaque formation is a complex and dynamic process and no two 
plaques develop or progress in a similar manner. The oxidative and antioxidant biomarkers 
analyzed in these plaques, not only differed between the plaques but also within the different 
sections of the same plaque. Huge variation in the concentration and localization of the 
markers suggest that there are multiple mechanisms involved, not only in formation of 
different plaques but also in the different sections along the length of an individual plaque. 
This indicates that there are many contributing factors to the etiology and progression of an 
atherosclerotic plaque. 
Almost all the plaque used in the study were in their advanced stages of development, 
representing slow, chronic inflammation and oxidative stress associated with lipid deposition 
over a lifetime of an individual. This accompanied by the age, sex, health, hypertension, 
smoking status and medications received, could add to the complexity of the disease and alter 
the progression of an atherosclerotic plaque. At such an advanced stage of development, there 
is such a diverse range of morphology and biochemistry within the plaques, which is clearly 
seen in the photographs taken and the biomarker concentrations tested within them. 
Significant correlations were rarely observed in more than one plaque and the trends between 
the oxidative biomarkers showed a great variation within the plaques and within the different 
sections of one plaque (table 4.3). There was no overall trend between the markers of 
oxidation or antioxidant status that was observed, probably due to the changes introduced by 
diet, genetics, immune activation/infection, medications or due to complications introduced by 
any other medical ailment. 
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Individually, the plaques showed a great deal of variation across the sections. Within each of 
the plaques analyzed, there were both positive and negative correlations between the different 
biomarkers. Concentrations of the markers varied between plaques, such that it was difficult to 
decipher any strong relationship between the markers. It was interesting sometimes to note 
correlation between biomarkers which one might not have expected and vice versa. 
Previous studies in our laboratory have noted significantly elevated levels of neopterin in the 
bifurcation regions of the plaques when compared to the pre- and post-bifurcation regions 
(Genet 2010). The plaques in this study could have been used to do a similar analysis, 
however, not all of the carotid plaques analyzed had a bifurcation and none of the femoral 
plaques had any bifurcation. So the numbers were difficult to collate in terms of their pre-, 
bifurcation or post-bifurcation locations. Since the anatomical location of the plaques could 
define the symptoms of the disease and in this case, atherosclerosis, we also looked at any 
relationships between oxidative biomarker concentrations across carotid and femoral plaques. 
4.5.2 Comparison of carotid and femoral plaque biomarker concentrations with 
published literature
Of the twelve biomarkers measured by our laboratory, eight have been previously studied and 
quantified in the literature (Fu et al., 1998, Brown et al., 1997, Upston et al., 2002, Nishi et 
al., 2002). There is no published literature on protein carbonyls AAS and GGS measured in 
atherosclerotic plaques by other laboratories. Although neopterin was detected in 
atherosclerotic plaques by a couple of other studies done by Adachi et al., (Adachi et al., 
2007) and Sugioka et al., (Lum et al., 1979) using histological techniques, none of these 
studies actually quantified neopterin levels.  Although some inflammatory markers like matrix 
metalloproteinases (MMP’s) have been quantified in carotid and femoral plaques (Zhou et al., 
2010), there have been no studies comparing the range of various biomarkers in carotid and 
femoral plaques either which is novel to this study. Therefore our laboratory is the first to 
quantify and correlate neopterin and 7,8-dihydroneopterin as well as AAS and GGS protein 
carbonyls in atherosclerotic plaques and compare the biomarkers between carotid and femoral 
plaques. 
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Few of the biomarkers were comparable to the values found in literature while others were 
either higher or lower than previously published values. Average TBARS concentration 
reported by Nishi et al., (Nishi et al., 2002) was 36 ± 3 nmole/g of plaque tissue, which is 
much higher than the average found in this study of 12.7 ± 0.3 nmole/g of plaque tissue. Since 
a large amount of variation in TBARS was also noticed by Jachec et al., (Jache• et al., 2003)
which ranged from 0.2 to 37 µg/g of tissue, this could be attributed to the individual variations 
and the extent of the disease in the patients. If we compare TBARS between carotid and 
femoral plaques, it measured 23.4 ± 0.5 nmoles/g of plaque and 2.1 ± 0.1 nmole/g of plaque. 
Increased inflammation and ROS due to increased infiltration of monocytes/macrophages 
could explain this increase.  
The average amount of cholesterol was recorded as 48 ±  6 µmole/g of plaque by Iuliano et al., 
(Iuliano et al., 2003), which is about two thirds of the average that was found in the plaques in 
this study which measured 79 ± 4 µmole/g of plaque. Total cholesterol content ranged from 2 
to 24 mg/g in plaques as studied by Jachec et al., (Jache• et al., 2003), which translates to 
about 4 µmole/g to 61 µmole/g of plaque tissue, which is comparable to what we have 
measured in our plaques. When compared between the average cholesterol levels in plaques 
from different arterial origins, there was a ten-fold difference. In carotid plaques, cholesterol 
was quantified at an average of 146 ± 5 µmole/g of plaque while in femoral plaques it 
measured 13 ± 3 µmole/g of plaque. This hints at increased oxLDL entry into the carotid 
intima as compared to femoral artery intima. 
•-Tocopherol was quantified to be 86 ± 62 nmole/g of plaque tissue by Iuliano et al., (Iuliano
et al., 2003), which is similar to 81 ± 6 nmole/g plaque tissue reported by us. In spite of 
similar overall values, there was a large variation amongst carotid and femoral plaques. Where 
carotid plaques measured 123 ± 7 nmole/g of plaque, femoral plaques measured very low 
levels of 39 ± 5 nmole/g of plaque. 
DOPA and dityrosine concentrations in the study performed by Fu et al., (Fu et al., 1998)
were in the range of 14 ± 4 and 5 ± 5 nmole/g of plaque tissue respectively. In our study, 
DOPA measured an average of 13 ± 2 nmole/g of plaque and dityrosine on an average 
measured 2.5 ± 0.3 nmole/g of plaque tissue which was close to what was reported in the 
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literature. However carotid plaques measured 4 ± 0.4 nmole/g of plaque which was similar to 
what was measured by Fu et al., (Fu et al., 1998) in their studies. Femoral artery plaques 
recorded very low levels of dityrosine at 1.0 ± 0.2 nmole/g of plaque. 
With regards to the free KC values in plaques Iuliano et al., (Iuliano et al., 2003) reported 36 ± 
22 nmole/g of tissue and we found 64 ± 11 nmole/g of plaque, although a large variation of 
free KC has been recorded (Jache• et al., 2003). For the total KC content in plaques, Brown et 
al., (Brown et al., 1997) measured 117 ± 42 nmole/g of plaque, whereas our average total KC 
content in the ten plaques measured 291 ± 60 nmole/g of plaque, which is more than two-fold 
as observed by them. However, the range of total KC in our plaques was between 32 ± 3 
nmole/g to 1263 ± 333 nmole/g of plaque. Carotid and femoral plaques again showed a high 
degree of variation in free and total KC concentrations. Free KC levels were measured 92 ± 14 
nmole/g of plaque in carotid plaques, and 37 ± 8 nmole/g of plaque in femoral origin plaques. 
Same kind of variation was observed with total KC too, where it was measured 471 ± 100 
nmole/g of plaque in carotid plaques and 111 ± 21 nmole/g of plaque in femoral plaques. 
4.5.3 Combined Correlation of biomarkers across atherosclerotic plaques
A large level of variation was found in the biomarker concentrations across the length of the 
plaque as well as between individual plaques. These differences may be due to individual 
variations in the patients from which the plaques were excised, their age, diet, other diseases 
(eg. diabetes), medications they were on and the stages of plaque growth every individual 
plaque was in. All the above factors would affect the ability of an individual to modulate and 
handle the oxidative stress, which in turn might affect the constant variation in the chemical 
changes and composition of the lesion.
Lipid content changes due to an individual’s diet would complicate and add up to the plaque 
growth. Significant correlations between the biomarkers across the plaque and in between the 
plaques were observed in spite of these differences, which provide valuable insights in the 
underlying complex interactions between the various biomarkers and how they relate and 
influence each other (table 4.3). 
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4.5.3.1 Lipid oxidation 
One of the major correlations observed among the lipid oxidation products was a positive 
correlation between free KC and total KC, which was observed equally in four of the ten 
plaques. Free KC positively associated with total pterin, TBARS, DOPA and GGS in three of 
the five carotid plaques but not in any femoral plaques. Although both free and total KC are 
formed by the free radical attack on cholesterol, a relationship with cholesterol was found in 
only three of the ten plaques. Free KC was dependent on cholesterol in both carotid and 
femoral plaques (one each, plaque C and H respectively), only total KC positively correlated 
in carotid plaque (plaque F). Free KC showed a significant correlation with AAS protein 
carbonyls in three of the ten plaques (plaques E, F and H). Total KC was positively associated 
with both the AAS and GGS protein carbonyls in two plaques (plaques E and F) but not in 
femoral plaques. As AAS and GGS are the major oxidized proteins of metal catalysed 
oxidations systems it suggests that they might play a role in oxidation of cholesterols in vivo. 
Oxidation of nearby protein by the reactive oxygen species formed by lipid peroxidation could 
also be a contributor to this relationship (Berlett and Stadtman, 1997, Gieseg et al., 2003). 
Statistically significant correlation was also found between total KC and TBARS in three of 
the ten plaques analyzed (plaques A, B and F). This suggests the involvement of similar 
peroxidation processes of lipid oxidation for both of these biomarker formations. Nishi et al.,
(Nishi et al., 2002) showed there was a strong correlation between lipid peroxidation and the 
total lipid content within atherosclerotic plaques. TBARS showed positive correlation with 
total pterin in four of the ten plaques (plaques A, C, F and H), two of which were carotid and 
the other two were femoral plaques. This indicates a role for pro-inflammatory cytokines such 
as IFN-• in increased oxidative stress along with increased 7,8-dihydroneopterin production.  
TBARS showed a positive correlation with neopterin in just one femoral plaque (plaque A)
while significant positive relationship between TBARS and cholesterol occurred in three of 
the ten plaques (plaques C, D and F) which was expected as most of the lipids in 
atherosclerotic plaques is believed to be from LDL. MDA in plasma is also known to be 
positively associated with LDL cholesterol and negatively correlated with LDL particles peak 
size pointing towards LDL in plaques (Tanaga et al., 2002). An interesting correlation 
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between TBARS and protein content was found in two carotid plaques (F and C), which might 
be due to the increased flux of apo B moieties of lipoproteins accumulated in the plaques. 
4.5.3.2 Protein oxidation biomarkers
Among the protein oxidation biomarkers DOPA and dityrosine had significant correlations 
with the other biomarkers. DOPA amounts positively correlated with protein content in three 
of the ten plaques (plaques C, G and I) which was expected as increased protein in the form of 
more cells or LDL enters the milieu of oxidants in the plaque. DOPA also showed positive 
correlation with •-tocopherol in two of the ten plaques (plaques B and E). Since •-tocopherol 
is the main antioxidant in LDL particles, the DOPA in this case could be on protein moiety on 
LDL which is found elevated in atherosclerotic plaques. DOPA also showed negatively 
significant correlations with cholesterol (plaque J) and TBARS (plaque D) in two of the five 
femoral plaques. This could happen when the lipid oxidation intermediates further inflict and 
damage adjacent proteins. Also protein bound DOPA could increase the oxidation via redox 
cycling of metal ions further amplifying the damage (Rodgers and Dean, 2000). Negative 
correlation of DOPA with neopterin (plaque B) in one of the carotid plaques could be a result 
of HOCl damage on proteins in the absence of 7,8-dihydroneopterin protection. Only 
significant correlation dityrosine showed was positive correlation with neopterin and negative 
correlation with 7,8-dihydroneopterin (plaque E). This further strengthens the observation that 
myeloperoxidase, which also produces HOCl leading to increased neopterin and reduced 7,8-
dihydroneopterin , could employ H2O2 to yield tyrosyl radicals leading to dityrosine formation 
(Heinecke et al., 1993). DOPA levels were found to be consistently higher than dityrosine in 
all the plaques tested here which has been documented previously by Fu et al., (Fu et al., 
1998). The reason for this has been suggested that the formation of tyrosyl radical depends on 
the radical flux and is not linearly proportional with increased free radical concentration. 
DOPA and dityrosine were more prominent and displayed significant correlations in carotid 
plaques than in femoral plaques. 
Both AAS and GGS protein carbonyls are formed by a similar process of metal catalysed 
oxidation. So it was not surprising that four of the ten plaques showed significant positive 
correlation between AAS and GGS (plaques D, G, H andJ). AAS content was always higher 
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than GGS in all the plaques analyzed. AAS showed a positive correlation with protein in three 
of the ten plaques and with cholesterol in four of the ten plaques. This coincides with the fact 
that lysine residues from which AAS is formed is the 3rd highest amino acid (~8%) in apo B-
100 protein of LDL, while arginine (3.3%) and proline (3.7%) which form GGS are found in 
lower concentrations. 
With apoB-100 protein being an important ligand for the LDL receptor on cells, high amounts 
of LDL found in the plaques and lysine playing an important role in binding of atherogenic 
lipoprotein a molecule collectively suggests the easy access of oxidants to lysine residues. 
Elevated inflammatory stimulus such as IFN-• would also boost protein synthesis, which 
could explain positive relationship of AAS and GGS with proteins along with neopterin and 
total pterin. AAS and GGS were major protein oxidation products with significant correlations 
with other biomarkers of femoral plaques suggesting that metal catalysed oxidation of proteins 
could be a major determinant in formation of femoral plaques. 
4.5.3.3 Antioxidants •-tocopherol and 7,8-dihydroneopterin 
•-Tocopherol being a major antioxidant in LDL, plays a major role in preventing oxidative 
modification of cholesterol and proteins. It correlates negatively with HOCl oxidative product 
neopterin in three of the ten plaques and with 7,8-dihydroneopterin in one of the plaques. It is 
possible when increased HOCl mediated oxidation of lipid or protein on LDL depletes •-
tocopherol. •-Tocopherol showed positive correlation with cholesterol in four of the ten 
plaques, which was expected as it is the major antioxidant found in LDL. This relationship of 
•-tocopherol with neopterin could also be due to enhancement of the oxidative potential of 
ROS by neopterin (which only occurs at high micromolar concentrations), thereby increasing 
the oxidative stress (Adachi et al., 2007).  A significant positive correlation of total pterin was 
found with TBARS, in four of the ten plaques. This could possibly suggest the pro-
inflammatory role of MDA-modified LDL in stimulating IFN-• production and 7,8-
dihydroneopterin production as MDA-modified LDL mediate a range of pro-inflammatory 
processes (Dalle-Donne et al., 2006). With regards to the correlations between these 
antioxidants and other biomarkers there were no specific strong correlations observed among 
carotid or femoral plaques. 
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Although a few correlations emerged two or more times in a few plaques, there were no strong 
correlations observed in all the plaques. Some correlations occurred once. The major 
correlations observed were between AAS and GGS, free and total KC, cholesterol and •-
tocopherol, cholesterol and AAS and total pterin and TBARS. 
4.5.4 Biomarker comparison between carotid and femoral plaques
Biomarker variations between carotid and femoral plaques were in line with the previously 
observed differences in their inflammation and macrophage sub-types (Herisson et al., 2011, 
Shaikh et al., 2012, Bamberg et al., 2012). Inflammation, as indicated by neopterin and 7,8-
dihydroneopterin concentrations, had a huge variation across the carotid plaques (figure 4.34 
C and D). Average neopterin concentration in carotid plaques was approximately 2.5 fold 
higher than in femoral plaques. Femoral plaques did not show a huge variation in pterin range. 
It seems that the higher oxidative stress and ROS produced due to increased inflammation on 
oxLDL interaction in carotid plaques than in femoral plaques could be responsible for this 
(Herisson et al., 2011, Shaikh et al., 2012, Bamberg et al., 2012). The immune status of an 
individual and the contribution of other infections or diseases, along with the medications, diet 
and genetics of an individual might alter the inflammatory response and the subsequent 
oxidative effects. The amount of protein and cholesterol also showed a wide variation, where 
the carotid plaque had an overall higher amounts of both the biomolecules (figure 4.34 A and 
B). The increased protein could be due to the increased inflammation where more 
monocytes/macrophages, T-cells enter the atherosclerotic site. Apo B100 protein from LDL 
molecules could also contribute to increased protein at the plaque site. Possibility of LDL 
molecules accounting for the increased cholesterol in carotid plaques could not be excluded. 
This also brings to light the increased lipid accumulation in carotid plaques as compared to 
femoral plaques (Shaikh et al., 2012) and probably its oxidation leading to increased 
inflammation. One of the reasons for increased tendency of lipid or LDL accumulation of 
carotid plaques could be the increased endothelial shear stress (ESS) which is highest in 
carotid plaques and lowest in femoral plaques. This ESS related change in physiology of the 
arterial wall has also been implicated in increased calcification of femoral plaques as 
compared to carotid plaques (Reneman and Hoeks, 2008, Wu et al., 2004, Stroev et al., 2007). 
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Higher amounts of the antioxidant •-tocopherol in carotid plaques (figure 4.35 A), which is 
associated with LDL molecules, also suggest increased LDL entry into the atherosclerotic site. 
Increased oxidative stress status of carotid artery plaques as compared to femoral plaques is 
evident with overall increased values of lipid oxidation such as TBARS, free and total KC as 
well as protein oxidation markers like DOPA, dityrosine, protein carbonyls (AAS and GGS)
(figure 4.35 and 4.36). 
4.5.4.1 Lipid oxidation biomarker variation between carotid and femoral plaques
One of the major correlations observed among the lipid oxidation products was a positive 
correlation between free KC and total KC, which was observed equally in two of the carotid 
and two of the femoral plaques (table 4.4). Higher TBARS content points at increased lipid 
content in carotid plaques which most probably stem from increased LDL entry into the intima 
of carotid arteries more than that of femoral arteries. Total oxysterols have been found to 
strongly correlate with total cholesterol detected in plaques during other studies where the 
whole plaques is converted into one sample for analysis (Poli et al., 2009), 7-KC being one of 
the major oxysterols in plaques and more than 50% of cholesterol is converted to oxysterols 
during LDL oxidation by direct radical attack (Lyons and Brown, 1999), it seems most likely 
that 7-KC found in plaques originates from oxLDL. Both free and total 7-KC were found to be 
higher with a great variation in carotid plaques than in femoral plaques. 
4.5.4.2 Protein oxidation biomarker variation between carotid and femoral plaques
Protein oxidation in carotid plaques is significantly higher in femoral plaques plaques (figure 
4.35 C and D, figure 4.36 A and B). Since protein concentrations in cells are extremely high, it 
is not surprising that increased DOPA, dityrosine and protein carbonyls are found in carotid 
plaques than in femoral plaques. This is due to increased infiltration of immune cells and 
inflammation in carotid plaques as compared to femoral counterparts (Zhou et al., 2010, 
Shaikh et al., 2012).  PB-DOPA formed on cellular proteins during the hydroxyl radical 
damage (Gieseg et al., 1993) could be one of the major sources of protein oxidation. Under 
normal conditions metal-catalysed oxidation seems to be the major source of protein damage 
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(Stadtman and Levine, 2000) and PB-DOPA can amplify oxidative damage by reducing 
transition metals, it is not surprising that protein carbonyl content is higher than DOPA and 
dityrosine. Protein hydroperoxide has been shown to be the major oxidation product of 
copper-mediated, peroxyl and cell-mediated oxidation of LDL in vitro (Gieseg et al., 2003).  
Protien hydroperoxides could breakdown forming protein carbonyls. Protein carbonyls have 
been implicated in playing a major role in cellular dysfunction induced by oxidative stress 
(Stadtman and Levine, 2000), which also explains why their concentrations are elevated in 
carotid plaques than femoral ones. Thus apo B100 could be a major contributor to protein 
carbonyls in both carotid and femoral plaques due to its higher lysine content (~8%) than 
arginine (3.3%) and proline (3.7%). 
4.5.4.3 Oxidized LDL and inflammation in carotid and femoral plaques 
The link between oxLDL, carotid plaques and femoral plaques becomes clearer when we look 
at the circulatory plasma oxLDL concentrations in CHD patients. Although proatherogenic 
modifications of LDL can occur in circulating plasma, several arguments suggest that major 
part of oxLDL is generated in the vascular wall and diffuses into the circulation after release 
from ruptured or permeable plaques (Hulthe, 2004).  In contrast to the circulation, the 
subendothelial space of the arterial wall is a locally sequestered micro-environment in which 
LDLs are not protected by plasma antioxidants. Pathologic studies have demonstrated 
accumulation of oxLDL in macrophage-rich atherosclerotic plaque (Ehara et al., 2001, Tanaga
et al., 2002). High levels of circulating oxLDL have been independently associated with the 
echolucent plaque phenotype that is more vulnerable to rupture (Sigurdardottir et al., 2007). 
These observations suggest that carotid and femoral plaques can be a major source of 
circulating oxLDL.
The AIR study which evaluated the relationship between plasma oxLDL and subclinical 
atherosclerosis, observed that elevated oxLDL concentrations were associated with femoral 
plaques and not carotid plaques (Hulthe and Fagerberg, 2002).   Another study by Rietzschel 
et al (Rietzschel et al., 2007) and Langlois et al (Baldwin et al., 2004), the Asklepios study 
reported that plasma oxLDL concentrations were elevated in carotid vascular damage patients 
only when they had concomitant femoral plaques. This suggests that the previous observations 
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linking increased plasma oxLDL and carotid atherosclerosis may be confounded by the 
presence of underlying femoral plaques in the populations studied. This doesn’t seem unlikely 
when occurrence of plaques in one arterial region indicates that the individual is likely to be 
prone to development of plaques in other regions (Rothwell, 2001). Also oxidation of LDL 
leads to formation of all the biomarkers tested in our study. Although we haven’t measured 
plasma oxLDL concentrations during our study, assuming the plasma oxLDL is diffused from 
the atherosclerotic plaques, it appears that plasma/systemic oxLDL associates negatively with 
the plaque oxidative biomarkers. Its highly plausible that oxLDL formed in carotid plaques is 
localized to the plaque formation site, not able to diffuse into the blood stream, whereas in 
case of femoral plaques, the oxLDL formed in the plaques is able to diffuse out into the 
plasma. Increased anti-inflammatory macrophage sub-types M2 found in femoral plaques 
support this hypothesis, whereas M1, the pro-inflammatory macrophage subtype is dominant 
in carotid plaques (Shaikh et al., 2012, Herisson et al., 2011). The same was true for pro-
inflammatory T-cells and cholesterol content found in both plaque types. Findings that more 
calcified plaques tend to be associated with increased plasma oxLDL (Bamberg et al., 2012)
further support the idea that femoral plaques could be associated with elevated of oxLDL 
burden in plasma and more anti-inflammatory plaque phenotype. Although Bamberg et al., 
(Bamberg et al., 2012) only studied carotid plaques and the observation was limited by the 
relatively small number of patients, it is an important observation as most of the carotid 
plaques are non-calcified, also observed by Herisson et al., (Herisson et al., 2011) and 
historically, non-calcified carotid plaques have been found to be the major culprits in 
thrombotic strokes. In our study too, we found that all the femoral plaques showed high degree 
of calcification while only 1 of the 5 carotid plaques showed slight calcification. Further 
studies are needed to prove this hypothesis.
However, oxLDL results show large variability and must be interpreted with caution in the 
individual patient, taking into account several biological and lifestyle factors that affect 
oxLDL (Baldwin et al., 2004). Molecular heterogeneity of what is called “oxidized LDL” is 
an important issue to be addressed as well as many different components in LDL can be 
oxidized and a few of them are currently used as a target epitope for specific antibodies for 
detection and quantification of oxLDL. In published data, “oxidized” or “modified” LDLs 
cannot be considered identical because of the differences in oxidation protocols, particularly in 
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the specific antibodies and target epitopes, differences in reported units, and lack of 
standardization. These issues need to be further addressed before oxLDL can be recommended 
as a clinically valuable biomarker.  
4.5.5 Biomarker comparison of carotid and femoral plaques with control artery
The aim of this study was to establish that the plaques are indeed a much more oxidative 
environment than that of the control artery using the oxidative biomarker levels. In contrast to 
our expectations, the control artery tested study showed oxidative biomarkers in the range of 
that of some of the plaques tested (figures 4.37, 4.38 and 4.39). Overall, although TBARS, 
cholesterol, protein carbonyls, free and total KC, DOPA and dityrosine and total pterin 
measured lower in the control artery when compared to the ten combined plaques, neopterin 
and protein content was higher in control artery (figure 4.37 C and D). When the biomarkers 
were compared between the control artery, carotid and femoral plaques, it was seen that the 
average neopterin, total pterin, protein, cholesterol, protein carbonyls and free and total KC 
content was higher in the control artery than the femoral plaques. Although the biomarker 
concentrations were overall higher in carotid plaques, the range of biomarkers in some of the 
sections of carotid plaques was similar to that observed in the control artery sections. So even 
though we have compared the carotid and the femoral plaques against the control artery, 
increased biomarkers in the control artery might obscure any specific biomarker differences in 
plaques. Also there was only one control artery with 3 sections as opposed to 37 sections for 
carotid and 29 sections for femoral plaques, which could hide real differences or show false 
results. Another important reason for the presence of biomarkers could be that the control 
artery sections were excised from an iliac artery of a 62-year old patient undergoing kidney 
transplant. So any possible underlying inflammation and oxidative stress in the arterial tree 
due to kidney failure and old-age cannot be excluded. 
4.5.6 Atherosclerotic plaque are a source of 7,8-dihydroneopterin and neopterin
Although some other studies have detected neopterin in plaques through 
immunohistochemical staining (Adachi et al., 2007) it is yet to be seen if this neopterin is 
actually produced in the plaques. This study is the first to show that neopterin and 7,8-
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dihydroneopterin could be produced by the plaques in culture under the influence of IFN-• and 
that monocyte/macrophages are in their immune active state and responsive to stimulus. This 
shows how dynamically active and responsive the plaque is to different stimuli, which can 
drive the plaque progression and development. This establishes plaques as one of the direct 
sources of neopterin and 7,8-dihydroneopterin. 
Neopterin is elevated at inflammatory sites as analyzed in pus as studied by Firth et al., (Firth, 
2006) in our laboratory. So we hypothesized that since inflammation is a major driver of 
atherosclerotic progression, neopterin and 7,8-dihydroneopterin could be produced by the 
plaques themselves. Atherosclerotic lesions are known to be abundant in macrophages, T-
cells, endothelial cells and smooth muscle cells. To prove plaque as a direct source of 
neopterin, it was important to validate that the cells inside the atherosclerotic lesion are alive 
and metabolizing, which was done by measuring the lactate produced by the plaque sections in 
the culture medium. Continual production of lactate in millimolar amounts over a period of 48 
hours after their removal and immediate culture was an easy and representative measure of 
active metabolism by the cells in atherosclerotic plaques (figures 4.41, 4.43, 4.45 and 4.47). 
IFN-• stimulated 7,8-dihydroneopterin/neopterin production by monocytes/macrophages in 
vitro is well documented, but this process has not been demonstrated in atherosclerotic plaques 
till date. As demonstrated in figures 4.42, 4.44, 4.46 and 4.48, IFN-• stimulation of sections of 
four atherosclerotic plaques responded by production of neopterin and 7,8-dihydroneopterin in 
culture medium. The maximum increase for neopterin on IFN-• stimulation in one of the 
sections was about 6 times and 7,8-dihydroneopterin increased in the surrounding media 
approximately 20 times (figure 4.48 B, section 2 of plaque 4).  
Differential production of 7,8-dihydroneopterin by different sections of various plaques is 
most probably due to differential number of macrophages that are immunologically still active 
in these sections. Higher ratio of neopterin to 7,8-dihydroneopterin in some of the plaque 
sections on IFN-• stimulation could be due to the IFN-• induced oxidative stress in the plaque 
milieu, where the 7,8-dihydroneopterin  produced gets used up to keep the reactive oxygen 
species from terminally damaging the cells. Also lack of lymphocyte (T-cells or natural killer 
(NK) cells) infiltration in the plaque or their functional impairment and/or death could result in 
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reduced or no IFN-• produced which means no production of 7,8-dihydroneopterin as they are 
the main source of IFN-•. Macrophages and dendritic cells are also known to produce IFN-• 
under certain conditions. Further studies using stimulating agents for T-cells like PMA are 
needed to elucidate their role in 7,8-dihydroneopterin production. This shows the variation in 
the inflammation across the length of the plaque. Interestingly, in the in vitro culture 
environment the ratio of neopterin to 7,8-dihydroneopterin was approximately 1:3, calculated 
every day or over the 2 days of the cytokine stimulation  as reported in blood/plasma by 
(Hoffmann et al., 2003).
This study shows that plaque is one of the main sources of 7,8-dihydroneopterin and neopterin 
production. Release of these pterins in culture medium also shows that once produced at an 
inflammatory site, both the oxidized and reduced form of the pterins can diffuse through the 
tissue into the plasma. It is this neopterin and 7,8-dihydroneopterin in plasma which increases
with increased production of pterins at different inflammatory sites of the body. This study 
also supports the role of inflammation in modulating the plaque progression and the idea that 
increased 7,8-dihydroneopterin production could in fact protect the macrophages in the 
atherosclerotic plaques from the oxidative insult.  
4.5.7 Neopterin and 7,8-dihydroneopterin concentrations in atherosclerotic patients and 
healthy volunteers
Plasma neopterin concentrations have been well studied in patients with coronary heart disease 
and various forms and stages of it, but till date there have been no published studies 
documenting the levels of both neopterin and 7,8-dihydroneopterin together in patients or in 
healthy subjects (Erren et al., 1999, Sahin et al., 2008, Schumacher et al., 1997, Rudzite et al., 
2003, Garcia-Moll et al., 2000).  In this study we have measured the levels of both 7,8-
dihydroneopterin and neopterin in patients undergoing endarterectomy to understand the 
inflammatory state of the patients. Overall average of neopterin concentration in both groups 
of patients was 20.2 ± 0.4 nM, which agrees with the published values of 18.5 nM (Sahin et 
al., 2008), 13.7 nM (Schumacher et al., 1997) as well as previous studies done in our 
laboratory (14 ± 2 nM (Genet, 2010)). The published values of 5 nM neopterin for healthy 
volunteers is also in agreement with the previous studies done in our lab and other published 
literature 6.8 nM (Schumacher et al., 1997) and 8.7 nM (Sahin et al., 2008).   
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In the endarterectomy patients, the ratio of 7,8-dihydroneopterin to neopterin was 1.3 which 
was a complete contrast to what was found previously with atherosclerotic patients studied in 
our lab where it 7,8-dihydroneopterin was found to be approximately 4 times higher (Genet 
2010 unpublished data). Incidentally the ratio of neopterin to 7,8-dihydroneopterin in healthy 
controls was approximately about 1:3 (5 nM for neopterin vs 18 nM for 7,8-dihydroneopterin). 
In our study the neopterin was about 5 times higher and 7,8-dihydroneopterin was only 2 times 
higher in the patient group. 
Of course any other inflammatory sources of neopterin in the body or an infection cannot be 
ruled out which might also trigger the neopterin and 7,8-dihydroneopterin production and 
priming of the immune response by IFN-•. Patient 8 plasma sample was of particular interest 
as it did not present with any detectable neopterin or 7,8-dihydroneopterin. This could be due 
to a very rare GTPCH 1 deficiency, due to which there is very little or no production of 
neopterin (Vásquez-Vivar, 2009). There also exists a possibility that even though the enzyme 
is present its activity is lost due to some mutation, which results in its inability to catalyze the 
rate-limiting step for the formation of neopterin and 7,8-dihydroneopterin. Genetic disorders 
due to autosomal recessive GTPCH 1 deficiency along with a missense mutation and a point 
mutation have been described leading to very low levels of biopterin and neopterin production 
measured in urine (Blau et al., 1995, Sato et al., Niederwieser et al., 1984a). 
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4.5.8 Conclusion
The major finding of this study was that carotid and femoral plaques do indeed vary 
significantly in all of the oxidative biomarkers examined. Although there were not strong or 
consistent correlations observed between carotid and femoral plaques, there was a clear 
difference between the range and content of oxidative biomarkers. Protein, cholesterol, •-
tocopherol, dityrosine and free KC were significantly lower in femoral plaques as compared to 
carotid plaques (P< 0.05*). DOPA, AAS and total KC showed a more significantly lower 
concentrations (P< 0.01**) in femoral plaques in comparison to carotid plaques. As for 
neopterin, 7,8-dihydroneopterin and TBARS, although the difference between their levels in 
carotid and femoral plaques were not significant, the variations between their concentrations 
were significantly different (f-test for equality of variance P <0.01** for neopterin, P 
<0.001*** for 7,8-dihydroneopterin and P <0.001*** for TBARS) which masked the 
difference. So apart from GGS protein carbonyls, all the other biomarkers showed a 
significant difference or variation.
In this study five carotid and five femoral plaques were analyzed for the different oxidative 
biomarkers, which is a small sample size. In spite of this there was a significant trend of lower 
oxidative biomarkers in femoral plaques, which emphasizes the differences in inflammation, 
morphology and macrophage subtypes in both of these kinds of plaques (Shaikh et al., 2012, 
Herisson et al., 2011, Rothwell et al., 2003). Biomarker concentrations represent the processes 
undergoing in the formation and progression of atherosclerotic plaque. Further studies with 
increased number of atherosclerotic plaques would be needed to find possible correlations in 
biomarkers to the progression of plaques. There has been a previous study carried out relating 
the CRP, oxLDL and adiponectin concentrations in blood with varying compositions of 
coronary plaques (calcified and non-calcified) and patients with no plaque (Bamberg et al., 
2012). Apart from this, literature is very scarce about these kinds of correlational studies 
between types of plaque and biomarkers in blood. None of the studies so far have actually 
quantified and compared the biomarkers in carotid and femoral plaques directly apart from 
Zhou et al., who studied distribution of MMP’s in carotid and femoral plaques (Zhou et al., 
2010). Also when compared to some of the other studies it was observed that overall a lower 
degree of oxidative stress based on the oxidative biomarkers found in femoral plaques could 
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be associated with higher plasma oxLDL burden. This is possible when the oxLDL formed 
diffuses out of the subendothelial plaque site into the blood stream. The inverse seemed to be 
the case for carotid plaques, where the oxidative stress was very high and variable but not able 
to diffuse out of the atherosclerotic site, contributing to the progression and development. 
It was demonstrated in this study that atherosclerotic plaques are a source of inflammatory 
markers neopterin and 7,8-dihydroneopterin. This is the first time a study has examined 
plaques in culture and demonstrated the effect of inflammatory cytokine IFN-• on neopterin 
and 7,8-dihydroneopterin production in actual atherosclerotic tissue. Varying levels of 
production of 7,8-dihydroneopterin and neopterin across the plaque sections of an individual 
plaque reinforces how differences in oxidative stress and inflammatory responses can further 
modulate plaque inflammation effecting changes in plaque growth and responses. This also 
suggests that markers could in fact contribute to the development and progression of 
atherosclerotic disease. 
Plasma neopterin and 7,8-dihydroneopterin concentrations measured for atherosclerotic 
patients showed a significantly higher levels as compared to the healthy control subjects. This 
reinforces the effectiveness of measurement of 7,8-dihydroneopterin along with neopterin as a 
biomarker, where the ratio of 7,8-dihydroneopterin and neopterin could be used to predict 
coronary heart disease risks and clinical outcomes. More detailed studies with more numbers 
of plaque are needed to establish this but the fact that increased neopterin and 7,8-
dihydroneopterin could be used as biomarkers and that 7,8-dihydroneopterin/neopterin could 
potentially play a role in modulation of oxidative stress thereby playing a role in development 
and progression of atherosclerotic disease. 
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5. ROLE OF NUCLEOSIDE TRANSPORTERS IN 7,8-DIHYDRONEOPTERIN UPTAKE 
AND PROTECTION AGAINST OXIDATIVE STRESS IN ATHEROSCLEROSIS
5.1 Introduction
5.1.1 7,8-dihydroneopterin, uptake and protection 
7,8-Dihydroneopterin has been shown to be a potent antioxidant preventing LDL oxidation in
vitro (Gieseg et al., 1995), both by transition metals and cells (Gieseg and Cato, 2003). 7,8-
dihydroneopterin also is protective against oxLDL mediated cell death of human macrophages 
and U937 cells but surprisingly not THP-1 cells (Baird et al., 2005). Nor was 7,8-
dihydroneopterin protective of THP-1 cells against AAPH generated peroxyl radicals. 7,8-
dihydroneopterin is very effective at protecting proteins in solution and as well as LDL. These 
observations suggested the toxic oxidative events killing the cells were intracellular and the 
7,8-dihydroneopterin needed to build up to a significant concentration inside the cell to be 
protective.  If this was true the difference between protection and no protection could be 
attributable to the differential uptake rates of 7,8-dihydroneopterin by the cells.  Although 
literature exists on the protective effect of 7,8-dihydroneopterin, there is no published research 
investigating the route of its uptake into the cells or where inside the cell the protection is 
occuring. 
Uptake of 7,8-dihydroneopterin could also play a role when the cells capacity of 7,8-
dihydroneopterin production is impaired or insufficient under oxidative stress. During such 
situations it maybe imperative that the cells are able to “salvage” or take up the 7,8-
dihydroneopterin already present in the milieu by the other unaffected cells. This situation is 
relevant in atherosclerotic plaques, where monocytes/macrophages enter an oxidative 
environment. In such case, the cells may produce and secrete substantial amounts of 7,8-
dihydroneopterin on IFN-• stimulation. The cells already affected by oxLDL induced 
oxidative stress might be saturated in its 7,8-dihydroneopterin protection, and could possibly 
utilize the 7,8-dihydroneopterin from the surroundings to protect them from the intracellular 
oxidative stress. 
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Previous research carried out in this laboratory analyzing 7,8-dihydroneopterin content across 
the plaque supports this hypothesis. It was seen across many of the plaque sections that in 
spite of 7,8-dihydroneopterin being available in micromolar amounts, oxidative biomarker 
concentrations were still high. This suggests that either intracellular oxidation processes have 
triggered the necrotic processes to such a level that 7,8-dihydroneopterin could not rescue the 
cells, or the 7,8-dihydroneopterin is generated in response to the inflammation but the damage 
to the cells  limit the uptake of 7,8-dihydroneopterin into the cells. Presence of large amounts 
of 7,8-dihydroneopterin points towards the role of intracellular free-radical generation and 
stress resulting in cell death. It also showed that 7,8-dihydroneopterin concentration is often 
reduced around the bifurcation, and it is this region that shows highest concentrations of 
oxidative biomarkers (Flavall, 2008). This suggests that 7,8-dihydroneopterin, when present in 
sufficient amounts in the bifurcation region could protect against the oxidative stress and 
modulate cell death and progression of atherosclerotic plaques. 
If the above hypothesis holds true then the uptake of 7,8-dihydroneopterin could be a plausible 
way for cells to recover from or prevent oxidative stress.
5.1.2 7,8-dihydroneopterin and nucleoside transporters
We looked at nucleoside transporters as a possible candidates for 7,8-dihydroneopterin 
transport based on the observation of Sawabe et al., (Sawabe et al., 2005) who demonstrated 
that the transport of the pterin sepiapterin (SP), across the plasma membrane was equilibrative 
and bidirectional. Also the fact that IFN-• modulates the nucleoside transporters in 
macrophages where it downregulates the expression and activity of ENT 1 while upregulating 
CNT 1 and 2 expression and activity (Soler et al., 2003) made nucleoside transporters an 
obvious choice to examine. 
Knowing that 7,8-dihydroneopterin mediated protection of macrophage cell death during 
oxidative stress and inflammation could have a huge impact on cell survival and progression 
of atherosclerosis, we asked a fundamental question as to how does 7,8-dihydroneopterin enter 
the cells. In the following study, the role of 7,8-dihydroneopterin in the protection of oxidative 
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stress induced cell death has been investigated in terms of its uptake via the different types of 
nucleoside transporters. The study examined whether,
1) Nucleoside transporters are a plausible route for the uptake of 7,8-dihydroneopterin in 
U937 cells, THP-1 cells and monocytes. If so which is the major transporter of the 
uptake? 
2) Nucleoside transporters are essential for protection provided by exogenously added 
7,8-dihydroneopterin against the oxidative stress in U937 cells, THP-1 cells and 
human blood-derived monocytes. 
The study focused on U937 cells and THP-1 cells due to their differences in 7,8-
dihydroneopterin protection previously observed with these cell lines (Baird et al., 2005). 
U937 cells and THP-1 cells were incubated with and without the specific inhibitors of 
nucleoside transport. Equilibrative and concentrative transporters are the major groups of 
transporters found in mammalian cells. Four ENT isoforms have been described as ENT 1, 2, 
3 and 4 and three CNT isoforms have so far been described. ENT 1 and 2 were chosen as 
possible targets as they are the major forms of equilibrative transport and specific inhibitors 
have been discovered for them. NBMPR is a specific inhibitor of ENT 1, dipyridamole which 
inhibits both ENT 1 and ENT 2. Indomethacin is a drug that inhibits Na+ ion mediated 
transport across the membrane into the cells. As CNT transport is Na+ ion dependent, we used 
indomethacin to inhibit CNT mediated transport of nucleosides. The effect of these inhibitors 
on human monocytes was also examined as it was shown in our laboratory that monocytes 
produce substantial amounts of 7,8-dihydroneopterin when stimulated with IFN-• and take up 
exogenous added 7,8-dihydroneopterin.
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5.2 Results
5.2.1 THP-1 cells, but not U937 cells produce 7,8-dihydroneopterin on IFN-• stimulation
Both U937 cells and THP-1 cells were tested for their 7,8-dihydroneopterin production using 
IFN-• stimulation for functional differentiation. Both cells have been reported to produce 
neopterin on stimulation with IFN-• (Werner-Felmayer et al., 1990). Some groups reported no 
neopterin production by U937 cells on IFN-• stimulation. This is probably due to the different 
stages of differentiation of U937 cells or due to the different sub clones that are able to 
produce 7,8-dihydroneopterin. 
The initial study examined and characterized the basal levels of the pterin products produced 
by U937 cells and THP-1 cells. U937 cells or THP-1 cells were stimulated with a range of 
different concentrations of IFN-• (100, 200 and 500 U/ml IFN-•) in RPMI 1640 with phenol 
red, supplemented with 5% FBS and pen/strep. IFN-• stimulation of these cells results in the 
production of 7,8-dihydroneopterin, which can be oxidized to neopterin by the ROS. 7,8-
dihydroneopterin and neopterin together are referred to as total pterin. 
There was a basal level of neopterin and 7,8-dihydroneopterin produced by both U937 cells 
and THP-1 cells in the supernatants. There was no intracellular neopterin detected in U937 
cells under any of the treatments, which suggests that all the neopterin produced was secreted 
out of the cells. Neopterin levels in the supernatant did not change between any of the 
treatments in U937 cells, but there was a major difference between the basal neopterin levels 
in the supernatant of U937 cells and THP-1 cells (figure 5.1 and 5.2). Neopterin produced and 
secreted in the supernatant was about 4 times higher in THP-1 cells (41 ± 2 pmoles/million 
cells) than in U937 cells (10.4 ± 0.2 pmoles/million cells). 
The difference between both the cell lines becomes apparent with IFN-• treatment, where 
increasing concentration of IFN-• increased the 7,8-dihydroneopterin produced in the 
supernatant in THP-1 cells while there was no such difference observed in U937 cells. U937 
cells did not produce increased 7,8-dihydroneopterin on IFN-• stimulation over 24 hours even 
with increasing concentrations of IFN-• (figure 5.1 A). There was a small rise but insignificant 
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rise in the total pterin production as compared to the control cells in the supernatant. In THP-1 
cells, IFN-• stimulation significantly upregulated the total pterins produced, which was due to 
increased production of 7,8-dihydroneopterin. Although the highest amount of 7,8-
dihydroneopterin produced was with 500 U/ml of IFN-• (215 ± 6 pmoles/million cells), there 
was little difference between the amounts of 7,8-dihydroneopterin produced with lower IFN-• 
concentrations used. 7,8-dihydroneopterin produced reached significance at 100 U/ml of IFN-
• as compared to the controls, which did not change much with 250 and 500 U/ml of IFN-•.  
Similar results were obtained when intracellular concentration of neopterin was examined. 
U937 cells did not show any measurable intracellular neopterin, but IFN-• stimulation up 
regulated intracellular neopterin in THP-1 cells, which was significant at 250 U/ml of IFN-• 
(1.9 ± 0.4 pmoles/million cells). There was no statistical significance between the increased 
amounts of neopterin with other IFN-• concentrations. 
In both U937 cells and THP-1 cells, there was basal intracellular level of 7,8-dihydroneopterin 
production. In U937 cells, it was 1.09 ± 0.02 pmoles/million cells, while in THP-1 cells, it was 
1.7 ± 0.1 pmoles/million cells of 7,8-dihydroneopterin. In U937 cells, the total pterin produced 
on IFN-• stimulation was significantly reduced at all the concentrations tested when compared 
to the controls (Figure 5.1).
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Figure 5.1 IFN-• does not induce 7,8-dihydroneopterin production in U937 cells. U937 
cells at 1 million cells/ml cultured in RPMI 1640, 5% FCS and pen/strep were treated with 
different concentrations of IFN-• for 24 hours. Supernatant (A) and intracellular (B) neopterin 
and 7,8-dihydroneopterin (as Total pterin) were measured using SCX column. Results 
expressed as Mean ± SEM for triplicate of samples (Total pterin = neopterin+ 7,8-
dihydroneopterin).  Results expressed as Mean ± SEM for triplicate of samples.
In THP-1 cells (figure 5.2), however, there was increased amount of intracellular 7,8-
dihydroneopterin produced over 24 hours, with increased IFN-• stimulation. 
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Figure 5.2 IFN-• induces production of 7,8-dihydroneopterin in THP-1 cells. THP-1 cells 
at 1 million cells/ml cultured in RPMI 1640, 5% FCS and pen/strep were treated with different 
concentrations of IFN-• for 24 hours. Supernatant (A) and intracellular (B) neopterin and 7,8-
dihydroneopterin were measured using SCX column (Total pterin = neopterin+ 7,8-dihydroneopterin).  
Results expressed as Mean ± SEM for triplicate of samples.
Increase in 7,8-dihydroneopterin was significant at all the 3 concentrations of IFN-• tested. 
One more thing to note here was that 5 fold concentration of IFN-• did not yield 5 fold higher 
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concentration of neopterin or 7,8-dihydroneopterin in U937 cells or THP-1 cells. Either the 
threshold is reached for the effect of IFN-• after which the increased IFN-• has no added 
effect or the efficiency of production of 7,8-dihydroneopterin levels off after a specific 
concentration of IFN-• due to the limited availability of the nutrients or the enzyme capacity 
and/or amounts of it present inside the cells. 
5.2.2 Uptake of 7,8-dihydroneopterin by U937 cells and THP-1 cells 
We examined the uptake of 7,8-dihydroneopterin over a period of 24 hours to compare the rate 
of uptake over time in both the cell lines (figure 5.3).
Figure 5.3 Timecourse of U937 and THP-1 cells uptake of 7,8-dihydroneopterin in RPMI 
1640. U937 (A) and THP-1 cells (B) at 1 million cells/ml were incubated with 200 µM 7,8-
dihydroneopterin in RPMI 1640 medium with 5% FCS and pen/strep for 24 hours. 
Intracellular neopterin and 7,8-dihydroneopterin were measured at 0, 1, 3, 6, 9, 12 and 24 
hours using SCX column. (Total pterin = neopterin + 7,8-dihydroneopterin).  (C) shows the 
comparison of U937 cells and THP-1 cells uptake of 7,8-dihydroneopterin. Results expressed 
as Mean ± SEM for triplicate of samples.  
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For this both the cell lines were incubated in RPMI 1640 supplemented with 5% FCS and 
pen/strep with 200 µM 7,8-dihydroneopterin at 37ºC for 24 hours. 
Both cell lines took up similar amount of 7,8-dihydroneopterin inside the cells from the 
surrounding medium after 24 hours (Figure 5.3). Intracellular total pterin in U937 cells was 
measured as 190 ± 10 pmoles/million cells and in THP-1 cells intracellular total pterin was 
measured to be 174 ± 1 pmoles/million cells. But the rate at which both cell lines took up 7,8-
dihydroneopterin was completely different. U937 cells showed a high and rapid uptake of 7,8-
dihydroneopterin which was at its highest at 9 hours and then leveled off at 12 and 24 hours. 
THP-1 cells uptake of 7,8-dihydroneopterin started slower than that of U937 cells and 
progressed steadily, which reached its maximum at 24 hours. In THP-1 cells (about 66%) of 
the 7,8-dihydroneopterin uptake happens between 0 and 12 hours, whereas in U937 cells most 
of the uptake (about 98%) happens within 12 hours. 
Figure 5.4 Absence of serum in the RPMI 1640 does not affect 7,8-dihydroneopterin 
uptake in U937 cells. U937 cells at 1 million cells/ml were incubated with 200 µM 7,8-
dihydroneopterin  in RPMI 1640, NO serum, no phenol red with pen/strep for 24 hours. 
Intracellular neopterin and 7,8-dihydroneopterin were measured at 0, 1, 3, 6, 9, 12 and 24 
hours using SCX column. (Total pterin = neopterin + 7,8-dihydroneopterin). Results expressed 
as Mean ± SEM for triplicate of samples.
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Serum is a complex mix of chemokines, cytokines proteins and growth factors which could 
have an effect on the rate and the efficiency of uptake of 7,8-dihydroneopterin. To check if the 
presence of serum has an effect on the uptake, U937 cells were grown in RPMI 1640 plus 
pen/strep but without serum and the uptake of 7,8-dihydroneopterin was measured (figure 
5.5). As expected that the absence of serum reduced the uptake by about 20% as compared to 
the uptake in RPMI 1640 with serum after 24 hours. The uptake did not plateau after 12 hours, 
but continued to rise, to reach 287 ± 9 pmoles/million cells at its highest concentration after 24 
hours. Since absence of serum did reduced the uptake in U937 cells, similar results were 
expected in THP-1 cells with regards to its uptake. 
Figure 5.5 Uptake of 7,8-dihydroneopterin in minimal medium EBSS is reduced when 
compared to RPMI 1640 with or without serum in U937 cells. U937 cells at 1 million 
cells/ml were incubated with 200 µM 7,8-dihydroneopterin in RPMI 1640, NO serum no 
phenol red for 24 hours. Intracellular neopterin and 7,8-dihydroneopterin were measured at 0, 
1, 3, 6, 9, 12 and 24 hours using SCX column. (Total pterin = neopterin + 7,8-
dihydroneopterin). Results expressed as Mean ± SEM for triplicate of samples but only 
shown Total pterin values. 
When the uptake of 7,8-dihydroneopterin was compared, it was seen that the order of the 
uptake was RPMI 1640 with serum > RPMI 1640 without serum > EBSS only (figure 5.5). 
The protection of cells by 7,8-dihydroneopterin against AAPH induced oxidative stress and 
cell death has been previously examined in this laboratory in U937 cells and THP-1 cells 
using EBSS as a culture medium; as RPMI 1640 medium has large amount of proteins that 
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potentially react with the AAPH in the medium forming secondary radical products making it 
more toxic and reducing cell viability, hence RPMI 1640 medium was not chosen. In those 
studies U937 cells were protected by 7,8-dihydroneopterin but not the THP-1 cells (Baird et 
al., 2005). The uptake of 7,8-dihydroneopterin was measured in EBSS only medium and 
compared to RPMI 1640 with serum and RPMI 1640 only (figure 5.5). The uptake in EBSS 
medium was less than half of what was found in a complete medium of RPMI 1640 with 
serum for U937 cells. Rate of 7,8-dihydroneopterin uptake in EBSS was also different 
Figure 5.6 Comparison of U937 and THP-1 cells 7,8-dihydroneopterin uptake in EBSS 
only medium. U937 and THP-1 cells at 1 million cells/ml were incubated with 200 µM 7,8-
dihydroneopterin in Earle's Balanced Salt solution only for 24 hours. Intracellular neopterin
and 7,8-dihydroneopterin were measured at 0, 1, 3, 6, 9, 12 and 24 hours using SCX column.
(Total pterin = neopterin + 7,8-dihydroneopterin). (C) shows comparison between U937 cells 
and THP-1 cells. Results expressed as Mean ± SEM for triplicate of samples.
between U937 cells and THP-1 cells (figure 5.6). In U937 cells the uptake was highest at 6 
hours (135 ± 10 pmoles/million cells) and then decreased gradually to 98 ± 8 pmoles/million 
cells by 24 hours (figure 5.6).
Similar results were obtained with THP-1 cells (figure 5.6) as 7,8-dihydroneopterin uptake 
was examined in the minimal EBSS medium over 24 hours. For the first hour there was no 
difference in its uptake profile as compared to U937 cells after which the uptake in THP-1 
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cells slowed down and changed little by about 6 hours. The uptake then increased slightly at 9 
hours, and was rapid between 9 and 12 hours.  The uptake rate increased steadily, consistent 
with the behavior of THP-1 cells observed in RPMI 1640 with serum. 
The profile was distinct when compared to U937 cells (Figure 5.6). The uptake gradually 
increased but not as rapidly as seen in U937 cells, to its highest at 12 hours (107 ± 7 
pmoles/million cells) before it fell down to 58 ± 5 pmoles/million cells at the end of 24 hours. 
The uptake of 7,8-dihydroneopterin in THP-1 cells was about 40% less as compared to that of 
U937 cells at 24 hours. There was no significant increase in the neopterin content over the 
course of 24 hours in both cell lines stressing the fact that cells were not subjected to any 
oxidative stress during this time. Cell viability was measured using trypan blue over the time 
course, and the cell viability was unaffected when compared to the controls. 
At 6 hours, THP-1 cells take up only about 50% of what U937 cells take up at the same time 
point and by 12 hours, both cell lines take up similar amount of 7,8-dihydroneopterin (Figure 
5.7). Uptake in both the cell lines decreased after 12 hours, and the overall uptake in both the 
cell lines after 24 hours was a lot lesser as compared to RPMI 1640 with serum. 
It is clearly seen that U937 cells take up 7,8-dihydroneopterin at a more rapid rate and 
efficiently than THP-1 cells in both RPMI 1640 (figure 5.3) and EBSS only medium (figure 
5.6 C). There was not much of difference between U937 cells and THP-1 cells uptake of 7,8-
dihydroneopterin in a RPMI 1640 with 5% serum (figure 5.3). The uptake decrease of 7,8-
dihydroneopterin observed in EBSS only medium as compared to  RPMI 1640 with 5% serum 
at 24 hours was about 67% in THP-1 cells and 50% in U937 cells. 
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5.2.3 Inhibition of 7,8-dihydroneopterin uptake in U937 cells and THP-1 cells by ENT 
inhibitors NBMPR and DP 
During systemic or local 7,8-dihydroneopterin deficiency, supplementation of 7,8-
dihydroneopterin from the surrounding medium could prevent oxidative stress induced cell 
death in cells. Following the lead provided by the observation of Ohashi et al., (2010), we 
studied the key transporters involved in the uptake and transport of 7,8-dihydroneopterin in 
U937 cells and THP-1 cells. 
NBMPR is a specific inhibitor for equilibrative nucleoside transporter 1 (ENT 1). We looked 
at the inhibition of transport of 7,8-dihydroneopterin over 24 hours in U937 cells and THP-1 
cells. It was important to establish that the inhibitors themselves aren’t responsible for any 
production of neopterin and 7,8-dihydroneopterin in the cell lines used for the study. We 
examined the U937 cells and THP-1 cells at different concentrations of the ENT 1 inhibitor to 
check the 7,8-dihydroneopterin synthesis and oxidation to neopterin. 
The viability of cells in the presence of inhibitors only and inhibitor plus 7,8-dihydroneopterin 
was also examined to rule out any unwanted effects on cell viability, and subsequent under 
evaluation of 7,8-dihydroneopterin uptake. Cell viability was measured using propidium 
iodide method on flow cytometer. There was no adverse effect on cell viability at any of the 
concentrations of NBMPR tested, nor any neopterin or 7,8-dihydroneopterin production was 
observed in the presence of the inhibitors (figure 5.7). 
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A)
B)
Figure 5.7 ENT 1 inhibitor NBMPR at various concentrations tested does not induce 7,8-
dihydroneopterin production in U937 cells. U937 cells at 1 million cells/ml were 
supplemented with 200 µM 7,8-dihydroneopterin and various concentrations of ENT 1 
inhibitor NBMPR in RPMI 1640 with 5% FCS and pen/strep for 24 hours. A) Intracellular 
neopterin and total Pterin concentrations were measured using SCX column on the HPLC.
(Total pterin = neopterin + 7,8-dihydroneopterin).  Results displayed as Mean ± SEM of 
triplicate of samples. B) Cell viability of U937 cells is unaffected by NBMPR at the 
concentrations tested above. Cell viability of U937 cells with ENT 1 inhibitor NBMPR and 
NBMPR + 7,8-dihydroneopterin using PI on flow cytometer. M1 represents live cells and M2 
represents dead cells. 
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A)
B)
Figure 5.8 ENT 1 inhibitor NBMPR at various concentrations tested does not affect the 
uptake of 7,8-dihydroneopterin in U937 cells. U937 cells at 1 million cells/ml were 
supplemented with 200 µM 7,8-dihydroneopterin and various concentrations of ENT 1 
inhibitor NBMPR in RPMI 1640 with 5% FCS and pen/strep for 24 hours. A) Intracellular 
neopterin and total Pterin concentrations were measured using SCX column on the HPLC.
(Total pterin = neopterin + 7,8-dihydroneopterin).  Results displayed as Mean ± SEM of 
triplicate of samples. B) Cell viability of U937 cells is unaffected by NBMPR at the 
concentrations tested above. Cell viability of U937 cells with ENT 1 inhibitor NBMPR and 
NBMPR + 7,8-dihydroneopterin using PI on flow cytometer.
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A)
B)
Figure 5.9 ENT 1 inhibitor NBMPR at various concentrations tested does not induce 7,8-
dihydroneopterin production in THP-1 cells. THP-1 cells at 1 million cells/ml were 
supplemented with 200 µM 7,8-dihydroneopterin and various concentrations of ENT 1 
inhibitor NBMPR in RPMI 1640 with 5% FCS and pen/strep for 24 hours. A) Intracellular 
neopterin and total Pterin concentrations were measured using SCX column on the HPLC.
(Total pterin = neopterin + 7,8-dihydroneopterin).  Results displayed as Mean ± SEM of 
triplicate of samples. B) Cell viability of U937 cells is unaffected by NBMPR at the 
concentrations tested above. Cell viability of U937 cells with ENT 1 inhibitor NBMPR and 
NBMPR + 7,8-dihydroneopterin using PI on flow cytometer.
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A)
B) 
Figure 5.10 ENT 1 inhibitor NBMPR inhibits the uptake of 7,8-dihydroneopterin in 
THP-1 cells. U937 cells at 1 million cells/ml were supplemented with 200 µM 7,8-
dihydroneopterin and various concentrations of ENT 1 inhibitor NBMPR in RPMI 1640 with 
5% FCS and pen/strep for 24 hours. A) Intracellular neopterin and total Pterin concentrations 
were measured using SCX column on the HPLC. (Total pterin = neopterin + 7,8-
dihydroneopterin).  Results displayed as Mean ± SEM of triplicate of samples. B) Cell 
viability of U937 cells is unaffected by NBMPR at the concentrations tested above. Cell 
viability of U937 cells with ENT 1 inhibitor NBMPR and NBMPR + 7,8-dihydroneopterin 
using PI on flow cytometer.
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In U937 cells, all the concentrations tested did not inhibit the uptake of 7,8-dihydroneopterin 
over 24 hours (figure 5.8 A). 7,8-dihydroneopterin control cells without any inhibitors showed 
an uptake of 323 ± 35 pmoles/million cells over 24 hours. There was a slight drop in the 
measured 7,8-dihydroneopterin concentrations at 100 nM (283 ± 16 pmoles/million cells) and 
10 µM (277 ± 18 pmoles/million cells), which was statistically insignificant.
ENT 1 involvement in the uptake of 7,8-dihydroneopterin in THP-1 cells was tested at the 
different NBMPR concentrations. There was no effect of the different concentrations of 
NBMPR on neopterin and 7,8-dihydroneopterin production (figure 5.10 A). The uptake of 7,8-
dihydroneopterin was comparable to the previously observed values and the neopterin 
concentrations observed were also similar during both the experiments. 
In 7,8-dihydroneopterin control cells at 24 hours, the uptake observed was 245 ± 15 
pmoles/million cells. With 1 nM NBMPR concentration, there was noticeable inhibition of 
7,8-dihydroneopterin uptake (213 ± 17 pmoles/million cells) as compared to the 7,8-
dihydroneopterin controls. At 100 nM NBMPR concentration, the uptake was reduced 
significantly by about 40% (147 ± 9 pmoles/million cells). Further increase in the NBMPR 
concentrations to 1 µM and 10 µM did not have any increased inhibition of 7,8-
dihydroneopterin uptake. At 1 µM NBMPR the uptake measured was 131 ± 5 pmoles/million 
cells and at 10 µM NBMPR it measured 153 ± 20 pmoles/million cells. 
Since NBMPR is specific and strong inhibitor of ENT 1 transport at lower (nM) 
concentrations, 100 nM NBMPR was chosen for further experiments as it showed close to 
about 50% inhibition of 7,8-dihydroneopterin uptake.  Preliminary results suggested that ENT 
1 was the major transporter responsible for the uptake of 7,8-dihydroneopterin in THP-1 cells 
but not in U937 cells. Since ENT 1 was only responsible for about 50% uptake, we looked at 
the other transporters which might be involved in 7,8-dihydroneopterin uptake in these cells. 
Equilibrative nucleoside transporter 2 (ENT 2) seemed another possible candidate that could 
play a part in the membrane transport of 7,8-dihydroneopterin into the cells. So an inhibitor of 
ENT transport, Dipyridamole (DP) which inhibits both ENT 1 and ENT 2 was examined in 
both U937 cells and THP-1 cells. 
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A)
B)
Figure 5.11 ENT 2 inhibitor dipyridamole (DP) at various concentrations tested does not 
induce 7,8-dihydroneopterin production in U937 cells. U937 cells at 1 million cells/ml 
were supplemented with 200 µM 7,8-dihydroneopterin and various concentrations of ENT 2 
inhibitor DP in RPMI 1640 with 5% FCS and pen/strep for 24 hours. A) Intracellular 
neopterin and total Pterin concentrations were measured using SCX column on the HPLC.
(Total pterin = neopterin + 7,8-dihydroneopterin).  Results displayed as Mean ± SEM of 
triplicate of samples. B) Cell viability of U937 cells is unaffected by DP at the concentrations 
tested above. Cell viability of U937 cells with ENT 2 inhibitor DP and DP + 7,8-
dihydroneopterin using PI on flow cytometer.
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A)
B)
Figure 5.12 A) ENT 2 inhibitor Dipyridamole (DP) inhibits the uptake of 7,8-
dihydroneopterin in U937 cells. U937 cells at 1 million cells/ml were supplemented with 200 
µM 7,8-dihydroneopterin and various concentrations of ENT 2 inhibitor DP in RPMI 1640 
with 5% FCS and pen/strep for 24 hours. A) Intracellular neopterin and total Pterin 
concentrations were measured using SCX column on the HPLC. (Total pterin = neopterin + 
7,8-dihydroneopterin).  Results displayed as Mean ± SEM of triplicate of samples. B) Cell 
viability of U937 cells is unaffected by DP at the concentrations tested above. Cell viability of 
U937 cells with ENT 2 inhibitor DP and DP + 7,8-dihyroneopterin using PI on flow 
cytometer.
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The cell lines were tested to rule out any additional effect of various concentration of DP on 
neopterin or 7,8-dihydroneopterin production. In U937 cells there was no effect of DP on 
neopterin or 7,8-dihydroneopterin at 24 hours. Significant drop in neopterin and 7,8-
dihydroneopterin at 100 µM could be explained by the loss of cell viability at that 
concentration of DP (figure 5.11). There was a significant drop of 80% drop seen in the 7,8-
dihydroneopterin uptake at 100 µM was attributed to the slight loss of cell viability. DP was 
very toxic to cells and this drop was a result of loss of cell viability rather than the decreased 
uptake as close to a 50% of cells were dead as seen in the PI assay on flow cytometer. 
With the uptake of 7,8-dihydroneopterin at different DP concentrations, it was found that 1 
µM DP significantly inhibit the 7,8-dihydroneopterin uptake (figure 5.12 A). There was a little 
inhibitory effect of 100 nM DP but was insignificant. There was significant inhibition of 7,8-
dihydroneopterin uptake observed across the range of concentrations of DP (5, 10, 50 and 100 
µM), however DP affected the cell viability of U937 cells slightly at a concentration of 50 
µM, which was more pronounced at 100 µM as observed by flow cytometer. 
ENT 2 inhibitor DP was also tested on THP-1 cells uptake of 7,8-dihydroneopterin. There was 
no additional effect of DP on neopterin and 7,8-dihydroneopterin production. The amount of 
neopterin and total pterin was similar to that of the control cells over 24 hours (figure 5.13). 
There was a slight drop at the 100 µM and 200 µM concentration of DP used due to DP being 
toxic to THP-1 cells at those concentrations. 
7,8-dihydroneopterin uptake in THP-1 cells was tested using the same concentrations and it 
was seen that the uptake of 7,8-dihydroneopterin was significantly inhibited at 1 µM as well as 
10 µM DP without any loss of cell viability (figure 5.14). The high uptake inhibition of about 
87% at 100 µM and 200 µM DP concentrations was not due to increased inhibition but due to 
the toxicity of DP to cells and the subsequent cell viability loss of THP-1 cells. This was
observed by the PI viability tested using flow cytometer. There was not much difference 
between the 7,8-dihydroneopterin uptake inhibition between 1 µM and 10 µM DP, as it might 
be that 1 µM DP is enough to block all the ENT 2 mediated transport of 7,8-dihydroneopterin. 
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A)
B)
Figure 5.13 ENT 2 inhibitor DP at various concentrations tested does not induce 7,8-
dihydroneopterin production in THP-1 cells. THP-1 cells at 1 million cells/ml were 
supplemented with 200 µM 7,8-dihydroneopterin and various concentrations of ENT 2 
inhibitor DP in RPMI 1640 with 5% FCS and pen/strep for 24 hours. A) Intracellular 
neopterin and total Pterin concentrations were measured using SCX column on the HPLC.
(Total pterin = neopterin + 7,8-dihydroneopterin).  Results displayed as Mean ± SEM of 
triplicate of samples. B) Cell viability of THP-1 cells is unaffected by DP at the 
concentrations tested above. Cell viability of THP-1 cells with ENT 2 inhibitor DP and DP + 
7,8-dihydroneopterin using PI on flow cytometer.
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A)
B)
Figure 5.14 ENT 2 inhibitor DP inhibits the uptake of 7,8-dihydroneopterin in THP-1 
cells. THP-1 cells at 1 million cells/ml were supplemented with 200 µM 7,8-dihydroneopterin 
and various concentrations of ENT 2 inhibitor DP in RPMI 1640 with 5% FCS and pen/strep 
for 24 hours. A) Intracellular neopterin and total Pterin concentrations were measured using 
SCX column on the HPLC. (Total pterin = neopterin + 7,8-dihydroneopterin).  Results 
displayed as Mean ± SEM of triplicate of samples. B) Cell viability of THP-1 cells is 
unaffected by DP at the concentrations tested above. Cell viability of THP-1 cells with ENT 2 
inhibitor DP and DP + 7,8-dihydroneopterin using PI on flow cytometer.
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The presence of 7,8-dihydroneopterin does not protect the cell viability loss caused by DP 
toxicity to U937 cells or THP-1 cells. So the mode of loss of cell viability could be unrelated 
to or a different form of oxidative stress where 7,8-dihydroneopterin is ineffective. 
After exploring the role of ENT’s, we sought to understand the time at which the effect of 
inhibitors sets in after their addition and how long the inhibition lasts for. A timecourse of 7,8-
dihydroneopterin uptake in presence of ENT 2 inhibitor DP was performed. A concentration 
of 1 µM DP was used as it inhibit the uptake by approximately 50% and did not cause any 
change in cell viability in both the cell lines used in this study (figure 5.12 and 5.14) . 
Figure 5.15 Timecourse of U937 cells uptake of 7,8-dihydroneopterin with 1 µM of ENT 
2 inhibitor Dipyridamole (DP). U937 cells were incubated with 1 µM DP and 200 µM 7,8-
dihydroneopterin  to measure the uptake of 7,8-dihydroneopterin in RPMI 1640 with 5% FCS 
and pen/strep, over the course of 24 hours. Total pterin concentrations inside the cells were 
measured using SCX column on the HPLC. (Total pterin = neopterin + 7,8-dihydroneopterin).
Results are expressed as Mean ± SEM of triplicate of samples.  
In U937 cells about 50% of the 7,8-dihydroneopterin is taken up in the first 3 hours of 
incubation, and the rest of the 50% is taken up during the next 21 hours of incubation (180 ± 
0.6 pmoles/million cells at 3 hours and 357 ± 19 pmoles/million cells at 24 hours (figure 5.15). 
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The effect of DP was significant as soon as 3 hours after it was added. This rate of 7,8-
dihydroneopterin uptake inhibition was highest (about 67%) at 3 hours (180 ± 0.6 
pmoles/million cells without DP against 60 ± 7 pmoles/million cells with 1 µM DP). The 
inhibition of 7,8-dihydroneopterin uptake was about 50% at 12 hours, which decreased to 
about 43% at 24 hours.  The bulk of the uptake still occurred in the first 12 hours, with or 
without the inhibitor but the amount was less with the inhibitor. 
It was seen that the efficiency of inhibition is more at 3 hours (67%), which decreases over 
time to approximately 50% at the end of 24 hours. The specific inhibitors do not seem to affect 
the cells rate of uptake via any other unknown transporter mechanisms. 
Figure 5.16 Timecourse of THP-1 cells uptake of 7,8-dihydroneopterin with 1 µM of 
ENT 2 inhibitor Dipyridamole (DP). THP-1 cells were incubated with 1 µM DP and 200
µM 7,8-dihydroneopterin  to measure the uptake of 7,8-dihydroneopterin in RPMI 1640 with 
5% FCS and pen/strep over the course of 24 hours. Total pterin concentrations inside the cells 
were measured using SCX column on the HPLC. (Total pterin = neopterin + 7,8-
dihydroneopterin). Results are expressed as Mean ± SEM of triplicate of samples.  
THP-1 cells showed a different uptake kinetic (figure 5.16) for the first 3 hours. The 
inhibitor’s effect on 7,8-dihydroneopterin uptake was significant at 6 hours instead of 3 hours 
as seen in U937 cells. This delayed effect indicates that it takes some time for DP to bind to 
the transporter and inhibit the transport. The rate of uptake of 7,8-dihydroneopterin in the 
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presence of 1 µM DP remains consistent at about 50% from 6 hours to 24 hours of the 
experiment as compared to their uptake in the absence of the inhibitor at the respective time 
points. The final uptake of 7,8-dihydroneopterin in the presence of DP was about 50% as 
observed with U937 cells. 
If we compare the dynamics of the uptake of 7,8-dihydroneopterin in presence and absence of 
1 µM DP, it is observed that the U937 cells took up higher concentration of 7,8-
dihydroneopterin as compared to what was observed before in the study (figure 5.15 and 
5.16). The uptake in THP-1 cells was more steady and constant at 24 hours. The rate and 
efficiency of uptake remained the same in both cell lines as it was observed before, preserving 
the difference between the cell lines. This difference in the uptake inhibition suggests 
involvement of two different transporters, where the binding efficiency of DP differs. 
5.2.4 Inhibition of 7,8-dihydroneopterin uptake in U937 cells and THP-1 cells by CNT 
inhibitor (INDO)
Since there was substantial uptake of 7,8-dihydroneopterin observed in the presence of ENT 
inhibitors, we also looked at other major kind of transporters present in cells, the concentrative 
nucleoside transporters (CNT’s) as a possible gateway for 7,8-dihydroneopterin into these 
cells. 
Since CNT's take up the nucleosides against the concentration gradient in presence of Na+ ions 
we tested 7,8-dihydroneopterin uptake in U937 cells and THP-1 cells using inhibitor 
indomethacin (INDO) which blocks Na+-ion mediated transport. As the inhibition effect was 
seen as early as 3 and 6 hours, we checked the inhibition of CNT's at 6 hours. Initial control 
studies showed indomethacin did not induce any neopterin or 7,8-dihydroneopterin production 
in both U937 cells and THP-1 cells nor was it cytotoxic (figure 5.17 and 5.18). There was no 
inhibition of 7,8-dihydroneopterin uptake with the concentrations of INDO tested with either 
U937 cells or THP-1 cells (figure 5.17 A and 5.18 A). 
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A)
B)
Figure 5.17 CNT inhibitor Indomethacin did not inhibit the uptake of 7,8-
dihydroneopterin in U937 cells. U937 cells at 1 million cells/ml were supplemented with 200 
µM 7,8-dihydroneopterin and various concentrations of CNT inhibitor INDO in RPMI 1640 
with 5% FCS and pen/strep for 24 hours. A) Intracellular neopterin and total Pterin 
concentrations were measured using SCX column on the HPLC. (Total pterin = neopterin + 
7,8-dihydroneopterin).  Results displayed as Mean ± SEM of triplicate of samples. B) Cell 
viability of U937 cells is unaffected by INDO at the concentrations tested above. Cell viability 
of U937 cells with CNT inhibitor INDO using PI on flow cytometer.
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A)
B)
Figure 5.18 CNT inhibitor Indomethacin did not inhibit the uptake of 7,8-
dihydroneopterin in THP-1 cells. THP-1 cells at 1 million cells/ml were treated with 200 
µM 7,8-dihydroneopterin and various concentrations of CNT inhibitor INDO in RPMI 1640 
with 5% FCS and pen/strep for 24 hours. A) Intracellular neopterin and total Pterin 
concentrations were measured using SCX column on the HPLC. (Total pterin = neopterin + 
7,8-dihydroneopterin).  Results displayed as Mean ± SEM of triplicate of samples. B) Cell 
viability of THP-1 cells is unaffected by INDO at the concentrations tested above. Cell 
viability of THP-1 cells with CNT inhibitor INDO using PI on flow cytometer.
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5.2.5 Additive effect of ENT and CNT inhibitors
After individual effects of the nucleoside transport inhibitors on 7,8-dihydroneopterin uptake 
were tested, we analyzed if there was any additive effect of ENT 1, ENT 2 and CNT inhibitors 
in 7,8-dihydroneopterin inhibition.
Figure 5.19 In U937 cells there is no additive effect of the ENT 1 and 2 & CNT inhibitors 
at their tested effective concentrations in RPMI 1640 with 5% FCS and pen/strep. 7,8-
dihydroneopterin uptake in U937 cells at 1 million cells/ml was tested by supplementing with 
200µM 7,8-dihydroneopterin and a combination of NBMPR (100 nM), Dipyridamole (1 µM) 
and Indomethacin (5 µM, Na+ transport inhibitor- for CNT's) inhibitors for 6 hours in RPMI 
(phenol red), 5%FCS with pen/strep. Intracellular neopterin and total pterin concentrations 
were measured using SCX column on the HPLC. (Total pterin = neopterin + 7,8-
dihydroneopterin). Results displayed as Mean ± SEM of triplicate of samples.
To test this U937 cells (figure 5.19) and THP-1 (figure 5.20) cells were treated with the 
inhibitor concentrations which led to approximately 50% inhibition in the cell lines in RPMI 
1640. For INDO, 5 µM was chosen as a desired concentration for further studies. 
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Figure 5.20 In THP-1 cells there is no additive effect of the ENT 1 and 2 & CNT 
inhibitors at their tested effective concentrations in RPMI 1640. 7,8-dihydroneopterin  
uptake in THP-1 cells at 1 million cells/ml was tested by supplementing with 200µM 7,8-
dihydroneopterin and a combination of NBMPR (100 nM), Dipyridamole (1 µM) and 
Indomethacin (5 µM, Na+ transport inhibitor- for CNT's) inhibitors for 6 hours in RPMI 
(phenol red), 5%FCS with pen/strep and intracellular neopterin and total pterin concentrations 
were measured using SCX column on the HPLC. (Total pterin = neopterin + 7,8-
dihydroneopterin). Results displayed as Mean ± SEM of triplicate of samples.
There was no additive effect on the inhibition of 7,8-dihydroneopterin uptake in U937 cells 
and THP-1 cells (figure 5.19 and 5.20). Inhibitors NBMPR and DP, which inhibit the pterin 
transport of 7,8-dihydroneopterin in THP-1 cells and U937 cells respectively, when used 
together did not show any additive inhibitory effect. There was significant inhibition as 
demonstrated before inhibitors were used by themselves (NBMPR and DP) at the above 
mentioned concentrations. The result obtained when both ENT 1 and ENT 2 inhibitors were 
used together, were similar to the ones obtained when they were used separately. 
Chapter 5
259
Figure 5.21 In U937 cells there is no additive effect of the ENT 1 and 2 & CNT inhibitors 
at their tested effective concentrations in EBSS only medium. 7,8-dihydroneopterin  uptake 
in U937 cells at 1 million cells/ml was tested by supplementing with 200µM 7,8-
dihydroneopterin and a combination of NBMPR (100 nM), Dipyridamole (1 µM) and 
Indomethacin (5 µM, Na+ transport inhibitor- for CNT's) inhibitors for 6 hours in EBSS only. 
Intracellular neopterin and total pterin concentrations were measured using SCX column on 
the HPLC. (Total pterin = neopterin + 7,8-dihydroneopterin). Results displayed as Mean ±
SEM of triplicate of samples.
As experiments using AAPH as an oxidative stress inducing agent were to be performed in 
EBSS, it was important to understand the 7,8-dihydroneopterin uptake inhibition in EBSS. So 
the additive effect of ENT and CNT inhibitors were tested in EBSS only medium. 
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Figure 5.22 In THP-1 cells there is no additive effect of the ENT 1 and 2 & CNT 
inhibitors at their tested effective concentrations in EBSS only medium. 7,8-
dihydroneopterin  uptake in THP-1 cells at 1 million cells/ml was tested by supplementing 
with 200µM 7,8-dihydroneopterin and a combination of NBMPR (100 nM), Dipyridamole (1
µM) and Indomethacin (5 µM, Na+ transport inhibitor- for CNT's) inhibitors for 6 hours in
EBSS only medium. Intracellular neopterin and total Pterin concentrations were measured 
using SCX column on the HPLC. (Total pterin = neopterin + 7,8-dihydroneopterin). Results 
displayed as Mean ± SEM of triplicate of samples.
Similar results were observed in EBSS only as found in RPMI 1640 with serum as a medium 
for U937 cells (figure 5.21) and THP-1 cells (figure 5.22). From preliminary results it was 
observed that, ENT 2 was responsible for 7,8-dihydroneopterin uptake in U937 cells and both 
ENT 1 and ENT 2 appear to play a role in the uptake of 7,8-dihydroneopterin in THP-1 cells. 
INDO did not affect the uptake, so it is possible that CNT’s are absent in both the cell lines or 
does not specifically transport 7,8-dihydroneopterin. 
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5.2.6 7,8-dihydroneopterin protection of AAPH mediated oxidative stress and cell death 
in U937 cells and THP-1 cells 
To test the hypothesis that nucleoside transporter mediated uptake of 7,8-dihydroneopterin is 
essential in protection of AAPH mediated oxidative stress and cell death, AAPH toxicity and 
7,8-dihydroneopterin protection of both U937 cells and THP-1 cells were examined. In the 
previous studies performed in our laboratory by Baird et al., (Baird, 2003), 10 mM AAPH 
resulted in about 50% loss of cell viability at 12 hours. So 10 mM AAPH was used in the 
experiments to test the cell viability loss and 7,8-dihydroneopterin protection. U937 cells and 
THP-1 cells were incubated with 10 mM AAPH and increasing concentrations of 7,8-
dihydroneopterin for 6 and 12 hours to confirm if the protection provided by 7,8-
dihydroneopterin was as previously observed. In U937 cells (figure 5.23 A), approximately 
18% loss of cell viability was seen at 6 hours, was significantly protected by 50 µM 7,8-
dihydroneopterin. At 200 µM 7,8-dihydroneopterin, the cell viability loss was completely 
prevented in U937 cells. At 12 hours (figure 5.23 B), approximately 48% of cells succumbed 
to the AAPH toxicity. With increasing 7,8-dihydroneopterin concentrations, the loss of cell 
viability recovered reaching significance at 100 µM 7,8-dihydroneopterin. The cell viability 
did not reach the control levels even at the highest 7,8-dihydroneopterin concentration of 200 
µM (77 ± 1 % of the control cells). This result was similar to that observed previously in our 
laboratory where the U937 cells loss of cell viability was completely protected by 200 µM 
7,8-dihydroneopterin. The number of cells may have affected the protection provided by 7,8-
dihydroneopterin, as only 0.5 million cells were used in the previous study as opposed to 1 
million cells in this study. In THP-1 cells, AAPH resulted in a 25% loss of cell viability at 6 
hours. Increasing concentrations of 7,8-dihydroneopterin did not provide any protection 
against the AAPH mediated cell viability loss (figure 5.24 A). At 12 hours (figure 5.24 B) of 
incubation with AAPH and 7,8-dihydroneopterin, THP-1 cells showed a 33% protection from 
the AAPH toxicity as shown by MTT assay. This protection reached significance at 100 µM, 
which did not increase significantly at 200 µM 7,8-dihydroneopterin. THP-1 cells (25% loss at 
6 hours and 90% loss at 12 hours) seemed more sensitive to AAPH mediated oxidative stress 
as compared to U937 cells (18% loss at 6 hours and 48% loss at 12 hours). The protection of 
THP-1 cells against AAPH was clearly dependent on time but was not brought up to the 
control levels.
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A)
B)
Figure 5.23 7,8-dihydroneopterin protects U937 cells against the AAPH mediated cell 
viability loss at 6 and 12 hours. U937cells at 1 million cells/ml were incubated with 10 mM 
AAPH and increasing 7,8-dihydroneopterin concentrations in Earle's balanced salt solution 
for 6 hours (A) and 12 hours (B). Cell viability was measured using MTT assay. Results are 
expressed as Mean ± SEM of triplicates. ‘*’ indicates significance of protection when 
compared to the 0 µM concentration of 7,8-dihydroneopterin. 
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Figure 5.24 7,8-dihydroneopterin does not protect THP-1 cells against the AAPH 
mediated cell viability loss at 6 but protects at 12 hours. THP-1 cells at 1 million cells/ml 
were incubated with 10 mM AAPH and increasing 7,8-dihydroneopterin concentrations in 
Earle's balanced salt solution for 6 hours (A) and 12 hours (B). Cell viability was measured 
using MTT assay. Results are expressed as Mean ± SEM of triplicates. ‘*’ indicates 
significance of protection when compared to the 0 µM concentration of 7,8-dihydroneopterin. 
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5.2.7 Inhibition of 7,8-dihydroneopterin protection of AAPH mediated cell viability loss 
by nucleoside transport inhibitors in U937 cells 
A)
B)
Figure 5.25 Dipyridamole inhibits the 7,8-dihydroneopterin protection to U937 cells from 
AAPH mediated cell viability loss at 6 and 12 hours. Effect of ENT 2 inhibitor 
dipyridamole (DP) on 7,8-dihydroneopterin protection of AAPH-mediated loss of cell 
viability in U937 cells in EBSS. U937cells at 1 million cells /ml were incubated with 10 mM 
AAPH and 200 µM 7,8-dihydroneopterin with or without DP in Earle's Balanced salt solution 
for 6 (A) and 12 (B) hours. Cell viability was measured using MTT assay. Results expressed
as Mean ± SEM of triplicates.
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The effect of nucleoside transport inhibitors on 7,8-dihydroneopterin protection of AAPH 
mediated oxidative stress and cell death was examined at 6 and 12 hours. DP inhibits the 
protection provided by 7,8-dihydroneopterin both at 6 and 12 hours (figure 5.25). AAPH (10 
mM) resulted in about a 21% loss of cell viability at 6 hours, which was completely protected 
by 200 µM 7,8-dihydroneopterin. A control for AAPH with DP was also included, which did 
not affect the AAPH killing of cells. Inhibitor only control was not included as there was no 
loss of cell viability observed at this concentration of DP used (figure 5.11). When inhibitor 
was included along with 7,8-dihydroneopterin and AAPH, the protection provided by 7,8-
dihydroneopterin was lost completely. The results obtained were similar at 12 hours (figure 
5.25 B), where AAPH toxicity of U937 cells was protected by 7,8-dihydroneopterin (cell 
viability 90% for AAPH plus 7,8-dihydroneopterin, as compared to AAPH only cell viability 
of 69%). The presence of DP, inhibiting the entry of 7,8-dihydroneopterin into the cells, 
completely abolished the protection provided by 7,8-dihydroneopterin. 
In THP-1 cells, NBMPR was used as an inhibitor to inhibit 7,8-dihydroneopterin uptake to test 
7,8-dihydroneopterin protection against AAPH toxicity. At 6 hours (figure 5.26 A) there was 
no protection of cell viability loss by 7,8-dihydroneopterin observed. Cell viability measured 
about 66% in both AAPH only samples and AAPH plus 7,8-dihydroneopterin samples. In the 
sample where NBMPR was added along with AAPH and 7,8-dihydroneopterin there was an 
additional loss in cell viability of about 20%. There is a slightly greater loss of cell viability in 
the inhibitor plus AAPH control too which was noticeably odd as there was no loss in cell 
viability at this concentration of NBMPR used as observed by PI assay on flow cytometer. 
At 12 hours (figure 5.26 B), the protective effect of 7,8-dihydroneopterin was significant in 
THP-1 cells. The cell viability loss was about 86% which was reduced to about 69% in the 
presence of 7,8-dihydroneopterin. The AAPH plus inhibitor control sample however, did not 
show any additional loss in cell viability as observed at 6 hours. When NBMPR was used as 
an inhibitor of 7,8-dihydroneopterin uptake, the approximately 16% protection provided by 
7,8-dihydroneopterin was completely inhibited, enabling AAPH killing effect again. 
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A)
B)
Figure 5.26 NBMPR does not affect 7,8-dihydroneopterin protection to THP-1 cells from 
AAPH mediated cell viability loss at 6 hours but does inhibit the protection of cell 
viability loss at 12 hours. Effect of ENT 1 inhibitor NBMPR on 7,8-dihydroneopterin 
protection of AAPH-mediated loss of cell viability in THP 1 cells in EBSS. THP 1 cells at 1 
million cells/ml were incubated with 10 mM AAPH and 200 µM 7,8-dihydroneopterin with 
or without NBMPR in Earle's Balanced salt solution for 6 (A) and 12 (B) hours. Results were 
analyzed by MTT assay and shown as Mean ± SEM of triplicates. (#)- Not significant.
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5.2.8 Uptake of neopterin via nucleoside transporters – A comparison of neopterin 
uptake by U937 cells and THP-1 cells in RPMI and EBSS media  
Having tested the importance of the uptake of 7,8-dihydroneopterin in protection against the 
cellular oxidative stress, we tested if the transporters involved in the uptake of 7,8-
dihydroneopterin also take up its oxidized derivative, neopterin. It was important as neopterin 
has been implicated in exacerbating the effect of ROS thereby amplifying the harmful and 
toxic effects caused by ROS. Nucleoside transporter mediated modulation of neopterin could 
affect the balance of 7,8-dihydroneopterin and neopterin which could then determine the 
overall impact of ROS mediated cell protection and death. 
Figure 5.27 Comparison of U937 cells neopterin uptake in RPMI + 5% FCS + pen/strep 
and EBSS only over 12 hours. U937 cells at 1 million cells/ml were incubated with 100 µM 
neopterin for different time points in RPMI 1640 + 5% serum + pen/strep and EBSS only 
medium. Intracellular neopterin concentrations were measured using SCX column on the 
HPLC. Results displayed as Mean ± SEM of triplicate of samples.
The uptake of neopterin by U937 cells in RPMI 1640 seems to occur in two phases (figure 
5.27). There is an initial rapid uptake of neopterin in the first hour, which stabilizes over the 
next 5 hours during which there is not much of uptake. At 12 hours the uptake increases 
rapidly again, and the increase in neopterin uptake at 12 hours is about 100% as compared to 6 
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hours. Overall, out of the 100% uptake of neopterin which measured 91 ± 8 pmoles/million 
cells at 12 hours, approximately 50% of the uptake was in the first hour and the rest of the 
50% neopterin was taken up between 6 and 12 hours. There was minimal uptake between 1 
and 6 hours.
The timecourse of uptake of neopterin was also performed in a minimal medium of EBSS 
only. Without the availability of nutrients and serum, the transporters were not able to perform 
the efficient uptake of neopterin over the 12 hours in U937 cells (figure 5.27). About 75% of 
the neopterin uptake occurred in the first hour, while in the next 11 hours the cells hardly took 
up about 25%. There was a drop in the neopterin uptake between 6 and 12 hours which could 
be due to metabolism or release of neopterin.
The behavior of U937 cells uptake of neopterin in RPMI 1640 was completely different than 
the uptake in EBSS. While there are two time points where there was a spike in neopterin 
uptake in RPMI 1640 at 1 and 12 hours, the uptake follows a more slow and steady trend in 
EBSS, probably due to lack of nutrients and serum factors. The uptake at each time point in 
EBSS was a lot lower than what was observed at the same point in RPMI 1640. The overall 
uptake of neopterin in RPMI 1640 was about 5 times higher as expected than in EBSS. 
The uptake of neopterin was also examined in THP-1 cells (figure 5.28). The dynamics of 
neopterin uptake was completely different in THP-1 cells as compared to U937 cells. This 
difference in the profile and dynamics of neopterin uptake imply different transporters 
involved in the transport and different binding affinity, to 7,8-dihydroneopterin. Firstly, THP-
1 cells took up almost twice the amount of neopterin (194 ± 20 pmoles/million cells as 
opposed to 91 ± 8 pmoles/million cells) over the 12 hour timecourse. The uptake of neopterin 
in THP-1 cells was steadier, less rapid than U937 cells as just 18% of the uptake happens in 
the first hour. Over the course of 6 hours, just 25% of the neopterin is taken up by the cells. 
However there is a very rapid and bulk of the uptake (75%) of neopterin between 6 and 12 
hours. This may suggest the synthesis of an additional transporter. 
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Figure 5.28 Comparison of THP-1 cells neopterin uptake in RPMI + 5% FCS + pen/strep 
and EBSS only over 12 hours. THP 1 cells at 1 million cells/ml were incubated with 100 µM 
neopterin for different time points in RPMI 1640 + 5% serum + pen/strep and EBSS only 
medium. Intracellular neopterin concentrations were measured using SCX column on the 
HPLC. Results displayed as Mean ± SEM of triplicate of samples.
THP-1 cells behaved differently in the absence of serum during the 12 hours for neopterin 
uptake (figure 5.28). While in the presence of serum, the uptake was not rapid but steady in 
the first 6 hours, in the absence of serum and nutrients the neopterin uptake was rapid and high 
for the first 6 hours. The uptake of neopterin decreased from about 75.1 ± 0.8 pmoles/million 
cells to about 44 ± 11 pmoles/million cells between 6 and 12 hours similar to the trend 
observed in U937 cells.  
The profile of neopterin uptake of THP-1 cells in RPMI 1640 and EBSS was completely 
different than what is observed in U937 cells (figure 5.33). The overall neopterin uptake in 
RPMI 1640 and EBSS at 12 hours was about 5 times and 2 times higher than what was found 
in U937 cells respectively although the trend of higher uptake in RPMI 1640 was preserved in 
both the cell lines. Another major difference was that, the uptake of neopterin followed closely 
with what was observed in RPMI 1640 till 6 hours. 
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The effect of the medium became apparent in between 6 and 12 hours of culture, where there 
was a 40% drop in the uptake in EBSS, whereas in RPMI 1640, there was a 400% rise in the 
uptake of neopterin. 
The peak of neopterin uptake was observed at 6 hours for U937 cells and 6 hours for THP-1 
cells in EBSS which was different from the peak timings of 7,8-dihydroneopterin uptake. 
When the uptake profiles of neopterin for U937 cells and THP-1 cells were compared in 
RPMI 1640 and EBSS a distinct tendency of uptake was observed for neopterin. In RPMI 
1640 (figure 5.29) the rise of neopterin uptake is higher and rapid for THP-1 cells as compared 
to U937 cells between 6 and 12 hours. Till 6 hours, both the cell lines behave in a similar 
fashion. 
Figure 5.29 Comparison of U937 and THP-1 cells neopterin uptake in RPMI + 5% FCS 
+ pen/strep over 12 hours.
In EBSS (figure 5.30), U937 cells uptake of neopterin does not change much over the course 
of 12 hours, whereas in THP-1 cells it continues to rise till 6 hours to reach its highest 
neopterin accumulation and drops at 12 hours. THP-1 cells show a higher neopterin 
accumulation than U937 cells, which might be related to them being more sensitive to 
oxidative damage and cell death. 
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Figure 5.30 Comparison of U937 and THP-1 cells neopterin uptake in EBSS only over 12
hours.
5.2.9 A comparison of neopterin and 7,8-dihydroneopterin uptake by U937 cells and 
THP-1 cells in RPMI and EBSS media
The uptake profiles of 7,8-dihydroneopterin and neopterin in U937 cells and THP-1 cells was 
compared to better understand the behavior of these two cell lines towards the two types of 
pterins and their rates of uptake in different mediums. 
With U937 cells (figure 5.31) in RPMI 1640 medium with 5% serum, there is a continuous 
increase in the uptake of 7,8-dihydroneopterin as soon as its added to the medium. Almost 
63% of the uptake happens in the first 3 hours. The uptake of neopterin however follows a 
different course. In the first hour, there is a large rise in the uptake, similar to 7,8-
dihydroneopterin, which levels off till 6 hours. This plateau phase is followed by another 
increased phase of uptake between 6 and 12 hours. The amount of neopterin accumulated in 
the cells through the uptake is approximately 50% of that of 7,8-dihydroneopterin . 
THP-1 cells in RPMI 1640 behave in a very different way with regards to both neopterin and 
7,8-dihydroneopterin uptake (figure 5.32). The uptake of both neopterin and 7,8-
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dihydroneopterin follows a similar trend till 6 hours. After 6 hours, however, there is a steady 
increase in the rate of uptake of 7,8-dihydroneopterin, while the increase in rate of neopterin 
uptake is sudden and rapid. Between 6 and 12 hours, the uptake of neopterin supersedes 
Figure 5.31 Comparison of U937 cells neopterin and 7,8-dihydroneopterin uptake in 
RPMI + 5% FCS + pen/strep over 12 hours.
Figure 5.32 Comparison of THP-1 cells neopterin and 7,8-dihydroneopterin uptake in
RPMI + 5%  FCS + pen/strep over 12 hours.
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uptake of 7,8-dihydroneopterin such that by the end of 12 hours, there is 40% more 
intracellular pterin with neopterin than 7,8-dihydroneopterin. 
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Figure 5.33 Comparison of U937 cells neopterin and 7,8-dihydroneopterin uptake in 
EBSS only medium over 12 hours.
Figure 5.34 Comparison of THP-1 cells neopterin and 7,8-dihydroneopterin uptake in 
EBSS only medium over 12 hours.
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When we compare the uptake pattern of neopterin and 7,8-dihydroneopterin of U937 cells in 
EBSS only medium (figure 5.33), there is a rapid increase in the 7,8-dihydroneopterin uptake 
(from 7 ± 4 pmoles/million cells at 0 hours to 135 ± 10 pmoles/million cells at 6 hours) which 
drops to 115 ± 2 pmoles/million cells between 6 and 12 hours. 
In U937 cells, most of the neopterin uptake occurs in the first hour after (from 1.3 ± 0.3 
pmoles/million cells at 0 hour to 15.8 ± 0.7 pmoles/million cells at 1 hour) which rises very 
slowly to 24 ± 2 pmoles/million cells at 6 hours dropping slightly to 20 ± 2 pmoles/million 
cells of neopterin at 12 hours. With THP-1 cells in EBSS, both neopterin and 7,8-
dihydroneopterin follow a similar trend till 6 hours. After 6 hours, the uptake of neopterin 
drops about 40%, while there is no effect of the medium on 7,8-dihydroneopterin uptake, as it 
continues to rise between 6 to 12 hours (figure 5.34). 
One interesting observation is that the uptake pattern of 7,8-dihydroneopterin in EBSS of 
THP-1 cells resembles closely to the uptake of neopterin in RPMI 1640 by U937 cells. And 
the uptake patter of neopterin in EBSS by THP-1 cells closely resembles the uptake pattern of 
7,8-dihydroneopterin by U937 cells in EBSS. 
5.2.10 Inhibition of neopterin uptake by nucleoside transport inhibitors in U937 cells and 
THP-1 cells in RPMI 1640 and EBSS media
The effect of various ENT and CNT inhibitors was tested on the uptake of neopterin in U937 
cells and THP-1 cells in RPMI 1640 and EBSS at 6 and 12 hours. 
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Figure 5.35 NBMPR (100 nM), Dipyridamole (1 µM) and Indomethacin (5 µM) inhibit 
uptake of Neopterin in U937 cells at 6 hours but not at 12 hours. U937 cells at 1 million 
cells/ml were incubated with 100 µM neopterin and various concentrations of inhibitors for 6 
and 12 hours in RPMI + 5% FCS + pen/strep. Intracellular neopterin concentrations were 
measured using SCX column on the HPLC. Results displayed as Mean ± SEM of triplicate of 
samples. ‘*’ indicates significance of inhibition of neopterin uptake when compared to the 
cells + neopterin only controls. 
Neopterin uptake was inhibited by ENT 1 inhibitor NBMPR as well as ENT 2 inhibitor DP 
(figure 5.35). There was a small but significant inhibition of uptake via the CNT’s as the CNT 
inhibitor INDO inhibited the uptake of neopterin. All the inhibition happened at 6 hours, and 
by 12 hours the inhibition had disappeared. With all the 3 inhibitors at 12 hours, there was a 
slight increase in the uptake of neopterin due to which the significance of inhibition was lost. 
The uptake of neopterin at 12 hours in control cells did not change. 
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Figure 5.36 NBMPR (100 nM), Dipyridamole (1 µM) and Indomethacin (5 µM) inhibit 
uptake of Neopterin in THP-1 cells at 6 hours but not at 12 hours. THP 1 cells at 1 million 
cells/ml were incubated with 100 µM neopterin and various concentrations of inhibitors for 6 
and 12 hours in RPMI + 5% FCS + pen/strep. Intracellular neopterin concentrations were 
measured using SCX column on the HPLC. Results displayed as Mean ± SEM of triplicate of 
samples. ‘*’ indicates significance of inhibition of neopterin uptake when compared to the 
cells + neopterin only controls.
When the neopterin uptake was tested with different inhibitors of nucleoside transporters in 
THP-1 cells (figure 5.36), a similar result was observed. At 6 hours there was a significant 
inhibition with all the 3 inhibitors tested. But at 12 hours, the significance between the control 
cells uptake of neopterin and the uptake of cells with inhibitors was lost, due to reduced 
uptake in the control cells. The uptake of neopterin in the cells with inhibitors did not show 
any change between 6 and 12 hours, which was different behavior than what was shown by 
U937 cells. The drop in neopterin uptake between 6 and 12 hours was in contrast to the 
previous observation where neopterin uptake increased about 3-fold between 6 and 12 hours 
(figure 5.28)
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Figure 5.37 NBMPR (100 nM), Dipyridamole (1 µM) inhibit uptake of Neopterin in U937 
cells at 6 hours but not at 12 hours in EBSS. Indomethacin (5 µM) has no inhibitory 
effect. U937 cells at 1 million cells/ml were incubated with 100 µM neopterin and various 
concentrations of inhibitors for 6 and 12 hours in EBSS only. Intracellular neopterin 
concentrations were measured using SCX column on the HPLC. Results displayed as Mean ± 
SEM of triplicate of samples. ‘*’ indicates significance of inhibition of neopterin uptake when 
compared to the cells + neopterin only controls.
U937 cells inhibition of neopterin uptake in EBSS showed similar results as its uptake in 
RPMI 1640 (figure 5.37), with an exception that inhibition by CNT inhibitor INDO was not 
significant at 6 hours. There was a drop in neopterin uptake at 12 hours in control cells and a 
slight rise in the cells with inhibitors and neopterin, due to which the significant difference in 
the inhibition of uptake by NBMPR was lost. Also the inhibition using DP as an inhibitor 
showed a significant inhibition both at 6 and 12 hours. The values of neopterin uptake 
observed were in accordance with the previously observed values of uptake found in other 
experiments. Also the trend of slightly reduced uptake at 12 hours by the control cells is 
typical of U937 cells. 
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Figure 5.38 NBMPR (100 nM), Dipyridamole (1 µM) inhibit uptake of Neopterin in 
THP-1 cells at 6 hours but not at 12 hours in EBSS. Indomethacin (5 µM) has no 
inhibitory effect. THP 1 cells at 1 million cells/ml were incubated with 100 µM neopterin and 
various concentrations of inhibitors for 6 and 12 hours in EBSS only. Intracellular neopterin 
concentrations were measured using SCX column on the HPLC. Results displayed as Mean ± 
SEM of triplicate of samples. ‘*’ indicates significance of inhibition of neopterin uptake when 
compared to the cells + neopterin only controls.
THP-1 cells inhibition of neopterin uptake in EBSS at 6 and 12 hours showed that there indeed 
was significant inhibition by both ENT 1 and ENT 2 inhibitors, except that CNT inhibitor was 
unable to inhibit neopterin’s uptake at both 6 and 12 hours (figure 5.38). The neopterin uptake 
concentrations were in the broadly comparable as before with some other experiments. A 
sharp drop in the neopterin uptake at 12 hours and the final neopterin concentration is typical 
for THP-1 cells as seen before. By 12 hours with all the 3 samples of cells with the inhibitors, 
there is increase in the uptake of neopterin, which is probably the reason of the loss of 
inhibitory significance. 
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5.2.11 Uptake of 7,8-dihydroneopterin and protection of AAPH mediated oxidative stress 
and cell death in human monocytes
Monocytes have been shown in our laboratory to produce 7,8-dihydroneopterin on IFN-• 
stimulation and take up 7,8-dihydroneopterin in culture. Monocytes entering arterial wall into 
the plaque environment could be subjected to oxidative stress and exogenous 7,8-
dihydroneopterin could aid in their protection against the oxidative stress. As this is more 
relevant to the in vivo situation of plaque development effect of ENT and CNT inhibitors were 
tested on human monocytes in this section of experiments.
Figure 5.39 Monocyte cell viability is not affected by the concentrations of ENT and CNT 
inhibitors used. Effect of different inhibitors on loss of cell viability in Human monocytes in 
RPMI 1640 using MTT assay. Monocytes at 1 million cells /ml were incubated with the 
mentioned concentration of inhibitors in RPMI 1640 solution with 10% human serum and 
pen/strep for 12 hours and cell viability was measured using MTT reagent.  Results are shown 
as Mean ± SEM of triplicates.
Before the effect of inhibitors was examined on human monocytes, it was important to check 
that the inhibitors did not cause any loss in cell viability during the incubation times. As the 
inhibitors themselves did not affect the cell viability in U937 cells and THP-1 cells at the 
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concentrations that were used, we performed a viability check in monocytes with 7,8-
dihydroneopterin and inhibitors together to rule out any adverse effect of inhibitors on them. 
MTT was preferred as a method to test cell viability to be consistent with the previous 
experiments performed in the laboratory with oxidative stress studies (figure 5.39). There was 
no viability loss with any of the inhibitors used along with 7,8-dihydroneopterin . 
5.2.11.1 Inhibition of 7,8-dihydroneopterin uptake by nucleoside transport inhibitors in 
human monocytes in RPMI 1640 and EBSS media
Figure 5.40 NBMPR (100 nM), Dipyridamole (1 µM) and Indomethacin (5 µM) inhibit 
uptake of 7,8-dihydroneopterin in human monocytes in RPMI 1640 with 10% human 
serum at 6 hours. Monocytes at 1 million cells/ml were treated with 200 µM 7,8-
dihydroneopterin and various concentrations of inhibitors for 6 hours in RPMI (phenol red), 
10% Human serum with pen/strep. Intracellular neopterin and total Pterin concentrations were 
measured using SCX column on the HPLC. Results displayed as Mean ± SEM of triplicate of 
samples. ‘*’ indicates significance of inhibition of 7,8-dihydroneopterin uptake when 
compared to the 7,8-dihydroneopterin only controls.
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7,8-dihydroneopterin  uptake is inhibited significantly by the inhibitors tested (figure 5.40). 
Inhibition by ENT 1 inhibitor NBMPR and CNT inhibitor INDO is greater than inhibition by 
ENT 2 inhibitor DP. There was no increase in neopterin with any of the inhibitors used over 
the 6 hours of incubation. Inhibition reduced the 7,8-dihydroneopterin uptake in cells to the 
basal levels as found in the control cells incubated without any 7,8-dihydroneopterin. 
Figure 5.41 NBMPR (100 nM), Dipyridamole (1 µM) and Indomethacin (5 µM)
inhibitory effect on uptake of 7,8-dihydroneopterin disappears in human monocytes in 
RPMI 1640 with 10% human serum at 12 hours. Monocytes at 1 million cells/ml were 
treated with various concentrations of inhibitors for 12 hours in RPMI (phenol red), 10% 
Human serum with pen/strep and intracellular neopterin and total Pterin concentrations were 
measured using SCX column on the HPLC. Results displayed as Mean ± SEM of triplicate of 
samples. ‘*’ indicates significance of inhibition of 7,8-dihydroneopterin uptake when 
compared to the 7,8-dihydroneopterin only controls.
Inhibition of 7,8-dihydroneopterin uptake was performed at both 6 and 12 hours to see if there 
is any difference between the timing of inhibition. At 12 hours (figure 5.41), the inhibition 
effect had lost its significance. As expected the uptake of 7,8-dihydroneopterin was 
approximately 200% of what it was at 6 hours in the controls. Cells with 7,8-dihydroneopterin 
Chapter 5
282
and inhibitors, also showed increased uptake of 7,8-dihydroneopterin at 12 hours, that was 
similar to the 7,8-dihydroneopterin control cells. The inhibition effect was completely lost 
with ENT 1 and ENT 2 inhibitors, and the CNT inhibitor INDO showed a 50% increase in 
7,8-dihydroneopterin uptake in human monocytes. 
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Figure 5.42 Comparison of inhibitory effect of NBMPR (100 nM), Dipyridamole (1 µM) 
and Indomethacin (5 µM) on uptake of 7,8-dihydroneopterin in human monocytes in 
RPMI 1640 with 10% human serum at 6 and 12 hours. Monocytes at 1 million cells/ml 
were treated with 200 µM 7,8-dihydroneopterin and various concentrations of inhibitors for 6 
and 12 hours in RPMI (phenol red), 10% Human serum with pen/strep. Intracellular neopterin 
and total Pterin concentrations were measured using SCX column on the HPLC. Results 
displayed as Mean ± SEM of triplicate of samples. ‘*’ indicates significance of inhibition of 
7,8-dihydroneopterin uptake when compared to the 7,8-dihydroneopterin only controls.
The loss of inhibitory effect of ENT and CNT inhibitors is clearly seen when we compare the 
7,8-dihydroneopterin uptake of human monocytes in RPMI 1640 at 6 and 12 hours (figure 
5.42).  It seems that the inhibitory effect reaches a threshold and the cells take up 7,8-
dihydroneopterin via alternative transporter pathways or mechanisms. 
Chapter 5
283
When the inhibition of 7,8-dihydroneopterin was examined in a minimal medium of EBSS 
only at 6 hours (figure 5.43), exactly the same kind of results were obtained as in RPMI 1640.
Figure 5.43 NBMPR (100 nM), Dipyridamole (1 µM) and Indomethacin (5 µM) inhibit 
uptake of 7,8-dihydroneopterin in human monocytes in EBSS only at 6 hours. Monocytes 
at 1 million cells/ml were treated with 200 µM 7,8-dihydroneopterin and various 
concentrations of inhibitors for 6 hours in EBSS only. Intracellular neopterin and total Pterin 
concentrations were measured using SCX column on the HPLC. Results displayed as Mean ± 
SEM of triplicate of samples. ‘*’ indicates significance of inhibition of 7,8-dihydroneopterin 
uptake when compared to the 7,8-dihydroneopterin only controls.
But in EBSS the uptake in the 7,8-dihydroneopterin control cells was 200% than what was 
observed in RPMI 1640 at 6 hours. Again the inhibition by ENT 1 inhibitor NBMPR and CNT 
inhibitor INDO were stronger as compared to ENT 2 inhibitor DP. Another noticeable 
difference in EBSS medium at 6 hours was that, in the inhibitor samples with 7,8-
dihydroneopterin the  neopterin ratio to 7,8-dihydroneopterin was lower than what was 
observed in RPMI 1640 with DP and INDO while it was proportional to the 7,8-
dihydroneopterin uptake in cells with NBMPR. 
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Figure 5.44 NBMPR (100 nM), Dipyridamole (1 µM) and Indomethacin (5 µM)
inhibitory effect on uptake of 7,8-dihydroneopterin disappears in human monocytes in 
EBSS only at 12 hours. Monocytes at 1 million cells/ml were treated with 200 µM 7,8-
dihydroneopterin and various concentrations of inhibitors for 12 hours in EBSS only. 
Intracellular neopterin and total Pterin concentrations were measured using SCX column on 
the HPLC. Results displayed as Mean ± SEM of triplicate of samples.
A similar trend in 7,8-dihydroneopterin uptake inhibition was found in monocytes at 12 hours 
in EBSS (figure 5.44) which was observed with monocytes grown in RPMI 1640 at 12 hours. 
The inhibitory effect had lost its significance. The uptake of 7,8-dihydroneopterin at 12 hours 
had increased 300% of what it was at 6 hours while in the cells with inhibitors the increase 
was about 1200% for NBMPR, about 500% for DP and about 1500% for INDO as compared 
to the uptake at 6 hours. At 12 hours, the uptake between the cells with different inhibitors was 
similar, which was an interesting observation. 
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Figure 5.45 Comparison of inhibitory effect of NBMPR (100 nM), Dipyridamole (1 µM) 
and Indomethacin (5 µM) on uptake of 7,8-dihydroneopterin in human monocytes EBSS 
only at 6 and 12 hours. Monocytes at 1 million cells/ml were treated with 200 µM 7,8-
dihydroneopterin and various concentrations of inhibitors for 6 and 12 hours in EBSS only. 
Intracellular neopterin and total Pterin concentrations were measured using SCX column on 
the HPLC. Results displayed as Mean ± SEM of triplicate of samples. ‘*’ indicates 
significance of inhibition of 7,8-dihydroneopterin uptake when compared to the 7,8-
dihydroneopterin only controls.
When compared the monocyte uptake of 7,8-dihydroneopterin in EBSS at 6 and 12 hours 
(figure 5.45), it is clear that with time the inhibitory effect of various inhibitors is lost, and the 
uptake of 7,8-dihydroneopterin via these transporters was increased many fold . There was no 
difference observed between the 7,8-dihydroneopterin uptake by cells with ENT inhibitors and 
CNT inhibitor at 12 hours in EBSS which was not the case in RPMI 1640. CNT inhibitor 
stood out as it resulted in an increased uptake as compared to the 7,8-dihydroneopterin control 
cells at 12 hours in RPMI 1640. 
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5.2.12 7,8-dihydroneopterin protection of AAPH induced cell viability loss in human 
monocytes. 
After the uptake of 7,8-dihydroneopterin was tested in human monocytes, we tested if 7,8-
dihydroneopterin was able to protect human monocytes against AAPH mediated toxicity and 
cell viability loss and how did the protection differ at 6 and 12 hours. 
At 6 hours (figure 5.46 A), 10 mM AAPH killed about 40% of the cells while 200 µM 7,8-
dihydroneopterin was able to protect the monocytes completely, bringing up the cell viability 
to a 100% in presence of AAPH. A 7,8-dihydroneopterin control was also included which 
showed that 7,8-dihydroneopterin  alone had no effect on cell viability. 
After 12 hours (Figure 5.46 B), the killing of monocytes with 10 mM AAPH was slightly 
higher at 45%. There was also a 10% increase in 7,8-dihydroneopterin control monocytes, 
which has been observed previously in our laboratory. At 12 hours protection of 7,8-
dihydroneopterin against the AAPH mediated cell viability loss was about 25%, bringing up 
the viability from about 55% to 80%. The cell viability was not brought up to 100% as 
observed at 6 hours. It was interesting to note that between 6 to 12 hours the monocytes were 
resistant to killing by AAPH as the cell viability only decreased by 5% during this time. The 
protection provided by 7,8-dihydroneopterin decreased from about 40% to 25% during this 
time possibly due to oxidative loss of 7,8-dihydroneopterin  with time.
As it was established that 7,8-dihydroneopterin did protect human monocytes from an 
oxidative insult of AAPH and subsequent cell death, we tested the effect of inhibition of 7,8-
dihydroneopterin uptake on its protection of cells. 
5.2.13 Inhibition of 7,8-dihydroneopterin protection of AAPH induced cell viability loss 
in human monocytes by nucleoside transport inhibitors
Before the effect of inhibitors on 7,8-dihydroneopterin protection of AAPH mediated 
oxidative stress, inhibitors were tested in combination with AAPH to check their effect on 
AAPH mediated cell killing.
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A)
B)
Figure 5.46 7,8-dihydroneopterin protects human monocytes against the AAPH 
mediated cell viability loss at 6 (A) and 12 (B) hours. Effect of 7,8-dihydroneopterin on 
AAPH-mediated loss of cell viability in U937 cells in EBSS: MTT assay. Human monocytes 
at 1 million cells/ml were incubated with 10 mM AAPH and 200 µM 7,8-dihydroneopterin in 
Earle's balanced salt solution for 6 (A) and 12 hours (B). Results were analyzed by MTT assay 
and shown as Mean ± SEM of triplicates. Cells + AAPH was compared with control and Cells 
+ AAPH + 7,8-dihydroneopterin was compared with Cells + AAPH for significance. 
As expected AAPH mediated cell death was unaffected in the presence of the inhibitors at 12 
hours (figure 5.47).
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Figure 5.47 Effect of NBMPR, DP (ENT inhibitors) and INDO (CNT inhibitor) on 
human monocytes cell viability at 12 hours. Monocytes at 1 million cells/ml were incubated 
with 10 mM AAPH and ENT inhibitors (NBMPR and DP) and CNT inhibitor (INDO) in 
Earle's balanced salt solution for 12 hours. Cell viability was analyzed by MTT assay results 
are expressed as Mean ± SEM of triplicates.
When monocytes were incubated with 7,8-dihydroneopterin and AAPH and uptake of 7,8-
dihydroneopterin was blocked using nucleoside transport inhibitors, protective effect of 7,8-
dihydroneopterin was lost (figure 5.53). The protection provided by 7,8-dihydroneopterin was 
approximately 40% with AAPH, but the presence of inhibitors reduced the protection down to 
about 25% only. The 40% protection by 7,8-dihydroneopterin was knocked down to 15% at 6 
hours. Ideally this protection of 40% should have been completely inhibited, but the exact 
reason for this residual protection of 15% could be due to the small amount of 7,8-
dihydroneopterin getting into the cells (figure 5.48 A and B). 
The result at 12 hours was the same. The killing by AAPH was slightly higher at 45%. At 12 
hours the protection provided by 7,8-dihydroneopterin against AAPH decreased from about 
40% to 25%. In the presence of inhibitors this 25% protection provided by 7,8-
dihydroneopterin was completely inhibited (figure 5.48 B). There was no residual protection 
provided by the presence of inhibitors as seen at 6 hours. 
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A)
B)
Figure 5.48 NBMPR, DP (ENT inhibitors) and INDO (CNT inhibitor) inhibit 7,8-
dihydroneopterin protection to monocytes from AAPH mediated toxicity and cell 
viability loss at 6 and 12 hours. Monocytes at 1 million cells /ml were incubated with 10 mM
AAPH and 200 µM 7,8-dihydroneopterin  with ENT inhibitors (NBMPR and DP) and CNT 
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inhibitor (INDO) in Earle's Balanced salt solution for 6 (A) and 12 hours (B). Cell viability 
was analyzed by MTT assay results are expressed as Mean ± SEM of triplicates.
All the 3 inhibitors inhibited the 25% protection provided by 7,8-dihydroneopterin indicating 
the presence and involvement of all the 3 types of transporters in the transport and protection 
of 7,8-dihydroneopterin against AAPH induced oxidative stress.
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5.3 Discussion
5.3.1 7,8-dihydroneopterin production by U937 cells and THP-1 cells
U937 cells produce basal levels of supernatant and intracellular 7,8-dihydroneopterin which 
did not increase on IFN-• stimulation (figure 5.1). In contrast in the THP-1 cell line which also 
produced similar basal levels of 7,8-dihydroneopterin in the cells and in the supernatant, IFN-• 
induced a two-fold increase in 7,8-dihydroneopterin production in the supernatant and a 3-fold 
increase inside the cells (figure 5.2). On IFN-• stimulation, THP-1 cells produced 2-fold more 
7,8-dihydroneopterin than U937 cells (215 ± 6 vs 104 ± 14 pmoles/million cells respectively).
There have been reports of subclones of U937 cells which produce 7,8-dihydroneopterin on 
IFN-• stimulation (Wachter et al., 1989, Werner-Felmayer et al., 1990) but the U937 cells 
used in this study did not seem to belong to those subclones. 
If we compare the supernatant values of 7,8-dihydroneopterin in macrophages reported by 
Weiss et al., (Weiss et al., 1992) a similar amount of IFN-• (300 U/ml) produced about 50% 
of what was observed in our experiments. In the studies performed by Troppmair et al.,
(Troppmair et al., 1988), the PBMC’s also produced about 50% of supernatant 7,8-
dihydroneopterin as observed during our experiments. However, monocyte derived 
macrophages in their studies produced similar amounts of neopterin as observed in our studies. 
One of the reasons could be that our THP-1 cells subclone has undergone some changes or 
have become more differentiated which might explain in part, the increased production of 7,8-
dihydroneopterin observed.
In THP-1 cells, five-fold higher IFN-• concentration did not induce five-fold higher 
production of 7,8-dihydroneopterin (figure 5.2). The increase was in the range of 172% and 
193% as compared to the control cells in the supernatant. The intracellular increase in 7,8-
dihydroneopterin was more pronounced where the increase was in the range of 412% to 510% 
as compared to the controls in THP-1 cells. The reason possibly, could be that a threshold of 
neopterin and 7,8-dihydroneopterin production is reached beyond which any extra IFN-• does 
not induce any effect. Also the efficiency of production reaches its maximum at a certain 
threshold IFN-• concentration, beyond which the cellular resources are insufficient for 
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increased 7,8-dihydroneopterin production. Also the increase in supernatant neopterin 
production with higher IFN-• in THP-1 cells, suggests an IFN-• associated increase in oxidant 
production associated with the modulation of cells to a pro-inflammatory phenotype. 
5.3.2 7,8-dihydroneopterin uptake and inhibition in U937 cells and THP-1 cells
The uptake of 7,8-dihydroneopterin was studied in U937 cells and THP-1 cells for the first 
time to investigate the role of nucleoside transporters in its uptake. Studies over 24 hours 
showed a different pattern of its uptake in the two cell lines studied. U937 cells showed a very 
rapid uptake of 7,8-dihydroneopterin, about 58% of the total uptake in the first 3 hours. 
The rate of uptake of 7,8-dihydroneopterin in THP-1 cells was slower (only 28% of the total 
uptake at 3 hours), steadier and almost linear as compared to U937 cells but the final 7,8-
dihydroneopterin concentrations in U937 cells and THP-1 cells was similar in RPMI 1640  
(figure 5.3). Neopterin concentrations did not rise throughout the incubation period, so we can 
conclude that most of the 7,8-dihydroneopterin taken up stays as 7,8-dihydroneopterin in both 
the cell lines tested. When these curves were compared to the rate of uptake of pterins via 
hENT 1 and hENT 2 as reported by Ohashi et al.,  (Ohashi et al., 2011b), we can see that the 
curve of uptake in U937 cells resemble ENT 2 and ENT 1 in THP-1 cells respectively. Since 
these transporters mediate the influx as well as efflux of their substrates, the 7,8-
dihydroneopterin concentration could represent the equilibrium between the two processes, 
where the rate of influx is greater than the rate of efflux. This appears to be the case in U937 
cells where after 12 hours the uptake reaches a plateau where the efflux could be equal to the 
rate of influx.  
Every class of transporter is characterized by distinct substrate specificity and sensitivity, 
which also determines the rate of uptake of its substrate. Higher rate of uptake of 7,8-
dihydroneopterin in U937 cells might be due to higher affinity of the this substrate to the 
transporter involved. The rate of 7,8-dihydroneopterin transport in THP-1 cells being slower 
suggests a different transporter could be involved or a different binding site with a different 
affinity for the substrate on the same transporter. The involvement of nucleoside transporters 
in 7,8-dihydroneopterin transport is a novel finding.  
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5.3.2.1 ENT 1 in 7,8-dihydroneopterin uptake
Facilitated diffusion systems were the first type of nucleoside transporters to be studied and 
classified based on their sensitivity to NBMPR (Griffith and Jarvis, 1996).  NBMPR is a 
specific inhibitor for ENT 1 mediated transport as described by a number of studies and 
reviews as well (Belt et al., 1993, Rietzschel et al., 2007, Young et al., 2008, Griffith and 
Jarvis, 1996). Based on our studies in U937 cells, it was found that, NBMPR did not inhibit 
7,8-dihydroneopterin uptake in U937 cells (figure 5.8). The uptake observed with inhibitor 
was almost similar to control cells suggesting that bulk of this transport was mediated by 
another transporter. At high micromolar concentration (10 µM) of NBMPR both ENT 1 and 
ENT 2 transporters are blocked (Ohashi et al., 2011a, Young et al., 2008, Belt et al., 1993). 
The slight decrease observed at 10 µM could be due to inhibition of ENT 2 mediated transport 
of 7,8-dihydroneopterin. A similar but lesser decrease is also seen at 100 nM, the reason for 
which is unknown. 
In THP-1 cells, however, low nanomolar (1 nM) NBMPR concentration decreased the uptake 
by approximately 15% (figure 5.10). At 100 nM there was about 40% decrease in uptake of 
7,8-dihydroneopterin which did not change at higher NBMPR concentrations. This was 
consistent with the ENT 1 type transport mechanism which was sensitive to inhibition at low 
NBMPR (nM) levels. Higher micromolar concentration of NBMPR (10 µM), which was 
known to inhibit both ENT 1 and ENT 2 mediated transport, did not result in a further 
decrease in 7,8-dihydroneopterin uptake. This observation rules out any possible ENT 2 
mediated transport of 7,8-dihydroneopterin in THP-1 cells. 
There are seven known nucleoside transport proteins (hENT 1/2/3/4 and hCNT 1/2/3), with 
several other corresponding orthologues present in other mammalian species (Young et al., 
2008). So the residual uptake in both U937 cells and THP-1 cells could be mediated via any of 
the other mentioned transporter. 
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5.3.2.2 ENT 2 in 7,8-dihydroneopterin uptake
DP is known to inhibit both es and ei mediated ENT transport of nucleosides (Belt et al., 1993, 
Kong et al., 2004). DP also inhibits both ENT 1 and 2 mediated transport at 1 µM 
concentration in recombinant ENT 2 transporters (Mackey et al., 1998). Significant inhibition 
of 7,8-dihydroneopterin uptake in U937 cells starting at 1 µM and only slightly greater 
inhibition of 7,8-dihydroneopterin uptake at 50 µM suggests that almost all ENT 2 
transporters are blocked at 1 µM (figure 5.12). Our observations suggest that ENT 2 is the 
major transporter of 7,8-dihydroneopterin in U937 cells. 
In THP-1 cells too, 1 µM DP inhibit approximately 50% of 7,8-dihydroneopterin uptake 
(figure 5.14) as most of the ENT 1 and ENT 2 transporters are completely blocked at a 
concentration of 1 µM. Based on our observations that, 1 µM DP inhibits similar percentage 
of 7,8-dihydroneopterin uptake as 100 nM NBMPR and NBMPR being a specific ENT 1 
inhibitor,  and that DP inhibits both ENT 1 and ENT 2, we concluded that most of the 
transport of 7,8-dihydroneopterin in THP-1 cells is ENT 1 mediated. 
5.3.2.3 CNT's in 7,8-dihydroneopterin uptake
The possibility of concentrative transporters being one of possible transporters for 7,8-
dihydroneopterin was tested by different concentrations of the inhibitor INDO (which inhibits 
Na+ ion mediated transport).  There was no inhibition of 7,8-dihydroneopterin mediated 
uptake in both U937 cells and THP-1 cells (figure 5.17 and 5.18). This could be possible if 
there are no CNT’s expressed in U937 cells and THP-1 cells or 7,8-dihydroneopterin is not a 
substrate for the CNT’s. Belt et al., (Belt et al., 1993) reported a component of Na+-dependent 
nucleoside transport activity in U937 cells. It is highly possible in this case, that 7,8-
dihydroneopterin does not act as a substrate for CNT’s. Marginal increase in neopterin could 
be due to the drug itself or due to any oxidative side-effects on the cells. Preincubation of cells 
for 60 minutes with INDO did not affect the 7,8-dihydroneopterin uptake. Another reason why 
there was no uptake via CNT's could be that CNT expression in leukemic cell lines could be 
significantly impaired (Pastor-Anglada et al., 2008)
Chapter 5
295
None of the inhibitors used caused any oxidative stress or perturbation of normal cellular 
homeostasis as observed by the cell viability on flow cytometer and no increase in intracellular 
neopterin observed. This was true except for 100 µM and 200 µM DP which were observed to 
cause a significant loss of cell viability in U937 cells and THP-1 cells. Also it was observed 
that the inhibitors were more effective when added simultaneously with 7,8-dihydroneopterin 
rather than pre-incubating them for an hour. 
5.3.2.4 Additive effect of inhibitors on 7,8-dihydroneopterin uptake
To understand the additive effect of nucleoside transport inhibitors, and on cells we treated the 
cells with a combination of inhibitors. In U937 cells, DP and INDO together did not super 
induce inhibition of the 7,8-dihydroneopterin transport. As expected the inhibition of 7,8-
dihydroneopterin transport in the presence of all the 3 transporters was almost the same as the 
inhibition observed with DP (figure 5.19). As predicted from the individual inhibition profiles 
of all the inhibitors, there was inhibition observed by DP only at higher (1 µM) concentration. 
This reinforces the notion that 50-60% or most of the 7,8-dihydroneopterin enters U937 cells 
via ENT 2. A combination of inhibitors would have resulted in blocking of all the different 
types of transporters at one time, which ideally would inhibit all the relevant transporters 
involved in the 7,8-dihydroneopterin uptake.
With THP-1 cells, the inhibition of 7,8-dihydroneopterin uptake by NBMPR and DP, but not 
INDO, showed that the transport is equilibrative transporter mediated. Since there is no 
statistically significant difference between the inhibition by NBMPR and DP, and NBMPR 
specifically inhibits ENT 1 but DP inhibits both ENT 1 and ENT 2, it strongly suggests that 
ENT 1 is the major transporter for 7,8-dihydroneopterin in THP-1 cells. Similar percentage  
inhibition by NBMPR and DP together, as NBMPR alone suggests inhibition caused by DP is 
the inhibition of ENT 1. Absence of ENT 2 expression in THP-1 cells could also be possible, 
which could be verified in the future by western blotting. Presence of INDO along with 
NBMPR and DP increased the uptake slightly, the reason for which is still unclear. It is 
possible that some other transporters insensitive to of all the 3 inhibitors NBMPR, DP and 
INDO were upregulated in their presence (figure 5.20). This upregulation could also be a 
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result of cell cycle mediated regulation of other transporters as suggested for CNT 1 by Valdes 
et al., (Valdes et al., 2002). 
The observation that there is still  substantial uptake of 7,8-dihydroneopterin in U937 cells and 
THP-1 cells in the presence of both ENT and CNT transport inhibitors hints at alternative 
transporters or other unknown routes of 7,8-dihydroneopterin uptake. Effect was not additive 
most probably due to presence of only one type of transporter in U937 cells and THP-1 cells. 
5.3.3 Effect of serum and nutrient medium on 7,8-dihydroneopterin uptake
The dependence of nucleoside transport on serum was tested by measuring the uptake of 7,8-
dihydroneopterin in RPMI 1640 without 5% serum in U937 cells (figure 5.4). 7,8-
dihydroneopterin uptake was slightly lower in the absence of serum. Increased uptake in the 
presence of serum has been described by Strauss, (Strauss, 1974), in rabbit lung macrophages, 
where serum was proposed to open up the hidden sites for transport. Similar increased uptake 
due to increase in transport in the presence of serum was observed by Plagemann et al.,
(Plagemann et al., 1975) in Novikoff rat hepatoma cell line (N1S1-67). This increase was 
attributed to the cell cycle and growth dependent changes in the transport of nucleosides. 
These cell cycle dependent alterations in the transporter expression and rate of transport of 
these cells, could explain in part, why there was variation in the 7,8-dihydroneopterin uptake 
in U937 cells (figures 5.3, 5.4 and 5.5). Cell cycle dependent regulation of nucleoside 
transporters (CNT1) and its uptake of nucleoside-derived anticancer drugs has also been 
demonstrated by Valdes et al., (Valdes et al., 2002). The sites described as ‘hidden’ by Strauss 
(Strauss, 1974), might well be the increase in the number and expression of transport sites in 
presence of serum or activation (appearance) of new transporters or sites. Also as Ohashi et 
al., (Ohashi et al., 2011b) described in their work, how different ENT substrates compete with 
the transporters decreasing the transport of sepiapterin. This effect of nucleoside permeant’s 
competitive inhibition of NBMPR binding to erythrocyte membranes has also been 
demonstrated (Griffith and Jarvis, 1996). The same effect might explain the decrease in 7,8-
dihydroneopterin uptake observed in the presence of serum as nucleosides are also present in 
serum. 
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A time course of uptake of 7,8-dihydroneopterin was examined in a minimal medium like 
EBSS so as to observe if the absence of nutrients and serum affect the level of uptake in these 
cells. When the uptake in U937 cells in EBSS was compared to the uptake in RPMI 1640 only 
and RPMI 1640 with serum, it was observed that the uptake followed a similar profile till 3 
hours. After 3 hours, the uptake rate and the amount dropped in EBSS as compared to RPMI 
1640 as well as RPMI 1640 supplemented with serum. In EBSS, the uptake of 7,8-
dihydroneopterin rapidly increased till 6 hours, after which it steadily dropped at 24 hours. 
The distinct 7,8-dihydroneopterin uptake profile of THP-1 cells in RPMI 1640 supplemented 
with serum and in EBSS only as compared to U937 cells hints towards the involvement of two 
distinct transporter mechanisms has been described for the first time. The decreased uptake 
after 6 hours in U937 cells and after 12 hours in THP-1 cells, in part, might be due to loss of 
function and decreased rate of transport. The possibilities of increased rate of efflux as some 
of the transporters have been described as ‘bidirectional’ and ‘facilitative’. This also suggests 
that the nutrients other than glucose present in RPMI 1640 and serum, but absent in EBSS 
could play a role in keeping the transporter functions optimal. 
The effect of a minimal medium like EBSS only on the uptake and inhibition of 7,8-
dihydroneopterin in U937 cells and THP-1 cells revealed similar results (figure 5.6). Although 
the overall uptake was lower than that observed in RPMI 1640, the effect of inhibitors did not 
change. The overall uptake lowering could be due to lack of nutrients in EBSS. 
In U937 cells, DP caused 50% of the inhibition of 7,8-dihydroneopterin uptake observed, 
while NBMPR or INDO did not enhance its inhibitory effect (figure 5.19). In THP-1 cells, the 
change in the medium did not affect the transport characteristics in terms of the inhibitor effect 
on 7,8-dihydroneopterin transport (figure 5.20). NBMPR and DP were the effective inhibitors 
of 7,8-dihydroneopterin transport to a similar degree, and INDO did not. DP did not enhance 
the inhibition of 7,8-dihydroneopterin by NBMPR. In THP-1 cells, it was NBMPR alone that 
was responsible for the 40% inhibition. 
Substantial uptake of 7,8-dihydroneopterin in the presence of these inhibitors warrants more 
detailed investigation of the transporters or the non-transporter mediated routes involved in its 
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uptake and the differential expression patterns of various transporter subtypes in these 
macrophage like cell lines. 
This also brings to light that the overall reduction in the nutrients and absence of amino acids 
and vitamins does not alter the transport behavior of these transporters although their 
expression might be affected as in the studies of Sakowicz et al., (Sakowicz et al., 2004). This 
would be particularly important when monocytes enter the atherosclerotic site with limited 
nutrients from the blood stream which is replete with all the nutrients. 
Looking at the bigger picture, this shows that absence of nutrients or serum within the plaque 
environment could affect how 7,8-dihydroneopterin protects  monocytes/macrophages from 
the surrounding oxidative stress and aid in its progression. 
5.3.4 Importance of 7,8-dihydroneopterin uptake in protection from oxidative stress in 
U937 cells and THP-1 cells 
A lot research has been published in the literature about the role of 7,8-dihydroneopterin in 
protection of cellular oxidative stress and cell death (Baird et al., 2005, Gieseg et al., 1998, 
Gieseg et al., 1995, Gieseg et al., 2001). In cell, THP-1 cell-mediated oxidation of LDL 
described by Gieseg et al., (Gieseg and Cato, 2003) the protection seems to be extracellular. In 
U937 cells, where impact of oxidative stress leads to loss of thiols and proteins and cell death 
(Gieseg et al., 2002), protection could occur intracellularly. This protection of oxidative stress 
in cells could be intra- as well as extracellular. Although 7,8-dihydroneopterin has been shown 
to be a potent radical scavenger preventing LDL oxidation in vitro in culture, the mechanism 
of its entry into the cells for intracellular protection still remains unknown. So far there has 
been no research showing the possible gateways of 7,8-dihydroneopterin entry in to the cells 
and how they play a role in 7,8-dihydroneopterin mediated protection. 
U937 cells and THP-1 cells were subjected to oxidative stress by incubating them with AAPH 
(figure 5.23 and 5.24). AAPH is a free radical generator that generates peroxyl radicals at a 
constant rate at a certain concentration and temperature. It is water-soluble; heat labile, azo 
compound that undergoes thermal decomposition to produce carbon centered free radicals. 
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which could react with oxygen to produce alkoxyl or peroxyl radicals (Krishna et al., 1994, Li
et al., 2001, Feril et al., 2004).  Three possibilities exist for the free radicals thus generated. 
Firstly, they may react with the cell’s plasma membrane and initiate lipid and protein 
peroxidation. Secondly, the free radicals may react with the molecules present in the medium 
and form secondary oxidation products that could then continue the oxidation of the medium 
components or inflict the damage to the cells. Lastly, the radicals might react with each other 
to give a non-radical, neutral product and the free radical chain reaction could be terminated. 
All the three possibilities would exist in a medium full of nutrients and amino acids like RPMI 
1640, but in EBSS, which just has half the glucose as RPMI 1640 and salts, the second 
possibility is very limited. This would increase the ‘hits’ of free radicals onto the cells and 
their interaction with each other. Interestingly, previous studies comparing the damage of 
AAPH to cells in RPMI 1640 and EBSS revealed that the damage in both the cases was 
comparable, suggesting that the secondary oxidation products do not cause increased damage. 
AAPH may also be taken into the cells generating radicals within. 
Studies with U937 cells and AAPH in our laboratory by Duggan et al., (Duggan et al., 2001)
using EBSS as a medium showed that protein peroxidation provided a better explanation of 
cell viability loss. We hypothesize that AAPH inflicts the damage both inside and onto the cell 
surface, both of which could be protected in the presence of 7,8-dihydroneopterin as a radical 
scavenging antioxidant. Feril et al., (Feril et al., 2004) also observed increased intracellular 
peroxyl radicals as a result of ultrasound treatment of cells and suspected that AAPH could be 
taken up into the cells where free radicals are generated intracellularly when incubated at 
37ºC, as a plausible mechanism of cell killing and apoptosis. So for 7,8-dihydroneopterin to be 
protective to the cells, it has to be taken up into the cells where most of the damage happens. 
Damage by the free radicals in the medium, outside the cells cannot be completely ruled out, 
but as seen through the uptake of 7,8-dihydroneopterin and the protection provided by it to the 
U937 cells and THP-1 cells, it validates the intracellular mode of cell killing and oxidative 
stress mediated cell viability loss. 
Both the cell types were subjected to the same amount of radical flux. U937 cells were 
protected with increasing 7,8-dihydroneopterin concentrations reaching significance at 50 µM 
7,8-dihydroneopterin at both 6 and 12 hours (figure 5.23). In THP-1 cells there was no 
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protection at any of the 7,8-dihydroneopterin concentrations at 6 hours , but at 12 hours the 
protection was significant with 50 µM 7,8-dihydroneopterin (figure 5.24 A and B). THP-1 
cells protection by 7,8-dihydroneopterin was about 35% as opposed to the protection observed 
in U937 cells which was just about 24% as compared to just AAPH. The difference was that in 
U937 cells the protection brought the cell viability closer to the control levels than what was 
observed with THP-1 cells. 7,8-dihydroneopterin by itself also protects against the loss of cell 
viability possibly due to prevention of the normal cellular apoptosis (Gieseg et al., 2001). 
The difference between the observed protection could be due to the difference in their 7,8-
dihydroneopterin uptake at 6 and 12 hours in EBSS. If the uptake is compared at 6 hours, 
THP-1 cells take up just about 50% of 7,8-dihydroneopterin as compared to U937 cells. When 
the uptake at 12 hours is compared, it’s clear that THP-1 cells take up similar amount as U937 
cells (figure 5.6, 5.33 and 5.34). This suggest for protection from AAPH (10 mM) mediated 
oxidative stress and cell viability loss, there must be a certain amount of intracellular 7,8-
dihydroneopterin. From the uptake curves over 24 hours in EBSS medium, both U937 cells 
and THP-1 cells should take up approximately at least 100 pmoles/million cells to minimally 
begin to combat the oxidative flux generated intracellularly by 10 mM AAPH over 12 hours. 
When the 7,8-dihydroneopterin uptake is inhibited in U937 cells and THP-1 cells during 
oxidative stress using DP and NBMPR respectively (figure 5.25 and 5.26 respectively), it can 
be seen that the protection provided by 7,8-dihydroneopterin was significantly lost in U937 
cells. In THP-1 cells there was no protection provided by 7,8-dihydroneopterin against the 
AAPH mediated oxidative stress at 6 hours but at 12 hours the 7,8-dihydroneopterin mediated 
protection of about 15% was lost in presence of inhibitor NBMPR (figure 5.26). This is the 
evidence that 7,8-dihydroneopterin  site of action for protection against AAPH is intracellular. 
5.3.5 Neopterin uptake in U937 cells and THP-1 cells via nucleoside transporters
U937 cells and THP-1 cells also markedly differ in their profile of the uptake of the oxidized 
component of 7,8-dihydroneopterin, neopterin. U937 cells intracellular accumulation of 
neopterin is about 50% as compared to 7,8-dihydroneopterin accumulated (fig 5.31) and THP-
1 cells can accumulate about 40% more neopterin as compared to 7,8-dihydroneopterin 
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concentration when cultured in RPMI 1640 with 5% serum (figure 5.32). Also THP-1 cells 
show 100% more accumulation of neopterin than U937 cells in RPMI 1640 supplemented 
with serum, but about the same amount of uptake in EBSS only (figure 5.35 and 5.36 
respectively). In RPMI 1640 with serum, almost the entire 100% increased uptake of neopterin 
by THP-1 cells occurs between 6 and 12 hours, while in EBSS, uptake is reduced to about 
40% between 6 and 12 hours. This might be due to the differential effect of the media on the 
balance of transporters and their efflux transporters. RPMI 1640 with serum might confer 
increased affinity for neopterin as a substrate for the uptake transporters in THP-1 cells, and in 
U937 cells it’s the increased efflux which could reduce intracellular neopterin. Also the 
affinity and efficiency of neopterin as a substrate could differ due to the nutrients and glucose 
in the two media affecting their rates of uptake along with the transporter expressions (Strauss, 
1974, Sakowicz et al., 2004). In RPMI 1640 with serum, 7,8-dihydroneopterin is preferred 
more than neopterin by U937 cells while neopterin is slightly preferred over 7,8-
dihydroneopterin by THP-1 cells. 
This behavior of U937 cells and THP-1 cells is also seen in EBSS but with a twist.  U937 cells 
prefer 7,8-dihydroneopterin over neopterin and take up 6 times more 7,8-dihydroneopterin 
than neopterin (figure 5.33). Whereas THP-1 cells, prefer to accumulate 2 times more of 7,8-
dihydroneopterin than neopterin, which is completely different than what is observed in RPMI 
1640 with serum (figure 5.34 and 5.32). In EBSS the preferences for the two pterins as a 
substrate appears to stay the same in U937 cells but THP-1 cells   prefer to accumulate more 
7,8-dihydroneopterin concentrations inside the cells than neopterin (figure 5.34). This 
increased propensity for neopterin accumulation of THP-1 cells could render THP-1 cells 
more susceptible to oxidative stress in presence of oxidants as compared to U937 cells as 
neopterin has been proven to enhance the effect of oxidants on cells (Oettl and Reibnegger, 
2002). 
One should also consider the role of efflux transporters like ABC transporters in an increased 
efflux of neopterin as compared to its uptake in U937 cells and reduced efflux and increased 
uptake in THP-1 cells as a plausible mechanism, giving them distinct profiles observed with 
neopterin uptake. After all the intracellular accumulation of 7,8-dihydroneopterin and 
neopterin is the product of import as well as export processes and ABC family and its 
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members are known to play a role in nucleoside and nucleoside drug resistance by their ability 
to efflux nucleosides and their analogues (Fukuda and Schuetz, 2012). 
5.3.6 Inhibition of neopterin uptake in U937 cells and THP-1 cells 
Neopterin uptake inhibition in U937 cells by NBMPR suggests 25% of ENT 1 mediated 
uptake at 6 hours indicating neopterin as a substrate (figure 5.35). This was in contrast to our 
previous results of 7,8-dihydroneopterin uptake inhibition where there was no inhibition 
observed by NBMPR. Cell cycle dependent variation between the experiments and cellular 
differentiation cannot be ruled out as a possible modulator of transporters (Plagemann et al., 
1975, Jones et al., 1994, Valdes et al., 2002). DP also caused a further 25% inhibition of 
neopterin uptake, implicating ENT 2 mediated transport of neopterin. DP previously 
accounted for the entire 50% inhibition of 7,8-dihydroneopterin uptake in U937 cells.  A small 
portion of CNT mediated transport was also seen, which was inhibited by INDO, which was 
not observed previously with 7,8-dihydroneopterin (figure 5.35). 
In THP-1 cells as well, the neopterin uptake was inhibited by NBMPR, DP and INDO (figure 
5.36). Since our results suggest ENT 1 as the major transporter in THP-1 cells, neopterin could 
act as a substrate for ENT 1. It is highly possible that neopterin is a substrate for ENT's and 
CNT's. It was interesting that this inhibition of neopterin disappeared by the end of 12 hours, 
which testifies the probability that cell cycle dependent changes could result in increased 
neopterin uptake. This is in agreement of previous observation of increased uptake between 6 
to 12 hours, which might overcome the inhibitory effect. Since this uptake seems to be 
independent of ENT's and CNT's (figure 5.36). It’s possible that solute carrier family SLC 22 
transporter members OAT and OCT known to transport nucleoside analogues (Fukuda and 
Schuetz, 2012) might play a role in the increased uptake of these pterins during these times 
although decreased efflux could play its part in increasing intracellular accumulation. 
More recently there have been reports about PPAR• and PPAR• also regulating nucleoside 
transporter hENT 1 (Montero et al., 2012). Konopleva et al., (Konopleva et al. 2004) reported 
high expression levels of PPAR• in U937 cells while Inoue (Inoue et al., 2001) reported lack 
of PPAR• expression in them. THP-1 cells have been shown to possess PPAR• using PPAR• 
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activators to produce VEGF in the studies performed by (Inoue et al., 2001). So it is possible 
that ENT 1 is transiently expressed by our U937 cells. The disappearance of the inhibitory 
effect of neopterin in presence of the inhibitor after 12 hours could also be due to neopterin 
behaving as a competitive inhibitor of the ENT 2 itself, resulting in the dislodging of the 
inhibitor binding and the increased uptake. This is in accordance with the observation that 
many of the substrates of ENT's act as competitive inhibitors of each other (Ohashi et al., 
2011b). Neopterin could be a competitive inhibitor of ENT 2 as seen with the increase of 
intracellular neopterin between 6 and 12 hours in U937 cells. 
There is also a possibility that U937 cells and THP-1 cells both express ENT 1 transporters but 
the ability of these transporters to transport 7,8-dihydroneopterin, the dihydro-form of the 
pterin is a very limited as compared to its oxidized form as seen with the uptake of BP and its 
reduced dihydro-form BH2 in case of (Ohashi et al., 2011b). They found that the ranking order 
of the pterin transport was SP>BH2>BH4, which is what seems to happen in our experiments 
also. Difference in the uptake rates of 7,8-dihydroneopterin and neopterin in THP-1 cells as 
compared to U937 cells could be attributable to the properties of the transporters involved. 
7,8-dihydroneopterin seems to be a substrate of greater affinity for ENT 2 transporter, as 
compared to neopterin. While for ENT 1 transporters binding affinity and transport of 
neopterin and 7,8-dihydroneopterin is very similar. This specificity of preference of substrates 
by ENT's 1 and 2, are typical and could explain the different profiles and rates of uptake of 
both neopterin and 7,8-dihydroneopterin by U937 cells and THP-1 cells. As there was no 
increase in intracellular neopterin between 6 and 12 hours, it suggests that competitive 
inhibition of neopterin is limited to ENT 2 and does not affect ENT 1. This also seems to be 
the case with CNT's. Although 7,8-dihydroneopterin inhibition was not observed previously, 
inhibition of neopterin reveals the affinity of neopterin to CNT's and the possibility that 
neopterin could be a more preferred with greater affinity for CNT's.
The transporters function in a similar fashion in EBSS although the overall efficiency and 
uptake was expectedly lower in this medium. ENT 1, 2 and CNT's were involved in the 
neopterin transport in U937 cells at 6 hours but the CNT's inhibitor lost its potency with the 
inhibition as it was not statistically significant (figure 5.37). The absence of serum reduced 
neopterin uptake at 12 hours and also prevented any further increase of neopterin uptake in the 
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presence of inhibitors (figure 5.37). The drop in the uptake between 6 and 12 hours was also 
consistent as observed before. In THP-1 cells the NBMPR inhibition of ENT 1 mediated 
uptake of neopterin was stronger in EBSS medium (figure 5.38). ENT 1 was the major 
transporter of neopterin in THP-1 cells. Reduced inhibition by DP might be due to incomplete 
inhibition of NBMPR. CNT's mediated uptake of neopterin is also inhibited by INDO but it 
was not significant. With THP-1 cells in EBSS, there seemed to be a slight increase in 
presence of the CNT inhibitor (figure 5.37). This could be due to reduced efflux capacity of 
ABC transporters in the absence of serum as this effect of serum on ABC transporter efflux 
has been observed with protoporphyrin IX (Ogino et al., 2011). 
5.3.7 7,8-dihydroneopterin uptake and inhibition in human monocytes
Human monocytes took up 7,8-dihydroneopterin which was significantly inhibited by 
NBMPR as well as DP at 6 hours (figure 5.40). In this case, since the inhibition by ENT 2 is 
not as strong as ENT 1 could mean that ENT 1 is the major carrier of 7,8-dihydroneopterin in 
monocytes. There have been different isoforms of equilibrative transporters known to be 
expressed with differential binding capacity to the inhibitors (Kong et al., 2004) that could 
explain incomplete inhibition. It could also be that the CNT's uptake of 7,8-dihydroneopterin 
is enhanced with DP inhibiting the ENT mediated transport completely. INDO also inhibits 
the CNT’s mediated transport in monocytes, revealing that the 7,8-dihydroneopterin is a 
substrate for CNT's. All the inhibitors resulted in inhibition of 7,8-dihydroneopterin uptake 
comparable to the control cells. Virtually all the 7,8-dihydroneopterin uptake is inhibited by 
NBMPR and INDO, individually. So either there is no non-transporter mediated uptake of 7,8-
dihydroneopterin or complete inhibition of one inhibitor (ENT's in this case)  inhibits the 
uptake by the other (CNT's in this case) and vice versa. At 12 hours the inhibition disappears 
even in the presence of the inhibitors (figure 5.41). The cells with inhibitors take up similar 
amounts of 7,8-dihydroneopterin as the control monocytes. The increased uptake in the 
presence of INDO was unexpected. Since the Na+ ion mediated transport is completely 
blocked by INDO, cells might adapt by increase in the non-transporter mediated or 
equilibrative transporter mediated uptake of 7,8-dihydroneopterin. 
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It was an interesting observation that monocytes took up twice as much 7,8-dihydroneopterin 
in EBSS only medium as compared to RPMI 1640 with serum at 6 hours (figure 5.44 and 
5.40). Almost 90% of 7,8-dihydroneopterin uptake was mediated via NBMPR sensitive 
transporter. CNT inhibition also blocked about 90% of the 7,8-dihydroneopterin uptake as 
observed in RPMI 1640 with serum. DP inhibition was less as compared to NBMPR and 
INDO, which points at less affinity and incomplete blocking of ENT 1. Non-specific uptake 
via other transporters or non-transport mechanism at higher concentrations could account for 
about 10%.  CNT 1 and CNT 2 are co-expressed in macrophages (Aymerich et al., 2005). 
Soler et al., (Soler et al., 2001) have also reported the expression of ENT 1 and ENT 2 
transporters along with CNT 1 and CNT 2 in mouse macrophages which were differentially 
regulated by IFN-•. 
However, Moreau et al., (Moreau et al., 2011b) have extensively characterized nucleoside 
transporters and ABC transporters in human macrophages and monocytes. Of the nucleoside 
transporters, human monocytes were found to express ENT 3 and CNT 3 and of the ABC 
transporters they express ABCC1, ABCC3, ABCC4 and ABCC5 which form a part of 
multidrug resistance protein family. Apart from the above transporters, monocytes were also 
found to express some OAT’s, OCT’s, MCT’s PHT’s and PEPT’s (Moreau et al., 2011b). 
ENT- 3 was found to be expressed at an intermediate level (10-50 arbitrary units), while CNT 
3 was found at a lower expression level (2-10 arbitrary units). Moreau et al., (Moreau et al., 
2011b) found no difference in GM-CSF derived or M-CSF derived macrophages in terms of 
their transporters.  This fits in nicely with our observation that there is Na+ ion mediated 
transport which is INDO sensitive, suggesting the involvement of CNT 3. But we observed 
NBMPR-sensitive transport that was strongly inhibited, which implicates ENT 1 in 7,8-
dihydroneopterin transport in monocytes (figure 5.442). More detailed investigation of 
expression of ENT 1 m-RNA and protein is needed to ascertain the presence of ENT 1. 
Another group (Flanagan and MecklingGill, 1997) reported the presence of a NBMPR-
sensitive, guanosine transporting concentrative nucleoside transporter system (N5 or CNT 5) 
in human acute promyelocytic leukemia cells. Going by our results of similar amount of 7,8-
dihydroneopterin uptake inhibition by NBMPR and INDO, it seems that the transporter 
responsible for the 7,8-dihydroneopterin uptake in these monocytes could be CNT 5 and ENT 
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1 might be absent as found in monocyte studies of Moreau et al. There have been arguments 
about the existence of additional concentrative transport systems (CNT 4 and CNT 5), as no 
evidence has been found for additional CNT type related genes in the human genome. CNT 4 
and CNT 5 are suspected to be the putative polymorphic variants of the 3 known CNT 
members or associated with other non-related family of transporter proteins (Pastor-Anglada
et al., 2008). If ENT 1 is absent in our monocytes, inhibition by DP suggests the presence of 
ENT 2 or other DP sensitive transporters of ENT family like ENT 3 or ENT- 4. 
Overall we can conclude that monocytes do transport 7,8-dihydroneopterin via a CNT 
mediated component and an ENT mediated transporter component. From our experiments, 
ENT component most probably could be ENT 2 while CNT component responsible for 7,8-
dihydroneopterin uptake is most likely to be CNT 5 based on its NBMPR sensitivity. 
Increased neopterin in 7,8-dihydroneopterin control cells and cells with inhibitor and 7,8-
dihydroneopterin in EBSS suggests that the cells were under some kind of oxidative stress, 
which caused the 7,8-dihydroneopterin to be oxidized to neopterin in both RPMI 1640 and 
EBSS. The neopterin increase in the different treatments were more or less proportional to the 
7,8-dihydroneopterin taken up, suggesting that it was this 7,8-dihydroneopterin that was used 
up during the oxidative stress. 
The observed increase in the uptake of 7,8-dihydroneopterin in the presence of the inhibitors 
between 6 and 12 hours (figure 5.45) might be due to the trafficking, internalization, recycling 
and degradation of transporters as described for hENT 1 by Nivillac et al., (Nivillac et al., 
2011). As reported by Nivillac et al., (Nivillac et al., 2011) the half-life of hENT 1 transporter 
is ~7 hours, which is probably why we see the inhibition of uptake being significant around 
that time. It is after 6 hours that the protein is internalized, a proportion of it being recycled 
back to the plasma membrane, with the other proportion is sent for degradation. This recycling 
and turnover of hENT 1 is suspected as the localization of hENT 1 is not continuous on the 
plasma membrane. The hENT 1 content of human cancer cells, in culture appears to be co-
ordinated with the cell cycle, levels of transporter approximately doubling between the G1 and 
G2-M phases (Baldwin et al., 2004, Young et al., 2008). It could be that monocytes are also in 
their transition from G1 to G2-M phase between 6-12 hours; however there is little evidence to 
corroborate the same. The increase in the 7,8-dihydroneopterin uptake between 6 and 12 hours 
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could represents the non-transporter mediated uptake, as a portion of transporters is being 
degraded. 
It has also been proposed that distinct populations of hENT 1 exist at the plasma membrane 
with subtle differences in the binding of NBMPR, which could mediate the uptake (Boumah et 
al., 1992). This measurement of 7,8-dihydroneopterin is halfway between the time points 
where the uptake and efflux have not yet reached their complete equilibrium due to the cell 
cycle changes the transporter types and subtype expression. Also the heterogeneity between 
the monocyte populations obtained from different donors could also explain the variation in 
the uptake profiles of 7,8-dihydroneopterin by the monocytes in RPMI 1640 and EBSS. 
5.3.8 7,8-dihydroneopterin protects human monocytes from AAPH mediated cell 
viability loss
AAPH (10 mM) induced oxidative stress caused a loss in the cell viability of human 
monocytes cultured in EBSS media (figure 5.46). Most of the AAPH killing of monocytes 
(40%) occurred within 6 hours, with just 5% more killing between 6 and 12 hours. 7,8-
dihydroneopterin did protect the cells against the AAPH mediated cell viability loss. 
Protection by 7,8-dihydroneopterin against the AAPH induced oxidative stress was better at 6 
hours than at 12 hours (figure 5.46). Protection due to 7,8-dihydroneopterin at 6 hours was 
about 40% and brought the cell viability back up to the control cells but at 12 hours the 
protection dropped down to just 25%.  This was in spite of the previous observation that at 12 
hours, control monocytes took up 3 times more 7,8-dihydroneopterin as compared to 6 hours. 
The batch to batch variation of monocytes may have played a role in the uptake of 7,8-
dihydroneopterin and thus its protection in this case. It could be that this batch of monocytes
did not take up as much of 7,8-dihydroneopterin as the previous batch. Also as observed 
before, cells also seemed to be under more oxidative stress at 12 hours as 2 times more 
neopterin was detected in control monocytes at 12 hours as compared to 6 hours, even without 
any AAPH added to the medium. With AAPH addition the oxidative stress at 6 hours would 
be considerably less than the oxidative stress at 12 hours. Consequently the amount of 7,8-
dihydroneopterin used to dissipate this oxidative stress would be more at 12 hours than at 6 
hours. This increased intracellular oxidative flux might explain the reduced protection of 7,8-
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dihydroneopterin with the 2nd batch of monocytes, simply due to increased oxidative stress in 
a nutritionally starved media. 
5.3.9 Inhibition of 7,8-dihydroneopterin uptake by nucleoside transport inhibitors 
abrogates its protection of AAPH mediated cell viability loss 
Inhibition of 7,8-dihydroneopterin uptake at 6 hours did reduce the protection from 40% to 
15% with the individual inhibitors tested (figure 5.48). This residual of 15% protection could 
have been due to 7,8-dihydroneopterin uptake mediated by non-transporters or other types of 
transporters. At 12 hours, the entire 25% of protection provided by 7,8-dihydroneopterin was
lost when inhibitors were used to block the 7,8-dihydroneopterin uptake (figure 5.48). This 
shows that uptake of 7,8-dihydroneopterin is essential for its protection against AAPH induced 
oxidative stress and subsequent loss of cell viability. 
There was no protection provided by the inhibitors themselves on AAPH mediate cell toxicity 
in the absence of 7,8-dihydroneopterin (figure 5.47). 
5.3.10 Summary
We have shown that 7,8-dihydroneopterin is one of the substrates of equilibrative nucleoside 
proteins in U937 cells, THP-1 cells and human monocytes. In U937 cells it is ENT 2, in THP-
1 cells 7,8-dihydroneopterin transport is ENT 1 mediated. CNT mediated uptake inhibition 
was absent in these cells. In human monocytes, strong inhibition of 7,8-dihydroneopterin 
uptake was observed with all the 3 inhibitors, but it is difficult without further studies to 
confirm the presence of all the 3 transporters. As Moreau et al., (Moreau et al., 2011a) have 
explained, the uptake is most probably mediated by ENT 3 and CNT 3. Since the location of 
ENT 3 is predominantly intracellular in location (Young et al., 2013) and CNT 3 is widely 
distributed in cells and tissues (Young et al., 2013), it appears to be CNT 3 which takes 7,8-
dihydroneopterin as its substrate. Since there was specific inhibition by NBMPR and DP, ENT 
1 and ENT 2 mediated uptake could not be completely ruled out. So prima facie it appears that 
both ENT’s and CNT’s could be involved in the transport of 7,8-dihydroneopterin across the 
plasma membrane in human monocytes. The subtypes of the transporters involved could also 
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make a big difference to the 7,8-dihydroneopterin transport efficiency and susceptibility of 
cells to oxidative stress as found with the potency of the nucleoside transport drug inhibitors 
(Sinclair et al., 2001). Also nucleoside transporters are indispensible for uptake and AAPH 
mediated oxidative stress protection provided by 7,8-dihydroneopterin in U937 cells, THP-1 
cells and human monocytes.
Finally, let us assume U937 cells as representatives of cells that cannot produce 7,8-
dihydroneopterin and THP-1 cells as representatives of cells that are still able to produce 7,8-
dihydroneopterin. If both the types of cells are subjected to oxidative stress using AAPH, 
nucleoside transporter mediated uptake of surrounding 7,8-dihydroneopterin is important for 
both the cell types. Even when the monocyte/macrophage cells in the oxidative milieu are able 
to produce 7,8-dihydroneopterin under IFN-• stimulation, nucleoside transporter mediated 
uptake of 7,8-dihydroneopterin could come in handy to the cells so as to combat the 
intracellular oxidative stress and prevent cell death and progression of plaque. 
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6. FUTURE STUDIES
This research has shown that U937, THP-1 cells and monocytes protection by exogenous 7,8-
dihydroneopterin from oxidative stress is dependent on the transport/uptake of 7,8-
dihydroneopterin into the cells via nucleoside transporters. Macrophages and monocytes 
readily produce 7,8-dihydroneopterin but it appears that some areas of the plaque have very 
low levels this pterin. The production is dependent on T-cells ability to generate interferon 
suggesting that where T-cell activity or concentration is low, cells generating 7,8-
dihydroneopterin in one region can protect cells in another region by the uptake of 
extracellular 7,8-dihydroneopterin. This could be examined using live plaque culture where 
the tissue is placed under oxidative stress and the ability of exogenous 7,8-dihydroneopterin to 
protect would be examined using the procedures described in the chapter 5. The addition of 
the various inhibitors described in this chapter would further measure the effect of both 
intracellular and extracellular 7,8-dihydroneopterin in that protection. The oxidative stress 
could be provided using radical generators such as AAPH or oxLDL itself. Measurement of 
the oxidation of 7,8-dihydroneopterin to neopterin and dihydroxanthopterin in plaque culture 
would give direct measure of the nature of the oxidant scavenging in situ.
Biochemical analysis of plaque showed that 7,8-dihydroneopterin varies across throughout the 
plaque sections, with some sections having very high 7,8-dihydroneopterin content while 
some sections with very low 7,8-dihydroneopterin content. When 7,8-dihydroneopterin is 
present in higher amounts in plaques, it should ideally protect monocytes/macrophages from 
the oxidative insult. It has been shown in the previous studies that 7,8-dihydroneopterin 
concentrations tends to be lower around the bifurcation regions of plaque where the oxidative 
stress generally tends to be higher. This lower 7,8-dihydroneopterin production could be due 
to impaired IFN-• production by the T-cells. T-cells have also been found along with 
macrophages in carotid plaques (Rekhter and Gordon, 1995) and are the major source of IFN-
• that results in 7,8-dihydroneopterin production. In plaque tissue the role of T-cells in 
macrophage protection by 7,8-dihydroneopterin becomes critical. This hypothesis should be 
tested first in isolated T-cells to verify if the ability of T-cells to produce IFN-• is impaired by 
oxidative stress. To test this hypothesis of T-cell dependent IFN-• production and 
subsequently 7,8-dihydroneopterin production in actual plaque tissue would be examined. The 
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plaque tissue would be stimulated with IFN-• activating agents such as phorbol esters that 
trigger IFN-• release by T-cells.
This would elucidate if the hypothesis that oxidative stress in plaque tissue is exacerbated by 
impairment of T-cells through decreased 7,8-dihydroneopterin production holds true in vivo.  
This will also open up another avenue of research to protect macrophages via T-cell 
stimulation to boost the 7,8-dihydroneopterin amounts in the plaque tissue to modulate its 
progression. This would be particularly important where the 7,8-dihydroneopterin levels are 
insufficient in certain plaque sections where oxidative is high and 7,8-dihydroneopterin levels 
are lower. 
Further characterization of the nucleoside transporter profile of U937 cells and THP-1 cells 
using Western blotting would corroborate the findings in this thesis. Also a possible follow up 
experiments using siRNA knockout studies to knock out different transporters in 
monocytes/macrophages would elucidate further transporters that could be involved in 7,8-
dihydroneopterin transport and oxidative stress protection. 
Also since nucleosides are the natural substrates to the transporters and could be competitive 
inhibitors of the inhibitors, it would be interesting to perform competitive inhibition 
experiments to demonstrate if physiological nucleosides play a role in uptake inhibition of 7,8-
dihydroneopterin in human monocytes/macrophages. 
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APPENDIX 
Table A.1 Correlation of Inflammatory and Oxidative Markers within Plaques A-K
Significant correlations were determined based on the average of each section a (n=3) within 
plaques A-E. N is the number of sections within each plaque. Combined plaque analysis was 
performed on plaques A-N, P-R, where N is the collated number of sections of the plaques. 
For neopterin correlations plaques F-I were excluded. For AAS and GGS protein carbonyls 
correlations only data from plaques from A-E was analyzed, and for 7-ketocholesterol 
correlations only data from plaques B-E was analyzed. Protein was expressed in mg/g plaque, 
cholesterol µmole/g plaque and neopterin, •-tocopherol, TBARS, DOPA, Dityrosine, AAS 
and GGS protein carbonyls and 7-ketocholesterol as nmole/g plaque. Statistical significance 
represented by P<0.05 * P<0.01 ** P<0.001 *** 
Markers r(Pearson) P value N
Plaque A
Neopterin vs. Total pterin 
Neopterin vs. TBARS
Total pterin vs. TBARS
TBARS vs. Total KC
Cholesterol vs. •-tocopherol
Plaque B
Neopterin vs. DOPA
Neopterin vs. Free 7-ketocholesterol
Neopterin vs. •-tocopherol
TBARS vs. Total 7-ketocholesterol
Cholesterol vs. •-tocopherol
DOPA vs. •-tocopherol
Plaque C
Total pterin vs. TBARS
Total pterin vs. Protein
Total pterin vs. Cholesterol
0.9942
0.8568
0.8972
0.8897
0.9662
-0.7813
-0.8357
-0.7733
0.9113
0.9223
0.8180
0.7115
0.8484
0.6740
0.0001
0.0290
0.0150
0.0180
0.0020
0.0380
0.019
0.041
0.0040
0.0030
0.025
0.032
0.004
0.046
***
*
*
*
**
*
*
*
**
**
*
*
**
*
6
6
6
6
6
7
7
7
7
7
7
9
9
9
334
Total pterin vs. •-tocopherol
TBARS vs. Protein
-0.9183
0.7246
0.0001
0.027
***
*
9
9
Table A.1 Continued-Correlation of Inflammatory and Oxidative Markers within 
Plaques A-K
Markers r(Pearson) P value N
TBARS vs. Cholesterol
Protein vs. DOPA
Protein vs. AAS protein carbonyl
Protein vs. •-tocopherol
Cholesterol vs. Free 7-ketocholesterol
Cholesterol vs. •-tocopherol
DOPA vs. AAS protein carbonyl
Plaque D
Neopterin vs. Free 7-ketocholesterol
TBARS vs. Cholesterol
TBARS vs. DOPA
TBARS vs. GGS protein carbonyl
DOPA vs. AAS protein carbonyl
AAS vs. GGS protein carbonyl
Free vs. Total 7-ketocholesterol
Free KC vs. •-tocopherol
Plaque E
Neopterin vs. Total pterin
Neopterin vs. Dityrosine
Total pterin vs. Dityrosine
DOPA vs. AAS protein carbonyl
DOPA vs. Free 7-ketocholesterol
DOPA vs. •-tocopherol
0. 8550
0.7845
0.7934
-0.8266
0.7100
-0.6764
0.8430
0.7697
0.7840
-0.8083
-0.7989
0.7623
0.8989
0.7648
0.9111
-0.9178
0.9358
-0.7891
0.8596
0.9061
0.8596
0.003
0.012
0.011
0.006
0.032
0.045
0.004
0.043
0.037
0.028
0.031
0.046
0.006
0.045
0.004
0.004
0.002
0.035
0.013
0.005
0.013
**
*
*
**
*
*
**
*
*
*
*
*
**
*
**
**
**
*
*
**
*
9
9
9
9
9
9
9
7
7
7
7
7
7
7
7
7
7
7
7
7
7
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AAS vs. Free 7-ketocholesterol
GGS vs. Total 7-ketocholesterol
Free vs. Total 7-ketocholesterol
Free KC vs. •-tocopherol
Plaque F
Total pterin vs. TBARS
Total pterin vs. Protein
Total pterin vs. Cholesterol
Total pterin vs. AAS protein carbonyl
Total pterin vs. Total 7-ketocholesterol
TBARS vs. Protein
TBARS vs. Cholesterol
TBARS vs. AAS protein carbonyl
TBARS vs. Free 7-ketocholesterol
TBARS vs. Total 7-ketocholesterol
Protein vs. Cholesterol
Protein vs. AAS protein carbonyl
Protein vs. Free 7-ketocholesterol
Protein vs. Total 7-ketocholesterol
Cholesterol vs. AAS protein carbonyl
Cholesterol vs. Total 7-ketocholesterol
AAS vs. Free 7-ketocholesterol
AAS vs. Total 7-ketocholesterol
Plaque G
Neopterin vs. Protein
Neopterin vs. Cholesterol
Neopterin vs. AAS protein carbonyl
Neopterin vs. GGS protein carbonyl
Protein vs. Cholesterol
0.8482
0.9101
0.7988
0.8482
0.7713
0.8803
0.9239
0.6912
0.9546
0.9368
0.8934
0.7219
0.7151
0.7727
0.9701
0.8014
0.7090
0.8622
0.7158
0.8727
0.7049
0.6750
0.9401
0.9863
0.9601
0.8817
0.8907
0.016
0.004
0.031
0.016
0.015
0.0020
0.0001
0.0390
0.0001
0.001
0.0001
0.0280
0.0300
0.0150
0.0001
0.0090
0.0320
0.0030
0.0300
0.002
0.034
0.046
0.0170
0.0020
0.0100
0.0480
0.0430
*
**
*
*
*
**
***
*
***
**
***
*
*
*
***
**
*
**
*
**
*
*
*
**
*
*
*
7
7
7
7
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
9
5
5
5
5
5
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Protein vs. DOPA
Cholesterol vs. AAS protein carbonyl
Cholesterol vs. GGS protein carbonyl
AAS vs. GGS protein carbonyl
Free vs. Total 7-ketocholesterol
Plaque H
Total pterin vs. TBARS
Total pterin vs. Total 7-ketocholesterol
Protein vs. Cholesterol
Protein vs. AAS protein carbonyl
Protein vs. Free 7-ketocholesterol
Cholesterol vs. AAS protein carbonyl
Cholesterol vs. Free 7-ketocholesterol
AAS vs. GGS protein carbonyl
AAS vs. Free 7-ketocholesterol
Plaque I
Neopterin vs. Cholesterol
Neopterin vs. •-tocopherol
Total pterin vs. GGS
Total pterin vs. Free 7-ketocholesterol
Protein vs. DOPA
Cholesterol vs. •-tocopherol
GGS vs. Free 7-ketocholesterol
Free vs. Total 7-ketocholesterol
Plaque J
Neopterin vs. AAS carbonyl
Neopterin vs. •-tocopherol
0.8932
0.9849
0.9417
0.9738
0.9310
0.9559
0.8188
0.9184
0.9193
0.8726
0.8823
0.9131
0.9386
0.9812
-0.9024
-0.8940
0.9857
0.8986
0.9537
0.9895
0.9179
0.9441
0.010
-0.9636
0.0410
0.0020
0.0170
0.0050
0.0220
0.0030
0.0460
0.0100
0.0100
0.0230
0.0200
0.0110
0.0060
0.0010
0.0360
0.0410
0.0020
0.0380
0.0120
0.0010
0.0280
0.0160
0.0100
0.0080
*
**
*
**
*
**
*
*
*
*
*
*
**
**
*
*
**
*
*
**
*
*
*
**
5
5
5
5
5
6
6
6
6
6
6
6
6
6
5
5
5
5
5
5
5
5
5
5
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Total pterin vs. GGS
Cholesterol vs. DOPA
Cholesterol vs. AAS carbonyl
Cholesterol vs. GGS carbonyl
Cholesterol vs. •-tocopherol
AAS vs. GGS protein carbonyl
AAS vs. •-tocopherol
Plaque K
Neopterin vs. Cholesterol
TBARS vs. Cholesterol
TBARS vs. AAS protein carbonyl
Protein vs. GGS protein carbonyl
Free 7-ketocholesterol vs. •-tocopherol
-0.9616
-0.9375
0.9355
0.8976
0.9271
0.9038
0.9298
0.9993
0.9972
0.9980
-1.0000
-0.9970
0.0090
0.0190
0.0190
0.0390
0.0230
0.0350
0.0220
0.0240
0.0480
0.0280
0.0050
0.0490
**
*
*
*
*
*
*
*
*
*
**
*
5
5
5
5
5
5
5
3
3
3
3
3
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Table A.2 Summary of Plaques (1-29) Plaques 1-10 and control in the following tables were 
analyzed during this study (which are represented in the thesis as plaques A-K), Plaques 11-15 
were analyzed by Genet (2010), 16-17 by Firth (2006), Plaques 18-23 were analyzed by 
Flavall (2008) and plaques 24-29 by Crone (2008).
Plaque Plaque
No.
Plaque
Database
No.
Total
Mass 
(g)
Morp. Comp. Sections
N
Location
Carotid Femoral
1 25 27 0.948 Linear Calcified 6 Þ
2 26 30 1.270 Y Thrombus 7 Þ
3 27 26 0.667 Y Neither 9 Þ
4 28 38 1.071 Linear Calcified 7 Þ
5 29 41 1.376 Y Thrombus 7 Þ
6 30 44 1.507 Y Thrombus 9 Þ
7 31 54 2.616 Linear Calcified 5 Þ
8 32 59 1.435 Linear Calcified 6 Þ
9 33 64 0.852 Y Neither 5 Þ
10 34 66 3.240 Linear Calcified 5 Þ
Control 35 52 0.441 Y Neither 3 Þ
11 18 18 1.179 Small Neither 9 Þ
12 19 19 0.406 Y Neither 6 Þ
13 21 21 0.167 Linear Neither 4 Þ
14 23 23 0.536 Small Calcified 6 Þ
15 24 24 0.914 Small Neither 6 Þ
16 3 3 0.909 Linear Neither 6 Þ
17 4 4 2.857 Linear Calcified 7 Þ
18 5 5 1.500 Small Neither 8 Þ
19 6 6 0.763 Small Thrombus 7 Þ
20 7 7 1.306 Small Calcified 7 Þ
21 8 8 0.822 Y Thrombus 6 Þ
22 9 9 0.597 Y Calcified 6 Þ
23 10 10 0.377 Small Thrombus 6 Þ
24 11 11 1.156 Y Calcified 8 Þ
339
25 12 12 0.472 Linear Calcified 3 Þ
26 14 14 0.814 Linear Neither 7 Þ
27 15 15 1.238 Y Thrombus 7 Þ
28 16 16 0.943 Small Thrombus 8 Þ
29 17 17 0.692 Linear Unknown Whole Þ
Table A.3 Summary of the Average Overall Concentrations of Protein, Cholesterol, 
Neopterin, Total Pterin, •-Tocopherol and TBARS in Plaques 1-29. Control plaque was 
excluded while calculating the overall average.Data represents mean ± SEM of the average 
of all the sections in a plaque. ND = Not detected.Neopterin and Total pterin values from 
plaques 11-29 were multiplied by 1000 to represent them in pmoles/g plaque. 
Plaque
No.
Protein
mg/g plaque
Cholesterol
µmole/g 
plaque
Neopterin &
Total Pterin
pmole/g plaque
•-
Tocopherol
nmole/g 
plaque
TBARS
nmole/g 
plaque
1 80.48 ± 7.82 12.89 ± 2.22 117 ± 94.45
274 ± 125.91
70.47 ± 8.89 2.54 ± 0.55
2 116.16 ± 10.86 90.12 ± 
14.06
4.60 ± 0.24
58.46 ± 4.68
123.14 ± 
20.62
74.03 ± 8.09
3 167.92 ± 13.95 358.55 ± 76 550.59 ± 299.10
4761.16 ± 
2021.7
66.24 ± 
13.97
20.44 ± 4.62
4 57.26 ± 5.94 27.81 ± 1.76  65.02 ± 1.82
241.62  ± 17.66
92.99 ± 
19.11
3.02 ± 0.28
5 101.25 ± 12.14 96.26 ± 6.99 169.25 ± 38.42
1580.39 ± 
192.34
208.08 ± 
16.97
5.66 ± 0.54
6 107.66 ± 14.51 142.08 ± 
22.84
ND
287.12 ± 11.95
192.74 ± 
44.66
12.94 ± 2.18
7 20.63 ± 2.38 4.50 ± 1.05 35.92 ± 6.76
338.97 ± 33.52
7.23 ± 1.39 1.90 ± 0.25
8 29.84 ± 1.75 12.89 ± 1.74 71.06 ± 12.94
236.04 ± 28.23
13.54 ± 3.85 2.75 ± 0.40
9 47.00 ± 2.60 40.83 ± 168.63 ± 17.20 22.07 ± 3.66 ± 0.5
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10.86 569.01 ± 39.46 10.64
10 33.33 ± 3.45 7.03 ± 0.84 92.97 ± 5.97
259.45 ± 16.68
12.10 ± 2.17 0.26 ± 0.04
Control 148.18 ± 22.72 18.81 ± 2.05 169.35 ± 16.46
424.63 ± 16.91
4.28 ± 0.26 1.24 ± 0.22
11 93.68 ± 3.80 58.99 ± 6.85 1770 ± 130
Not measured
139.41 ± 
13.45
4.75 ± 0.17
12 136.34 ± 7.09 32.10 ± 2.56 ND
ND
86.52 ± 7.78 4.73 ± 0.45
13 119.93 ± 15.09 34.93 ± 8.49 ND
10 ± 0.00
157.84 ± 
23.46
8.00 ± 0.03
14 151.1 ± 21.98 52.90 ± 4.39 60 ± 10
200 ± 60
235.08 ± 
26.21
10.99 ± 2.60
15 86.20 ± 3.63 62.87 ± 3.53 50 ± 10
130 ± 30
151.67 ± 
10.14
3.88 ± 0.25
16 77.62 ± 4.49 37.15 ± 5.01 210 ± 10* 32.33 ± 4.96 4.59 ± 0.70
17 66.71 ± 4.02 84.75 ± 
12.10
160 ± 0.010* 44.49 ± 2.84 3.39 ± 0.41
18 70.30 ± 6.19 75.82 ± 8.21 90 ± 0.00* 57.04 ± 6.57 7.48 ± 0.77
19 92.04 ± 5.13 80.89 ± 6.38 210 ± 10* 37.94 ± 5.72 7.43 ± 1.13
20 64.26 ± 2.20 57.95 ± 4.47 1590 ± 110 127.09 ± 
6.84
4.53 ± 0.85
21 92.14 ± 3.22 47.42 ± 3.28 1790 ± 150 213.09 ± 
6.84
7.13 ± 1.15
22 94.78 ± 13.10 25.81 ± 2.20 1260 ± 180 60.00 ± 5.54 14.28 ± 1.59
23 140.33 ± 5.45 29.31 ± 3.95 920 ± 60 152.27 ± 
10.42
15. 49 ± 1.61
24 69.23 ± 7.06 7.85 ± 0.38 2340 ± 410 21.84 ± 1.66 21.31 ± 4.41
25 45.16 ± 6.02 6.68 ± 0.69 1570 ± 160 9.64 ± 1.79 76.32 ± 
16.49
26 104.29 ± 6.14 43.39 ± 4.94 2020 ± 150 161.70 ± 
16.27
12.31 ± 1.24
27 120.47 ± 4.10 64.21 ± 2.34 1930 ± 150 95.40 ± 5.25 12.16 ± 0.30
28 186.59 ± 22.78 44.86 ± 4.46 2000 ± 290 200.56 ± 
25.30
4.20 ± 0.29
29 91.76 ± 4.04 92.61 ± 0.41 720 ± 10 360.20 ± 
24.74
9.84 ± 0.68
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Overall
Average
91.87 ± 7.61 59.77 ± 7.68  688.44 ± 80.23
639.01 ± 184.43
103.88 ± 12 12.41 ± 1.7
Table A.4 Summary of Protein and lipid oxidation products (Plaque 1-29).Plaques A-K 
were analysed in this study. Data represents Mean ± SEM of the section averages. ND = Not 
detected.
Plaque
No.
DOPA
nmole/g 
plaque
Dityrosine
nmole/g 
plaque
AAS 
GGS
nmole/g 
plaque
General 
Protein 
Carbonyls
Free 7-KC
Total 7-KC
nmole/g plaque
1 10.34 ± 1.30 2.94 ± 0.32 41.76 ± 4.998.62 ± 1.39
23.04 ± 8.67
90.93 ± 16.65
2 16.41 ± 5.79 5.55 ± 0.67 84.78 ± 9.3814.56 ± 1.31
65.49 ± 12.40
673.69 ± 125.6
3 25.01 ± 2.80 4.32 ± 1.20 70.54 ± 9.3816.87 ± 1.81
62.86 ± 16.25
638.65 ± 
129.23
4 14.57 ± 2.92 1.57 ± 0.09 50.46 ± 2.8720.16 ± 2.38
42.54 ± 14.04
101.38 ± 12.59
5 22.02 ± 3.09 7.51 ± 2.98 85.11 ± 8.2825.16 ± 4.73
78.13 ± 10.16
373.75 ± 70.68
6 13.52 ± 1.92 1.83 ± 0.46 83.14 ± 11.7019.19 ± 1.48
66.25 ± 9.22
301.92 ± 59.11
7 6.72 ± 1.28 0.13 ± 0.03 4.86 ± 1.272.06 ± 0.44
39.88 ± 8.26
78.58 ± 23.16
8 2.39 ± 0.16 ND 12.99 ± 2.726.62 ± 1.04
44.87 ± 14.06
229.31 ± 51.38
9 21.19 ± 4.05 0.92 ± 0.10 18.63 ± 0.9763.53 ± 3.54
185.49 ± 24.98
366.13 ± 37.41
10 1.51 ± 0.12 0.25 ± 0.04 2.92 ± 0.332.04 ± 0.29
33.83 ± 2.53
52.96 ± 7.74
Control 3.92 ± 0.78 0.84 ± 0.04 30.37 ± 3.379.17 ± 1.17
46.56 ± 26.62
128.80 ± 14.15
11 13.15 ± 0.75 2.19 ± 0.70 59.29 ± 7.0225.69 ± 5.24
12 7.99 ± 1.49 7.77 ± 1.59 109.25 ± 9.4815.39 ± 1.32
56.03 ± 9.60
190.03 ± 26.63
13 24.69 ± 1.64 6.19 ± 0.76 28.77 ± 3.023.65 ± 0.37
15.55 ± 2.04
63.84 ± 4.96
14 27.29 ± 1.60 2.70 ± 0.37 99.78 ± 14.2442.45 ± 3.24
74.85 ± 22.48
157.53 ± 39.60
15 8.86 ± 0.48 3.17 ± 0.32 36.87 ± 1.8415.33 ± 0.81
108.32 ± 9.18
454.84 ± 48.64
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16 12.79 ± 0.66 0.50 ± 0.10 161.52 ± 25.88
17 11.58 ± 0.67 4.86 ± 1.21 357.32 ± 19.78
18 15.66 ± 0.71 0.59 ± 0.14 310.21 ± 32.37
19 29.13 ± 3.45 11.62 ± 2.92 140.86 ± 13.26
20 4.93 ± 0.61 0.91 ± 0.15 287.52 ± 25.25
21 15.50 ± 3.47 8.86 ± 1.54 445.04 ± 50.85
22 7.59 ± 1.96 ND 276.18 ± 46.51
23 10.80 ± 0.70 9.19 ± 0.89 389.90 ± 38.25
24 6.44 ± 0.76 0.05 ± 0.03 266.54 ± 62.89
25 7.01 ± 0.81 ND 159.63 ± 47.15
26 25.41 ± 2.04 9.11 ± 2.35 369.50 ± 29.29
27 16.22 ± 1.08 9.86 ± 1.21 137.32 ± 30.96
28 13.86 ± 1.47 2.27 ± 0.61 434.20 ± 35.63
29 16.24 ± 1.63 3.94 ± 0.12 256.10 ± 56.94
Overall
Average 14.09 ± 1.69 3.75 ± 0.72
52.61 ± 5.83
18.75 ± 1.95
287.27 ± 
28.93
64.08 ± 11.75
269.53 ± 46.67
343
Table A.5 Neopterin, 7,8-Dihydroneopterin and Total Pterin Concentrations in the 
Control Group of Healthy Volunteers (Genet 2010). Concentrations neopterin and total 
pterin are in nM ± SEM of duplicates. Concentrations of 7,8-dihydroneopterin are in nM, 
obtained by subtracting the neopterin concentration from the total pterin concentration. All 
samples were taken from the forearm vein
Neopterin
(nM)
7,8-Dihydroneopterin
(nM)
Total Pterin
(nM)
RP 3.28±0.40 40.67 43.96±0.60
MH 16.13±0.23 27.44 43.57±0.02
UF 4.89±0.29 16.98 21.87±0.64
LX 6.88±0.01 18.46 25.35±0.30
H 1 5.02±0.03 17.18 22.20±0.47
H 2 3.09±0.17 21.14 24.24±0.85
H 3 1.24±0.04 18.10 19.35±0.41
H 4 1.68±0.31 15.07 16.75±0.30
H 5 5.76±0.01 16.90 22.67±0.69
H 6 6.10±0.16 18.06 24.16±0.51
H 7 5.03±0.01 10.46 15.49±0.46
H 8 4.42±0.16 5.81 10.24±0.04
H 9 4.62±1.06 15.19 19.81±7.23
H 10 5.91±0.67 11.62 17.53±0.20
H 11 2.61±0.15 20.85 23.47±0.43
H 12 4.97±0.16 7.30 12.28±0.34
H 13 5.37±0.71 17.97 23.35±0.73
H 14 3.99±0.44 19.81 23.81±0.44
H 15 4.42±0.18 15.11 19.53±0.08
H 16 6.52±0.02 28.21 34.73±0.80
H 17 4.10±0.11 6.45 10.55±1.04
Average 5.05 17.56 22.61
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Table A.6 Neopterin, 7,8-Dihydroneopterin and Total Pterin Concentrations in the 
Plasma of Patients with Atherosclerotic Cardiovascular Heart Disease Group 
undergoing endartectomy. Concentrations neopterin and total pterin are in nM ± SEM of 
duplicates. Concentrations of 7,8-dihydroneopterin are in nM, obtained by subtracting the 
neopterin concentration from the total pterin concentration. All samples were taken during the 
endarterectomy. 
Neopterin
(nM)
Total Pterin
(nM)
7,8-dihydroneopterin
 (nM)
P 1 27.81 78.15 50.33
P 2 36.55 86.52 49.97
P 3 25.16 56.75 31.59
P 4 25.63 46.53 20.91
P 5 25.25 64.59 39.34
P 6 20.77 86.72 65.95
P 7 21.30 57.95 36.65
P 8 0.00 0.00 0.00
P 9 34.24 88.12 53.88
P 10 13.36 50.48 37.12
P 11 17.50 66.64 49.14
P 12 12.17 41.69 29.52
P 13 32.26 62.61 30.35
P 14 11.29 48.31 37.02
P 15 28.34 45.58 17.25
P 16 15.82 37.92 22.11
P 17 23.61 66.47 42.86
P 18 15.82 59.23 43.41
P 19 10.05 47.74 37.69
P 20 46.15 68.62 22.47
P 21 47.47 55.69 8.22
P 22 52.07 81.59 29.52
P 23 35.28 60.46 25.18
P 24 31.04 61.23 30.19
P 25 23.99 48.24 24.25
P 26 24.06 63.34 39.29
P 27 39.84 63.79 23.95
P 28 58.28 66.79 8.51
P 29 29.14 71.60 42.46
P 30 35.16 109.60 74.44
P 31 17.87 52.65 34.77
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P 32 24.22 64.37 40.15
P 33 35.74 85.92 50.19
P 34 15.79 60.21 44.42
P 35 18.52 46.58 28.07
P 36 27.31 57.25 29.95
P 37 34.74 54.81 20.07
P 38 30.46 46.02 15.56
P 39 26.73 65.62 38.89
P 40 14.55 63.96 49.40
P 41 26.73 65.62 38.89
P 42 14.55 63.96 49.40
P 43 22.28 44.66 22.38
P 44 38.41 48.86 10.45
P 45 23.66 62.50 38.85
Average 26.47 60.58 34.11
Table A.7 Statistical results comparing biomarkers between carotid and femoral 
plaques.  Levene’s test was performed to test the homogeneity of variances. A Welsh’s 
correction was performed wherever the variances were significantly different to determine 
significance. Statistical significance represented by P<0.05 * P<0.01 ** P<0.001 *** . NS- not 
significant, 
Raw Data Log transformed data
Biomarkers ANOVA
p-value*
Levene’s 
test
p-value*
Welsch’s 
correction
p-value*
ANOVA
p-value*
Levene’s 
test
p-value*
Welsch’s 
correction
p-value*  
Protein *** ** *** *** NS -
Cholesterol *** *** *** *** NS -
Neopterin NS NS - NS *** NS
Total pterin * *** ** * *** *
•-
tocopherol
** * *** *** NS -
TBARS *** *** *** *** *** ***
DOPA *** ** *** *** NS -
Dityrosine *** *** *** *** NS -
AAS *** NS - *** *** ***
GGS *** ** *** *** * ***
Free KC *** ** *** *** NS
Total KC *** *** *** *** NS
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Table A.8 Statistical results of the ANOVA on the raw data and log transformed data 
comparing biomarkers of carotid and femoral plaques with the control artery. Levene’s 
test was performed to test the homogeneity of variances. A Welsh’s correction was performed 
wherever the variances were significantly different to determine significance. Statistical 
significance represented by P<0.05 * P<0.01 ** P<0.001 *** . NS- not significant, 
Raw Data Log transformed data
Biomarkers ANOVA
p-value*
Levene’s 
test
p-value*
Welsch’s 
correction
p-value*
ANOVA
p-value*
Levene’s 
test
p-value*
Welsch’s 
correction
p-value*  
Protein *** ** ** *** NS -
Cholesterol *** *** *** *** NS -
Neopterin NS NS - NS - -
Total pterin * *** *** NS *** NS
•-
tocopherol
** * *** *** NS -
TBARS *** *** *** *** *** ***
DOPA *** *** *** *** * ***
Dityrosine ** *** *** *** * ***
AAS *** * *** *** *** ***
GGS *** ** *** *** ** ***
Free KC *** * * *** NS
Total KC *** *** *** *** NS
